var images_info;if (!images_info) images_info =[]; images_info["111"]={"111000":{"type":"graphic_table","displayName":"Malignant pleural mesothelioma TNM staging AJCC 2017","title":"Malignant pleural mesothelioma TNM staging AJCC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignant pleural mesothelioma TNM staging AJCC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor limited to the ipsilateral parietal pleura with or without involvement of: <ul class=\"decimal_heading\"> <li>Visceral pleura </li> <li>Mediastinal pleura </li> <li>Diaphragmatic pleura </li> </ul> </td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: <ul class=\"decimal_heading\"> <li>Involvement of diaphragmatic muscle </li> <li>Extension of tumor from visceral pleura into the underlying pulmonary parenchyma </li> </ul> </td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Describes locally advanced but <strong>potentially resectable</strong> tumor.<br /> Tumor involving all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: <ul class=\"decimal_heading\"> <li>Involvement of the endothoracic fascia </li> <li>Extension into the mediastinal fat </li> <li>Solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall </li> <li>Nontransmural involvement of the pericardium </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Describes locally advanced <strong>technically unresectable</strong> tumor.<br /> Tumor involving all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: <ul class=\"decimal_heading\"> <li>Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction </li> <li>Direct transdiaphragmatic extension of tumor to the peritoneum </li> <li>Direct extension of tumor to the contralateral pleura </li> <li>Direct extension of tumor to mediastinal organs </li> <li>Direct extension of tumor into the spine </li> <li>Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion, or tumor involving the myocardium </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastases</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis present</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T2 or T3</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1-3</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111000 Version 2.0</div></div></div>"},"111002":{"type":"graphic_figure","displayName":"Malignant pleural mesothelioma OS by stage TNM AJCC 2017","title":"Malignant pleural mesothelioma overall survival by stage TNM AJCC 2017","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Malignant pleural mesothelioma overall survival by stage TNM AJCC 2017</div><div class=\"cntnt\"><img style=\"width:594px; height:342px;\" src=\"images/ONC/111002_MalignantpleuralmsthlmOS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival according to \"best\" overall stage, AJCC 8th edition. Included cases: All classifiable cases. Best stage is defined as pathological stage where available, clinical stage otherwise. Statistical method: Kaplan-Meier.</div><div class=\"graphic_footnotes\">MST: median survival time.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111002 Version 2.0</div></div></div>"},"111003":{"type":"graphic_figure","displayName":"MPM OS by stage and histology TNM AJCC 2017","title":"Malignant pleural mesothelioma overall survival by stage and histology TNM AJCC 2017","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Malignant pleural mesothelioma overall survival by stage and histology TNM AJCC 2017</div><div class=\"cntnt\"><img style=\"width:604px; height:699px;\" src=\"images/ONC/111003_MPMOSstagehistologyTNM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival according to \"best\" overall stage, AJCC 8th edition, for (A) cases with epithelioid histology, and (B) cases with non-epithelioid histology. Included cases: All classifiable cases. Best stage is defined as pathological stage where available, clinical stage otherwise. Statistical method: Kaplan-Meier.</div><div class=\"graphic_footnotes\">MST: median survival time.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111003 Version 2.0</div></div></div>"},"111006":{"type":"graphic_picture","displayName":"Condylomata acuminata extensive disease","title":"Condylomata acuminata","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Condylomata acuminata</div><div class=\"cntnt\"><img style=\"width:700px; height:546px;\" src=\"images/DERM/111006_Condylomata_acuminata_extns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive disease on the perineum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111006 Version 1.0</div></div></div>"},"111007":{"type":"graphic_movie","displayName":"3D images mitral valve","title":"Three-dimensional images of the mitral valve","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Three-dimensional images of the mitral valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/111007_3Dimagesmitralvalvevid.mp4\" style=\"width:608px;height:448px\"></div><img style=\"width:720px; height:540px;\" src=\"images/CARD/111007_3Dimagesmitralvalveimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On TEE imaging, a full volume acquisition of the mitral valve in a patient with rheumatic mitral stenosis shows the typical commissural fusion with a small oval central orifice in diastole. Images are shown from the perspective of the left atrial side of the valve&nbsp;and from the left ventricular side of the valve.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiogram; LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 111007 Version 2.0</div></div></div>"},"111008":{"type":"graphic_movie","displayName":"Long-axis 3D image MS","title":"Long-axis, three-dimensional image of mitral stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Long-axis, three-dimensional image of mitral stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/111008_Longaxis3DimageMSvid.mp4\" style=\"width:608px;height:448px\"></div><img style=\"width:720px; height:548px;\" src=\"images/CARD/111008_Longaxis3DimageMSimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A real-time, three-dimensional TEE image in a long-axis orientation shows the thickened mitral leaflet with commissural fusion and diastolic doming, typical for rheumatic mitral valve disease.</div><div class=\"graphic_footnotes\">LA: left atrium; Ao: aorta; LV: left ventricle; TEE: transesophageal echocardiogram.</div><div id=\"graphicVersion\">Graphic 111008 Version 1.0</div></div></div>"},"111009":{"type":"graphic_diagnosticimage","displayName":"3D mitral valve area","title":"Three-dimensional mitral valve area","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Three-dimensional mitral valve area</div><div class=\"cntnt\"><img style=\"width:713px; height:721px;\" src=\"images/CARD/111009_3Dmitralvalvearea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From the full volume data acquisition, image planes are defined by the colored lines and boxes (A: green, B: red, and C: blue), which allow positioning of the image plane. A long-axis view (upper left) shows the red line through the center of the mitral valve with the corresponding image plane shown in the upper right panel. The blue line is adjusted in both the red and green planes to be at the mitral leaflet tips and aligned with the mitral orifice for measurement of the valve area as shown in the lower left panel. This three-dimensional approach is more accurate and reproducible than two-dimensional imaging because the three-dimensional approach ensures the image plane is correctly positioned.</div><div class=\"graphic_footnotes\">LA: left atrium; Ao: aorta; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 111009 Version 2.0</div></div></div>"},"111012":{"type":"graphic_table","displayName":"Focused history hyperventilation","title":"Focused history for hyperventilation syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Focused history for hyperventilation syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>General features of the episode: Potential triggers, severity, duration, associated symptoms (especially cough, hemoptysis, fever, lightheadedness, palpitations, chest tightness, chest pain or pressure) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Subjective paresthesias or carpopedal spasm </li> </ul> </td> </tr> <tr> <td> <ul> <li>Psychological symptoms such as agitation, anxiety, and/or fear </li> </ul> </td> </tr> <tr> <td> <ul> <li>Usual exercise tolerance compared with current symptoms </li> </ul> </td> </tr> <tr> <td> <ul> <li>Prior similar episodes of dyspnea as well as triggers and duration of those episodes </li> </ul> </td> </tr> <tr> <td> <ul> <li>History of respiratory disease (eg, asthma, COPD, pneumothorax) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Recent surgery, immobilization, prior or familial thromboembolic disease </li> </ul> </td> </tr> <tr> <td> <ul> <li>Recent travel that might be a risk factor for&nbsp;venous thromboembolism&nbsp;or infection </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ingestion of medications, including ASA, NSAID, antibiotics, ACEI </li> </ul> </td> </tr> <tr> <td> <ul> <li>Oral or inhalational exposure to potential toxins (eg, methanol, ethylene glycol, carbon monoxide, organophosphates, cocaine) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Trauma that might have caused pneumothorax, lung contusion, airway injury </li> </ul> </td> </tr> <tr> <td> <ul> <li>Illicit drug use </li> </ul> </td> </tr> <tr> <td> <ul> <li>Any treatments or interventions provided for previous episodes of hyperventilation </li> </ul> </td> </tr> <tr> <td> <ul> <li>Any prior testing for conditions causing hyperventilation (including for hyperventilation syndrome) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease;&nbsp;ASA: acetyl salicylic acid (aspirin); NSAID: nonsteroidal antiinflammatory drug; ACEI: angiotensin-converting enzyme inhibitor.</div><div id=\"graphicVersion\">Graphic 111012 Version 2.0</div></div></div>"},"111013":{"type":"graphic_table","displayName":"Differential diagnosis hyperventilation","title":"Differential diagnosis of hyperventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hyperventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Acute hyperventilation episode</td> <td class=\"subtitle1\">Intermittent, episodic hyperventilation episodes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pulmonary disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Pneumothorax </li> <li>Pulmonary embolism </li> <li>Pneumonia</li> <li>Exacerbation of asthma/COPD</li> <li>Upper airway obstruction</li> <li>Intrapulmonary shunt </li> <li>Interstitial lung disease </li> <li>High altitude sickness </li> </ul> </td> <td> <ul> <li>Asthma </li> <li>COPD </li> <li>Paradoxical vocal fold motion </li> <li>Upper airway obstruction </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cardiovascular disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Acute coronary syndrome </li> <li>Heart failure </li> <li>Dysrhythmias </li> <li>Shock </li> </ul> </td> <td> <ul> <li>Angina </li> <li>Heart failure </li> <li>Dysrhythmias </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Metabolic disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Anion gap acidosis (eg, ketoacidosis, lactic acidosis, salicylate poisoning, non-ethanol alcohol toxicity, carbon monoxide poisoning) </li> <li>Nonanion gap acidosis (eg, renal failure) </li> <li>Hypocalcemia </li> <li>Hypoglycemia </li> </ul> </td> <td> <ul> <li>Diabetic ketoacidosis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Endocrine disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hyperthyroidism </li> <li>Pheochromocytoma </li> </ul> </td> <td> <ul> <li>Hyperthyroidism </li> <li>Pheochromocytoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic and psychologic disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Central nervous system tumor </li> <li>Certain stroke syndromes (eg, hemispheric) </li> <li>Anxiety, panic </li> <li>Pain </li> </ul> </td> <td> <ul> <li>Anxiety, panic </li> <li>Pain </li> <li>Hyperventilation syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pregnancy </li> <li>Hepatic failure </li> <li>Sepsis </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 111013 Version 1.0</div></div></div>"},"111015":{"type":"graphic_algorithm","displayName":"Suspected iron overload","title":"Algorithm for evaluating suspected iron overload","html":"<div class=\"graphic\"><div style=\"width: 1036px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluating suspected iron overload</div><div class=\"cntnt\"><img style=\"width:1016px; height:423px;\" src=\"images/HEME/111015_Suspected_iron_overload.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a general approach and should not substitute for the judgment of the treating clinician. It presumes the patient has already had a history, examination, and complete blood count (CBC). Refer to UpToDate for details of the evaluation. Other diagnostic approaches such as determining the response to a course of therapeutic phlebotomy may be appropriate in some settings.</div><div class=\"graphic_footnotes\">RBC: red blood cell; TSAT: transferrin saturation (serum iron &divide; TIBC &times; 100); HH: hereditary hemochromatosis; HIV: human immunodeficiency virus; MRI: magnetic resonance imaging; TIBC: total iron-binding capacity.<br />* Ideally two measurements are performed when the patient is not acutely ill, especially if results are borderline.<br />&para; The threshold for ferritin and TSAT above which to pursue additional testing depends on the patient's age, family history, medical history, and number of transfusions received.<br />&Delta; Findings of a very high ferritin and TSAT may be sufficient to diagnose iron overload in some individuals (eg, known <em>HFE</em> mutation, multiple transfusions). However, quantitation of iron stores remains useful for decisions about when to start and stop therapy and the urgency of intervening.<br /><span class=\"lozenge\">&loz;</span> MRI is increasingly accepted as the best test. However, liver biopsy may be preferable in some settings (eg, increased hepatic enzymes). Liver MRI may be done in combination with cardiac MRI in some institutions. Cardiac MRI is important in many cases, especially those associated with ineffective erythropoiesis and transfusional iron overload, because hepatic and cardiac iron deposition may not be uniform.</div><div id=\"graphicVersion\">Graphic 111015 Version 2.0</div></div></div>"},"111016":{"type":"graphic_algorithm","displayName":"Diagnosis of lymphangioleiomyomatosis","title":"Algorithm for the diagnosis of lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis of lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:592px; height:704px;\" src=\"images/PULM/111016_DX_lymphangioleiomyomatosis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LAM: lymphangioleiomyomatosis; PFTs: pulmonary function tests; DLCO: diffusing capacity carbon monoxide; HRCT: high resolution computed tomography; TSC: tuberous sclerosis; VEGF-D: vascular endothelial growth factor-D; AML: angiomyolipoma; VATS: video-assisted thoracoscopic surgery.<br />* PFTs may be normal in early LAM.<br />&para; Additional features on HRCT that may be helpful diagnostically include: Pleural effusion, pneumothorax, adenopathy, lymphangiomyoma, ground glass opacity (may suggest chylous congestion), or multifocal micronodules (suggestive of multifocal micronodular pneumocyte hyperplasia [MMPH] as seen in TSC-LAM). In some patients, LAM cysts are atypical.<br />&Delta; Refer to UpToDate text regarding diagnosis of TSC. Diagnosis of TSC often requires referral to TSC specialist. Features that may suggest TSC include:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Family history of TSC</li>&#xD;&#xA;    <li>Subungual fibromas</li>&#xD;&#xA;    <li>Facial angiofibromas</li>&#xD;&#xA;    <li>Hypomelanotic macules</li>&#xD;&#xA;    <li>Confetti lesions</li>&#xD;&#xA;    <li>Shagreen patches</li>&#xD;&#xA;    <li>Seizures, cognitive impairment</li>&#xD;&#xA;    <li>Autism</li>&#xD;&#xA;    <li>Cortical dysplasias, subependymal nodules, and/or features of subependymal giant cell astrocytoma on brain imaging</li>&#xD;&#xA;</ul>&#xD;&#xA;<span class=\"lozenge\">&loz;</span> Refer to UpToDate text regarding patients who present with a low cyst burden (&lt;10) or atypical cysts (eg, nonuniform or irregular shape).<br />&sect; In the United States, VEGF-D is ONLY available through the Translational Trials Laboratory at Cincinnati Children's Hospital Medical Center (www.cincinnatichildrens.org/ttdsl).<br />&yen; Pleural fluid should be assessed for chyle and LAM cells. If no evidence of chylous pleural fluid and abdominal-pelvic HRCT shows ascites, perform paracentesis with assessment for chyle and LAM cells.<br />&Dagger; The diagnosis of renal AML and cystic lymphangioleiomyomas is based on radiographic appearance. Of note, cystic lymphangioleiomyomas should not be aspirated or biopsied due to the risk of prolonged chyle leak.<br />&dagger; Chylous effusion: Triglycerides &gt;110 mg/dL; cholesterol &lt;200 mg/dL.<br />** For patients with lymphadenopathy (typically retroperitoneal or pelvic and less commonly thoracic), some experts perform lymph node aspiration before resorting to lung biopsy. Diagnostic lung tissue can often be obtained via transbronchial biopsy. Occasionally, biopsy may be deferred based on mild or nonprogressive disease or patient preference.<br />&para;&para; A pathologist with experience in the diagnosis of LAM is essential.</div><div id=\"graphicVersion\">Graphic 111016 Version 1.0</div></div></div>"},"111021":{"type":"graphic_table","displayName":"Strategies for responding to disclosure of abuse or assault","title":"Strategies for responding to disclosure of abuse or assault in pregnant women​","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for responding to disclosure of abuse or assault in pregnant women​</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Obstetrically focused response to disclosure of past sexual abuse or assault</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"3\"> <ol> <li>Offer mental health referral. </li> <li>Create obstetric care plan (trigger avoidance and preparation for unavoidable stressors at delivery). </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Preparation for delivery stressors</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Generate plan to address intrapartum triggers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Involve multidisciplinary team for birth planning and counseling early in pregnancy (including but not limited to trauma-trained nurse educators, certified nurse midwives, psychologists, social workers, and clergy when appropriate). </li> <li>If team not available, consider nurse educator trained in trauma-informed birth planning to assist the woman in identifying triggers and generating a feasible birth plan. </li> <li>Final coordination and collaboration between the obstetrician, the woman, and the trauma-trained multidisciplinary team or educator in preparation for delivery. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">A few common triggers and possible modifications</td> </tr> <tr> <td class=\"subtitle2\">Triggers identified antepartum</td> <td class=\"subtitle2\">Intrapartum modifications</td> <td class=\"subtitle2\">Postpartum modifications</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Undressing, genital exposure. </li> </ul> </td> <td> <ul> <li>Drape adequately during examinations and at delivery. </li> <li>Limit spectator cheering/sensitive photos at delivery. </li> <li>Avoid shining bright light directly at perineum. </li> </ul> </td> <td> <ul> <li>Cover breasts adequately when examining or assisting with breast feeding. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Feeling of fluid escaping from vagina, loss of bowel/bladder control. </li> </ul> </td> <td> <ul> <li>Attend to keeping perineum clean during labor and at delivery. </li> </ul> </td> <td> <ul> <li>Encourage staff to warn a woman before touching her and explain why they are doing so. </li> <li>Pay close attention to perineal care. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Intrusive touch. </li> </ul> </td> <td> <ul> <li>Always ask before touching. </li> <li>Limit vaginal examinations and caregivers performing internal examination when possible. </li> <li>Avoid rushing. </li> <li>Encourage woman to bring calming music and/or support persons. </li> </ul> </td> <td> <ul> <li>Avoid pressure to breastfeed if triggers unwanted memories. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Feeling powerless, limited mobility. </li> </ul> </td> <td> <ul> <li>Avoid overpowering words/behaviors (eg, command to relax). </li> <li>Avoid leaning over patient for vaginal examinations. </li> <li>Consider intermittent monitoring to allow greater mobility. </li> <li>Discuss epidural timing with emphasis on the loss of mobility and improved pain control. </li> </ul> </td> <td> <ul> <li>Encourage postpartum social work or multidisciplinary team involvement. </li> <li>Consider home visitation program. </li> <li>Ask about stressors at postpartum visit. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Special issues to consider</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Timing of abuse disclosure</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Disclosure of past abuse may occur at any time, often later in pregnancy when trust is established. Allow the woman to control the timing of her own disclosure. </li> <li>Consider repeating abuse inquiry later in pregnancy if anxiety behaviors or comments lead you to suspect an abuse history, but respect her boundaries if she denies such a history. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Patient privacy, perception of safety, and control</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Seek permission before sharing the woman's past abuse history with the obstetrical care team, other providers, and especially family members who may be unaware of this history. </li> <li>Avoid unrealistic promises (eg, \"Don't worry, you'll be fine\"), which can undermine trust. </li> <li>Emphasize realistic goals (eg, \"We'll try to follow the delivery plan as much as possible, and if we have to change the plan because of concerns for you or the baby, we will discuss it with you\"). </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Suspected ongoing abuse</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Goal of safety planning takes precedence. </li> <li>Offer crisis hotline number, safety card, or educational material (National Domestic Violence Hotline <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-799-SAFE<a href=\"#\" title=\"Call: 1-800-799-SAFE\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\"><img alt=\"\" title=\"Call: 1-800-799-SAFE\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>). </li> <li>Offer community resources (shelters, law enforcement contacts, mental health services, referral to social worker or multidisciplinary team if available to assist with safety planning). </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Special safety issues when screening adolescents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Disclosure of childhood abuse for adolescent patients may suggest ongoing abuse. If ongoing abuse is suspected, state-specific mandatory reporting requirements apply. </li> <li>An immediate and coordinated response (including law enforcement involvement) is needed to assist the young woman in securing a safe environment. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Reimbursement and office time concerns</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Consider using CPT codes for extended counseling. </li> <li>Involve nurse educator or experienced certified nurse midwives if appropriately trained to address trauma-related issues. This may alleviate office time concerns for birth planning and counseling. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Coordinating care with labor and delivery staff and postpartum staff</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Obtain the patient's permission first before discussing her unique birth plan with labor and delivery staff and explain the reasons for sharing the plan. </li> <li>The delivery team will need to be aware of specific triggers and planned modifications upfront. </li> <li>Postpartum nurses will also need to be aware of specific triggers and planned modifications. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Obstetrical emergencies</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"> <ul> <li>Discuss the possibility of obstetrical emergencies during birth planning. </li> <li>Encourage the presence of support persons during labor, especially a trained labor coach or doula to facilitate adaptive stress coping. </li> <li>When unplanned obstetrical interventions are necessary to expedite delivery, discuss the labor course with the woman after delivery and encourage her to describe her feelings about the birth experience. </li> <li>Consider referral for postpartum birth counseling for abuse survivors who describe an unsettling birth experience or desire such counseling. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">While the strategies presented in the table are for pregnant women with a history of prior sexual abuse, the information regarding disclosure, privacy, and safety can be applied to any adult patient.</div><div class=\"graphic_footnotes\">CPT: current procedural terminology.</div><div class=\"graphic_reference\">From: White A. Responding to prenatal disclosure of past sexual abuse. Obstet Gynecol 2014; 123:1344. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=06000&amp;article=00028&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000000266</A>. Copyright © 2014 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111021 Version 1.0</div></div></div>"},"111022":{"type":"graphic_diagnosticimage","displayName":"Thoracic ultrasound in spontaneous pneumomediastinum","title":"Thoracic ultrasound in spontaneous pneumomediastinum","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Thoracic ultrasound in spontaneous pneumomediastinum</div><div class=\"cntnt\"><img style=\"width:728px; height:539px;\" src=\"images/PEDS/111022_Thoracic_US_pneumomediastnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bedside ultrasound images of patient with pneumomediastinum. (A) The subxiphoid view demonstrated normal cardiac contractility, normal chamber size, and lack of pericardial effusion. The parasternal long (B), parasternal short (C), and apical views of the heart were of poor quality with diffuse A lines (D), suggesting air artifact. These findings were suggestive of the presence of a pneumomediastinum.</div><div class=\"graphic_reference\">Zachariah S, Gharahbaghian L1, Perera P, Joshi N. Spontaneous pneumomediastinum on bedside ultrasound: case report and review of the literature. West J Emerg Med. 2015; 16:321. Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" id=\"creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 111022 Version 1.0</div></div></div>"},"111024":{"type":"graphic_movie","displayName":"Video ultrasound of spontaneous pneumomediastinum","title":"Video ultrasound of spontaneous pneumomediastinum","html":"<div class=\"graphic normal\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Video ultrasound of spontaneous pneumomediastinum</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/111024_USspontpneumothoraxvid.mp4\" style=\"width:656px;height:384px\"></div><img style=\"width:648px; height:414px;\" src=\"images/PEDS/111024_USspontpneumothoraximg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using the phased array probe, the subxiphoid view demonstrates normal cardiac contractility, normal chamber size, and lack of pericardial effusion. However, parasternal long, parasternal short, and apical views of the heart are of poor quality with diffuse A lines, suggesting air artifact, consistent with pneumomediastinum. The presence of bilateral lung sliding is confirmed with a linear transducer in the 2<sup>nd</sup> intercostal spaces, thus decreasing the likelihood for a spontaneous pneumothorax.</div><div class=\"graphic_reference\">Zachariah S, Gharahbaghian L1, Perera P, Joshi N. Spontaneous pneumomediastinum on bedside ultrasound: case report and review of the literature. West J Emerg Med. 2015; 16:321. Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" id=\"creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 111024 Version 1.0</div></div></div>"},"111027":{"type":"graphic_table","displayName":"Medical volunteer needs for mass participation road races","title":"Medical volunteer needs for mass participation endurance road races","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical volunteer needs for mass participation endurance road races</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Race distance</td> <td class=\"subtitle1\">Physicians</td> <td class=\"subtitle1\">RNs/ATs/PAs/<br /> NPs/Paramedics/EMTs</td> <td class=\"subtitle1\">General medical volunteers for course</td> <td class=\"subtitle1\">Dedicated EMS team and vehicle</td> </tr> <tr> <td>5K</td> <td class=\"centered\">0 to 2</td> <td class=\"centered\">0 to 4</td> <td class=\"centered\">0 to 4</td> <td>1 may be adequate for up to 5000 entrants</td> </tr> <tr> <td>10K</td> <td class=\"centered\">2 to 4</td> <td class=\"centered\">2 to 4</td> <td class=\"centered\">2 to 4</td> <td>1 may be adequate for up to 5000 entrants</td> </tr> <tr> <td>Half marathon</td> <td class=\"centered\">2 to 4</td> <td class=\"centered\">2 to 4</td> <td class=\"centered\">4 to 6</td> <td>1 may be adequate for up to 5000 entrants</td> </tr> <tr> <td>Marathon</td> <td class=\"centered\">5 to 10</td> <td class=\"centered\">5 to 10</td> <td class=\"centered\">5 to 10</td> <td>1 for every 2000 entrants</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table summarizes the number of medical volunteers needed for mass participation endurance road races. These estimates are per 1000 entrants and are based on the author's experience with the Twin Cities in Motion races. The table may not reflect the minimum number needed for a race that has medical stations attached to each fluid station, in which case more volunteers are needed. Each medical aid station along a marathon or half marathon course is best staffed with five providers, assuming the number of entrants ranges from 1000 to 10,000 and weather conditions are ideal. If temperatures are higher than usual for the season, aid stations can require several additional providers to handle the medical case load. In general for a marathon, half the medical staff is located on the course and half at the finish area. For smaller race fields, staffing one to three mobile units (eg, vans) may be a more efficient use of personnel than fully staffing each aid station. After three to five years of experience with a given race, the staffing numbers needed become more clearly defined.</div><div class=\"graphic_footnotes\">RNs: registered nurses; ATs: athletic trainers; PAs: physician assistants; NPs: nurse practitioners; EMTs: emergency medical technicians; EMS: emergency medical service.</div><div class=\"graphic_reference\">Courtesy of William Roberts, MD.</div><div id=\"graphicVersion\">Graphic 111027 Version 1.0</div></div></div>"},"111028":{"type":"graphic_picture","displayName":"Medical bicycle patrol for Twin Cities Marathon","title":"Medical bicycle patrol for Twin Cities Marathon","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Medical bicycle patrol for Twin Cities Marathon</div><div class=\"cntnt\"><img style=\"width:612px; height:972px;\" src=\"images/SM/111028_Med_bike_patrol_Twn_Cts_Mrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The volunteers pictured above were part of the mobile team that helped to provide medical care at a Twin Cities Marathon and 10 mile road race. The brightly colored, easily identified vests help participants and spectators locate medical help, and the vests fit easily over warm clothing.</div><div class=\"graphic_reference\">Courtesy of William Roberts, MD.</div><div id=\"graphicVersion\">Graphic 111028 Version 1.0</div></div></div>"},"111029":{"type":"graphic_table","displayName":"Studies of proactive PST in hospitalized patients","title":"Studies of proactive penicillin skin testing in hospitalized patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies of proactive penicillin skin testing in hospitalized patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Patients enrolled/tested</td> <td class=\"subtitle1\">Penicillin skin testing (PST) results</td> <td class=\"subtitle1\">Use of beta-lactam antibiotics as a result of PST</td> <td class=\"subtitle1\">Study details/comments</td> </tr> <tr class=\"divider_bottom\"> <td>Arroliga (2003<span style=\"white-space: nowrap;\">)<sup>[1]</sup></span></td> <td>100/96</td> <td> <ul> <li>1 positive</li> <li>10 nondiagnostic</li> <li>85 negative</li> </ul> </td> <td> <ul> <li>38 patients received antibiotics</li> <li>31 of 38 received beta-lactams</li> </ul> </td> <td>Intensive care unit patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Wall (2004<span style=\"white-space: nowrap;\">)<sup>[2]</sup></span></td> <td>26/23</td> <td> <ul> <li>1 indeterminate</li> <li>22 negative</li> </ul> </td> <td> <ul> <li>26 of 26 received a beta-lactam antibiotic</li> </ul> </td> <td>PST performed by allergist-trained pharmacist. Almost all patients (n = 22) were referred for evaluation by infectious diseases consultation.</td> </tr> <tr class=\"divider_bottom\"> <td>Park (2011<span style=\"white-space: nowrap;\">)<sup>[3]</sup></span></td> <td>503/71</td> <td> <ul> <li>4 positive</li> <li>67 negative</li> </ul> </td> <td> <ul> <li>29 of 71 received a beta-lactam</li> <li>Patients enrolled but not evaluated</li> <li>54 (26%) received a beta-lactam</li> </ul> </td> <td>Pharmacist screened all patients and recommended allergy consultation for PST in select patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Rimawi (2013<span style=\"white-space: nowrap;\">)<sup>[4]</sup></span></td> <td>482/146</td> <td> <ul> <li>1 positive</li> <li>145 negative</li> </ul> </td> <td> <ul> <li>145 received beta-lactam antibiotics</li> </ul> </td> <td>Most inclusive study with about one-third of inpatients with penicillin allergy included in study. Beta-lactam antibiotics used were predominantly broad-spectrum, including piperacillin-tazobactam (n = 42), ceftriaxone (n = 27), and cefepime (n = 23). In this study, 217 patients were excluded because of uncertain allergy history, but were PST-eligible.</td> </tr> <tr class=\"divider_bottom\"> <td>King (2016<span style=\"white-space: nowrap;\">)<sup>[5]</sup></span></td> <td>NA/50</td> <td> <ul> <li>50 negative</li> </ul> </td> <td> <ul> <li>37 of 50 were changed to beta-lactam antibiotic</li> </ul> </td> <td>Patients were highly selected, including screened for skin test eligibility and already prescribed a broad-spectrum antibiotic.</td> </tr> <tr class=\"divider_bottom\"> <td>Heil (2016<span style=\"white-space: nowrap;\">)<sup>[6]</sup></span></td> <td>90/76</td> <td> <ul> <li>64 negative</li> <li>9 nondiagnostic</li> <li>3 positive</li> </ul> </td> <td> <ul> <li>54 of 64 had changed to antibiotic therapy (34 of 54 more narrow spectrum, 43 of 54 more effective therapy, 33 of 54 less costly therapy)</li> </ul> </td> <td>Skin testing service run by infectious diseases fellows and patients were highly selected through antibiotic stewardship team referral, infectious diseases consultation service, or the direct request of hospital team.</td> </tr> <tr class=\"divider_bottom\"> <td>Chen (2016<span style=\"white-space: nowrap;\">)<sup>[7]</sup></span></td> <td> <p>252/228</p> PST was completed in 19% of penicillin-allergic inpatients</td> <td> <ul> <li>223 negative</li> <li>5 positive</li> <li>(5 negative history only)</li> </ul> </td> <td> <ul> <li>49 patients were on a penicillin or cephalosporin before PST versus 77 after</li> <li>Active orders for broad-spectrum antibiotics decreased (vancomycin decreased 33%, clindamycin decreased 61%, quinolones decreased 36%, carbapenems decreased 50%, and aztreonam decreased 68%)</li> </ul> </td> <td>Electronic health record screened 1203 patients with penicillin allergy. Pharmacist prioritized based on patient length of stay, antibiotic therapy, and comorbidities.</td> </tr> <tr> <td>Blumenthal (2017<span style=\"white-space: nowrap;\">)<sup>[8]</sup></span></td> <td> <p>278/42</p> Included all internal medicine patients at a tertiary care academic medical center with penicillin allergy being treated for an infection</td> <td> <ul> <li>43 negative</li> </ul> </td> <td> <ul> <li>For all enrolled patients: Odds of receiving a penicillin or cephalosporin as an inpatient were not increased as a result of this policy (adjusted odds ratio [OR] 1.3 [0.8, 2.0])</li> <li>In the subgroup of patients who were skin tested (43): Odds of receiving a penicillin or cephalosporin as an inpatient (adjusted OR 5.6 [2.5, 12.4]) and on discharge (adjusted OR 2.5 [1.04, 6.2]) were both increased</li> </ul> </td> <td>Only study that provides insight into policy impact of proactive PST with adjusted analyses.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PST: penicillin skin testing; NA: not available.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Arroliga ME, Radojicic C, Gordon SM, et al. A prospective observational study of the effect of penicillin skin testing on antibiotic use in the intensive care unit. Infect Control Hosp Epidemiol 2003; 24:347.</li>&#xD;&#xA;    <li>Wall GC, Peters L, Leaders CB, Wille JA. Pharmacist-managed service providing penicillin allergy skin tests. Am J Health Syst Pharm 2004; 61:1271.</li>&#xD;&#xA;    <li>Park MA, McClimon BJ, Ferguson B, et al. Collaboration between allergists and pharmacists increases beta-lactam antibiotic prescriptions in patients with a history of penicillin allergy. Int Arch Allergy Immunol 2011; 154:57.</li>&#xD;&#xA;    <li>Rimawi RH, Cook PP, Gooch M, et al. The impact of penicillin skin testing on clinical practice and antimicrobial stewardship. J Hosp Med 2013; 8:341.</li>&#xD;&#xA;    <li>King EA, Challa S, Curtin P, Bielory L. Penicillin skin testing in hospitalized patients with beta-lactam allergies: Effect on antibiotic selection and cost. Ann Allergy Asthma Immunol 2016; 117:67.</li>&#xD;&#xA;    <li>Heil EL, Bork JT, Schmaizie SA, et al. Implementation of an infectious disease fellow managed penicillin allergy skin testing service. Open Forum Infect Dis 2016; 3:ofw155. eCollection 2016.</li>&#xD;&#xA;    <li>Chen JR, Tarver SA, Alvarez KS, et al. A proactive approach to penicillin allergy testing in hospitalized patients. J Allergy Clin Immunol Pract 2016.</li>&#xD;&#xA;    <li>Blumenthal KG, Wickner PG, Hurwitz S, et al. Tackling inpatient penicillin allergies: Assessing tools for antimicrobial stewardship. J Allergy Clin Immunol 2017.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 111029 Version 2.0</div></div></div>"},"111032":{"type":"graphic_figure","displayName":"Survival distal bile duct cancer based on T category","title":"Survival of cholangiocarcinoma of the distal bile duct based on AJCC tumor (T) categories","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Survival of cholangiocarcinoma of the distal bile duct based on AJCC tumor (T) categories</div><div class=\"cntnt\"><img style=\"width:508px; height:424px;\" src=\"images/ONC/111032_SurvdistalbileductTcat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival based on T stage category. Results from 147 United States patients who underwent resection of distal bile duct carcinoma confirm earlier study results from 222 Korean patients regarding the use of depth of tumor invasion to predict prognosis and stratify T category.</div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111032 Version 2.0</div></div></div>"},"111033":{"type":"graphic_diagnosticimage","displayName":"LV distention from aortic regurgitation during CPB","title":"Hemodynamic tracing during LV distention due to aortic regurgitation during CPB","html":"<div class=\"graphic\"><div style=\"width: 952px\" class=\"figure\"><div class=\"ttl\">Hemodynamic tracing during LV distention&nbsp;due to&nbsp;aortic regurgitation during CPB</div><div class=\"cntnt\"><img style=\"width:932px; height:314px;\" src=\"images/ANEST/111033_LV_dstntn_artc_rgrgttn_CPB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><P class=\"MsoNormal\"><FONT size=3 face=Calibri>These traces were recorded from a patient with severe regurgitation of a porcine aortic valve prosthesis. In contrast to the hemodynamic pattern normally seen during initiation of cardiopulmonary bypass, the arterial blood pressure (ART) trace remains pulsatile while the patient is in sinus rhythm, despite the fact that good venous drainage to the pump has been achieved, as indicated by the pulmonary artery pressure (PAP) and central venous pressure (CVP) traces, which approach 0 mmHg (left panel). This hemodynamic pattern is seen typically in patients with significant aortic valve regurgitation and reflects the continued left ventricular filling through the incompetent aortic valve and its subsequent ejection with each heartbeat. A serious problem arises when this situation is not recognized, and the heart stops beating, either in asystole or in ventricular fibrillation (middle panel). Aortic regurgitation continues, but the fibrillating left ventricle no longer ejects the regurgitant volume, and left ventricular distention results. This pattern is recognized by the progressive rise in PAP caused by back-filling of the left ventricle from the aorta. Note that PAP can rise to equal systemic pressure, as shown here where PAP (24 mmHg) and ART (27 mmHg) are nearly identical (middle panel). Under these circumstances, the coronary perfusion pressure gradient, estimated as ART – PAP, approaches 0 mmHg, and severe myocardial ischemia will occur if corrective action is not taken. Left ventricular venting will relieve left ventricular distention and restore a pressure gradient for coronary perfusion (right panel). This hemodynamic pattern now resembles the normal one during cardiopulmonary bypass, where the ART trace is nonpulsatile and the CVP and PAP are approximately 0 mmHg. Note that effective venting ameliorates left ventricular distention but does not guarantee adequate systemic blood flow in patients with severe aortic valve regurgitation. </FONT><o:p></o:p></div><div class=\"graphic_footnotes\">LV: left ventricular; CPB: cardiopulmonary bypass; ECG: electrocardiogram; ART: systemic arterial pressure; PAP: pulmonary artery pressure; CVP: central venous pressure.</div><div class=\"graphic_reference\">Originally published in: Mark JB. Atlas of cardiovascular monitoring. Churchill Livingstone Inc, Philadelphia 1998. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111033 Version 1.0</div></div></div>"},"111035":{"type":"graphic_figure","displayName":"Central to peripheral arterial pressure gradients after CPB","title":"Central to peripheral arterial pressure gradients after cardiopulmonary bypass","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Central to peripheral arterial pressure gradients after cardiopulmonary bypass</div><div class=\"cntnt\"><img style=\"width:684px; height:551px;\" src=\"images/ANEST/111035_Cntrl_prphrl_prsr_grdnt_CPB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">Arterial</SPAN><SPAN style=\"COLOR: black\"> pressure gradients following cardiopulmonary bypass.<br />(A) Femoral and radial&nbsp;arterial pressure tracings recorded two minutes after bypass (2 minutes post-bypass), when radial&nbsp;arterial pressure underestimates the more centrally measured femoral arterial pressure and 30 minutes later (30 minutes post-bypass), when radial and femoral arterial pressures have equalized and radial pressure has resumed a more typical morphology. Note that dicrotic notch (arrows) is visible in the femoral pressure tracing immediately after bypass, but is delayed in the radial pressure tracing.<br />(B) Femoral and radial&nbsp;arterial pressure tracings recorded before cardiopulmonary bypass (pre-bypass), two minutes following bypass (2 minutes post-bypass), and 30 minutes following bypass (30 minutes post-bypass). Note changing relationship between femoral and radial arterial pressure measurements at these different times.</SPAN></div><div class=\"graphic_reference\">Reproduced from: Schroeder R, Barbeito A, Bar-Yosef S, Mark JB. Cardiovascular monitoring. In: Miller's Anesthesia, 8th ed, Miller RD, Eriksson LI, Fleisher LA, et al (Eds), Saunders 2014. p.1345. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111035 Version 1.0</div></div></div>"},"111036":{"type":"graphic_picture","displayName":"Condylomata acuminata of the anus in a child","title":"Condylomata acuminata of the anus in a child","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Condylomata acuminata of the anus in a child</div><div class=\"cntnt\"><img style=\"width:468px; height:487px;\" src=\"images/EM/111036_Condylm_accumint_anus_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture demonstrates circumferential condylomata acuminata of the anus in a prepubertal child caused by human papilloma virus. Transmission may be sexual or nonsexual. Consultation with a child abuse specialist is warranted to determine the need for further evaluation for sexual abuse. </div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ. Vulvovaginal problems in the prepubertal child. In: Emans, Laufer, and Goldstein's Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 111036 Version 1.0</div></div></div>"},"111041":{"type":"graphic_picture","displayName":"Legs up recovery position","title":"Legs up recovery position","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Legs up recovery position</div><div class=\"cntnt\"><img style=\"width:720px; height:557px;\" src=\"images/SM/111041_Legs_up_recovery_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uncomplicated exercise-associated collapse, or exercise-associated postural hypotension, is relatively common among participants in endurance races. The condition is self-limited and usually resolves within 10 to 30 minutes. Leg elevation, shown above using a chaise lounge, is a common part of treatment.</div><div class=\"graphic_reference\">Courtesy of William Roberts, MD.</div><div id=\"graphicVersion\">Graphic 111041 Version 1.0</div></div></div>"},"111042":{"type":"graphic_picture","displayName":"Perioral vasoconstriction in patient with EAC","title":"Perioral vasoconstriction in patient with exercise-associated collapse, or exercise-associated postural hypotension","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Perioral vasoconstriction in patient with exercise-associated collapse, or exercise-associated postural hypotension</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/SM/111042_Perioral_vasoconstrictn_EAC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exercise-associated collapse (EAC), or exercise-associated postural hypotension, is marked by facial flushing combined with perioral vasoconstriction, as seen in the photograph above. The diamond-shaped configuration of perioral pallor is common in patients with EAC. The patient's eyes usually remain closed until they have recovered.</div><div class=\"graphic_reference\">Courtesy of William Roberts, MD.</div><div id=\"graphicVersion\">Graphic 111042 Version 1.0</div></div></div>"},"111045":{"type":"graphic_figure","displayName":"Survival of resected distal bile duct cancer based upon N stage","title":"Survival after potentially curative resection in a multi-institutional series of 370 patients undergoing pancreaticoduodenectomy for a distal bile duct cancer","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Survival after potentially curative resection in a multi-institutional series of 370 patients undergoing pancreaticoduodenectomy for a distal bile duct cancer</div><div class=\"cntnt\"><img style=\"width:784px; height:620px;\" src=\"images/ONC/111045_Surv_distal_bile_duct_N_stg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival according to the number of involved nodes in 370 patients. P&lt;0.001 (pN0 versus pN1, 1 to 3 involved nodes; pN0 versus pN1, 4 or more involved nodes) (log rank test).</div><div class=\"graphic_reference\">From: Kiriyama M, Ebata T, Aoba T, et al. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg 2015; 102:399. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/bjs.9752/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1002/bjs.9752/abstract</a>. Copyright &copy; 2015 British Journal of Surgery Society Ltd. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 111045 Version 1.0</div></div></div>"},"111046":{"type":"graphic_table","displayName":"Indications for IV fluids following endurance race*","title":"Indications for IV fluid administration following endurance race*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for IV fluid administration following endurance race*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\"><strong><span style=\"color: #ff0000;\">WARNING: Before giving any IV fluids, the clinician must be certain the runner or racer does not have acute hyponatremia</span></strong> (most likely from excessive hydration during race)</td> </tr> <tr class=\"divider_top\"> <td> <ol class=\"numbers_to_nine\"> <li>Persistent orthostatic blood pressure drop or persistent symptoms of exercise-associated collapse (EAC) despite 20 to 30 minutes of supine rest with leg elevation and oral fluids </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Persistent temperature &#62;104&#176;F (40&#176;C) or &#60;95&#176;F (35&#176;C) despite appropriate, standard interventions to warm or cool the patient </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Hypoglycemia &#60;60 mg/dL (3.3 mmol/L) </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Severe, unabating muscle cramps in legs or throughout body </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Persistent nausea and vomiting, and unable to tolerate oral fluids </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"6\"> <li>Significant diarrhea with ongoing fluid losses </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"7\"> <li>Confused or clouded sensorium </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"8\"> <li>\"Not doing well\" per judgment of experienced medical staff </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*This is a list of some relatively common and important indications. It is not meant to be exhaustive and clinicians must use their judgement to determine whether placement of an intravenous catheter is necessary.</div><div id=\"graphicVersion\">Graphic 111046 Version 2.0</div></div></div>"},"111047":{"type":"graphic_figure","displayName":"Survival after resection of perihilar cholangiocarcinoma","title":"Overall survival after resection of a perihilar cholangiocarcinoma in a series of 1352 patients, stratified according to AJCC 8th edition prognostic stage groupings","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">Overall survival after resection of a perihilar cholangiocarcinoma in a series of 1352 patients, stratified according to AJCC 8th edition prognostic stage groupings</div><div class=\"cntnt\"><img style=\"width:810px; height:510px;\" src=\"images/ONC/111047_Survresctprhlrchlngcrcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival after surgical resection of perihilar cholangiocarcinoma at Nagoya University, Japan. Changes from the 7th Edition include removal of Bismuth-Corlette type IV tumors from the T4 category and downstaging of T4 tumors from stage IVA to IIIB.</div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111047 Version 2.0</div></div></div>"},"111048":{"type":"graphic_figure","displayName":"Survival for intrahepatic cholangiocarcinoma","title":"Stratification for survival in a series of 861 patients with intrahepatic cholangiocarcinoma based on revised AJCC/UICC 8th edition definitions for stage IA, IB, and II disease","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Stratification for survival in a series of 861 patients with intrahepatic cholangiocarcinoma based on revised AJCC/UICC 8th edition definitions for stage IA, IB, and II disease</div><div class=\"cntnt\"><img style=\"width:576px; height:486px;\" src=\"images/ONC/111048_Survintrahepatcchlngcrcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stratification of survival for 861 N0M0 patients with confirmed intrahepatic cholangiocarcinoma based on new stage IA, IB, and II classification using National Cancer Data Base (NCDB) registry data.</div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111048 Version 2.0</div></div></div>"},"111049":{"type":"graphic_algorithm","displayName":"Management of acute pediatric hyperkalemia","title":"Management of acute pediatric hyperkalemia","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Management of acute pediatric hyperkalemia</div><div class=\"cntnt\"><img style=\"width:480px; height:700px;\" src=\"images/PEDS/111049_Mgmt_act_hyperkalemia_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; IV: intravenous.<br />* Electrocardiographic changes suggestive of hyperkalemia include widening of the QRS complex, loss of P waves, or arrhythmias, but not isolated peaked T waves.<br />¶ For details of therapy, please refer to UpToDate topics on the management of hyperkalemia in children.<br />Δ Nonemergent therapy given as adjunctive therapy to patients who receive emergent therapy and for patients with acute asymptomatic hyperkalemia with potassium levels &lt;7 mEq/L not at risk for continued rise in potassium.</div><div id=\"graphicVersion\">Graphic 111049 Version 1.0</div></div></div>"},"111051":{"type":"graphic_diagnosticimage","displayName":"PET-CT T2 primary","title":"PET-CT T2 primary","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">PET-CT T2 primary</div><div class=\"cntnt\"><img style=\"width:763px; height:458px;\" src=\"images/ONC/111051_PET-CT_T2_primary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sixty-eight-year-old man with urothelial bladder cancer (T2 primary tumor with lymphovascular invasion). PET-CT showing bilateral common iliac and paraaortic lymph node disease.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; CT: computed tomography; SUV: standardized uptake values.</div><div id=\"graphicVersion\">Graphic 111051 Version 1.0</div></div></div>"},"111052":{"type":"graphic_diagnosticimage","displayName":"PET and invasive bladder cancer","title":"PET and invasive bladder cancer","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">PET and invasive bladder cancer</div><div class=\"cntnt\"><img style=\"width:762px; height:503px;\" src=\"images/ONC/111052_PET_invasive_bladder_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eighty-five-year-old man with high-great muscle invasive bladder cancer and bilateral hydronephrosis. PET-CT is useful to identify lymph node involvement of the pelvis and retroperitoneum.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; SUV: standardized uptake values; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 111052 Version 1.0</div></div></div>"},"111053":{"type":"graphic_table","displayName":"Radiotherapy-induced nausea and vomiting, MASCC ESMO update 2016","title":"Radiotherapy emetic risk levels and MASCC ESMO antiemetic guidelines update 2016","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiotherapy emetic risk levels and MASCC ESMO antiemetic guidelines update 2016</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Emetic risk level</td> <td class=\"subtitle1\">Area of treatment</td> <td class=\"subtitle1\">Antiemetic guideline</td> </tr> <tr> <td>High</td> <td>Total body irradiation.</td> <td>Prophylaxis with a 5-HT<sub>3</sub>-RA + DEX.</td> </tr> <tr> <td>Moderate</td> <td>Upper abdomen, craniospinal.</td> <td>Prophylaxis with a 5-HT<sub>3</sub>-RA + optional DEX.</td> </tr> <tr> <td rowspan=\"2\">Low</td> <td>Cranium.</td> <td>Prophylaxis or rescue with DEX.</td> </tr> <tr> <td>Head and neck, thorax region, pelvis.</td> <td>Prophylaxis or rescue with DEX, a dopamine RA, or a 5-HT<sub>3</sub>-RA.</td> </tr> <tr> <td>Minimal</td> <td>Extremities, breast.</td> <td>Rescue with DEX, a dopamine RA, or a 5-HT<sub>3</sub>-RA.</td> </tr> <tr> <td>Concomitant CRT</td> <td colspan=\"2\">In patients undergoing concomitant CRT, the antiemetic prophylaxis should be according to the guidelines for CINV for the used CT. However, in case the emetic risk of RT is higher than that of the concomitant CT, then the risk level of RT has to be chosen to tailor the antiemetic treatment.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MASCC: Multinational Association for Supportive Care in Cancer; ESMO: European Society for Medical Oncology; 5-HT<SUB>3</SUB>-RA: 5-HT<SUB>3</SUB> receptor antagonist; DEX: dexamethasone; RA: receptor antagonist; CRT: chemoradiotherapy; CINV: chemotherapy-induced nausea and vomiting; CT: chemotherapy,&nbsp;RT: radiotherapy.</div><div class=\"graphic_reference\">Adapted from: Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27(suppl 5):v119-v133, by permission of Oxford University Press on behalf of the European Society of Medical Oncology. Copyright &copy; 2017.</div><div id=\"graphicVersion\">Graphic 111053 Version 3.0</div></div></div>"},"111054":{"type":"graphic_table","displayName":"Autoimmune encephalitis syndromes with antibodies","title":"Autoimmune encephalitis syndromes with antibodies against neuronal cell surface/synaptic proteins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Autoimmune encephalitis syndromes with antibodies against neuronal cell surface/synaptic proteins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antigen target</td> <td class=\"subtitle1\">Clinical syndrome</td> <td class=\"subtitle1\">Tumor or other associations</td> </tr> <tr class=\"divider_bottom\"> <td>NMDAR</td> <td>Multistage syndrome with psychosis, insomnia,&nbsp;memory and behavioral disturbances, seizures, dyskinesias, and autonomic dysfunction</td> <td>Age-dependent presence of ovarian teratoma; rarely other tumors in older patients or males; often has viral-like prodrome</td> </tr> <tr class=\"divider_bottom\"> <td>LGI1</td> <td>Limbic encephalitis, seizures, facio-brachial dystonic seizures</td> <td>5-10%&nbsp;(thymoma); 60%&nbsp;with hyponatremia</td> </tr> <tr class=\"divider_bottom\"> <td>AMPAR</td> <td>Limbic encephalitis, psychiatric disturbances</td> <td>70% (variable solid tumors); relapses are common</td> </tr> <tr class=\"divider_bottom\"> <td>GABA-A receptor</td> <td>Rapidly progressive encephalopathy, refractory seizures, status epilepticus, epilepsia partial continua</td> <td>40% (thymoma); MRI with multifocal cortical-subcortical FLAIR and T2 abnormalities without contrast enhancement</td> </tr> <tr class=\"divider_bottom\"> <td>GABA-B receptor</td> <td>Seizures, limbic encephalitis</td> <td>50%&nbsp;with cancer (mostly SCLC)</td> </tr> <tr class=\"divider_bottom\"> <td>Caspr2</td> <td>Morvan syndrome, limbic encephalitis, neuropathic pain, peripheral neuropathy, autonomic dysfunction, cerebellar ataxia,&nbsp;isolated neuromyotonia</td> <td>Thymoma and variable solid tumors</td> </tr> <tr class=\"divider_bottom\"> <td>IgLON5</td> <td>REM and non-REM parasomnias, obstructive sleep apnea, stridor, brainstem dysfunction</td> <td>No cancer association; often chronic and slowly progressive</td> </tr> <tr class=\"divider_bottom\"> <td>DPPX</td> <td>Encephalopathy with CNS hyperexcitability, hyperekplexia,&nbsp;myoclonus, tremor, often preceded by weight loss, diarrhea, or gastrointestinal symptoms</td> <td>Two&nbsp;patients reported with B-cell neoplasms</td> </tr> <tr class=\"divider_bottom\"> <td>GlyR</td> <td>Encephalomyelitis with muscle spasms, rigidity, myoclonus, hyperekplexia</td> <td>A past history of cancer and a concurrent cancer diagnosis have been reported</td> </tr> <tr class=\"divider_bottom\"> <td>mGluR5</td> <td>Encephalitis</td> <td>Hodgkin lymphoma* or no tumor</td> </tr> <tr> <td>mGluR1</td> <td>Cerebellar ataxia</td> <td>Hodgkin lymphoma or no tumor</td> </tr> <tr> <td>Neurexin 3-alpha&nbsp;</td> <td>Confusion, seizures, encephalitis, dyskinesias&nbsp;</td> <td>No cancer association reported</td> </tr> <tr> <td>Dopamine-2 receptor&nbsp;</td> <td>Basal ganglia encephalitis</td> <td>No cancer association reported</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NMDAR: N-methyl-D-aspartate receptor; LGI1: leucine-rich glioma inactivated protein-1; AMPAR: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GABA: gamma-aminobutyric acid; MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; SCLC: small cell lung cancer; Caspr2: contactin-associated protein-like 2; IgLON5: IgLON family member 5; REM: rapid eye movement; DPPX: dipeptidyl-peptidase-like protein-6; CNS: central nervous system; GlyR: glycine receptor; mGluR: metabotropic glutamate receptor.<br />* The co-occurrence of limbic encephalitis and Hodgkin lymphoma is known as Ophelia syndrome.</div><div id=\"graphicVersion\">Graphic 111054 Version 2.0</div></div></div>"},"111055":{"type":"graphic_table","displayName":"Clinical manifestations of obstructive sleep apnea in children","title":"Clinical manifestations of obstructive sleep apnea in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of obstructive sleep apnea in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Nighttime symptoms</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Snoring </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Labored breathing; paradoxical abdominal movements </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Apneas, pauses in breathing, or gasping </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mouth breathing </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Restless or agitated sleep </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sleeping in unusual positions (neck extended) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nighttime sweating, preference for minimal clothing </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nocturnal enuresis or nocturia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sleepwalking, sleep terrors or confusional arousals </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Daytime symptoms</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mouth breathing, hyponasal speech </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Poor school functioning or other behavioral concerns (inattentiveness, difficulty learning, hyperactivity, impulsivity, irritability, rebelliousness, aggression) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sleepiness (eg, falls asleep at school or in the car, or excessive napping) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Morning headache </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Potential Consequences in childhood</td> </tr> <tr> <td class=\"indent1\"> <ul> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Attention deficit hyperactivity disorder (ADHD) or disruptive behavior disorders</span> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Poor growth (especially in infants and young children) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hypertension </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Altered cardiac morphology (right and left ventricular hypertrophy) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pulmonary hypertension </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Shalini Paruthi, MD.</div><div id=\"graphicVersion\">Graphic 111055 Version 2.0</div></div></div>"},"111056":{"type":"graphic_table","displayName":"PSG variables in children","title":"Polysomnographic variables in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polysomnographic variables in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"14%\"></colgroup><colgroup span=\"2\" width=\"43%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Events</td> </tr> <tr> <td class=\"indent1\">Apnea</td> <td>&#62;90 percent decrease in airflow signal that lasts &#8805;90 percent of the duration of at least two normal breaths, as determined from the baseline breathing pattern.</td> <td> <ul> <li>Apnea is <strong>obstructive</strong> if there is continued or increased inspiratory effort during the entire period of decreased airflow. </li> <li>Apnea is <strong>central</strong> if inspiratory effort is absent during the entire period of airflow cessation.* </li> <li>Apnea is <strong>mixed</strong> if there is absent respiratory effort during one portion of the event AND the presence of inspiratory effort in another portion, regardless of which portion comes first. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypopnea</td> <td>&#8805;30 percent decrease in airflow signal that lasts &#8805;90 percent of the duration of at least two normal breaths, as determined from the baseline breathing pattern. The decreased airflow is associated with an arousal, or at least 3 percent oxyhemoglobin desaturation.</td> <td> <ul> <li>Hypopneas may be classified as either <strong>obstructive</strong> or <strong>central</strong>, depending on the presence or absence of snoring, flattening of nasal pressure signal, or paradoxical thoracoabdominal breathing. </li> <li><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">However, in practice, accurate classification of the etiology of hypopneas is challenging, and usually not performed. In a patient who has clear obstructive sleep apnea, hypopneas are usually assumed to have an obstructive basis.</span> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Respiratory effort related arousal (RERA)</td> <td>Respiratory event (increasing respiratory effort, flattening of the inspiratory portion of the nasal pressure waveform, snoring, or an elevation in the end-tidal PCO<sub>2</sub>), that leads to arousal and does not qualify as an apnea or hypopnea.<sup>&#182;</sup></td> <td> <ul> <li>RERAs can be detected with routinely used sensors on in-lab PSG or by addition of esophageal manometry. </li> <li>Upper airway resistance syndrome (UARS) was previously used to describe presence of RERAs in the absence of apneas or hypopneas. UARS is now subsumed into the category of OSA. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sleep-related hypoventilation</td> <td>The end-tidal or transcutaneous CO<sub>2</sub> &#62;50 mmHg for more than 25 percent of the total sleep time.</td> <td> <ul> <li>Some children with breathing disturbance due to increased upper airway resistance have hypoventilation, but not discrete apneas or hypopneas. </li> <li>Obstructive hypoventilation is now subsumed into the category of OSA. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Additional events</td> <td>Arousals, snoring, changes in body position, and limb movements.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Summary measures</td> </tr> <tr> <td class=\"indent1\">Apnea hypopnea index (AHI)</td> <td>The number of apneas plus hypopneas that occur per hour of sleep.</td> <td> <ul> <li>Concern for clinically significant OSA generally starts with an AHI &#62;1 or RDI &#62;1. </li> <li>An AHI &#8805;1.5 events per hour was considered abnormal based on a study of a group of healthy children not suspected of having sleep-related breathing disorders, in whom the mean AHI was 0.2 &#177; 0.6 events per hour.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Respiratory disturbance index (RDI)</td> <td>The number of apneas, hypopneas, and RERAs per hour of sleep.</td> <td> <ul> <li>Concern for clinically significant OSA generally starts with an AHI &#62;1 or RDI &#62;1. </li> <li>Some experts have advocated slightly higher RDI thresholds, such as 1.5, 2, or 3 events per hour. </li> <li>An RDI &#62;5 events per hour of sleep is often used to identify an abnormal RDI in adults, but is insufficiently sensitive for children. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RERA: respiratory effort related arousal; UARS: upper airway resistance syndrome; OSA: obstructive sleep apnea; AI: apnea index; OAI: obstructive apnea index; RDI: respiratory disturbance index; AHI: apnea hypopnea index; EEG: electroencephalographic.<br />* Central apnea also requires one of the following measures of duration: 1) The respiratory event is at least 20 seconds long; 2) Inspiratory effort is absent for the duration of two respiratory cycles and is followed by a cortical arousal, or oxygen desaturation &ge;3 percent; or 3) The event is associated with a decrease in the heart rate to less than 50 beats per minute for at least 5 seconds, or less than 60 beats per minute for 15 seconds (infants under one year of age only).<br />&para; Arousals are determined by electroencephalographic (EEG) criteria.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Witmans MB, Keens TG, Davidson Ward SL, Marcus CL. Obstructive hypopneas in children and adolescents: normal values. Am J Respir Crit Care Med 2003; 168:1540.</LI></OL>Data from: Berry RB, Brooks R, Gamaldo CE, Harding SM, Lloyd RM, Marcus CL and Vaughn BV for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.3. www.aasmnet.org. Darien, Illinois: American Academy of Sleep Medicine, 2016.</div><div id=\"graphicVersion\">Graphic 111056 Version 1.0</div></div></div>"},"111057":{"type":"graphic_algorithm","displayName":"Prophylaxis for PONV in adults","title":"Prophylaxis for postoperative nausea and vomiting (PONV) in adults","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Prophylaxis for postoperative nausea and vomiting (PONV) in adults</div><div class=\"cntnt\"><img style=\"width:720px; height:344px;\" src=\"images/ANEST/111057_Prophylaxis_PONV_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TIVA: total intravenous anesthesia.<br />* The choice of PONV prophylaxis must take into account the medical and surgical risks of PONV (eg, disruption of surgical repair, increase in intracranial pressure) and patient and provider preferences.<br />&para; When more than one antiemetic is administered, drugs from different classes should be chosen. The beneficial effects of antiemetics that act on different receptors are additive.<br />&Delta; While prophylaxis is not indicated, many clinicians offer PONV prophylaxis to low risk patients.</div><div id=\"graphicVersion\">Graphic 111057 Version 1.0</div></div></div>"},"111058":{"type":"graphic_figure","displayName":"SEER incidence 2004 to 2013","title":"SEER incidence 2004 to 2013","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">SEER incidence 2004 to 2013</div><div class=\"cntnt\"><img style=\"width:760px; height:541px;\" src=\"images/PC/111058_SEER_incidence_2004_2013.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: National Cancer Institute. SEER Data, 1973-2013 (including July-December 2005 Hurricane Katrina impacted Louisiana cases). Available at: <A href=\"https://seer.cancer.gov/data/\" target=_blank>https://seer.cancer.gov/data/</A> (Accessed on December 1, 2016).</div><div id=\"graphicVersion\">Graphic 111058 Version 1.0</div></div></div>"},"111061":{"type":"graphic_picture","displayName":"Recycled skin grafting for severe hidradenitis suppurativa","title":"Recycled skin grafting for severe hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recycled skin grafting for severe hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:448px; height:766px;\" src=\"images/SURG/111061_Hidradenitis_spprtv_bttcks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above&nbsp;(A)&nbsp;shows the buttocks of a 57-year-old male with debilitating hidradenitis suppurativa prior to skin grafting. He underwent staged excision and grafting first on the left side using \"recycled skin.\" After several months, the procedure was repeated on his right side. The skin was harvested from the involved areas with a dermatome at a thickness of 0.012 inches and meshed at 2:1. The inflamed deeper layers of the skin and subcutaneous tissues were excised and the graft applied to the fascia and secured using negative pressure wound therapy for five days. The photo below (B) shows him with healed buttocks three months following surgery.</div><div id=\"graphicVersion\">Graphic 111061 Version 1.0</div></div></div>"},"111064":{"type":"graphic_figure","displayName":"Rapid cycle of deterioration in right-sided shock","title":"Rapid cycle of deterioration in right-sided shock","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Rapid cycle of deterioration in right-sided shock</div><div class=\"cntnt\"><img style=\"width:754px; height:342px;\" src=\"images/ANEST/111064_Deteriortn_right-sided_shck.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">RV: right ventricle; CVP: central venous pressure; TR: tricuspid regurgitation; TSG:&nbsp;transseptal pressure gradient; IVS: interventricular septum; CO: cardiac output; LVEDP: left ventricular end-diastolic pressure.</SPAN></div><div class=\"graphic_reference\">Reproduced from: Hrymak C, Strumpher J, Jacobsohn E. Acute right ventricle failure in the intensive care unit: Assessment and management. Can J Cardiol 2017; 33:61. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111064 Version 1.0</div></div></div>"},"111067":{"type":"graphic_figure","displayName":"Schematic of vascular ligation for uterus removal for transplant","title":"Schematic of vascular ligation for uterus removal for transplantation","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Schematic of vascular ligation for uterus removal for transplantation</div><div class=\"cntnt\"><img style=\"width:656px; height:609px;\" src=\"images/OBGYN/111067_Schmtc_vsclr_lgtn_utrs_rmvl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic drawing of the arteries (red) and veins (blue) connected to the uterus. Transection lines are indicated by black lines.</div><div class=\"graphic_reference\">Reproduced from: Brännström M, Johannesson L, Dahm-Kähler P, et al. First clinical uterus transplantation trial: a six-month report. Fertil Steril 2014; 101:1228. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111067 Version 1.0</div></div></div>"},"111071":{"type":"graphic_table","displayName":"Antibiotic doses for mastitis in children and adolescents","title":"Doses of antimicrobial therapy for mastitis and breast abscess in children and adolescents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doses of antimicrobial therapy for mastitis and breast abscess in children and adolescents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Maximum daily dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral agents</td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> <td>25 to 50 mg/kg per day orally in three or four doses</td> <td>2&nbsp;g/day</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#182;</sup></td> <td>30 to 40 mg/kg per day orally in three or four doses</td> <td>1.8 g/day</td> </tr> <tr> <td class=\"indent1\">Cloxacillin<sup>&#916;</sup></td> <td>25 to 50 mg/kg per day orally in four doses</td> <td>2 g/day</td> </tr> <tr> <td class=\"indent1\">Dicloxacillin</td> <td>25 to 50 mg/kg per day orally in four doses</td> <td>2 g/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim-sulfamethoxazole<br /> (TMP-SMX)<sup>&#182;</sup><sup>&#9674;</sup></td> <td>8 to 12 mg TMP component/kg per day orally in two doses</td> <td>320 mg/day (TMP component)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Parenteral agents<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Cefazolin<sup>&#167;</sup></td> <td>50 to 100 mg/kg per day IV in three doses</td> <td>3 g/day (maximum of 6 g/day if severely ill appearing)</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#182;</sup></td> <td>30 to 40 mg/kg per day IV in three or four doses</td> <td>2.7 g/day</td> </tr> <tr> <td class=\"indent1\">Nafcillin</td> <td>100 to 200 mg/kg per day IV in four to six doses</td> <td>12 g/day</td> </tr> <tr> <td class=\"indent1\">Oxacillin</td> <td>100 to 200 mg/kg per day IV in four to six doses</td> <td>12 g/day</td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#182;&#165;</sup></td> <td>40 to 60 mg/kg per day IV in four doses, or<br /> 45 mg/kg per day in three doses</td> <td>4 g/day</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">TMP-SMX: trimethoprim and sulfamethoxazole; IV: intravenously; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Refer to UpToDate topic on mastitis and breast abscess in children and adolescents for additional information about the choice of regimen and duration of therapy.<br />¶ May be warranted in areas with incidence of community-associated methicillin-resistant <EM innerHtml>Staphylococcus aureus </EM>(CA-MRSA) greater than 10 percent of isolates or in patients with severe hypersensitivity to penicillins and cephalosporins.<br />Δ Not available in the United States.<br /><FONT class=lozenge>◊</FONT> TMP-SMX is not active against group A <EM>Streptococcus</EM>.<br />§ Doses at the upper end of the ranges shown in this table are appropriate for patients with mastitis or breast abscess in association with severe systemic signs and symptoms.<br />¥ Vancomycin trough concentrations should be used to guide dose adjustments; a target trough of 10 to 15 mcg/mL is appropriate for nonsevere infections; a higher trough level (15 to 20 mcg/mL) is warranted for MRSA infection with severe systemic signs and symptoms. </div><div class=\"graphic_reference\">1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147. <br />2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <EM>Staphylococcus aureus</EM> infections in adults and children. Clin Infect Dis 2011; 52:e18. <br />3. American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.884. <br /></div><div id=\"graphicVersion\">Graphic 111071 Version 1.0</div></div></div>"},"111073":{"type":"graphic_algorithm","displayName":"Diagnosis of LAM in patients with TSC","title":"Diagnosis of lymphangioleiomyomatosis in patients with tuberous sclerosis complex (TSC)","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Diagnosis of lymphangioleiomyomatosis in patients with tuberous sclerosis complex (TSC)</div><div class=\"cntnt\"><img style=\"width:476px; height:720px;\" src=\"images/PULM/111073_Dx_LAM_patients_TSC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LAM: lymphangioleiomyomatosis; TSC: tuberous sclerosis complex; PFT: pulmonary function test; HRCT: high resolution computed tomography; VEGF-D: vascular endothelial growth factor D; MMPH: multifocal micronodular pneumocyte hyperplasia.<br />* Some patients with TSC have multiple tiny nodules characteristic of MMPH.<br />¶ Refer to UpToDate content on sporadic LAM.<br />Δ VEGF-D is only available in the United States through the Translational Trials Laboratory at Cincinnati Children's Hospital Medical Center. A VEGF-D level &gt;800 pg/mL has high specificity for LAM.</div><div id=\"graphicVersion\">Graphic 111073 Version 1.0</div></div></div>"},"111078":{"type":"graphic_figure","displayName":"Plantar fasciitis injection","title":"Plantar fasciitis injection","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Plantar fasciitis injection</div><div class=\"cntnt\"><img style=\"width:478px; height:447px;\" src=\"images/RHEUM/111078_Plantar_fasciitis_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injection technique for plantar fasciitis: Locate the most tender area and inject perpendicular to the skin using a medial approach.</div><div class=\"graphic_reference\">Reproduced with permission from: Soomekh DJ. Platelet-Rich Plasma: Can It Have An Impact For Plantar Fasciitis? Podiatry Today 2012; 25:1. Copyright © 2012 HMP Communications LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111078 Version 1.0</div></div></div>"},"111079":{"type":"graphic_algorithm","displayName":"Evaluation of suspected pancreas allograft rejection","title":"Evaluation of the pancreas transplant recipient with a new elevation in serum lipase and/or amylase","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Evaluation of the pancreas transplant recipient with a new elevation in serum lipase and/or amylase</div><div class=\"cntnt\"><img style=\"width:798px; height:888px;\" src=\"images/NEPH/111079_Sspctd_pancrs_allgrft_rjctn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* In select patients with normal renal function, a computed tomography of the abdomen and pelvis with oral and intravenous contrast can be performed to better delineate the pancreas anatomy. Such patients should receive measures to help prevent the development of contrast-induced nephropathy.</div><div id=\"graphicVersion\">Graphic 111079 Version 1.0</div></div></div>"},"111080":{"type":"graphic_algorithm","displayName":"Treatment of Hb less than or equal to 10 g/dL in PD patients","title":"Initial treatment of hemoglobin ≤10 g/dL among peritoneal dialysis patients*","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Initial treatment of&nbsp;hemoglobin ≤10 g/dL among peritoneal dialysis patients*</div><div class=\"cntnt\"><img style=\"width:510px; height:358px;\" src=\"images/NEPH/111080_Trtmnt_Hb_lt_10gdL_PD_ptnts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TSAT: transferrin saturation (TSAT = plasma iron / total iron-binding capacity &times; 100); ESA: erythropoiesis-stimulating agent; Hb: hemoglobin.<br />* The treatment of peritoneal dialysis patients with mild anemia (ie, Hb 10 to 12 g/dL) is controversial. Refer to UpToDate topic on treatment of anemia in peritoneal dialysis patients.<br />&para; Iron and/or ESAs should only be given if there is a clinical decision to increase the Hb.</div><div id=\"graphicVersion\">Graphic 111080 Version 3.0</div></div></div>"},"111081":{"type":"graphic_diagnosticimage","displayName":"MRI limbic encephalitis","title":"Magnetic resonance imaging (MRI) in a patient with limbic encephalitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) in a patient with limbic encephalitis</div><div class=\"cntnt\"><img style=\"width:756px; height:450px;\" src=\"images/NEURO/111081_MRI_limbic_encephalitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">56-year-old woman presenting with a three-month history of faciobrachial dystonic seizures and progressive mood and cognitive changes. Serum and cerebrospinal fluid (CSF) revealed anti-LGI1 antibodies. Axial and coronal MRI at initial visit show increased fluid attenuated inversion recovery (FLAIR) signal abnormalities in the bilateral mesial temporal lobes (arrows).</div><div id=\"graphicVersion\">Graphic 111081 Version 1.0</div></div></div>"},"111082":{"type":"graphic_table","displayName":"Diagnostic criteria for anti-NMDA receptor encephalitis","title":"Diagnostic criteria for anti-NMDA receptor encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for anti-NMDA receptor encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Probable anti-NMDA receptor encephalitis*</td> </tr> <tr class=\"divider_bottom\"> <td>All three criteria must be met: <ol> <li>Rapid onset (&#60;3 months) of at least four of the six following major groups of symptoms:<sup>&#182;</sup> <ul> <li>Abnormal (psychiatric) behavior or cognitive dysfunction </li> <li>Speech dysfunction </li> <li>Seizures </li> <li>Movement disorder, dyskinesias, or rigidity/abnormal postures </li> <li>Decreased level of consciousness </li> <li>Autonomic dysfunction or central hypoventilation </li> </ul> </li> <li>At least one of the following laboratory results: <ul> <li>Abnormal EEG (focal or diffuse slow or disorganized activity, epileptic activity, or extreme delta brush) </li> <li>CSF with pleocytosis or oligoclonal bands </li> </ul> </li> <li>Reasonable exclusion of other disorders </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Definite anti-NMDA receptor encephalitis*</td> </tr> <tr> <td> <ol> <li>IgG anti-GluN1 antibodies<sup>&#916;</sup> in the presence of one or more of the six major groups of symptoms, after reasonable exclusion of other disorders </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NMDA: N-methyl-D-aspartate; EEG: electroencephalogram; CSF: cerebrospinal fluid; IgG: immunoglobulin G.<br />* Patients with a history of herpes simplex virus encephalitis in the previous weeks might have relapsing immune-mediated neurologic symptoms (post-herpes simplex virus encephalitis).<br />¶ In the presence of a systemic teratoma, diagnosis can be made in the presence of three groups of symptoms.<br />Δ Antibody testing should include testing of CSF. If only serum is available, confirmatory tests should be included (eg, live neurons or tissue immunohistochemistry), in addition to cell-based assay.</div><div class=\"graphic_reference\">Reproduced from: Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15:391. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111082 Version 1.0</div></div></div>"},"111083":{"type":"graphic_table","displayName":"Differential diagnosis of paraneoplastic encephalitis","title":"Differential diagnosis of paraneoplastic and autoimmune encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of paraneoplastic and autoimmune encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical clues and diagnostic testing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infectious etiologies</td> </tr> <tr> <td class=\"indent1\">Viral encephalitis (eg, HSV, HHV6, VZV, EBV, CMV, HIV, enterovirus, arbovirus)</td> <td class=\"divider_bottom\" rowspan=\"7\"> <p>CSF testing: Cultures, AFB smear, HSV1/2 PCR, HHV6 PCR, VZV PCR, EBV PCR, CMV PCR, HIV RNA, VDRL, Lyme antibodies, arbovirus panel, enterovirus PCR, T. whipplei PCR, 14-3-3, tau</p> <p>Serum testing: HIV, Lyme serologies</p> Travel and exposure history</td> </tr> <tr> <td class=\"indent1\">Bacterial encephalitis (eg, Listeria, Bartonella, Mycoplasma, Rickettsia)</td> </tr> <tr> <td class=\"indent1\">Spirochetal encephalitis (eg, syphilis, Lyme, leptospirosis)</td> </tr> <tr> <td class=\"indent1\">Fungal infection (eg, cryptococcus, coccidiomycosis, histoplasmosis)</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Creutzfeldt-Jakob disease</td> </tr> <tr> <td class=\"indent1 divider_bottom\">Whipple disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Toxic-metabolic</td> </tr> <tr> <td class=\"indent1\">Drug ingestion (eg, alcohol, ketamine, phencyclidine, organophosphates)</td> <td>Serum and urine toxicology screens</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> <td>Carboxyhemoglobin, MRI (eg, diffusion restriction in basal ganglia, white matter)</td> </tr> <tr> <td class=\"indent1\">Wernicke encephalopathy</td> <td>Alcohol misuse or malnutrition, oculomotor dysfunction, MRI (periaqueductal gray, mamillary bodies, medial thalami)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neuroleptic malignant syndrome</td> <td>Causative medications (eg, neuroleptics, antiemetics, concomitant lithium), dopaminergic withdrawal, elevated creatine kinase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vascular disorders</td> </tr> <tr> <td class=\"indent1\">Reversible posterior leukoencephalopathy syndrome</td> <td>Headaches, hypertension, causative medications (eg, immunosuppression, angiogenesis inhibitors), MRI (posterior predominant or brainstem T2 hyperintensities)</td> </tr> <tr> <td class=\"indent1\">Primary or secondary angiitis of the central nervous system</td> <td>Abnormal vascular imaging, ANCA, cryoglobulins, aPL antibodies</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et disease</td> <td>Painful mucocutaneous ulcers, uveitis, positive pathergy test</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Susac syndrome (autoimmune vasculopathy)</td> <td>Hearing loss, branch retinal artery occlusions on fluorescein angiography, MRI (corpus callosum and periventricular white matter abnormalities)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neoplastic disorders</td> </tr> <tr> <td class=\"indent1\">Leptomeningeal metastases</td> <td>MRI (leptomeningeal enhancement, communicating hydrocephalus), CSF cytology</td> </tr> <tr> <td class=\"indent1\">Diffuse glioma</td> <td>MRI (expansile, T2 hyperintense lesion), normal CSF</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Primary or secondary central nervous system lymphoma</td> <td>MRI (parenchymal or leptomeningeal enhancement); CSF cytology, flow cytometry, and IgH gene rearrangement</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Demyelinating or inflammatory disorders</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> <td>CSF oligoclonal bands (nonspecific), lesions separated in time and space</td> </tr> <tr> <td class=\"indent1\">Neuromyelitis optica</td> <td>NMO antibodies</td> </tr> <tr> <td class=\"indent1\">Acute disseminated encephalomyelitis (ADEM)</td> <td>Preceding infection or vaccination; MRI with diffuse, multifocal, poorly demarcated lesions predominantly involving white matter; no new clinical or MRI findings after&nbsp;three months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neurosarcoidosis</td> <td>Hilar adenopathy or pulmonary parenchymal changes, elevated ACE level (nonspecific)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurodegenerative dementias</td> </tr> <tr> <td class=\"indent1\">Alzheimer disease dementia</td> <td class=\"divider_bottom\" rowspan=\"4\">MRI (often normal early in the course, may show focal atrophy);&nbsp;regional abnormalities on brain PET/SPECT,&nbsp;family history (for frontotemporal dementia)</td> </tr> <tr> <td class=\"indent1\">Frontotemporal dementia</td> </tr> <tr> <td class=\"indent1\">Dementia with Lewy bodies</td> </tr> <tr> <td class=\"indent1 divider_bottom\">Vascular cognitive impairment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Psychiatric disease</td> </tr> <tr> <td class=\"indent1\">Schizophrenia and other psychotic disorders</td> <td class=\"divider_bottom\" rowspan=\"4\"> <p>Toxicology screens</p> <p>Family history</p> Negative imaging and CSF</td> </tr> <tr> <td class=\"indent1\">Bipolar disorder</td> </tr> <tr> <td class=\"indent1\">Conversion disorder</td> </tr> <tr> <td class=\"indent1 divider_bottom\">Substance abuse</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inherited and metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Mitochondrial cytopathies</td> <td>Serum or CSF lactate elevation, lactate peak on MR spectroscopy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; HHV6: human herpes virus 6; VZV: varicella zoster virus; EBV: Epstein Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; CSF: cerebrospinal fluid; AFB: acid fast bacilli; PCR: polymerase chain reaction; RNA: ribonucleic acid; VDRL: Venereal Disease Research Laboratory; MRI: magnetic resonance imaging; ANCA: antineutrophil cytoplasmic antibodies; aPL: antiphospholipid; NMO: neuromyelitis optica; ACE: angiotensin converting enzyme; PET: positron emission tomography; SPECT: single photon emission computed tomography.</div><div id=\"graphicVersion\">Graphic 111083 Version 1.0</div></div></div>"},"111084":{"type":"graphic_table","displayName":"Diagnostic criteria for possible autoimmune encephalitis","title":"Diagnostic criteria for possible autoimmune encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for possible autoimmune encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td>All three of the following criteria must be met: <ol> <li>Subacute onset (rapid progression of &#60;3 months) of working memory deficits (short-term memory loss), altered mental status*, or psychiatric symptoms </li> <li>At least one of the following: <ul> <li>New focal CNS findings </li> <li>Seizures not explained by a previously known seizure disorder </li> <li>CSF pleocytosis (&#62;5 white blood cells per mm<sup>3</sup>) </li> <li>MRI features suggestive of encephalitis<sup>&#182;</sup> </li> </ul> </li> <li>Reasonable exclusion of alternative causes </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging.<br />* Altered mental status defined as decreased or altered level of consciousness, lethargy, or personality change.<br />¶ Brain MRI hyperintense signal on T2-weighted fluid-attenuated inversion recovery (FLAIR)&nbsp;sequences highly restricted to one or both medial temporal lobes (limbic encephalitis), or in multifocal areas involving grey matter, white matter, or both, compatible with demyelination or inflammation.</div><div class=\"graphic_reference\">Reproduced from: Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15:391. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111084 Version 1.0</div></div></div>"},"111085":{"type":"graphic_table","displayName":"Diagnostic criteria for definite autoimmune limbic encephalitis","title":"Diagnostic criteria for definite autoimmune limbic encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for definite autoimmune limbic encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td>All four of the following criteria must be met:* <ol> <li>Subacute onset (rapid progression of &#60;3 months) of working memory deficits (short-term memory loss), seizures, or psychiatric symptoms suggesting involvement of the limbic system </li> <li>Bilateral brain abnormalities on T2-weighted fluid-attenuated inversion recovery MRI highly restricted to the medial temporal lobes<sup>&#182;</sup> </li> <li>At least one of the following: <ul> <li>CSF pleocytosis (&#62;5 white blood cells per mm<sup>3</sup>) </li> <li>EEG with epileptic or slow-wave activity involving the temporal lobes </li> </ul> </li> <li>Reasonable exclusion of alternative causes </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; EEG: electroencephalogram; MRI: magnetic resonance imaging.<br />* If one of the first three criteria is not met, a diagnosis of definite limbic encephalitis can be made only with the detection of antibodies against cell-surface, synaptic, or onconeural proteins.<br />¶ 18-flueorodeoxyglucose positron emission tomography (FDG-PET) can be used to fulfil this criterion and may be more sensitive than MRI for detecting medial temporal lobe abnormalities.</div><div class=\"graphic_reference\">Reproduced from: Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15:391. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111085 Version 1.0</div></div></div>"},"111086":{"type":"graphic_table","displayName":"Signs and sxs suggestive of preeclampsia without proteinuria","title":"Signs and symptoms suggestive of diagnosis of preeclampsia without proteinuria rather than gestational hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms suggestive of diagnosis of preeclampsia without proteinuria rather than gestational hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Symptoms of central nervous system dysfunction:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">New-onset cerebral or visual disturbance, such as: <ul class=\"decimal_heading\"> <li>Photopsia, scotomata, cortical blindness, retinal vasospasm </li> <li>Severe headache (ie, incapacitating, \"the worst headache I've ever had\") or headache that persists and progresses despite analgesic therapy </li> <li>Altered mental status </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Hepatic abnormality:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by an alternative diagnosis or serum transaminase concentration &#8805;2 times the upper limit of the normal range, or both</td> </tr> <tr> <td class=\"subtitle1_single\">Thrombocytopenia:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#60;100,000 platelets/microL</td> </tr> <tr> <td class=\"subtitle1_single\">Renal abnormality:</td> </tr> <tr> <td class=\"indent1\">Progressive renal insufficiency (serum creatinine &#62;1.1 mg/dL [97.2 micromol/L] or doubling of serum creatinine concentration in the absence of other renal disease)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111086 Version 1.0</div></div></div>"},"111088":{"type":"graphic_picture","displayName":"Incontinentia pigmenti stage 1","title":"Stage 1 (vesicular) incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage 1 (vesicular) incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:442px; height:288px;\" src=\"images/DERM/111088_Incontinentia_pigmenti_stg1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicular lesions overlying an erythematous base in a pattern that follows the Blaschko lines are present in this newborn girl with incontinentia pigmenti.</div><div class=\"graphic_reference\">Courtesy of Moise Levy, MD.</div><div id=\"graphicVersion\">Graphic 111088 Version 1.0</div></div></div>"},"111089":{"type":"graphic_picture","displayName":"Incontinentia pigmenti stage 3","title":"Stage 3 (hyperpigmented) incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Stage 3 (hyperpigmented) incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/DERM/111089_Incontinentia_pigmenti_stg3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brown, irregular swirling macules in a female infant with incontinentia pigmenti.</div><div class=\"graphic_reference\">Courtesy of Richard Alan Lewis, MD, MS.</div><div id=\"graphicVersion\">Graphic 111089 Version 1.0</div></div></div>"},"111092":{"type":"graphic_table","displayName":"Medical event rates for endurance road races","title":"Medical event rates for endurance road races","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical event rates for endurance road races</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Ultra-marathon<br /> (&#62;42 km)<sup>[1,2]</sup></td> <td class=\"subtitle1\">Marathon<br /> (42 km)<sup>[3]</sup></td> <td class=\"subtitle1\">Half Marathon<br /> (21 km)<sup>[1,2]</sup></td> <td class=\"subtitle1\">10 mile<sup>[4]</sup></td> <td class=\"subtitle1\">Combined Data<br /> 10 &#38; 21 km<sup>[5]</sup></td> </tr> <tr> <td>Total participants</td> <td class=\"centered\">26354 ST</td> <td class=\"centered\">81277 EN<br /> 76714 FI</td> <td class=\"centered\">39511 ST</td> <td class=\"centered\">91750 ST</td> <td class=\"centered\">99163 EN</td> </tr> <tr> <td>Total medical encounters</td> <td class=\"centered\">342</td> <td class=\"centered\">1459</td> <td class=\"centered\">203</td> <td class=\"centered\">346</td> <td class=\"centered\">221</td> </tr> <tr> <td>All encounter rate</td> <td class=\"centered\">13/1000 ST</td> <td class=\"centered\">19/1000 EN<br /> 25/1000 FI</td> <td class=\"centered\">5/1000 ST</td> <td class=\"centered\">4/1000 ST</td> <td class=\"centered\">2/1000 EN</td> </tr> <tr> <td>Total medical rate</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">11.8/1000 EN<br /> 12.6/1000 FI</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1/1000 ST</td> <td class=\"centered\">0.7/1000 EN</td> </tr> <tr> <td>Serious medical rate</td> <td class=\"centered\">0.7/1000 ST</td> <td class=\"centered\">0.01/1000 EN<br /> 0.01/1000 FI</td> <td class=\"centered\">0.5/1000 ST</td> <td class=\"centered\">0.2/1000 AT</td> <td class=\"centered\">0.4/1000 EN</td> </tr> <tr> <td>Moderate and minor medical rate</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">11.7/1000 EN<br /> 12.4/1000 FI</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0.9/1000 ST</td> <td class=\"centered\">0.7/1000 EN</td> </tr> <tr> <td>MSK rate</td> <td class=\"centered\">1.8/1000 ST</td> <td class=\"centered\">3.2/1000 EN<br /> 3.4/1000 FI</td> <td class=\"centered\">0.96/1000 ST</td> <td class=\"centered\">1.7/1000 ST</td> <td class=\"centered\">0.8/1000 EN</td> </tr> <tr> <td>Derm rate</td> <td class=\"centered\">1.5/1000 ST</td> <td class=\"centered\">3.9/1000 EN<br /> 4.2/1000 FI</td> <td class=\"centered\">1.29/1000 ST</td> <td class=\"centered\">1/1000 ST</td> <td class=\"centered\">0.6/1000 EN</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table summarizes the rates for medical conditions managed at the finish line medical station for road races of various distances. At the marathon distance, 66 percent of encounters are for medical issues, 18 percent for musculoskeletal injuries (MSK), and 22 percent skin-related problems (eg, blisters). At the 10-mile distance, medical conditions comprise 27 percent of encounters, MSK 44 percent, and skin issues 27 percent. The denominators (entrants [EN], starters [ST], and finishers [FI]) vary by publication, in part due to the year of the study and the use of micro-chip technology for obtaining race data.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schwabe K, Schwellnus M, Derman W, et al. Medical complications and deaths in 21 and 56 km road race runners: a 4-year prospective study in 65 865 runners--SAFER study I. Br J Sports Med 2014; 48:912.</li>&#xD;&#xA;    <li>Schwabe K, Schwellnus MP, Derman W, et al. Less experience and running pace are potential risk factors for medical complications during a 56 km road running race: a prospective study in 26 354 race starters--SAFER study II. Br J Sports Med 2014; 48:905.</li>&#xD;&#xA;    <li>Roberts WO. A 12-yr profile of medical injury and illness for the Twin Cities Marathon. Med Sci Sports Exerc 2000; 32:1549.</li>&#xD;&#xA;    <li>Pasquina PF, Griffin SC, Anderson-Barnes VC, et al. Analysis of injuries from the Army Ten Miler: A 6-year retrospective review. Mil Med 2013; 178:55.</li>&#xD;&#xA;    <li>Tan CM, Tan IW, Kok WL, et al. Medical planning for mass-participation running events: a 3-year review of a half-marathon in Singapore. BMC Public Health 2014; 14:1109.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 111092 Version 1.0</div></div></div>"},"111093":{"type":"graphic_table","displayName":"Chronic pain syndromes associated with CA treatment","title":"Chronic pain syndromes associated with cancer treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic pain syndromes associated with cancer treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Chemotherapy-related pain syndromes</td> </tr> <tr> <td class=\"indent1\">Bony complications of long-term corticosteroids</td> </tr> <tr> <td class=\"indent1\">Avascular necrosis</td> </tr> <tr> <td class=\"indent2\">Vertebral compression fractures</td> </tr> <tr> <td class=\"indent3\">Carpal tunnel syndrome</td> </tr> <tr> <td class=\"indent1\">Chemotherapy-induced peripheral neuropathy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Raynaud's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Hormonal therapy-related pain syndromes</td> </tr> <tr> <td class=\"indent1\">Arthralgias</td> </tr> <tr> <td class=\"indent1\">Dyspareunia</td> </tr> <tr> <td class=\"indent1\">Gynecomastia</td> </tr> <tr> <td class=\"indent1\">Myalgias</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Osteoporotic compression fractures</td> </tr> <tr> <td class=\"subtitle1_single\">Radiation-related pain syndromes</td> </tr> <tr> <td class=\"indent1\">Chest wall syndrome</td> </tr> <tr> <td class=\"indent1\">Cystitis</td> </tr> <tr> <td class=\"indent1\">Enteritis and proctitis</td> </tr> <tr> <td class=\"indent1\">Fistula formation</td> </tr> <tr> <td class=\"indent1\">Lymphedema</td> </tr> <tr> <td class=\"indent1\">Myelopathy</td> </tr> <tr> <td class=\"indent1\">Osteoporosis</td> </tr> <tr> <td class=\"indent1\">Osteoradionecrosis and fractures</td> </tr> <tr> <td class=\"indent1\">Painful secondary malignancies</td> </tr> <tr> <td class=\"indent1\">Peripheral mononeuropathies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Plexopathies: Brachial, sacral</td> </tr> <tr> <td class=\"subtitle1_single\">Stem cell transplantation-mediated graft-versus-host disease</td> </tr> <tr> <td class=\"indent1\">Arthralgias/myalgias</td> </tr> <tr> <td class=\"indent1\">Dyspareunia, vaginal pain</td> </tr> <tr> <td class=\"indent1\">Dysuria</td> </tr> <tr> <td class=\"indent1\">Eye pain</td> </tr> <tr> <td class=\"indent1\">Oral pain and reduced jaw motion</td> </tr> <tr> <td class=\"indent1\">Paresthesias</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scleroderma-like skin changes</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical pain syndromes</td> </tr> <tr> <td class=\"indent1\">Lymphedema</td> </tr> <tr> <td class=\"indent1\">Postamputation phantom pain</td> </tr> <tr> <td class=\"indent1\">Postmastectomy pain</td> </tr> <tr> <td class=\"indent1\">Postradical neck dissection pain</td> </tr> <tr> <td class=\"indent1\">Postsurgery pelvic floor pain</td> </tr> <tr> <td class=\"indent1\">Postthoractomy pain/frozen shoulder</td> </tr> <tr> <td class=\"indent1\">Postsurgery extremity pain (eg, sarcoma)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Paice JA, Portenoy R, Lacchetti C, et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34(27):3325-45. Reprinted with permission. Copyright &copy; 2016 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111093 Version 1.0</div></div></div>"},"111095":{"type":"graphic_table","displayName":"Neuroendo duod and ampulla of Vater TNM 2017","title":"Neuroendocrine tumors of the duodenum and ampulla of Vater TNM staging AJCC UICC 2017 ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroendocrine tumors of the duodenum and ampulla of Vater TNM staging AJCC UICC 2017 </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the mucosa or submucosa only and is &#8804;1 cm (duodenal tumors).<br /> Tumor &#8804;1 cm and confined within the sphincter of Oddi (ampullary tumors).</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the muscularis propria or is &#62;1 cm (duodenal).<br /> Tumor invades through sphincter into duodenal submucosa or muscularis propria, or is &#62;1 cm (ampullary).</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades the pancreas or peripancreatic adipose tissue</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades the visceral peritoneum (serosa) or other organs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><em>NOTE:</em> Multiple tumors should be designated as such (and the largest tumor should be used to assign the T category): <ul class=\"decimal_heading\"> <li>If the number of tumors is known, use T(#); eg, pT3(4) N0 M0. </li> <li>If the number of tumors is unavailable or too numerous, use the m suffix, T(m); eg, pT3(m) N0 M0. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node involvement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node involvement</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastases</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis confined to liver</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastases in at least one extrahepatic site (eg, lung, ovary, nonregional lymph node, peritoneum, bone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Both hepatic and extrahepatic metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111095 Version 2.0</div></div></div>"},"111096":{"type":"graphic_table","displayName":"Neuroendo jejunum and ileum TNM 2017","title":"Neuroendocrine tumors of the jejunum and ileum TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroendocrine tumors of the jejunum and ileum TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1*</td> <td colspan=\"3\">Invades lamina propria or submucosa and less than or equal to 1 cm in size</td> </tr> <tr> <td class=\"indent1\">T2*</td> <td colspan=\"3\">Invades muscularis propria or greater than 1 cm in size</td> </tr> <tr> <td class=\"indent1\">T3*</td> <td colspan=\"3\">Invades through the muscularis propria into subserosal tissue without penetration of overlying serosa</td> </tr> <tr> <td class=\"indent1\">T4*</td> <td colspan=\"3\">Invades visceral peritoneum (serosal) or other organs or adjacent structures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> For any T, add (m) for multiple tumors [TX(#) or TX(m), where X = 1 to 4, and # = number of primary tumors identified<sup>&#182;</sup>]; for multiple tumors with different Ts, use the highest.<br /> &#182; <em>Example:</em> If there are two primary tumors, only one of which invades through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal), we define the primary tumor as either T3(2) or T3(m).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis has occurred</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis less than 12 nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Large mesenteric masses (&#62;2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis confined to liver</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastases in at least one extrahepatic site (eg, lung, ovary, nonregional lymph node, peritoneum, bone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Both hepatic and extrahepatic metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1, N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0, N1, N2</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1, N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0, N1, N2</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1, N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0, N1, N2</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1, N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0, N1, N2</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">For multiple synchronous tumors, the highest T category should be used and the multiplicity or the number of tumors should be indicated in parenthesis: eg, T3(2) or T3(m).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111096 Version 2.0</div></div></div>"},"111097":{"type":"graphic_table","displayName":"Antibiotics for mastitis/breast abscess in infants","title":"Suggested parenteral antibiotic regimens for mastitis or breast abscess in infants without severe complications*, according to most frequent Gram stain findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested parenteral antibiotic regimens for mastitis or breast abscess in infants without severe complications*, according to most frequent Gram stain findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parenteral antibiotics</td> <td class=\"subtitle1\" colspan=\"2\">Infants &#8804;7 days of age</td> <td class=\"subtitle1\" colspan=\"3\">Infants 8 to 28 days of age</td> <td class=\"subtitle1\" rowspan=\"2\">Infants &#62;28 days</td> </tr> <tr> <td class=\"subtitle2\">Weight &#8804;2 kg</td> <td class=\"subtitle2\">Weight &#62;2 kg</td> <td class=\"subtitle2\">Weight &#8804;2 kg</td> <td class=\"subtitle2\" colspan=\"2\">Weight &#62;2 kg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Gram-positive cocci</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>CA-MRSA not a concern</strong></td> </tr> <tr> <td class=\"indent2\">Nafcillin</td> <td>25 mg/kg IV every 12 hours</td> <td>25 mg/kg IV every 8 hours</td> <td>25 mg/kg IV every 8 hours</td> <td colspan=\"2\">25 mg/kg IV every 6 hours</td> <td>150 to 200 mg/kg IV per day in four to six doses</td> </tr> <tr> <td class=\"indent2\">Oxacillin</td> <td>25 mg/kg IV every 12 hours</td> <td>25 mg/kg IV every 8 hours</td> <td>25 mg/kg IV every 8 hours</td> <td colspan=\"2\">25 mg/kg IV every 6 hours</td> <td>150 to 200 mg/kg IV per day in four to six doses</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>CA-MRSA a concern</strong></td> </tr> <tr> <td class=\"indent2\">Clindamycin</td> <td>5 mg/kg IV every 12 hours</td> <td>5 mg/kg IV every 8 hours</td> <td>5 mg/kg IV every 8 hours</td> <td colspan=\"2\">5 mg/kg IV every 6 hours</td> <td>30 to 40 mg/kg IV per day in three or four doses</td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"4\">Vancomycin<sup>&#182;</sup></td> <td class=\"centered\" colspan=\"5\"><strong>Initial dose according to serum creatinine as indicated below</strong><sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"4\">40 to 60 mg/kg IV per day in three or four doses</td> </tr> <tr> <td class=\"centered\" colspan=\"5\"><strong>Serum creatinine concentration (mg/dL)</strong></td> </tr> <tr> <td class=\"subtitle2\">&#60;0.7</td> <td class=\"subtitle2\">0.7 to 0.9</td> <td class=\"subtitle2\">1.0 to 1.2</td> <td class=\"subtitle2\">1.3 to 1.6</td> <td class=\"subtitle2\">&#62;1.6</td> </tr> <tr class=\"divider_bottom\"> <td>15 mg/kg IV every 12 hours</td> <td>20 mg/kg IV every 24 hours</td> <td>15 mg/kg IV every 24 hours</td> <td>10 mg/kg IV every 24 hours</td> <td>15 mg/kg IV every 48 hours</td> </tr> <tr class=\"divider_bottom\"> <td style=\"padding-top: 0em; line-height: 1px; background-color: #009966;\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parenteral antibiotics</td> <td class=\"subtitle1\" colspan=\"2\">Infants &#8804;7 days of age</td> <td class=\"subtitle1\" colspan=\"3\">Infants 8 to 28 days of age</td> <td class=\"subtitle1\" rowspan=\"2\">Infants &#62;28 days</td> </tr> <tr> <td class=\"subtitle2\">Weight &#8804;2 kg</td> <td class=\"subtitle2\">Weight &#62;2 kg</td> <td class=\"subtitle2\">Weight &#8804;2 kg</td> <td class=\"subtitle2\" colspan=\"2\">Weight &#62;2 kg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Gram-negative organisms</td> </tr> <tr> <td class=\"indent1\">Amikacin<sup>&#916;</sup></td> <td>15 mg/kg IV every 48 hours</td> <td>15 mg/kg IV every 24 hours</td> <td>15 mg/kg IV every 24 hours</td> <td colspan=\"2\">17.5 mg/kg IV every 24 hours</td> <td> <ul> <li>15 to 22.5 mg/kg IV per day in two or three doses, or </li> <li>15 to 20 mg/kg per day in a single dose </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gentamicin<sup>&#916;</sup></td> <td>5 mg/kg IV every 48 hours</td> <td>4 mg/kg IV every 24 hours</td> <td>5 mg/kg IV every 36 hours</td> <td colspan=\"2\">4 to 5 mg/kg IV every 24 hours</td> <td> <ul> <li>6 to 7.5 mg/kg IV per day in three doses, or </li> <li>5 to 7.5 mg/kg IV per day in a single dose </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Cefotaxime<sup>&#9674;</sup></p> <p>(if available)</p> </td> <td>50 mg/kg IV every 12 hours</td> <td>50 mg/kg IV every 12 hours</td> <td>50 mg/kg IV every 8 to 12 hours</td> <td colspan=\"2\">50 mg/kg IV every 8 hours</td> <td>200 to 225 mg/kg IV per day in four or six doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftazidime<sup>&#9674;</sup> (if cefotaxime not available)</td> <td>50 mg/kg IV every 12 hours</td> <td>50 mg/kg IV every 12 hours&nbsp;</td> <td>50 mg/kg IV every 8 to 12 hours</td> <td colspan=\"2\">50 mg/kg IV every 8 hours</td> <td>150&nbsp;mg/kg IV per day&nbsp;in three doses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftriaxone<sup>&#9674;&#167;</sup> (if cefotaxime not available)&nbsp;</td> <td>50 mg/kg IV every 24 hours</td> <td>50 mg/kg IV every&nbsp;24 hours</td> <td>50 mg/kg IV every 24 hours</td> <td colspan=\"2\">50 mg/kg IV every&nbsp;24 hours</td> <td> <p>75 to 100 mg/kg IV per day in one or two doses</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Gram stain not available or no organisms seen</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>CA-MRSA not a concern</strong></td> </tr> <tr> <td class=\"indent2\">Nafcillin or oxacillin, plus one of the following: <ul class=\"decimal_heading\"> <li>Amikacin </li> <li>Gentamicin </li> <li>Cefotaxime<sup>&#9674;</sup> </li> <li>Ceftazidime<sup>&#9674;</sup> </li> <li>Ceftriaxone<sup>&#9674;</sup> </li> </ul> </td> <td style=\"vertical-align: middle;\" colspan=\"6\">Dosing regimens provided above</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>CA-MRSA a concern</strong></td> </tr> <tr> <td class=\"indent2\">Clindamycin<sup>&#165;</sup> or vancomycin, plus one of the following: <ul class=\"decimal_heading\"> <li>Amikacin </li> <li>Gentamicin </li> <li>Cefotaxime<sup>&#9674;</sup> </li> <li>Ceftazidime<sup>&#9674;</sup> </li> <li>Ceftriaxone<sup>​&#9674;</sup> </li> </ul> </td> <td style=\"vertical-align: middle;\" colspan=\"6\">Dosing regimens provided above</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topic on mastitis and breast abscess in infants for addition information. The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class=\"graphic_footnotes\">CA-MRSA: community-acquired methicillin-resistant <EM>Staphylococcus aureus</EM>; IV: intravenously; AUC<SUB>24</SUB>: area under the curve at 24 hours; MIC: minimum inhibitory concentration.<br />* Severe complications include extensive cellulitis, necrotizing fasciitis, osteomyelitis, and shock. Refer to UpToDate topics on mastitis in infants and shock.<br />¶ Initial vancomycin dose and interval are listed. Vancomycin serum concentrations should be monitored to determine subsequent dose and interval. In neonates, for confirmed or highly suspected MRSA infection, an initial target trough concentration of approximately 10 mcg/mL is suggested to achieve an AUC<SUB>24</SUB> &gt;400 for organisms with MIC ≤1 mcg/mL. The dosing algorithm for vancomycin is based upon serum creatinine concentration in neonates born at gestational age &gt;28 weeks. Serum creatinine concentration will take approximately 5 to 7 days after birth to reasonably reflect neonatal renal function. Cautious use of creatinine-based dosing strategy with frequent assessment of renal function and vancomycin serum concentrations are recommended in neonates ≤7 days old<SUP>[1]</SUP>. A vancomycin dosing method based upon postnatal age and weight is provided as an alternative to the serum creatinine-based method listed above and may be useful in some clinical situations. This particular algorithm was provided in the 2009 edition of the Red Book<SUP>[2]</SUP>. &#xD;&#xA;<UL style=\"LIST-STYLE-TYPE: none\">&#xD;&#xA;<LI>Postnatal age &lt;7 days: &#xD;&#xA;<UL style=\"LIST-STYLE-TYPE: square; MARGIN-LEFT:1.3em\">&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI>&#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 12 or 18 hours</LI>&#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI></UL></LI>&#xD;&#xA;<LI>Postnatal age ≥7 days: &#xD;&#xA;<UL style=\"LIST-STYLE-TYPE: square; MARGIN-LEFT:1.3em\">&#xD;&#xA;<LI>&lt;1200 g: 15 mg/kg IV every 24 hours</LI>&#xD;&#xA;<LI>1200 to 2000 g: 10 to 15 mg/kg IV every 8 or 12 hours</LI>&#xD;&#xA;<LI>&gt;2000 g: 10 to 15 mg/kg IV every 6 or 8 hours</LI></UL></LI></UL>Δ Initial aminoglycoside dosing is provided. The optimal, individualized dose of amikacin and gentamicin should be based on determination of serum concentrations.<br /><FONT class=lozenge>◊</FONT> Cefotaxime (if available), ceftazidime, or&nbsp;ceftriaxone&nbsp;is recommended if cerebrospinal fluid is abnormal.<br />§ Intravenous ceftriaxone should be avoided in infants who are also receiving or are expected to receive&nbsp;intravenous calcium in any form, including parenteral nutrition.<br />¥&nbsp;Clindamycin may be used if central nervous system infection is not a concern.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nelson's Pediatric Antimicrobial Therapy, 22<SUP>nd</SUP> ed, Bradley JS, Nelson JD, Cantey JB, et al (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2016.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Antibacterial drugs for newborn infants: Dose and frequency of administration. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28<SUP>th</SUP> ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.745.</LI></OL>Data adapted from: American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.</div><div id=\"graphicVersion\">Graphic 111097 Version 3.0</div></div></div>"},"111106":{"type":"graphic_picture","displayName":"Milia adult","title":"Milia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Milia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/111106_Milia_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tiny, white papules are present in the periocular area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111106 Version 1.0</div></div></div>"},"111118":{"type":"graphic_picture","displayName":"Frostbite injury of the hand - Grade 1","title":"Frostbite injury of the hand - Grade 1","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Frostbite injury of the hand - Grade 1</div><div class=\"cntnt\"><img style=\"width:612px; height:402px;\" src=\"images/EM/111118_Frostbite_injury_hand_Grd1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frostbite injury of the hand at day 0: No initial lesion except erythema (Grade 1).</div><div class=\"graphic_reference\">Reproduced from: Cauchy E, Chetaille E, Marchand V, Marsigny B. Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme. Wilderness Environ Med 2001; 12:248. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111118 Version 2.0</div></div></div>"},"111119":{"type":"graphic_picture","displayName":"Frostbite injury of the hand - Grade 2","title":"Frostbite injury of the hand - Grade 2","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Frostbite injury of the hand - Grade 2</div><div class=\"cntnt\"><img style=\"width:612px; height:384px;\" src=\"images/EM/111119_Frostbite_injury_hand_Grd2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frostbite injury of the hand at day 0: Initial lesion limited to the distal phalanx (Grade 2). Note the difference in skin color over the distal phalanx of the fingers.</div><div class=\"graphic_reference\">Reproduced from: Cauchy E, Chetaille E, Marchand V, Marsigny B. Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme. Wilderness Environ Med 2001; 12:248. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111119 Version 1.0</div></div></div>"},"111120":{"type":"graphic_picture","displayName":"Frostbite injury of the hand - Grade 3","title":"Frostbite injury of the hand - Grade 3","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Frostbite injury of the hand - Grade 3</div><div class=\"cntnt\"><img style=\"width:612px; height:387px;\" src=\"images/EM/111120_Frostbite_injury_hand_Grd3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frostbite injury of the hand at day 0: Initial lesion extends proximally&nbsp;beyond the distal phalanx (Grade 3).</div><div class=\"graphic_reference\">Reproduced from: Cauchy E, Chetaille E, Marchand V, Marsigny B. Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme. Wilderness Environ Med 2001; 12:248. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111120 Version 1.0</div></div></div>"},"111121":{"type":"graphic_picture","displayName":"Frostbite injury of the hand - Grade 4","title":"Frostbite injury of the hand - Grade 4","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Frostbite injury of the hand - Grade 4</div><div class=\"cntnt\"><img style=\"width:612px; height:399px;\" src=\"images/EM/111121_Frostbite_injury_hand_Grd4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frostbite injury of the hand at day 0: Initial lesion extending beyond the metacarpophalangeal joints (Grade 4). In the case pictured above, there is involvement of the entire hand, and injury&nbsp;extends just proximal to the wrist.&nbsp;</div><div class=\"graphic_reference\">Reproduced from: Cauchy E, Chetaille E, Marchand V, Marsigny B. Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme. Wilderness Environ Med 2001; 12:248. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111121 Version 2.0</div></div></div>"},"111122":{"type":"graphic_table","displayName":"Proposed classification scheme for severity of frostbite injurie","title":"Proposed classification scheme for severity of frostbite injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed classification scheme for severity of frostbite injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Frostbite injuries of the extremities</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> </tr> <tr> <td>Extent of initial lesion at day 0 after rapid rewarming</td> <td>Absence of initial lesion</td> <td>Initial lesion on distal phalanx</td> <td>Initial lesion on intermediary and proximal phalanx</td> <td>Initial lesion on carpal/ tarsal</td> </tr> <tr> <td>Bone scanning at day 2</td> <td>Useless</td> <td>Hypofixation of radiotracer uptake area</td> <td>Absence of radiotracer uptake area on the digit</td> <td>Absence of radiotracer uptake area on the carpal/tarsal</td> </tr> <tr> <td>Blisters at day 2</td> <td>Absence of blisters</td> <td>Clear blisters</td> <td>Hemorrhagic blisters on the digit</td> <td>Hemorrhagic blisters over carpal/tarsal</td> </tr> <tr> <td rowspan=\"2\">Prognosis at day 2</td> <td>No amputation</td> <td>Tissue amputation</td> <td>Bone amputation of digit</td> <td>Bone amputation of the limb &#177; systemic involvement &#177; sepsis</td> </tr> <tr> <td>No sequelae</td> <td>Fingernail sequelae</td> <td>Functional sequelae</td> <td>Functional sequelae</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Cauchy E, Chetaille E, Marchand V, Marsigny B. Retrospective study of 70 cases of severe frostbite lesions: a proposed new classification scheme. Wilderness Environ Med 2001; 12:248. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111122 Version 1.0</div></div></div>"},"111123":{"type":"graphic_table","displayName":"Countries with tuberculosis incidence >100 per 100,000","title":"Countries with tuberculosis incidence >100 per 100,000*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Countries with tuberculosis incidence &gt;100 per 100,000*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td>Afghanistan</td> <td>Greenland</td> <td>Namibia</td> </tr> <tr> <td>Angola</td> <td>Guinea</td> <td>Nepal</td> </tr> <tr> <td>Bangladesh</td> <td>Guinea-Bissau</td> <td>Nigeria</td> </tr> <tr> <td>Bhutan</td> <td>Guyana</td> <td>Pakistan</td> </tr> <tr> <td>Bolivia</td> <td>Haiti</td> <td>Papua New Guinea</td> </tr> <tr> <td>Botswana</td> <td>India</td> <td>Peru</td> </tr> <tr> <td>Burundi</td> <td>Indonesia</td> <td>Philippines</td> </tr> <tr> <td>Cape Verde</td> <td>Kenya</td> <td>Republic of Moldova</td> </tr> <tr> <td>Cambodia</td> <td>Kiribati</td> <td>Senegal</td> </tr> <tr> <td>Cameroon</td> <td>Kyrgyzstan</td> <td>Sierra Leone</td> </tr> <tr> <td>Central African Republic</td> <td>Lao People's Democratic Republic</td> <td>Somalia</td> </tr> <tr> <td>Chad</td> <td>Lesotho</td> <td>South Africa</td> </tr> <tr> <td>Congo</td> <td>Liberia</td> <td>South Sudan</td> </tr> <tr> <td>Cote d'Ivoire</td> <td>Madagascar</td> <td>Swaziland</td> </tr> <tr> <td>Democratic People's Republic of Korea</td> <td>Malawi</td> <td>Thailand</td> </tr> <tr> <td>Democratic Republic of the Congo</td> <td>Malaysia</td> <td>Timor-Leste</td> </tr> <tr> <td>Djibouti</td> <td>Marshall Islands</td> <td>Tuvalu</td> </tr> <tr> <td>Equatorial Guinea</td> <td>Mauritania</td> <td>Uganda</td> </tr> <tr> <td>Ethiopia</td> <td>Micronesia (Federated States of)</td> <td>United Republic of Tanzania</td> </tr> <tr> <td>Gabon</td> <td>Mongolia</td> <td>Viet Nam</td> </tr> <tr> <td>Gambia</td> <td>Morocco</td> <td>Zambia</td> </tr> <tr> <td>Georgia</td> <td>Mozambique</td> <td>Zimbabwe</td> </tr> <tr> <td>Ghana</td> <td>Myanmar</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There is no consensus regarding the appropriate threshold for&nbsp;tuberculosis screening. Guidelines are developed for public health goals and therefore may not represent the best clinical choice for individual patients. Decisions regarding&nbsp;tuberculosis screening should be based on risk, and local or regional&nbsp;tuberculosis incidence data should be used to help define such risk. </div><div class=\"graphic_footnotes\">* An incidence of TB of &gt;100 per 100,000 population is associated with an annual risk of infection of approximately 1 percent.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>World Health Organization. TB burden estimates. Available at: <a href=\"http://www.who.int/tb/country/data/download/en/\" target=\"_blank\">http://www.who.int/tb/country/data/download/en/</a> (Accessed on December 16, 2016).</li>&#xD;&#xA;    <li>World Health Organization. Global tuberculosis report 2016. Available at: <a href=\"http://www.who.int/tb/publications/global_report/en/\" target=\"_blank\">http://www.who.int/tb/publications/global_report/en/</a> (Accessed on December 16, 2016).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 111123 Version 3.0</div></div></div>"},"111124":{"type":"graphic_table","displayName":"European paid leave and unemployment benefits","title":"European paid leave and unemployment benefits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European paid leave and unemployment benefits</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"15\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indicator</td> <td class=\"subtitle1\">Denmark</td> <td class=\"subtitle1\">France</td> <td class=\"subtitle1\">Spain</td> <td class=\"subtitle1\">Netherlands</td> <td class=\"subtitle1\">Sweden</td> <td class=\"subtitle1\">Finland</td> <td class=\"subtitle1\">Italy</td> <td class=\"subtitle1\">Norway</td> <td class=\"subtitle1\">Austria</td> <td class=\"subtitle1\">Belgium</td> <td class=\"subtitle1\">Germany</td> <td class=\"subtitle1\">United Kingdom</td> <td class=\"subtitle1\">Switzerland</td> <td class=\"subtitle1\">Ireland</td> <td class=\"subtitle1\">United States</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"16\">Unemployment benefits</td> </tr> <tr> <td class=\"indent1\">Period covered</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pay</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"16\">Maternity-related entitlements</td> </tr> <tr> <td class=\"indent1\">Period covered</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pay</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"16\">Paternity-related entitlements</td> </tr> <tr> <td class=\"indent1\">Period covered</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pay</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"16\">Parental-related entitlements</td> </tr> <tr> <td class=\"indent1\">Period covered</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pay</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"16\">Annual leave</td> </tr> <tr> <td class=\"indent1\">Period covered</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Public holidays</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"16\">Sick pay</td> </tr> <tr> <td class=\"indent1\">Period covered</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #abd6ea;\">&nbsp;</td> <td style=\"background-color: #4575b4;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pay</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #313695;\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fee090;\">&nbsp;</td> <td>&nbsp;</td> <td style=\"background-color: #fdae61;\">&nbsp;</td> <td style=\"background-color: #d73027;\">&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>Aggregate score</strong></td> <td class=\"centered\">7.8</td> <td class=\"centered\">7.2</td> <td class=\"centered\">6.4</td> <td class=\"centered\">6.2</td> <td class=\"centered\">5.9</td> <td class=\"centered\">5.8</td> <td class=\"centered\">5.6</td> <td class=\"centered\">5.6</td> <td class=\"centered\">5.4</td> <td class=\"centered\">5.1</td> <td class=\"centered\">4.7</td> <td class=\"centered\">2.9</td> <td class=\"centered\">2.3</td> <td class=\"centered\">2.3</td> <td class=\"centered\">0.3</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"16\">&nbsp;</td> </tr> <tr> <td class=\"highlight_gray_text\"><strong>Key</strong></td> <td class=\"centered\" style=\"border-bottom: medium none; color: #fff; background-color: #313695;\" colspan=\"2\">Most generous</td> <td class=\"centered\" style=\"border-bottom: medium none; color: #fff; background-color: #4575b4;\" colspan=\"2\">Second most generous</td> <td class=\"centered\" style=\"border-bottom: medium none; background-color: #abd6ea;\" colspan=\"2\">Third most generous</td> <td class=\"centered\" style=\"background-color: #fff;\" colspan=\"3\">Tied</td> <td class=\"centered\" style=\"border-bottom: medium none; background-color: #fee090;\" colspan=\"2\">Third least generous</td> <td class=\"centered\" style=\"border-bottom: medium none; background-color: #fdae61;\" colspan=\"2\">Second least generous</td> <td class=\"centered\" style=\"border-bottom: medium none; background-color: #d73027;\" colspan=\"2\">Least generous</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Where scores are tied (ie, first equal/second equal/last equal), all tied countries are colored similarly.</div><div class=\"graphic_reference\">Reproduced with permission from: Glassdoor, LlewellynConsulting. Which countries in Europe offer the fairest paid leave and unemployment benefits? Available at: <a href=\"https://www.glassdoor.com/research/studies/europe-fairest-paid-leave-unemployment-benefits/\" target=\"_blank\">https://www.glassdoor.com/research/studies/europe-fairest-paid-leave-unemployment-benefits/</a> (Accessed on December 13, 2016).</div><div id=\"graphicVersion\">Graphic 111124 Version 1.0</div></div></div>"},"111125":{"type":"graphic_table","displayName":"Histologic grading scheme for GI and panc neuroendo neoplasms","title":"Histologic grading scheme for gastrointestinal and pancreatic neuroendocrine neoplasms from the WHO and AJCC/UICC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic grading scheme for gastrointestinal and pancreatic neuroendocrine neoplasms from the WHO and AJCC/UICC</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\">Cellular pleomorphism per se is not a useful feature for grading NETs. The following grading scheme has been proposed for gastrointestinal NETs.</td> </tr> <tr> <td class=\"subtitle1_left\">Grade</td> <td class=\"subtitle1_left\">Definition</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\">GX</td> <td>Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td>Mitotic count (per 10 HPF)* &#60;2 and Ki-67 index (%)<sup>&#182;</sup> &#60;3</td> </tr> <tr> <td class=\"indent1\">G2</td> <td>Mitotic count (per 10 HPF) = 2 to 20 or Ki-67 index (%)<sup>&#182;</sup> = 3 to 20</td> </tr> <tr> <td class=\"indent1\">G3</td> <td>Mitotic count (per 10 HPF) &#62;20 or Ki-67 index (%)<sup>&#182;</sup> &#62;20</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In cases of disparity between Ki-67 proliferative index and mitotic count, the result indicating a higher-grade tumor should be selected as the final grade. For example, a mitotic count of 1 per 10 HPF and a Ki-67 of 12% should be designated as a G2 NET.</div><div class=\"graphic_footnotes\">WHO: World Health Organization; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; NET: neuroendocrine tumor; HPF: high-power field.<br />* 10 HPF = 2 mm<SUP>2</SUP>; at least 50 HPFs (at 40 times magnification) must be evaluated in areas of highest mitotic density in order to adhere to WHO 2010 and 2017&nbsp;criteria.<br />¶ MIB1 antibody; % of 500 to 2000 tumor cells in areas of highest nuclear labeling.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111125 Version 4.0</div></div></div>"},"111126":{"type":"graphic_table","displayName":"Neuroendocrine tumors appendix TNM 2017","title":"Neuroendocrine tumors of the appendix TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroendocrine tumors of the appendix TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor 2 cm or less in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor more than 2 cm but less than or equal to 4 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor more than 4 cm or with subserosal invasion or involvement of the mesoappendix</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor perforates the peritoneum or directly invades other adjacent organs or structures (excluding direct mural extension to adjacent subserosa of adjacent bowel), eg, abdominal wall and skeletal muscle</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis confined to liver</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastases in at least one extrahepatic site (eg, lung, ovary, nonregional lymph node, peritoneum, bone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Both hepatic and extrahepatic metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111126 Version 2.0</div></div></div>"},"111127":{"type":"graphic_table","displayName":"Appendix carcinoma TNM 2017","title":"Appendix carcinoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Appendix carcinoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"4\">Carcinoma <em>in situ</em> (intramucosal carcinoma; invasion of the lamina propria or extension into but not through the muscularis mucosae)</td> </tr> <tr> <td class=\"indent1\">Tis(LAMN)</td> <td colspan=\"4\">Low-grade appendiceal mucinous neoplasm confined by the muscularis propria. Acellular mucin or mucinous epithelium may invade into the muscularis propria.<br /> T1 and T2 are not applicable to LAMN. Acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as T3 or T4a, respectively.</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"4\">Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria)</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"4\">Tumor invades the muscularis propria</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"4\">Tumor invades through the muscularis propria into the subserosa or the mesoappendix</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"4\">Tumor invades the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invades adjacent organs or structures</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"4\">Tumor invades through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"4\">Tumor directly invades or adheres to adjacent organs or structures</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"4\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"4\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"4\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"4\">One to three regional lymph nodes are positive (tumor in lymph node measuring &#8805;0.2 mm) or any number of tumor deposits is present, and all identifiable lymph nodes are negative</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td colspan=\"4\">One regional lymph node is positive</td> </tr> <tr> <td class=\"indent2\">N1b</td> <td colspan=\"4\">Two or three regional lymph nodes are positive</td> </tr> <tr> <td class=\"indent2\">N1c</td> <td colspan=\"4\">No regional lymph nodes are positive, but there are tumor deposits in the subserosa or mesentery</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"4\">Four or more regional lymph nodes are positive</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"4\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"4\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"4\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"4\">Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"4\">Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells</td> </tr> <tr> <td class=\"indent2\">M1c</td> <td colspan=\"4\">Metastasis to sites other than peritoneum</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"5\"><em>NOTE:</em> For specimens containing acellular mucin without identifiable tumor cells, efforts should be made to obtain additional tissue for thorough histologic examination to evaluate for cellularity.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Histologic grade (G)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>G</strong></td> <td colspan=\"4\"><strong>G definition</strong></td> </tr> <tr> <td class=\"indent1\">GX</td> <td colspan=\"4\">Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"4\">Well differentiated</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"4\">Moderately differentiated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td colspan=\"4\">Poorly differentiated</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>And grade is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>0</td> </tr> <tr> <td class=\"indent1\">Tis(LAMN)</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>IIC</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>&ndash;</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>&ndash;</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>&ndash;</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>&ndash;</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>&ndash;</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1a</td> <td>&ndash;</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>G1</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>G2, G3, or GX</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1c</td> <td>Any G</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111127 Version 2.0</div></div></div>"},"111128":{"type":"graphic_form","displayName":"Two-week sleep diary","title":"Two-week sleep diary: Sample entry by a patient with advanced sleep-wake phase disorder","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Two-week sleep diary: Sample entry by a patient with advanced sleep-wake phase disorder</div><div class=\"cntnt\"><img style=\"width:758px; height:538px;\" src=\"images/SLEEP/111128_Two-week_sleep_diary.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The darker, scribble-shaded areas represent sleep times as noted by a patient with advanced sleep-wake phase disorder. The lighter, blue&nbsp;shading represents the patient's&nbsp;desired sleep times (11:00 pm to 6:30 am).</div><div id=\"graphicVersion\">Graphic 111128 Version 1.0</div></div></div>"},"111129":{"type":"graphic_figure","displayName":"Air tracking in pneumomediastinum","title":"Air tracking in pneumomediastinum","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Air tracking in pneumomediastinum</div><div class=\"cntnt\"><img style=\"width:522px; height:491px;\" src=\"images/PEDS/111129_Air_tracking_in_pneumomediastinum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air from torn alveolus first enters perivascular interstitium (A), dissecting proximally within the bronchovascular sheath toward the mediastinum (B). As airway pressure rises, decompression occurs into cervical (C), subcutaneous (D), and pericardial (E) tissue spaces. Small arrows indicate the direction of air movement.</div><div id=\"graphicVersion\">Graphic 111129 Version 1.0</div></div></div>"},"111131":{"type":"graphic_algorithm","displayName":"Choice of therapy for symptomatic severe aortic stenosis","title":"Choice of therapy for symptomatic severe aortic stenosis*","html":"<div class=\"graphic\"><div style=\"width: 927px\" class=\"figure\"><div class=\"ttl\">Choice of therapy for symptomatic severe aortic stenosis*</div><div class=\"cntnt\"><img style=\"width:907px; height:446px;\" src=\"images/CARD/111131_Thrpy_sym_svr_artc_stn_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SAVR: surgical aortic valve replacement; TAVI: transcatheter aortic valve implantation.<br />* Refer to UpToDate content regarding diagnosis and evaluation of symptomatic severe aortic stenosis.<br />&para; Examples of absolute contraindications to SAVR not captured by STS-PROM include porcelain aorta and hostile chest (chest conditions that make operation through sternotomy or thoracotomy prohibitively hazardous).<br />&Delta; For patients with low surgical risk (STS-PROM &lt;4) with an absolute contraindication to SAVR, use of TAVI is off-label.<br /><span class=\"lozenge\">&loz;</span> A key issue influencing the choice of TAVI versus SAVR is lack of data on long-term outcomes with TAVI. Clinical factors influencing the choice between TAVI and SAVR include the patient's values and preferences, age, estimated life expectancy with AVR, as well as concurrent conditions. Factors that favor SAVR include presence of another indication for cardiac surgery (eg, need for coronary artery bypass graft surgery or mitral valve surgery); patient age &lt;75 years old; characteristics favoring mechanical valve replacement (ie, age &lt;65 and no contraindication for anticoagulation); as well as anatomic risk factors such as severe left ventricular outflow tract calcification. Factors that favor TAVI include patient age &gt;75 years old and presence of risk factors for SAVR (such as frailty, porcelain aorta, prior mediastinal irradiation or cirrhosis) that may not be captured by the STS-PROM score.<br />&sect; SAVR is preferred in this setting. In patients with a relative contraindication to SAVR, an individualized risk-benefit assessment of SAVR versus alternate access TAVI is performed. Examples of relative contraindications to SAVR not captured by STS-PROM include frailty, cirrhosis, and prior coronary artery bypass graft surgery with vulnerable graft location as assessed by computed tomography.<br />&yen; SAVR is preferred in this setting. Participation in a clinical trial comparing SAVR and TAVI is a reasonable alternative in this patient population. In patients with a relative contraindication to SAVR, an individualized risk-benefit assessment of SAVR versus off-label TAVI is performed.</div><div id=\"graphicVersion\">Graphic 111131 Version 3.0</div></div></div>"},"111133":{"type":"graphic_algorithm","displayName":"Assessment and management of elevated PVR in cardiac transplant","title":"Assessment and management of elevated pulmonary vascular resistance in adult cardiac transplantation candidates","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Assessment and management of elevated pulmonary vascular resistance in adult cardiac transplantation candidates</div><div class=\"cntnt\"><img style=\"width:628px; height:686px;\" src=\"images/CARD/111133_Mgmt_elvtd_PVR_crdc_trnsplt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate content on indications for cardiac transplantation.<br />&para; For all cardiac transplantation candidates, right heart catheterization is required prior to listing. Right heart catheterization should be repeated periodically in adult transplant candidates with frequency individualized according to the patient's clinical condition.<br />&Delta; Refer to UpToDate content regarding choice of a vasodilator to test the acute reversibility of pulmonary hypertension.<br /><span class=\"lozenge\">&loz;</span> Consensus is lacking on the optimum duration of medical therapy prior to repeat right heart catheterization. Refer to UpToDate content regarding components of optimized medical therapy.<br />&sect; However, some centers have successfully performed cardiac transplantation in patients with irreversible pulmonary vascular resistance &gt;3 Wood units on a case-by case basis.</div><div id=\"graphicVersion\">Graphic 111133 Version 1.0</div></div></div>"},"111135":{"type":"graphic_table","displayName":"Exocrine pancreatic CA TNM 2017","title":"Exocrine pancreatic cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Exocrine pancreatic cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em>.<br /> This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;2 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor &#8804;0.5 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor &#62;0.5 cm and &#60;1 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T1c</td> <td colspan=\"3\">Tumor 1 to 2 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#62;2 cm and &#8804;4 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor &#62;4 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor involves celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastases</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in one to three regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in four or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111135 Version 2.0</div></div></div>"},"111137":{"type":"graphic_figure","displayName":"Survival for exocrine pancreatic CA, stratified by T and N stage","title":"Survival according to T category and the number of positive nodes for patients undergoing resection of exocrine pancreatic cancer, stratified according to the revised AJCC 8th edition TNM staging criteria","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Survival according to T category and the number of positive nodes for patients undergoing resection of exocrine pancreatic cancer, stratified according to the revised AJCC 8th edition TNM staging criteria</div><div class=\"cntnt\"><img style=\"width:814px; height:435px;\" src=\"images/ONC/111137_Surv_exocrn_panc_CA_T_N_stg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Overall survival by T stage of 525 patients who underwent resection for node-negative pancreatic cancer, stratified by proposed AJCC 8th edition criteria (training set only).<br />(B) Overall survival by number of positive nodes for all patients who underwent a R0 resection (training set, n = 1551), stratified by proposed AJCC 8th edition criteria.</div><div class=\"graphic_footnotes\">T: tumor; AJCC: American Joint Committee on Cancer; TNM: tumor, node, metastasis; R0: no residual tumor.</div><div class=\"graphic_reference\">From: Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients with Pancreatic Adenocarcinoma. Ann Surg 2017; 265:185. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2017&amp;issue=01000&amp;article=00030&amp;type=abstract\" target=\"_blank\">10.1097/SLA.0000000000001763</a>. Copyright &copy; 2017 American Surgical Association and European Surgical Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111137 Version 1.0</div></div></div>"},"111141":{"type":"graphic_table","displayName":"Bendamustine and rituximab for non-Hodgkin lymphoma","title":"Bendamustine and rituximab for non-Hodgkin lymphoma<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bendamustine and rituximab for non-Hodgkin lymphoma<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Rituximab</td> <td>375 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) or 5% dextrose in water to a final concentration of 1 to 4 mg/mL. Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. In the absence of an initial infusion reaction, patients without clinically significant cardiovascular disease may receive subsequent infusions over 90 minutes.* For the 90-minute infusion, administer 20% of the total dose over the first 30 minutes and the remaining 80% over 60 minutes, as tolerated<sup>[3]</sup>.<sup>&#9674;</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Bendamustine</td> <td>90 mg/m<sup>2</sup> IV</td> <td>Dilute<sup>&#182;</sup> in 500 mL NS or 2.5% dextrose/0.45% sodium chloride to a final concentration of 0.2 to 0.6 mg/mL.<sup>&#916;</sup> Administer over 60 minutes.</td> <td>Days 1 and 2</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with acetaminophen and diphenhydramine, with or without an H2 receptor blocker, 30 minutes prior to at least the first and second infusions of rituximab.<sup>[4]</sup> There is no standard premedication for the initial bendamustine dose. Consider premedication with antihistamines, antipyretics, and corticosteroids for patients with a previous grade 1 or 2 infusion reaction to bendamustine.<sup>[5-7]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Bendamustine is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation (particularly by avoiding use of closed system transfer devices, adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene [ABS] with Treanda injection solution<sup>&#182;</sup>); monitor IV site for redness, swelling, or pain. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The specific incidence of febrile neutropenia was not reported, however, the incidence of grade 3 or 4 neutropenia was 29 to 49% and the incidence of grade 3 or 4 infection was 7 to 12%.<sup>[1,2]</sup> Primary prophylaxis with hematopoietic growth factors should be considered on an individual basis. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Treanda should not be used in patients with a creatinine clearance &#60;40 mL/min. Bedenka should not be used in patients with a creatinine clearance &#60;30 mL/min. Bendamustine should be used with caution in patients with mild hepatic and renal impairment. Bendamustine should not be used in patients with moderate to severe (AST or ALT &#62;2.5 times the ULN and total bilirubin &#62;1.5 times the ULN) hepatic impairment.<sup>[5-7]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatitis screening</strong></td> <td colspan=\"3\"> <ul> <li>Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for antiviral prophylaxis. </li> <li>Refer to UpToDate topic on \"Hepatitis B virus reactivation associated with immunosuppressive therapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential weekly (initially).<sup>[5-7]</sup> </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Carriers of hepatitis B or C virus should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. </li> <li>Refer to UpToDate topic on \"Hepatitis B virus reactivation associated with immunosuppressive therapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor IV infusion site for redness, swelling, pain, infection, and necrosis during and after the bendamustine infusion. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment if absolute neutrophil count &#60;1000/microL, platelet count &#60;75,000/microL, or if there is an active infection.<sup>[4-7]</sup> If grade 4 hematologic toxicity occurs, reduce dose to 60 mg/m<sup>2</sup> on days 1 and 2 of each cycle.<sup>[2,5-7]</sup> Further dose reductions or dose re-escalation may be done at the discretion of the physician. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or greater nonhematologic toxicity, reduce bendamustine dose to 60 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle.<sup>[5-7]</sup> If toxicity resolves, doses may be cautiously re-escalated on subsequent cycles. Further dose reductions or dose re-escalation may be done at the discretion of the physician. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; CBC: complete blood count.<br />* In the absence of an initial reaction, an alternative schedule for subsequent rituximab infusions is to start at 100 mg/hour and escalate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour as tolerated.<SUP>[4]</SUP> If there is an infusion reaction to any dose, follow the initial infusion guidelines described above.<br />¶ Standard bendamustine solution (Treanda injection<SUP>[5]</SUP>) is not compatible with closed system transfer devices, adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS), since these plastics can dissolve upon contact.<br />Δ Concentration and infusion length recommendations for Treanda are for lyophilized powder, which is available as 25 mg/vial or 100 mg/vial.<SUP>[6]</SUP> If using Treanda injection solution (which is available as a 45 mg/0.5 mL or 180 mg/2 mL solution), the recommended final concentration is 0.2 to 0.7 mg/mL, infused over 60 minutes.<SUP>[5]</SUP> If using Bendeka 25 mg/mL solution, dilute in 50 mL NS to a final concentration 1.85 to 5.6 mg/mL and infuse over 10 minutes<SUP>[7]</SUP>.<br />◊ A subcutaneous formulation (rituximab-hyaluronidase) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous rituximab<SUP>[8]</SUP>. Dosing varies by histology and clinicians should refer to the US Prescribing Information for details.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Flinn IW, et al. Blood 2014; 123:2944.</LI>&#xD;&#xA;<LI>Rummel MJ, et al. Lancet 2013; 381:1203.</LI>&#xD;&#xA;<LI>Sehn LH, et al. Blood 2007; 109:4171.</LI>&#xD;&#xA;<LI>Rituximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</LI>&#xD;&#xA;<LI>Treanda (bendamustine hydrochloride) injection, concentrate. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</LI>&#xD;&#xA;<LI>Treanda (bendamustine hydrochloride) injection powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</LI>&#xD;&#xA;<LI>Bendeka (bendamustine hydrochloride) injection solution, concentrate. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</LI>&#xD;&#xA;<LI>Rituximab and hyaluronidase human injection for subcutaneous use. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on June 30, 2017).</LI></OL></div><div id=\"graphicVersion\">Graphic 111141 Version 5.0</div></div></div>"},"111147":{"type":"graphic_figure","displayName":"WGBT threshold for Twin Cities race cancellation","title":"WGBT threshold for Twin Cities race cancellation","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">WGBT threshold for Twin Cities race cancellation</div><div class=\"cntnt\"><img style=\"width:573px; height:358px;\" src=\"images/SM/111147_WGBT_threshld_race_canceltn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The black curved line (curve of best fit) represents the number of runners who dropped out of the race plus the number seen in the finish line medical tent per 1000 race finishers. The red line intersecting the curve of best fit is placed just above the data points associated with an MCI—three hospitals forced onto ambulance diversion—and below the data points associated with a major MCI—six hospitals forced onto ambulance diversion and activation of regional EMS transport teams. The underlined numbers are the approximate number of runners who developed EHS per 10,000 finishers for a given WGBT range. Zones of relative risk for EHS by WBGT are designated by color: Green (low risk) is &lt;13°C or 55°F; yellow (moderate risk) is 13.5 to 18°C, or 56 to 64°F; red (high risk) is 18.5 to 20°C, or 65 to 68°F; and black, which is not drawn (very high risk; cancel race), is ≥20.5°C or 69°F.</div><div class=\"graphic_footnotes\">TCM: Twin Cities marathon; MCI: minor mass casualty incident; EHS:exertional heat stroke; EMS: emergency medical services; WGBT: wet-bulb globe temperature.</div><div class=\"graphic_reference\">Courtesy of William Roberts, MD.</div><div id=\"graphicVersion\">Graphic 111147 Version 1.0</div></div></div>"},"111155":{"type":"graphic_diagnosticimage","displayName":"Port-site hematoma","title":"Port-site hematoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Port-site hematoma</div><div class=\"cntnt\"><img style=\"width:756px; height:503px;\" src=\"images/SURG/111155_Port-site_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic (CT) finding of intra-abdominal bleeding from an abdominal trocar site. Arrow points to the trocar-site hematoma. Patients who are hemodynamically stable can be managed conservatively.</div><div id=\"graphicVersion\">Graphic 111155 Version 1.0</div></div></div>"},"111158":{"type":"graphic_picture","displayName":"Thumb UCL injury splint","title":"Prefabricated thumb splint used for ulnar collateral ligament injury","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Prefabricated thumb splint used for ulnar collateral ligament injury</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SM/111158_Thumb_UCL_injury_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prefabricated thumb splint shown above may be used for patients who have sustained an injury to the ulnar collateral ligament (skier's thumb). A mesh sleeve is worn beneath the splint for comfort.</div><div class=\"graphic_reference\">Courtesy of Matthew Gammons, MD.</div><div id=\"graphicVersion\">Graphic 111158 Version 1.0</div></div></div>"},"111189":{"type":"graphic_table","displayName":"Acute aortic dissection - Rapid overview","title":"Acute aortic dissection: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute aortic dissection: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Treatment of acute&nbsp;aortic dissection depends on the type/location.<strong><span style=\"color: #ff0000;\">&nbsp;Aortic dissection involving the ascending aorta is a cardiac surgical emergency</span></strong>. Aortic dissection limited to the descending thoracic and/or the abdominal aorta can often be managed medically, unless there is evidence of&nbsp;end-organ&nbsp;ischemia or rupture.</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features and evaluation</td> </tr> <tr> <td class=\"indent1\">Acute onset of severe, sharp, or knife-like pain in the anterior chest, with radiation to the neck, back, or abdomen. Pain may<span style=\"color: #0000ff;\"> </span>be migratory.</td> </tr> <tr> <td class=\"indent1\">Assess risk factors for TAAD*.</td> </tr> <tr> <td class=\"indent1\">Palpate carotid, subclavian, and femoral pulses; note any significant differences between sides. Obtain blood pressure in both arms.</td> </tr> <tr> <td class=\"indent1\">Auscultate for diastolic cardiac murmur of aortic regurgitation; assess for tamponade (muffled heart sounds, jugular venous distention, pulsus paradoxus).</td> </tr> <tr> <td class=\"sublist2_start\">Evaluate for signs of ischemic stroke, spinal cord ischemia, ischemic neuropathy, hypoxic encephalopathy.</td> </tr> <tr> <td class=\"sublist2\">Findings suggesting involvement of the <strong>ascending aorta</strong> include back pain, anterior chest pain, hemodynamic instability, diastolic cardiac murmur, tamponade, syncope or stroke (persistent or transient<sup>&#182;</sup>; right hemispheric stroke is most common, but bilateral can occur), Horner syndrome (typically partial with ptosis/miosis), weak or absent carotid or subclavian pulse, upper extremity pain/paresthesia/motor deficit.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Findings suggesting involvement of the <strong>descending aorta</strong> include back pain, chest pain, abdominal pain, weak or absent femoral pulses, lower extremity pain/paresthesia/motor deficit, acute paraplegia.</td> </tr> <tr> <td class=\"subtitle1_single\">Findings on initial studies</td> </tr> <tr> <td class=\"indent1\">Obtain ECG. Look for signs of ACS; extension of type A dissection to coronary ostia can cause coronary ischemia&nbsp;(right coronary artery most commonly affected). </td> </tr> <tr> <td class=\"indent1\">Obtain D-dimer, CBC, basic electrolytes, LDH, cardiac markers, coagulation parameters, and type and crossmatch. D-dimer &#60;500 ng/dL is less likely to be aortic dissection.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chest radiograph: Widened mediastinum and/or unexplained&nbsp;pleural effusion&nbsp;are consistent with dissection, particularly if unilateral.</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular imaging</td> </tr> <tr> <td class=\"indent1\">For hemodynamically stable patient without suspicion for ascending aortic involvement: Obtain thoracic CT angiography or MR angiography, depending upon <strong>resources and speed</strong> of acquisition. Dissection is confirmed by presence of intimal flap separating true and false lumen. If these are not readily available or there is a contraindication, obtain transesophageal echocardiogram.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For hemodynamically unstable patient or for strong suspicion of ascending aortic involvement: Obtain transesophageal echocardiogram. <strong>If not immediately available, obtain CT angiography</strong>.<span style=\"font-size: 9pt; font-family: 'Verdana',sans-serif;\"> Transthoracic echocardiography may be useful for identifying complications of ascending aortic dissection (eg, aortic valve regurgitation, hemopericardium, inferior ischemia) but is not sensitive for identification of dissection.</span></td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td class=\"indent1\">Place two large bore IVs; monitor heart rate and blood pressure continuously, preferably using an arterial line.</td> </tr> <tr> <td class=\"sublist2_start\">Control heart rate and blood pressure<sup>&#916;</sup>. Maintain heart rate &#60;60 BPM and systolic blood pressure between 100 and 120&nbsp;mmHg.</td> </tr> <tr> <td class=\"sublist2\">Administer esmolol (250 to 500 mcg/kg IV loading dose, then infuse at 25 to 50 mcg/kg/minute; titrate to maximum dose of 300 mcg/kg/minute); or&nbsp;labetolol (20 mg IV initially, followed by either 20 to 80 mg IV boluses every 10 minutes to a maximal dose of 300 mg, or an infusion of 0.5 to 2 mg/minute IV). If beta blockers are not tolerated, alternatives are verapamil, diltiazem, or nicardipine.</td> </tr> <tr> <td class=\"sublist2\">Once heart rate is consistently &#60;60 BPM, give vasodilator therapy. <strong>IF </strong>the&nbsp;systolic blood pressure remains above 120 mmHg, initiate nitroprusside infusion&nbsp;(0.25 to 0.5 mcg/kg/minute titrated to a maximum of 10 mcg/kg/minute) or nicardipine infusion (2.5 to 5 mg/hour titrated to a maximum of 15 mg/hour). Vasodilator therapy (eg, nitroprusside, nicardipine) should <strong>not</strong> be used without first controlling&nbsp;heart rate&nbsp;with beta blockade. </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Give IV opioids for analgesia (eg, fentanyl).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Place Foley catheter for assessment of urine output and kidney perfusion.</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical consultation</td> </tr> <tr> <td class=\"sublist2_start\">Obtain immediate surgical consultation (cardiothoracic surgery, vascular surgery) as soon as the diagnosis is strongly suspected (particularly for involvement of the ascending aorta) or confirmed.</td> </tr> <tr> <td class=\"sublist2\"><span style=\"color: #ff0000;\"><strong>Aortic dissection involving the ascending aorta is a cardiac surgical emergency</strong></span><strong><span style=\"color: #ff0000;\">.</span> </strong>Transesophageal echocardiography should be routinely performed in the operating room to <span style=\"color: #ff0000;\"><span style=\"color: black;\">assess aortic valve function, evidence of tamponade, and&nbsp;aortic root and ascending aortic diameter</span>.</span></td> </tr> <tr> <td class=\"sublist2\">Aortic dissection involving only the descending thoracic aorta or abdominal aorta <strong>and with</strong> evidence of malperfusion is treated with urgent aortic stent-grafting or surgery.</td> </tr> <tr> <td class=\"sublist2\">Aortic dissection involving only the descending thoracic aorta or abdominal aorta <strong>without </strong>evidence for ischemia is admitted to the ICU for medical management of hemodynamics and serial aortic imaging.</td> </tr> <tr> <td class=\"indent1\">If appropriate surgical services<sup>&#9674;</sup> are not available, initiate emergent transfer to nearest available cardiovascular center.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TAAD: thoracic aortic aneurysm/dissection; ECG: electrocardiogram; ACS: acute coronary syndrome; CBC: complete blood count; LDH: lactate dehydrogenase; CT: computed tomography; MR: magnetic resonance; IV: intravenous; BPM: beats per minute; ICU: intensive care unit; AAA: abdominal aortic aneurysm.<br />* Known history of TAAD, AAA, aortic intramural hematoma, penetrating aortic ulcer, family history of TAAD or AAA, recent aortic instrumentation, known bicupsid aortic valve, known aortic coarctation, known syndrome associated with TAAD (eg, Marfan, vascular Ehlers-Danlos, Loeys-Dietz, or Turner syndromes).<br />¶ Amaurosis fugax has been reported.<br />Δ Intravenous short-acting agents for control of heart rate and blood pressure should be administered immediately by clinicians who are trained and experienced in their titration using continuous noninvasive electronic monitoring of blood pressure, heart rate, and ECG. Patients should be admitted to an intensive care unit as rapidly as possible. <br />◊Surgical services should include cardiothoracic/vascular surgery by surgeons experienced in the treatment of aortic dissection, equipment and technical support for cardiopulmonary bypass, and endovascular stent-graft capability.</div><div id=\"graphicVersion\">Graphic 111189 Version 1.0</div></div></div>"},"111190":{"type":"graphic_table","displayName":"Stomach cancer TNM 2017","title":"Stomach cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stomach cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em>: Intraepithelial tumor without invasion of the lamina propria, high-grade dysplasia</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the lamina propria, muscularis mucosae, or submucosa</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor invades the lamina propria or muscularis mucosae</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor invades the submucosa</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the muscularis propria*</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades the serosa (visceral peritoneum) or adjacent structures<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Tumor invades the serosa (visceral peritoneum)</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Tumor invades adjacent structures/organs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified as T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified as T4.<br /> &#182; The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.<br /> &#916; Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph node(s) cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in one or two regional lymph nodes</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in three to six regional lymph nodes</td> </tr> <tr> <td class=\"indent1\">N3</td> <td colspan=\"3\">Metastasis in seven or more regional lymph nodes</td> </tr> <tr> <td class=\"indent2\">N3a</td> <td colspan=\"3\">Metastasis in 7 to 15 regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N3b</td> <td colspan=\"3\">Metastasis in 16 or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical (cTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1, N2, or N3</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1, N2, or N3</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1, N2, or N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N1, N2, or N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological (pTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N2</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N3a</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N2</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N3a</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N3b</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N3b</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N3a</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N3a</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N3b</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N3b</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N3a</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N3b</td> <td>M0</td> <td>IIIC</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Post-neoadjuvant therapy (ypTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N2</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N2</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N3</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111190 Version 2.0</div></div></div>"},"111191":{"type":"graphic_figure","displayName":"Regional lymph nodes of the stomach","title":"Regional lymph nodes of the stomach","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Regional lymph nodes of the stomach</div><div class=\"cntnt\"><img style=\"width:598px; height:772px;\" src=\"images/ONC/111191_Regionallymphnodestomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111191 Version 2.0</div></div></div>"},"111192":{"type":"graphic_figure","displayName":"Pathologic stage grouping and overall survival gastric CA","title":"Overall survival in gastric cancer patients who underwent surgical resection with adequate lymphadenectomy without prior chemotherapy or radiation therapy, stratified by pathologic stage groupings (8th edition AJCC, 2017)","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Overall survival in gastric cancer patients who underwent surgical resection with adequate lymphadenectomy without prior chemotherapy or radiation therapy, stratified by pathologic stage groupings (8th edition AJCC, 2017)</div><div class=\"cntnt\"><img style=\"width:730px; height:792px;\" src=\"images/ONC/111192_PathlgcsurvivalgastricCA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pathological stage (pTNM) and overall survival in gastric cancer patients who underwent surgical resection with adequate lymphadenectomy (D2) without prior chemotherapy or radiation therapy, stratified by pathological stage groupings, based on IGCA data (2000-2004; only patients with complete 5-year follow-up were included, n = 25,411).<br />(B) Pathological stage and 1-, 3-, and 5-year and median overall survivals in patients with gastric cancer who received curative surgery, stratified by pathological stage groupings, based on IGCA data.</div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; IGCA: International Gastric Cancer Association.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111192 Version 2.0</div></div></div>"},"111193":{"type":"graphic_figure","displayName":"Post neoadjuvant Rx stage and survival gastric cancer","title":"Post neoadjuvant therapy stage (ypTNM) and overall survival for patients who underwent resection and were given chemotherapy and/or RT prior to surgery, stratified by prognostic stage group (8th edition, 2017)","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Post neoadjuvant therapy stage (ypTNM) and overall survival for patients who underwent resection and were given chemotherapy and/or RT prior to surgery, stratified by prognostic stage group (8th edition, 2017)</div><div class=\"cntnt\"><img style=\"width:706px; height:674px;\" src=\"images/ONC/111193_PostneoadjRxsurvgastric.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Post neoadjuvant therapy stage (ypTNM) and overall survival in patients who underwent surgical resection and were given chemotherapy and/or RT before surgery, stratified by ypStage groupings, based on NCDB data (2004-2008; median follow-up, 23 months; n = 683).<br />(B) Post neoadjuvant therapy stage (ypTNM) and 1-, 3-, and 5-year and median overall survivals in patients with gastric cancer, stratified by ypStage groupings, based on NCDB data.</div><div class=\"graphic_footnotes\">RT: radiation therapy; n: number; NCDB: National Cancer Database.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111193 Version 2.0</div></div></div>"},"111204":{"type":"graphic_algorithm","displayName":"Initial treatment of low Hb among hemodialysis patients","title":"Initial treatment of low hemoglobin among hemodialysis patients","html":"<div class=\"graphic\"><div style=\"width: 1116px\" class=\"figure\"><div class=\"ttl\">Initial treatment of low hemoglobin among hemodialysis patients</div><div class=\"cntnt\"><img style=\"width:1096px; height:664px;\" src=\"images/NEPH/111204_Initial_tx_low_Hb_hemodial.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">IV is more effective than oral iron and is generally used among hemodialysis patients. Refer to UpToDate topic on the treatment of iron deficiency in hemodialysis patients.<br />​The treatment of ESA-treated patients who have ferritin &gt;500 ng/mL is controversial and must be individualized. Refer to UpToDate topic on the treatment of iron deficiency in hemodialysis patients.</div><div class=\"graphic_footnotes\">Hb: hemoglobin; TSAT: transferrin saturation (TSAT = plasma iron / total iron-binding capacity × 100); IV: intravenous; ESA: erythropoiesis-stimulating agent.<br />* The frequency of monitoring depends on the severity of anemia and whether patients are treated with a stable ESA dose. Refer to UpToDate topic on the&nbsp;treatment of anemia in hemodialysis patients.</div><div id=\"graphicVersion\">Graphic 111204 Version 1.0</div></div></div>"},"111205":{"type":"graphic_picture","displayName":"Thumb UCL injury: MRI and schematic diagram","title":"Thumb UCL injury: MRI and schematic diagram","html":"<div class=\"graphic\"><div style=\"width: 789px\" class=\"figure\"><div class=\"ttl\">Thumb UCL injury: MRI and schematic diagram</div><div class=\"cntnt\"><img style=\"width:769px; height:527px;\" src=\"images/SM/111205_ThmbUCLinjryMRIschmtdg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skier's thumb. A 21-year-old man presented with pain and instability of the thumb after a skiing accident.<br />(A) Coronal T2-weighted fat saturated MR image through the first metacarpophalangeal joint shows a tear of the ulnar collateral ligament (arrow), displaced under the aponeurotic hood of the adductor pollicis (Stener lesion).<br />(B) Mechanism of injury: normal ulnar collateral ligament (arrow).<br />(C) Abduction injury: The ulnar collateral ligament is ruptured at the metacarpal insertion (arrow).<br />(D) Postreduction Stener lesion: The ruptured ulnar collateral ligament is displaced under the aponeurotic hood (arrow) (compare with image (A)&mdash;MRI study).<br />(E) Postreduction non-Stener lesion: The ruptured ulnar collateral ligament remains under the aponeurotic hood (arrow).</div><div class=\"graphic_footnotes\">UCL: ulnar collateral ligament; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Radiologic evaluation of trauma. In: Orthopedic Imaging: A Practical Approach, 6th ed, Greenspan A, Beltran J (Eds), Wolters Kluwer Health, Philadelphia 2015. Copyright © 2015 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 111205 Version 1.0</div></div></div>"},"111206":{"type":"graphic_table","displayName":"Opioid agonists for chronic pain, adult dosing and equivalence","title":"Commonly used, oral, immediate-release and parenteral pure mu-opioid agonists for chronic pain: Adult dosing and approximate equivalence (refer to notes)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used, oral, immediate-release and parenteral pure mu-opioid agonists for chronic pain: Adult dosing and approximate equivalence (refer to notes)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"> <p>Drug</p> <p>(United States brand name)</p> </td> <td class=\"subtitle1\">Approximate equivalent doses*</td> <td class=\"subtitle1\">Sample initial dose<br /> (opioid na&#239;ve)<sup>&#182;</sup></td> <td class=\"subtitle1\">Serum half-life<br /> (hours)</td> <td class=\"subtitle1\">Duration of effect (hours)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oral immediate-release preparations</td> </tr> <tr> <td class=\"indent1\">Hydromorphone<br /> (Dilaudid)</td> <td>7.5 mg</td> <td>2 to 4 mg orally every 3 to 4 hours</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>High potency </li> <li>Use reduced dose in renal and/or hepatic impairment </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Methadone<br /> (Dolophine, Methadose)</td> <td>20 mg<sup>&#916;</sup></td> <td>2.5 to 10 mg orally every 4 to 8 hours</td> <td>12 to 150</td> <td> <p>3 to 4 initially;</p> increases after repeated use</td> <td> <ul> <li>Due to challenges inherent in safe prescribing of methadone, not a first-line analgesic choice </li> <li>Can be used as a long-acting opioid due to its prolonged half-life (0.5 to 7 days) </li> <li>Guidelines must be followed to reduce risk of unintentional overdose; refer to text<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Morphine</td> <td>30 mg</td> <td>15 to 30 mg orally every 4 hours</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Active metabolites are dependent on kidney function for clearance; avoid or use reduced dose frequency in organ dysfunction </li> <li>Accumulation of metabolite may contribute to hyperalgesia or other neurotoxicity </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Oxycodone<br /> (Oxy-IR, Roxicodone)</td> <td>20 mg</td> <td>5 to 15 mg orally every 4 to 6 hours</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Available as a single entity or combined with acetaminophen, aspirin, or ibuprofen; dose limits apply to combinations </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxymorphone<br /> (Opana)</td> <td>10 to 15 mg</td> <td>5 to 10 mg orally every 4 to 6 hours</td> <td>7 to 9</td> <td>3 to 6</td> <td> <ul> <li>Take on empty stomach </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Parenteral preparations</td> </tr> <tr> <td class=\"indent1\">Fentanyl<br /> (Sublimaze)</td> <td>0.1 mg (100 mcg)</td> <td>25 to 50 mcg IV or SQ every 1 to 2 hours</td> <td>7 to 12</td> <td> <p>0.5 to 1 (IV)</p> 1 to 2 (SQ)</td> <td> <ul> <li>Duration of effect increases after repeated use </li> <li>Can also be administered as a continuous IV or SQ infusion </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hydromorphone<br /> (Dilaudid)</td> <td>1.5 mg IV/SQ</td> <td> <p>0.3 to 1 mg IV every 2 to 4 hours</p> 0.3 to 1 mg SQ every 3 to 4 hours</td> <td>2 to 3</td> <td>3 to 4</td> <td> <ul> <li>High potency (small volume) useful for SQ administration </li> <li>Can also be administered as a continuous IV or SQ infusion </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Methadone</td> <td>10 mg IV/SQ<sup>&#916;</sup></td> <td>1.25 to 5 mg IV/SQ every 4 to 8 hours</td> <td>12 to 150</td> <td>3 to 4</td> <td> <ul> <li>Duration of effect increases after repeated use </li> <li>Refer to comments above and in text regarding safe use of methadone<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Morphine<br /> (Infumorph, others)</td> <td>10 mg IV/SQ</td> <td> <p>2 to 5 mg IV every 2 to 4 hours</p> 2 to 10 mg SQ every 3 to 4 hours</td> <td>2 to 3</td> <td>3 to 4</td> <td> <ul> <li>Can also be administered as a continuous IV or SQ infusion </li> <li>Active metabolites are dependent on kidney function for clearance; avoid or use reduced dose frequency in organ dysfunction </li> <li>Accumulation of metabolites may contribute to hyperalgesia or other neurotoxicity </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Oxymorphone<br /> (Opana)</td> <td>1 mg IV/SQ</td> <td> <p>0.5 mg IV every 4 to 6 hours</p> 0.5 to 1.5 mg SQ every 4 to 6 hours</td> <td>7 to 9</td> <td>3 to 6</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>NOTES:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents. For a review of multiple factors that must be considered for safely individualizing conversion of opioid analgesia, refer to UpToDate reviews of cancer pain management with opioids.</LI>&#xD;&#xA;<LI>Opioids have similar equianalgesic potency whether administered as an immediate-release form (ie, smaller, more frequently divided doses) or an extended-release preparation. To convert from oral immediate-release to an extended-release preparation of the same opioid, use the sum of doses of immediate-release administered during the usual interval of the extended-release form. As an example, morphine sulfate immediate-release 30 mg orally every&nbsp;four hours (total of 180 mg per day) may be converted to morphine sulfate extended-release 60 mg orally every&nbsp;eight hours (total of 180 mg per day).</LI>&#xD;&#xA;<LI>For information about extended-release and long-acting preparations, and fentanyl transmucosal preparations for breakthrough pain, refer to the separately available table within UpToDate and the individual drug monographs.</LI></UL></div><div class=\"graphic_footnotes\">mcg: micrograms; IV: intravenous; SQ: subcutaneous.<br />* When switching to a new opioid, the calculated dose of the new opioid should be reduced by 25 to 50% (75 to 90% for methadone<sup>&para;</sup>) to adjust for lack of complete mu receptor cross-tolerance. For a review of multiple factors that must be considered for safely individualizing conversion of opioid analgesia, refer to UpToDate topic on cancer pain management with opioids: Optimizing analgesia.<br />&para; Dose reduction of approximately 50% required for older or debilitated adults, or patients with low cardiac output or respiratory compromise.<br />&Delta; When switching to methadone, the calculated equianalgesic methadone dose should be reduced by 75 to 90% and initiated at no more than 30 mg orally per day (in divided doses), regardless of the previous opioid dose. Guidelines for safe dose adjustment must be followed to avoid unintentional overdose. Refer to UpToDate topic on cancer pain management with opioids: Optimizing analgesia, section on methadone.</div><div class=\"graphic_reference\">Courtesy of Kathleen Broglio, DNP, MN, ANP-BC, ACHPN and Russell K Portenoy, MD.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Comprehensive Cancer Network. Adult Cancer Pain, Version 2.2016.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 111206 Version 6.0</div></div></div>"},"111207":{"type":"graphic_table","displayName":"Opioid agonists for chronic pain in adults","title":"Commonly used, oral and transdermal, long-acting pure mu-opioid agonists for chronic pain in adults (refer to notes)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used, oral and transdermal, long-acting pure mu-opioid agonists for chronic pain in adults (refer to notes)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Brand name<br /> (United States)</td> <td class=\"subtitle1\">Sample initial dose in opioid-tolerant adults</td> <td class=\"subtitle1\">Serum half-life<br /> (hours)</td> <td class=\"subtitle1\">Duration of analgesic effect (hours)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oral, long-acting preparations</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hydrocodone</td> <td>Hysingla ER</td> <td>20 mg orally every 24 hours</td> <td>7 to 9</td> <td>24</td> <td rowspan=\"2\"> <ul> <li>May interact with drugs that alter CYP3A4 and 2D6 metabolism </li> <li>Converted to active metabolite by CYP2D6, which is subject to polymorphisms; individual effects vary </li> <li>Hysingla ER and Zohydro ER have abuse-deterrent* properties </li> </ul> </td> </tr> <tr> <td>Zohydro ER</td> <td>10 mg orally every 12 hours</td> <td>13</td> <td>&#8804;12 in patients with non-cancer back pain</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hydromorphone</td> <td>Exalgo</td> <td>8 mg orally every 24 hours</td> <td>11</td> <td>24</td> <td rowspan=\"2\"> <ul> <li>Use reduced dose in renal and/or hepatic impairment </li> <li>Exalgo has abuse-deterrent* properties </li> </ul> </td> </tr> <tr> <td>Hydromorph Contin (available in Canada)</td> <td>3 mg orally every 12 hours</td> <td>Not specified</td> <td>&#8805;12</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Morphine</td> <td>MS Contin, Oramorph SR</td> <td>15 mg orally every 12 hours</td> <td>Not specified</td> <td>8 to 12</td> <td rowspan=\"3\"> <ul> <li>Active metabolites are dependent on kidney function for clearance; avoid or use reduced dose-frequency in organ dysfunction </li> <li>Accumulation of metabolite may contribute to hyperalgesia or other neurotoxicity </li> <li>Arymo ER has abuse-deterrent* properties </li> </ul> </td> </tr> <tr> <td>Kadian</td> <td>30 mg orally daily in 1 or 2 divided doses</td> <td>11 to 13</td> <td>12 to 24</td> </tr> <tr> <td>Arymo ER</td> <td>15 mg orally every 8 or 12 hours</td> <td>Not specified</td> <td>8 to 12</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Oxycodone</td> <td>OxyContin, Oxaydo</td> <td>10 mg orally every 12 hours</td> <td>4.5</td> <td>8 to 12</td> <td> <ul> <li>OxyContin and Oxaydo have abuse-deterrent* properties </li> </ul> </td> </tr> <tr> <td>Xtampza ER</td> <td>9 mg orally every 12 hours</td> <td>5.6</td> <td>&#8804;12</td> <td> <ul> <li>Xtampza ER has abuse-deterrent* properties </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxymorphone</td> <td>Generic only</td> <td>5 mg orally every 12 hours</td> <td>9 to 11</td> <td>12</td> <td> <ul> <li>Take on empty stomach </li> <li>Opana ER brand, an&nbsp;abuse-deterrent formulation,&nbsp;was withdrawn from the United States market in mid-2017 due to concerns related to IV injection abuse, including reports of thrombotic microangiopathy; generic&nbsp;extended-release&nbsp;preparations of oxymorphone&nbsp;remain available </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Transdermal</td> </tr> <tr> <td class=\"indent1\">Fentanyl</td> <td>Duragesic</td> <td>12 or 25 mcg per hour, patch applied every 72 hours</td> <td>17 following patch removal</td> <td> <p>48 to 72</p> Some analgesic effect may persist for up to 12 hours following patch removal</td> <td> <ul> <li>Onset of analgesic effect is delayed 12 to 24 hours after initial application </li> <li>Approximate dose conversions for fentanyl transdermal and commonly used oral opioids are provided as a separate table in UpToDate </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>NOTES:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>The total daily dose requirement for a long-acting opioid formulation should be established first with the use of an appropriate immediate-release opioid analgesic. Details for initiating and adjustment of dose vary by each agent. Refer to UpToDate reviews on cancer pain management with opioids and individual drug monographs (ie, Lexicomp) for detailed information on individual agents.</LI>&#xD;&#xA;<LI>Opioids have similar equianalgesic potency whether administered as an immediate-release form (ie, smaller, more frequently divided doses) or an extended-release preparation. To convert from oral immediate-release to an extended-release preparation of the same opioid, use the sum of doses of immediate-release administered during the usual interval of the extended-release form. As an example, morphine sulfate immediate-release 30 mg orally every four hours (total of 180 mg per day) may be converted to morphine sulfate extended-release 60 mg orally every eight hours (total of 180 mg per day).</LI>&#xD;&#xA;<LI>Approximate equianalgesic dose equivalents and information on oral immediate-release and parenteral pure mu-opioid agonists that are commonly used in management of cancer pain are provided as separate tables within UpToDate.</LI></UL></div><div class=\"graphic_footnotes\">mcg: microgram; IV: intravenous.<br />* Abuse-deterrent formulations have one or more properties that make intentional manipulation of the dose form more difficult (eg, resistant to crushing and dissolution) or less likely to produce an opioid effect (eg, altered to minimize absorption through nasal mucosa). No oral opioid formulation prevents ingestion of an excessive dose.<br /></div><div class=\"graphic_reference\">Courtesy of Kathleen Broglio, DNP, MN, ANP-BC, ACHPN and Russell K Portenoy, MD.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Comprehensive Cancer Network. Adult Cancer Pain, Version 2.2016.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 111207 Version 6.0</div></div></div>"},"111216":{"type":"graphic_table","displayName":"Approximate dose conversions for commonly used opioids","title":"Approximate dose conversions for commonly used opioids (refer to important note below)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate dose conversions for commonly used opioids (refer to important note below)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"14%\"></colgroup><colgroup span=\"2\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\" colspan=\"6\">Approximate dose conversions for commonly used opioids (refer to important note below)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Hydromorphone (Dilaudid)</td> <td class=\"subtitle2\" colspan=\"2\">Morphine</td> <td class=\"subtitle2\">Oxycodone</td> <td class=\"subtitle2\">Fentanyl transdermal*</td> </tr> <tr> <td class=\"subtitle3\">IV (mg/day)</td> <td class=\"subtitle3\">Oral (mg/day)</td> <td class=\"subtitle3\">IV (mg/day)</td> <td class=\"subtitle3\">Oral (mg/day)</td> <td class=\"subtitle3\">Oral (mg/day)</td> <td class=\"subtitle3\">Patch (mcg/hour)</td> </tr> <tr> <td class=\"centered\">1.25</td> <td class=\"centered\">6.25</td> <td class=\"centered\">8.5</td> <td class=\"centered\">25</td> <td class=\"centered\">15</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"centered\">2.5</td> <td class=\"centered\">12.5</td> <td class=\"centered\">17</td> <td class=\"centered\">50</td> <td class=\"centered\">30</td> <td class=\"centered\">25</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">25</td> <td class=\"centered\">33</td> <td class=\"centered\">100</td> <td class=\"centered\">65</td> <td class=\"centered\">50</td> </tr> <tr> <td class=\"centered\">7.5</td> <td class=\"centered\">37.5</td> <td class=\"centered\">50</td> <td class=\"centered\">150</td> <td class=\"centered\">100</td> <td class=\"centered\">75</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">50</td> <td class=\"centered\">67</td> <td class=\"centered\">200</td> <td class=\"centered\">130</td> <td class=\"centered\">100</td> </tr> <tr> <td class=\"centered\">12.5</td> <td class=\"centered\">62.5</td> <td class=\"centered\">83</td> <td class=\"centered\">250</td> <td class=\"centered\">165</td> <td class=\"centered\">125</td> </tr> <tr> <td class=\"centered\">15</td> <td class=\"centered\">75</td> <td class=\"centered\">100</td> <td class=\"centered\">300</td> <td class=\"centered\">200</td> <td class=\"centered\">150</td> </tr> <tr> <td class=\"centered\">17.5</td> <td class=\"centered\">87.5</td> <td class=\"centered\">117</td> <td class=\"centered\">350</td> <td class=\"centered\">230</td> <td class=\"centered\">175</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">100</td> <td class=\"centered\">133</td> <td class=\"centered\">400</td> <td class=\"centered\">265</td> <td class=\"centered\">200</td> </tr> <tr> <td class=\"centered\">22.5</td> <td class=\"centered\">112.5</td> <td class=\"centered\">150</td> <td class=\"centered\">450</td> <td class=\"centered\">300</td> <td class=\"centered\">225</td> </tr> <tr> <td class=\"centered\">25</td> <td class=\"centered\">125</td> <td class=\"centered\">167</td> <td class=\"centered\">500</td> <td class=\"centered\">330</td> <td class=\"centered\">250</td> </tr> <tr> <td class=\"centered\">27.5</td> <td class=\"centered\">137.5</td> <td class=\"centered\">183</td> <td class=\"centered\">550</td> <td class=\"centered\">360</td> <td class=\"centered\">275</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">30</td> <td class=\"centered\">150</td> <td class=\"centered\">200</td> <td class=\"centered\">600</td> <td class=\"centered\">400</td> <td class=\"centered\">300</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\" colspan=\"6\">Approximate equianalgesic doses and ratios to determine daily morphine equivalent dose (MED) for commonly used opioids</td> </tr> <tr> <td class=\"subtitle2_left\" style=\"border-bottom: #555555 3px solid;\" colspan=\"2\">Drug</td> <td class=\"subtitle2_left\" style=\"border-bottom: #555555 3px solid;\" colspan=\"2\">Approximate equivalent oral dose</td> <td class=\"subtitle2_left\" style=\"border-bottom: #555555 3px solid;\">Approximate equivalent IV or subcutaneous dose</td> <td class=\"subtitle2_left\" style=\"border-bottom: #555555 3px solid;\">Ratio to determine daily MED<br /> (morphine:alternate opioid)</td> </tr> <tr> <td colspan=\"2\">Fentanyl</td> <td colspan=\"2\">Not available</td> <td>0.1 mg (100 mcg)</td> <td>100:1 (parenteral)</td> </tr> <tr> <td colspan=\"2\">Hydrocodone</td> <td colspan=\"2\">30 mg</td> <td>Not available</td> <td>1:1 (oral)<sup>&#182;</sup></td> </tr> <tr> <td colspan=\"2\">Hydromorphone</td> <td colspan=\"2\">7.5 mg</td> <td>1.5 mg</td> <td>4:1 (oral); 6.7:1 (parenteral)</td> </tr> <tr> <td colspan=\"2\">Morphine</td> <td colspan=\"2\">30 mg</td> <td>10 mg</td> <td>Reference standard</td> </tr> <tr> <td colspan=\"2\">Oxycodone</td> <td colspan=\"2\">20 mg</td> <td>Not available</td> <td>1.5:1 (oral)</td> </tr> <tr> <td colspan=\"2\">Oxymorphone</td> <td colspan=\"2\">10 to 15 mg</td> <td>1 mg</td> <td>3:1 to 2:1 (oral); 10:1 (parenteral)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Important note:</STRONG> Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents. When switching to a new opioid, the initial daily dose for the new opioid determined by using above conversions should be reduced by 25 to 50% to adjust for lack of complete mu receptor cross-tolerance (except when switching to methadone, which requires a 75 to &gt;90% reduction; refer to text). For a review of multiple factors that must be considered for safely individualizing conversion of opioid analgesia, refer to UpToDate topic on cancer pain management with opioids, optimizing analgesia.</div><div class=\"graphic_footnotes\">IV: intravenous; mcg: microgram.<br />* Suggested doses for conversion to transdermal fentanyl from other opioids are less conservative than recommendations in the United States product labeling. The recommendations in this table are based on guidance available at experienced centers.<br />¶ Wide interpatient variability in response.</div><div class=\"graphic_reference\">Courtesy of Kathleen Broglio, DNP, MN, ANP-BC, ACHPN and Russell K Portenoy, MD.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Comprehensive Cancer Network. Adult Cancer Pain, Version 2.2016.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 111216 Version 5.0</div></div></div>"},"111217":{"type":"graphic_table","displayName":"Fentanyl preparations for chronic pain in opioid-tolerant adults","title":"Commonly available fentanyl transmucosal preparations for breakthrough pain in opioid-tolerant adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly available fentanyl transmucosal preparations for breakthrough pain in opioid-tolerant adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Fentanyl transmucosal preparation</td> <td class=\"subtitle1\">Brand name<br /> (United States)</td> <td class=\"subtitle1\">Starting dose in an opioid-tolerant adult*</td> <td class=\"subtitle1\">Serum half-life<br /> (hours)<sup>&#182;</sup></td> <td class=\"subtitle1\">Duration of analgesic effect<br /> (hours)<sup>&#182;</sup></td> </tr> <tr> <td>Buccal tablet</td> <td>Fentora</td> <td>100 mcg</td> <td>13.3</td> <td>1 to 2</td> </tr> <tr> <td>Oral lozenge</td> <td>Actiq</td> <td>200 mcg</td> <td>7.6</td> <td>2</td> </tr> <tr> <td>Nasal spray</td> <td>Lazanda</td> <td>100 mcg</td> <td>15 to 25</td> <td>&#8805;1</td> </tr> <tr> <td>Sublingual spray</td> <td>Subsys</td> <td>100 mcg</td> <td>5 to 12</td> <td>&#8805;1</td> </tr> <tr> <td>Sublingual tablet</td> <td>Abstral</td> <td>100 mcg</td> <td>11.5 to 25</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An oral, immediate-release (IR) preparation (eg, oxycodone IR) is generally used for managing brief episodes of breakthrough pain not attributed to inadequate doses of scheduled long-acting opioids. A transmucosal fentanyl preparation can provide an alternative to oral IR opioid preparations in patients who may benefit from a more rapid onset of analgesia, ie, 5 to 15 minutes for transmucosal route compared with 10 to 15 minutes typically for oral IR opioids.</div><div class=\"graphic_footnotes\">mcg: microgram.<br />* Always initiate transmucosal fentanyl preparations at the lowest starting dose for breakthrough pain, even in patients with high baseline opioid requirements. Data do not support specific transmucosal fentanyl dose equivalents to other opioids. For additional detail, including recommendations on frequency of repeat dosing, dose titration, and recommendations on converting between transmucosal forms if necessary, refer to the Lexicomp fentanyl monograph included in UpToDate.<br />¶ Serum half-life and duration of effect are dose dependent.</div><div class=\"graphic_reference\">Courtesy of Kathleen Broglio, DNP, MN, ANP-BC, ACHPN and Russell K Portenoy, MD.<br />Additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Comprehensive Cancer Network. Adult Cancer Pain, Version 2.2016.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 111217 Version 5.0</div></div></div>"},"111218":{"type":"graphic_figure","displayName":"FEV1 vs BMI in adults with cystic fibrosis","title":"FEV<SUB>1</SUB> versus BMI in adults with cystic fibrosis, 20 to 40 years","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">FEV<SUB>1</SUB> versus BMI in adults with cystic fibrosis, 20 to 40 years</div><div class=\"cntnt\"><img style=\"width:756px; height:336px;\" src=\"images/PEDS/111218_FEV1_BMI_prcntl_CF_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For adults, the goal for FEV<SUB>1</SUB> percent predicted is&nbsp;&#8805;75. The goal for&nbsp;BMI is &#8805;22 kg/m<SUP>2</SUP>&nbsp;for females, and &#8805;23 kg/m<SUP>2</SUP>&nbsp;for males.</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second; BMI: body mass index.</div><div class=\"graphic_reference\">Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry: 2015 Annual Data Report, Bethesda, MD. Copyright &#169; 2016 Cystic Fibrosis Foundation.</div><div id=\"graphicVersion\">Graphic 111218 Version 1.0</div></div></div>"},"111221":{"type":"graphic_table","displayName":"Esophagus and esophagogastric junction cancer TNM 2017","title":"Esophagus and esophagogastric junction cancers TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Esophagus and esophagogastric junction cancers TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"6\">Primary tumor (T), squamous cell carcinoma and adenocarcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"5\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"5\">Tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"5\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"5\">High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"5\">Tumor invades the lamina propria, muscularis mucosae, or submucosa</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"5\">Tumor invades the lamina propria or muscularis mucosae</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"5\">Tumor invades the submucosa</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"5\">Tumor invades the muscularis propria</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"5\">Tumor invades adventitia</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"5\">Tumor invades adjacent structures</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"5\">Tumor invades the pleura, pericardium, azygos ven, diaphragm, or peritoneum</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"5\">Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Regional lymph nodes (N), squamous cell carcinoma and adenocarcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"5\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"5\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"5\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"5\">Metastasis in one or two regional lymph nodes</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"5\">Metastasis in three to six regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N3</td> <td colspan=\"5\">Metastasis in seven or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Distant metastasis (M), squamous cell carcinoma and adenocarcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"5\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"5\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"5\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Histologic grade (G), squamous cell carcinoma and adenocarcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">G</td> <td class=\"subtitle2_left\" colspan=\"5\">G definition</td> </tr> <tr> <td class=\"indent1\">GX</td> <td colspan=\"5\">Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"5\">Well differentiated</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"5\">Moderately differentiated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td colspan=\"5\">Poorly differentiated, undifferentiated</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Location (L), squamous cell carcinoma</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\">Location plays a role in the stage grouping of esophageal squamous cancers.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Location category</strong></td> <td colspan=\"5\"><strong>Location criteria</strong></td> </tr> <tr> <td class=\"indent1\">X</td> <td colspan=\"5\">Location unknown</td> </tr> <tr> <td class=\"indent1\">Upper</td> <td colspan=\"5\">Cervical esophagus to lower border of azygos vein</td> </tr> <tr> <td class=\"indent1\">Middle</td> <td colspan=\"5\">Lower border of azygos vein to lower border of inferior pulmonary vein</td> </tr> <tr> <td class=\"indent1\">Lower</td> <td colspan=\"5\">Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"6\"><em>NOTE:</em> Location is defined by the position of the epicenter of the tumor in the esophagus.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Prognostic stage groups, squamous cell carcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">Clinical (cTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When cT is...</strong></td> <td><strong>And cN is...</strong></td> <td colspan=\"2\"><strong>And M is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">0</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0-1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">I</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0-1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">II</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">II</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">III</td> </tr> <tr> <td class=\"indent2\">T1-3</td> <td>N2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">III</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0-2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N3</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td colspan=\"2\">M1</td> <td colspan=\"2\">IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">Pathological (pTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When pT is...</strong></td> <td><strong>And pN is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>And G is...</strong></td> <td><strong>And location is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>N/A</td> <td>Any</td> <td>0</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>G1</td> <td>Any</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>G2-3</td> <td>Any</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>GX</td> <td>Any</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>G1-3</td> <td>Any</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>GX</td> <td>Any</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>G1</td> <td>Any</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>G2-3</td> <td>Any</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>GX</td> <td>Any</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>Any</td> <td>Lower</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>G1</td> <td>Upper/middle</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>G2-3</td> <td>Upper/middle</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>GX</td> <td>Any</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>Any</td> <td>Location X</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N2</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N2</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1-2</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0-1</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N2</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IVA</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0-2</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N3</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>Any</td> <td>Any</td> <td>IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">Postneoadjuvant therapy (ypTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When yp T is...</strong></td> <td><strong>And yp N is...</strong></td> <td colspan=\"2\"><strong>And M is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T0-2</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">I</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">II</td> </tr> <tr> <td class=\"indent2\">T0-2</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T0-3</td> <td>N2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N1-2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>NX</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0-2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N3</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td colspan=\"2\">M1</td> <td colspan=\"2\">IVB</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Prognostic stage groups, adenocarcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">Clinical (cTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When cT is...</strong></td> <td><strong>And cN is...</strong></td> <td colspan=\"2\"><strong>And M is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">0</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">I</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIB</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">III</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0-1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">III</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0-1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">III</td> </tr> <tr> <td class=\"indent2\">T1-4a</td> <td>N2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0-2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N3</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td colspan=\"2\">M1</td> <td colspan=\"2\">IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">Pathological (pTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When pT is...</strong></td> <td><strong>And pN is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>And G is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>N/A</td> <td colspan=\"2\">0</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>G1</td> <td colspan=\"2\">IA</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>GX</td> <td colspan=\"2\">IA</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>G2</td> <td colspan=\"2\">IB</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>G1-2</td> <td colspan=\"2\">IB</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>GX</td> <td colspan=\"2\">IB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>G3</td> <td colspan=\"2\">IC</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>G1-2</td> <td colspan=\"2\">IC</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>G3</td> <td colspan=\"2\">IIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>GX</td> <td colspan=\"2\">IIA</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N1</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N2</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N1</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N2</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1-2</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0-1</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N2</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0-2</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N3</td> <td>M0</td> <td>Any</td> <td colspan=\"2\">IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>Any</td> <td colspan=\"2\">IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"6\">Postneoadjuvant therapy (ypTNM)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When yp T is...</strong></td> <td><strong>And yp N is...</strong></td> <td colspan=\"2\"><strong>And M is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T0-2</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">I</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">II</td> </tr> <tr> <td class=\"indent2\">T0-2</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T0-3</td> <td>N2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>N1-2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>NX</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>N0-2</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N3</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td colspan=\"2\">M1</td> <td colspan=\"2\">IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111221 Version 2.0</div></div></div>"},"111222":{"type":"graphic_algorithm","displayName":"Approach to the treatment of stiff-person syndrome","title":"Approach to the treatment of stiff-person syndrome","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Approach to the treatment of stiff-person syndrome</div><div class=\"cntnt\"><img style=\"width:536px; height:378px;\" src=\"images/RHEUM/111222_Trtmnt_stiff-person_syndrm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topic on stiff-person syndrome for detailed information on dosing regimens, dose titration, and adverse effects that may limit upward dose titration.<br />¶ Some improvement in mobility and function but continued impairment by symptoms of the illness.</div><div id=\"graphicVersion\">Graphic 111222 Version 1.0</div></div></div>"},"111223":{"type":"graphic_algorithm","displayName":"Algorithm for acute treatment of catatonia","title":"Algorithm for acute treatment of catatonia","html":"<div class=\"graphic\"><div style=\"width: 866px\" class=\"figure\"><div class=\"ttl\">Algorithm for acute treatment of catatonia</div><div class=\"cntnt\"><img style=\"width:846px; height:390px;\" src=\"images/PSYCH/111223_Algo_acute_trtmnt_catatonia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECT: electroconvulsive therapy.<br />* Malignant catatonia is life-threatening and is characterized by fever, autonomic instability, delirium, and rigidity. Catatonia occurs in the context of many mental disorders (eg, unipolar major depression, bipolar disorder, and psychotic disorders) and general medical disorders. Refer to UpToDate content that discusses the clinical features of catatonia.<br />¶ The initial choice for pharmacotherapy is typically a benzodiazepine, such as lorazepam 1 to 2 mg intravenously three times per day. For patients who are already receiving lorazepam for another indication when they present with catatonia, the starting dose of lorazepam for catatonia (eg, 1 mg three times per day) is added to the existing dose of lorazepam (eg, 1 mg each night for insomnia). Refer to UpToDate content that discusses treatment of catatonia.<br />Δ Pharmacotherapy is used while preparations are made to administer ECT. The medication is discontinued when ECT commences, unless the patient responds to drug therapy. Refer to the ¶ footnote definition above and UpToDate content that discusses treatment of catatonia.<br /><FONT class=lozenge>◊</FONT> The goal of treatment is full remission.<br />§ The same medication regimen continues while preparations are made to administer ECT. Pharmacotherapy is discontinued when ECT commences. Refer to UpToDate content that discusses treatment of catatonia and provides an overview of ECT.<br />¥ Use the same drug from the initial course of pharmacotherapy. Refer to UpToDate content that discusses treatment of catatonia.<br />‡ Resume same drug from the initial course of pharmacotherapy used during preparations for ECT.</div><div id=\"graphicVersion\">Graphic 111223 Version 1.0</div></div></div>"},"111224":{"type":"graphic_table","displayName":"ETV sucess score","title":"Endoscopic third ventriculostomy (ETV) success score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic third ventriculostomy (ETV) success score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <p><span style=\"white-space: nowrap;\"><strong>ETV success score =</strong> Age score + etiology score + previous shunt score</span></p> <p style=\"padding-left:10.4em;\"><em>&#8776; Percentage probability of ETV success</em></p> </td> </tr> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Score</td> </tr> <tr class=\"divider_bottom\"> <td>Age</td> <td> <ul> <li>&#60;1 month = 0 </li> <li>1 to &#60;6 months = 10 </li> <li>6 to &#60;12 months = 30 </li> <li>1 to &#60;10 years = 40 </li> <li>&#8805;10 years = 50 </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Etiology</td> <td> <ul> <li>Postinfectious = 0 </li> <li>Myelomeningocele, intraventricular hemorrhage, or nontectal brain tumor = 20 </li> <li>Aqueductal stenosis, tectal tumor, or other etiology = 30 </li> </ul> </td> </tr> <tr> <td>Previous shunt</td> <td> <ul> <li>Previous shunt = 0 </li> <li>No previous shunt = 10 </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Interpretation:</strong>&#xD;&#xA;<ul>&#xD;&#xA;    <li>The score in each category (age, etiology, previous shunt) are added together to determine the total score.</li>&#xD;&#xA;    <li>The total score estimates the percent probability of ETV success.&#xD;&#xA;    <ul>&#xD;&#xA;        <li>&ge;80 percent &ndash; High likelihood of success</li>&#xD;&#xA;        <li>50 to 70 percent &ndash; Moderate likelihood of success</li>&#xD;&#xA;        <li>&le;40 percent &ndash; Low likelihood of success</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Adapted from: Kulkarni AV, Drake JM, Mallucci CL, et al. Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus. J Pediatr 2009; 155:254.</div><div id=\"graphicVersion\">Graphic 111224 Version 1.0</div></div></div>"},"111225":{"type":"graphic_diagnosticimage","displayName":"Foramen of Monro obstruction","title":"Obstructive hydrocephalus due to foramen of Monro obstruction","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Obstructive hydrocephalus due to foramen of Monro obstruction</div><div class=\"cntnt\"><img style=\"width:872px; height:504px;\" src=\"images/PEDS/111225_Foramen_Monro_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted MRI of a child with obstruction of the foramen of Monro with associated dilation of the right lateral ventricle.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 111225 Version 1.0</div></div></div>"},"111226":{"type":"graphic_diagnosticimage","displayName":"Congenital aqueductal stenosis","title":"Congenital aqueductal stenosis","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Congenital aqueductal stenosis</div><div class=\"cntnt\"><img style=\"width:531px; height:264px;\" src=\"images/PEDS/111226_Congentl_aqueductl_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal (A) and axial (B) T1-weighted MR images of a term neonate with hydrocephalus due to congenital aqueductal stenosis. The infant was noted to have ventriculomegaly on prenatal ultrasound. Postnatal MRI showed focal stenosis in the midportion of the cerebral aqueduct (arrow) with associated dilation of the lateral and third ventricles.</div><div class=\"graphic_footnotes\">MR: magnetic resonance; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 111226 Version 1.0</div></div></div>"},"111227":{"type":"graphic_figure","displayName":"Schematic of uterus transplantation surgery ","title":"Schematic of uterus transplantation surgery for donor and recipient","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Schematic of uterus transplantation surgery for donor and recipient</div><div class=\"cntnt\"><img style=\"width:500px; height:715px;\" src=\"images/OBGYN/111227_Schematic_of_uterus_transplantation_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Schematic drawing of surgery in the donor.<br />(B) Schematic image of vascular connections in the recipient.</div><div class=\"graphic_reference\">Modified from:&nbsp;Brännström M. Uterine transplantation. In: The Essential Uterine Handbook: Current Applications in Clinical Medicine, Giudice L, Simon C (Eds), CRC Press, 2015 (in process).</div><div id=\"graphicVersion\">Graphic 111227 Version 1.0</div></div></div>"},"111228":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus from posterior fossa tumor","title":"Obstructive hydrocephalus due to posterior fossa tumor","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Obstructive hydrocephalus due to posterior fossa tumor</div><div class=\"cntnt\"><img style=\"width:782px; height:261px;\" src=\"images/PEDS/111228_Hydrocephals_pstr_fossa_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI images of a five-week-old infant with severe obstructive hydrocephalus due to congenital posterior fossa tumor. The infant presented with macrocephaly and irritability. The MRI images show a large posterior fossa tumor and diffuse hydrocephalus involving the entire ventricular system.<br />(A) Sagittal T1.<br />(B) Axial T1.<br />(C) Coronal FIESTA.<br /></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FIESTA: fast imaging employing steady-state acquisition.</div><div id=\"graphicVersion\">Graphic 111228 Version 1.0</div></div></div>"},"111229":{"type":"graphic_diagnosticimage","displayName":"4th ventricle outlet membranous obstruction","title":"Obstructive hydrocephalus due to membranous obstruction of the fourth ventricle outlet","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Obstructive hydrocephalus due to membranous obstruction of the fourth ventricle outlet</div><div class=\"cntnt\"><img style=\"width:607px; height:738px;\" src=\"images/PEDS/111229_4th_vntrcl_membrns_obstrctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted MRI images of a child with membranous obstruction of the outlet of the fourth ventricle. There is diffuse dilation of the entire ventricular system, including lateral, third, and fourth ventricles.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 111229 Version 1.0</div></div></div>"},"111230":{"type":"graphic_table","displayName":"Glucocorticoid dosing (upper limit of moderate daily dose range)","title":"Glucocorticoid dosing (upper limit of moderate daily dose range)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glucocorticoid dosing (upper limit of moderate daily dose range)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Glucocorticoid</td> <td class=\"subtitle1\">Adults</td> <td class=\"subtitle1\">Children</td> <td class=\"subtitle1\">Duration of action (hours)</td> </tr> <tr> <td>Prednisone</td> <td>40 mg</td> <td>1 mg/kg</td> <td>12 to 36</td> </tr> <tr> <td>Prednisolone</td> <td>40 mg</td> <td>1 mg/kg</td> <td>12 to 36</td> </tr> <tr> <td>Methylprednisolone</td> <td>31 mg</td> <td>0.8 mg/kg</td> <td>12 to 36</td> </tr> <tr> <td>Hydrocortisone</td> <td>160 mg</td> <td>4 mg/kg</td> <td>8 to 12</td> </tr> <tr> <td>Cortisone acetate</td> <td>200 mg</td> <td>5 mg/kg</td> <td>8 to 12</td> </tr> <tr> <td>Dexamethasone</td> <td>6 mg</td> <td>0.15 mg/kg</td> <td>26 to 72</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111230 Version 1.0</div></div></div>"},"111231":{"type":"graphic_diagnosticimage","displayName":"Viral myocarditis in an adolescent","title":"Chest radiograph of an adolescent with viral myocarditis","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of an adolescent with viral myocarditis</div><div class=\"cntnt\"><img style=\"width:612px; height:609px;\" src=\"images/PEDS/111231_Viral_myocarditis_adolescnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior (AP) chest radiograph of an adolescent with viral myocarditis. The child was a previously healthy 15-year-old boy who presented with severe chest pain in the setting of a viral prodrome. Chest radiograph demonstrates mild cardiomegaly, bilateral pleural effusions, prominence of the central pulmonary vessels, and interstitial haziness, suggestive of pulmonary edema.</div><div id=\"graphicVersion\">Graphic 111231 Version 1.0</div></div></div>"},"111232":{"type":"graphic_diagnosticimage","displayName":"Fulminant viral myocarditis in a child","title":"Chest radiograph of a child with fulminant viral myocarditis","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a child with fulminant viral myocarditis</div><div class=\"cntnt\"><img style=\"width:620px; height:676px;\" src=\"images/PEDS/111232_Fulminnt_vrl_myocrdts_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior-posterior (AP) chest radiograph of a child with fulminant viral myocarditis. The child was a previously healthy 9-year-old girl who presented with progressive orthopnea, cough, and respiratory distress following two weeks of a viral prodrome. Chest radiograph demonstrates bilateral lung opacities, sizable bilateral pleural effusions, and borderline cardiomegaly. The child presented in severe distress and suffered cardiopulmonary arrest shortly after arrival to the emergency department. Management included inotropic support, diuretic therapy, placement of bilateral chest tubes, and intravenous immune globulin. She subsequently made a full recovery.</div><div id=\"graphicVersion\">Graphic 111232 Version 1.0</div></div></div>"},"111236":{"type":"graphic_table","displayName":"Causes/risk factors: Newborn hearing loss","title":"Causes and risk factors for newborn hearing loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and risk factors for newborn hearing loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Conductive transient</td> <td class=\"divider_bottom\" rowspan=\"2\">Transient</td> <td class=\"divider_bottom\" rowspan=\"2\">Caused by abnormalities of the outer or middle ear, which limit the amount of external sound that gains access to the inner ear (cochlea and vestibular apparatus)</td> <td>Outer ear</td> <td> <ul> <li>Blockage of ear canal by cerumen or amniotic fluid </li> <li>Debris in ear canal </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Middle ear</td> <td> <ul> <li>Acute otitis media </li> <li>Middle ear effusion </li> <li>Tympanic membrane perforation </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Conductive permanent</td> <td class=\"divider_bottom\" rowspan=\"2\">Permanent</td> <td class=\"divider_bottom\" rowspan=\"2\">Caused by abnormalities of the outer or middle ear, which limit the amount of external sound that gains access to the inner ear (cochlea and vestibular apparatus)</td> <td>Outer ear</td> <td> <ul> <li>Congenital atresia </li> <li>Congenital microtia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Middle ear</td> <td> <ul> <li>Ossicular chain anomaly (eg, absent stapes) </li> <li>Temporal bone fracture (birth trauma) </li> <li>Craniofacial abnormalities of the pinna or ear canal </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Sensorineural*</td> <td>Permanent</td> <td>Caused by malfunction of inner ear structures (outer and inner hair cells and CN VIII components of the auditory neural pathway) resulting in impaired neuro-conduction of sound energy to the brainstem from the inner ear</td> <td>Inner ear, including outer and inner hair cells and CN VIII components of the auditory neural pathway</td> <td> <ul> <li>Bacterial sepsis or meningitis </li> <li>Congenital viral infections (eg, CMV and Zika) </li> <li>ECMO </li> <li>Extreme prematurity<sup>&#182;</sup> </li> <li>Genetic disorders (mutations in the <em>GJB2</em> gene that encodes the protein Connexin 26) </li> <li>Hyperbilirubinemia </li> <li>HIE </li> <li>Ototoxic medications (eg, aminoglycosides)</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Auditory neuropathy*</td> <td>Permanent</td> <td>Caused by impaired neural processing of auditory stimuli with a deficit in the perception or complete analysis of auditory information</td> <td>CN VIII, auditory brainstem, cerebral cortex</td> <td> <ul> <li>Bacterial meningitis </li> <li>Congenital syndromes with brain abnormalities </li> <li>Congenital viral infection (rubella, CMV, and Zika) </li> <li>Genetic disorders (mutations of the <em>OTOF</em> gene that encodes the protein otoferlin) </li> <li>HIE </li> <li>Hyperbilirubinemia </li> <li>Mitochondrial disease </li> <li>Ototoxic medications (eg, aminoglycosides) </li> <li>Prenatal exposure to heavy metals or alcohol </li> </ul> </td> </tr> <tr> <td>Mixed</td> <td>Permanent</td> <td>Caused by a combination of sensorineural or auditory neuropathy with transient or permanent conductive hearing loss</td> <td>Outer, middle, and inner ear</td> <td> <ul> <li>Congenital viral infection (eg, Zika) with both microtia and auditory neuropathy or sensorineural hearing loss </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CN: cranial nerve; CMV: cytomegalovirus; ECMO: extracorporeal membrane oxygenation; HIE: hypoxic ischemic encephalopathy.<br />* There is overlap of examples between sensorineural hearing loss and auditory neuropathy as some conditions affect both components of the inner ear and the neural processing of auditory stimuli through CN VIII, brain stem and cerebral cortex.<br />¶ Extreme prematurity is defined as a gestational age &lt;28 weeks.</div><div id=\"graphicVersion\">Graphic 111236 Version 3.0</div></div></div>"},"111237":{"type":"graphic_table","displayName":"Decision to restart anticoagulation","title":"Decision to restart anticoagulation after a bleeding event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Decision to restart anticoagulation after a bleeding event</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Characteristics that favor restarting the anticoagulant</td> <td class=\"subtitle1\">Characteristics that favor not restarting the anticoagulant</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Risk of thromboembolism of the anticoagulant is not restarted</td> </tr> <tr> <td class=\"indent1\">Strength of indication for anticoagulation</td> <td>A prior thromboembolic event, especially arterial, may indicate a greater thromboembolic risk and greater benefit of restarting the anticoagulant.</td> <td>Use of anticoagulation for primary prophylaxis, especially for VTE during a transient period of increased risk, may indicate less benefit of restarting the anticoagulant.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Persistence of thromboembolic risk</td> <td>Persistent thromboembolic risk may indicate a greater benefit of restarting the anticoagulant. Examples:&nbsp; <ul class=\"decimal_heading\"> <li>Prosthetic heart valve </li> <li>Atrial fibrillation </li> <li>High-risk thrombophilia (eg, APS, hereditary AT deficiency) </li> </ul> </td> <td>Transient thromboembolic risk that has been eliminated may indicate less benefit of restarting the anticoagulant. Examples: <ul class=\"decimal_heading\"> <li>Provoked&nbsp;VTE </li> <li>PNH treated with anti-complement therapy or HCT </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Risk of bleeding if the anticoagulant is restarted</td> </tr> <tr> <td class=\"indent1\">Type&nbsp;of bleeding</td> <td>Bleeding in a less life-threatening site (eg, epistaxis, dental) may indicate a lower risk of life-threatening bleeding from restarting the anticoagulant.</td> <td>Intracerebral bleeding, especially lobar or with evidence of microbleeds on CNS imaging, indicate a greater risk of serious rebleeding.</td> </tr> <tr> <td class=\"indent1\">Persistence of bleeding risk</td> <td>A bleeding source that has been eliminated indicates a lower risk of rebleeding. Examples: <ul class=\"decimal_heading\"> <li>CNS bleeding in the setting of severe HTN that has been treated </li> <li>Thrombocytopenia due to ITP that has been treated successfully </li> </ul> </td> <td>A persistent source of bleeding may indicate a persistent increased risk of rebleeding. Examples: <ul class=\"decimal_heading\"> <li>Multiple gastrointestinal telangiectasias </li> <li>CNS microbleeds </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anticoagulant-related issues</td> <td>Bleeding with a&nbsp;supratherapeutic INR due to a medication interaction may be addressed by switching to a&nbsp;DOAC.</td> <td>Bleeding with prophylactic-dose anticoagulation or a concurrent bleeding disorder may indicate a higher risk&nbsp;of rebleeding.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Patient values and preferences</td> </tr> <tr> <td class=\"indent1\">Concern about recurrent events</td> <td>Patients who place a higher value on avoiding recurrent thromboembolism may choose to restart the anticoagulant.</td> <td>Patients who place a higher value on avoiding recurrent bleeding may choose not to restart the anticoagulant.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinical judgment is required to make an individualized decision that weighs all of the relevant factors for each specific patient. Consultation with a specialist with expertise in anticoagulation may be appropriate. Refer to UpToDate for thromboembolic risks according to the underlying condition(s); risks of rebleeding according to the initial bleeding site(s); choice of anticoagulant; and optimal time to reinitiate anticoagulation. </div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; APS: antiphospholipid syndrome; AT: antithrombin; HCT: hematopoietic cell transplantation; CNS: central nervous system; HTN: hypertension; ITP: immune thrombocytopenia; INR: international normalized ratio; DOAC: direct oral anticoagulant.</div><div id=\"graphicVersion\">Graphic 111237 Version 1.0</div></div></div>"},"111239":{"type":"graphic_picture","displayName":"Necrolytic acral erythema","title":"Necrolytic acral erythema","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Necrolytic acral erythema</div><div class=\"cntnt\"><img style=\"width:765px; height:373px;\" src=\"images/ID/111239_Necrolytic_acral_erythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrolytic acral erythema is a rare cutaneous disorder associated with hepatitis C virus infection.&nbsp;<br />(A) Violaceous plaques extend from the distal interphalangeal joint to the fingertips.<br />(B) Confluent moderately well-defined erythematous to violaceous plaques with superficial erosions on the feet and lower legs.</div><div class=\"graphic_reference\">From: Iyengar S, Chang S, Ho B, et al. Necrolytic acral erythema masquerading as cellulitis. Dermatol Online J 2014; 20(11). Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111239 Version 1.0</div></div></div>"},"111241":{"type":"graphic_figure","displayName":"Risk-adjusted survival for adenoCA of the esophagus and EGJ","title":"Risk-adjusted survival after treatment decision for clinically staged (c), pathologically staged (p), and posttreatment pathologically staged (yp) adenocarcinoma of the esophagus and esophagogastric junction","html":"<div class=\"graphic\"><div style=\"width: 842px\" class=\"figure\"><div class=\"ttl\">Risk-adjusted survival after treatment decision for clinically staged (c), pathologically staged (p), and posttreatment pathologically staged (yp) adenocarcinoma of the esophagus and esophagogastric junction</div><div class=\"cntnt\"><img style=\"width:822px; height:730px;\" src=\"images/ONC/111241_RiskadjadenoCAesophEGJ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Risk-adjusted survival after treatment decision for clinically staged (c) adenocarcinoma of the esophagus based on WECC data.<br />(B) Risk-adjusted survival after treatment decision for pathologically staged (p) adenocarcinoma of the esophagus based on WECC data.<br />(C) Risk-adjusted survival after treatment decision for postneoadjuvant pathologically staged (yp) adenocarcinoma of the esophagus based on WECC data.</div><div class=\"graphic_footnotes\">WECC: Worldwide Esophageal Cancer Collaboration.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111241 Version 2.0</div></div></div>"},"111242":{"type":"graphic_table","displayName":"Distribution of nodal mets in EGJ adenoCA type I, II, and III","title":"Distribution of lymph node metastases in patients with resected adenocarcinoma of the esophagogastric junction (AEG) of Siewert type I, II, and III","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of lymph node metastases in patients with resected adenocarcinoma of the esophagogastric junction (AEG) of Siewert type I, II, and III</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Percent of tumors with lymph node metastases</td> <td class=\"subtitle1\">Location of nodal metastases</td> </tr> <tr> <td class=\"centered\">I</td> <td class=\"centered\">65</td> <td>Upper abdominal nodes&nbsp;(54%)<br /> Mediastinum (46%)</td> </tr> <tr> <td class=\"centered\">II</td> <td class=\"centered\">70</td> <td>Abdominal nodes (paracardial, lesser curvature, left gastric) (71%)<br /> Mediastinum (30%)</td> </tr> <tr> <td class=\"centered\">III</td> <td class=\"centered\">90</td> <td>Abdominal nodes (91%)<br /> Mediastinum (9%)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Mullen JT, Kwak EL, Hong TS. What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer. Ann Surg Oncol 2016; 23:3780.</div><div id=\"graphicVersion\">Graphic 111242 Version 1.0</div></div></div>"},"111243":{"type":"graphic_algorithm","displayName":"Neonatal erythroderma differential diagnosis 1","title":"Diagnostic approach to the neonate and infant with generalized nonbullous, scaly erythroderma","html":"<div class=\"graphic\"><div style=\"width: 1130px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the neonate and infant with generalized nonbullous, scaly erythroderma</div><div class=\"cntnt\"><img style=\"width:1110px; height:646px;\" src=\"images/DERM/111243_Neonatal_erythroderm_diag_1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCID: severe combined immunodeficiency; GVHD: graft-versus-host disease; IgE: immunoglobulin E; <em>SPINK5</em>: serine peptidase inhibitor, Kazal type 5; <em>RAG1</em> and <em>RAG2</em>: recombinase-activating genes 1 and 2; <em>DOCK8</em>: dedicator of cytokinesis 8; STAT3: signal transducer and activator of transcription 3; FISH: fluorescence in situ hybridization.<br/>* In the United States and in several countries in Europe, Asia, and Australia, newborn screening is performed for primary immunodeficiencies and several metabolic diseases.</div><div id=\"graphicVersion\">Graphic 111243 Version 2.0</div></div></div>"},"111244":{"type":"graphic_figure","displayName":"Risk-adjusted survival for esoph SCC","title":"Risk-adjusted survival after treatment decision for clinically staged (c), pathologically staged (p), and posttreatment pathologically staged (yp) esophageal squamous cell cancer","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Risk-adjusted survival after treatment decision for clinically staged (c), pathologically staged (p), and posttreatment pathologically staged (yp) esophageal squamous cell cancer</div><div class=\"cntnt\"><img style=\"width:760px; height:740px;\" src=\"images/ONC/111244_RiskadjsurvivalesophSCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Risk-adjusted survival after treatment decision for clinically staged (c) squamous cell carcinoma of the esophagus based on Worldwide Esophageal Cancer Collaboration (WECC) data.<br />(B) Risk-adjusted survival after treatment decision for pathologically staged (p) squamous cell carcinoma of the esophagus based on WECC data.<br />(C) Risk-adjusted survival after treatment decision for postneoadjuvant pathologically staged (yp) squamous cell carcinoma of the esophagus based on WECC data.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111244 Version 2.0</div></div></div>"},"111248":{"type":"graphic_form","displayName":"SOAPP (scoring instructions)","title":"Scoring instructions for Screener and Opioid Assessment for Patients with Pain (SOAPP)","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Scoring instructions for Screener and Opioid Assessment for Patients with Pain (SOAPP)</div><div class=\"cntnt\"><img style=\"width:544px; height:762px;\" src=\"images/ANEST/111248_SOAPP_scoring_instructions.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 Inflexxion, Inc., Newton MA. All rights reserved. <a href=\"http://www.inflexxion.com/\" target=\"_blank\">www.Inflexxion.com</a>.</div><div id=\"graphicVersion\">Graphic 111248 Version 2.0</div></div></div>"},"111254":{"type":"graphic_waveform","displayName":"12-lead ECG sustained monomorphic VT","title":"12-lead ECG sustained monomorphic VT","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">12-lead ECG sustained monomorphic VT</div><div class=\"cntnt\"><img style=\"width:766px; height:414px;\" src=\"images/CARD/111254_12ld_ECG_sstnd_monomrphc_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The electrocardiogram (ECG) hallmark for the diagnosis of sustained monomorphic ventricular tachycardia (SMVT) is a wide complex tachycardia with the obvious presence of atrioventricular (AV) dissociation. AV dissociation is suggested by the presence of fusion complexes (which reflect a supraventricular impulse coming from above the AV node fusing with an impulse generated in the ventricle) or captured complexes (which reflect an impulse coming from above the AV node that depolarizes the ventricles when they are no longer refractory but before the next ventricle-generated complex). Beats 12, 17, and 22 on this ECG likely represent capture beats.</div><div id=\"graphicVersion\">Graphic 111254 Version 1.0</div></div></div>"},"111255":{"type":"graphic_picture","displayName":"Lichen planus pigmentosus of vulva","title":"Lichen planus pigmentosus of vulva","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus pigmentosus of vulva</div><div class=\"cntnt\"><img style=\"width:433px; height:756px;\" src=\"images/OBGYN/111255_Lchn_plns_pigmentosus_vulva_.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 111255 Version 1.0</div></div></div>"},"111256":{"type":"graphic_picture","displayName":"Lichen sclerosus hyperpigmentation image 2","title":"Lichen sclerosus hyperpigmentation image 2","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus hyperpigmentation image 2</div><div class=\"cntnt\"><img style=\"width:640px; height:756px;\" src=\"images/OBGYN/111256_Lchn_scleross_hyperpgmnttn2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 111256 Version 1.0</div></div></div>"},"111257":{"type":"graphic_picture","displayName":"Lichen sclerosus hyperpigmentation image 3","title":"Lichen sclerosus hyperpigmentation image 3","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus hyperpigmentation image 3</div><div class=\"cntnt\"><img style=\"width:496px; height:756px;\" src=\"images/OBGYN/111257_Lchn_scleross_hyperpgmnttn3.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 111257 Version 1.0</div></div></div>"},"111258":{"type":"graphic_picture","displayName":"Lichen sclerosus postinflammatory pigmentation","title":"Lichen sclerosus postinflammatory pigmentation","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus postinflammatory pigmentation</div><div class=\"cntnt\"><img style=\"width:512px; height:756px;\" src=\"images/OBGYN/111258_Lchn_sclrs_pstnflmtry_pgmnt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 111258 Version 1.0</div></div></div>"},"111259":{"type":"graphic_picture","displayName":"Lymphangiomas of the labial edge","title":"Lymphangiomas of the edge of the right labium majus","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Lymphangiomas of the edge of the right labium majus</div><div class=\"cntnt\"><img style=\"width:495px; height:756px;\" src=\"images/OBGYN/111259_Lymphangiomas_labial_edge.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 111259 Version 1.0</div></div></div>"},"111260":{"type":"graphic_figure","displayName":"Diagram of the esophageal anatomy AJCC 2017","title":"AJCC regions of the esophagus ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AJCC regions of the esophagus </div><div class=\"cntnt\"><img style=\"width:440px; height:659px;\" src=\"images/ONC/111260_DiagramoftheesophagealanatomyAJCC2017.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of esophageal cancer primary site, including typical endoscopic measurements of each&nbsp;region measured from the incisors. Exact measurements depend on body size and height. For tumors of the EGJ and cardia, location of cancer primary site (ie, esophagus, stomach)&nbsp;is defined by cancer epicenter.</div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; v: vein.</div><div class=\"graphic_reference\">Modified from: Rice TW, Kelsen D, Blackstone EH, et al. Esophagus and esophagogastric junction. In: AJCC Cancer Staging Manual, 8th Ed, Amin MB (ed), Springer Science+Business Media, LLC, New York, 2017.</div><div id=\"graphicVersion\">Graphic 111260 Version 2.0</div></div></div>"},"111261":{"type":"graphic_picture","displayName":"Typhoid fever rose spots","title":"Rose spots of typhoid fever","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Rose spots of typhoid fever</div><div class=\"cntnt\"><img style=\"width:710px; height:1065px;\" src=\"images/PEDS/111261_Typhoid_fever_rose_spots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rose spots are small (1 to 5 mm), erythematous, blanchable, nontender papules, which begin early during the acute febrile period of typhoid fever. Crops of lesions (10 to 20) appear at irregular intervals for approximately 10 to 14 days, typically distributed on the abdomen, chest, and back. Rarely, vesicular or hemorrhagic lesions appear. The lesions persist for two to three days.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111261 Version 1.0</div></div></div>"},"111282":{"type":"graphic_table","displayName":"Select causes of FUO children","title":"Select causes of fever of unknown origin in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Select causes of fever of unknown origin in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition</td> <td class=\"subtitle1\" colspan=\"3\">Associated clinical findings (which may not be present)</td> </tr> <tr> <td class=\"subtitle2\">History</td> <td class=\"subtitle2\">Examination</td> <td class=\"subtitle2\">Laboratory, imaging, or other initial tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Generalized infections</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Brucellosis</td> <td> <ul> <li>Sustained fever pattern </li> <li>Lethargy </li> <li>Osteoarticular pain </li> </ul> <br /> <strong>Exposures:</strong> Animals or animal products (eg, unpasteurized milk/cheese, insufficiently cooked/raw meat)</td> <td> <ul> <li>Uveitis </li> <li>Hepatomegaly </li> <li>Splenomegaly </li> <li>Testicular tenderness </li> </ul> </td> <td> <ul> <li>Mild elevation of hepatic aminotransferases </li> <li>Lymphocytopenia </li> <li>Positive blood culture </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cat scratch disease</td> <td> <ul> <li>Gastrointestinal complaints </li> </ul> <br /> <strong>Exposures:</strong> Cats/kittens</td> <td> <ul> <li>Localized lymphadenopathy </li> <li>Hepatomegaly </li> <li>Splenomegaly </li> <li>Liver tenderness </li> <li>Papular lesion at entry site </li> </ul> </td> <td> <ul> <li>Lymphocytosis </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Leptospirosis</td> <td> <ul> <li>Rigors </li> <li>Myalgia</li> <li>Headache</li> <li>Cough </li> <li>Gastrointestinal complaints </li> </ul> <br /> <strong>Exposures:</strong> Animal urine, contaminated soil or water, infected animal tissue</td> <td> <ul> <li>Relative bradycardia* </li> <li>Bulbar conjunctivitis </li> <li>Pharyngeal hyperemia </li> </ul> </td> <td> <ul> <li>Thrombocytopenia </li> <li>Hyponatremia </li> <li>Proteinuria </li> <li>Pyuria </li> <li>Granular casts </li> <li>Small nodular densities on CXR </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malaria</td> <td> <ul> <li>Relapsing fever pattern </li> </ul> <br /> <strong>Exposures:</strong> Travel to malaria-endemic area</td> <td> <ul> <li>Splenomegaly </li> </ul> </td> <td> <ul> <li>Anemia </li> <li>Lymphocytopenia </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\"><em>Mycobacteria tuberculosis</em></td> <td> <ul> <li>Intermittent fever pattern </li> </ul> <br /> <strong>Exposures:</strong> Travel to endemic area or contact with traveler to endemic area</td> <td> <ul> <li>Phlyctenular conjunctivitis </li> <li>Funduscopy: Choroid tubercles </li> <li>Chronic nontender lymphadenopathy </li> </ul> </td> <td> <ul> <li>Positive TST or IGRA </li> <li>Anemia </li> <li>Lymphocytopenia </li> <li>Hilar lymphadenopathy (pulmonary TB) </li> <li>Sterile pyuria (in genitourinary TB) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Salmonellosis</td> <td> <ul> <li>Gastrointestinal symptoms </li> <li>Fatigue </li> <li>Malaise </li> <li>Headaches </li> <li>Urinary symptoms </li> <li>Respiratory symptoms </li> </ul> <br /> <strong>Exposures:</strong> Poultry, eggs, reptiles</td> <td> <ul> <li>Weight loss </li> <li>Hepatomegaly </li> <li>Splenomegaly </li> </ul> </td> <td>&nbsp;</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Toxoplasmosis</td> <td><strong>Exposures:</strong> Feline feces, pica (dirt), consumption of game meat</td> <td> <ul> <li>Lymphadenopathy (cervical or supraclavicular) </li> <li>Funduscopy: Chorioretinitis in nonvascular distribution </li> <li>Pharyngeal hyperemia </li> </ul> </td> <td> <ul> <li>Lymphocytosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tularemia</td> <td> <ul> <li>Fever </li> <li>Chills </li> <li>Anorexia </li> <li>Malaise </li> <li>Headache </li> <li>Fatigue </li> <li>Muscle soreness </li> <li>Gastrointestinal complaints </li> </ul> <br /> <strong>Exposures:</strong> Dead animal carcasses (eg, rabbits), ingestion of rabbit or squirrel meat; ticks, mosquitoes, lice, fleas, flies</td> <td> <ul> <li>Vary depending upon the portal of entry; may include: <ul> <li>Pharyngeal hyperemia </li> <li>Eschar at entry site </li> <li>Tender regional lymphadenopathy </li> <li>Bulbar and palpebral conjunctivitis </li> </ul> </li> </ul> </td> <td> <ul> <li>Thrombocytopenia </li> <li>Elevated hepatic aminotransferases </li> <li>Pyuria </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Typhoid fever</td> <td> <ul> <li>Abdominal pain </li> <li>Chills </li> <li>Diarrhea or constipation </li> <li>Headache </li> </ul> <br /> <strong>Exposures:</strong> Travel to endemic area</td> <td> <ul> <li>Relative bradycardia* </li> <li>Rose spots </li> </ul> </td> <td> <ul> <li>Anemia </li> <li>Leukopenia or leukocytosis (especially in children &#60;5 years of age) </li> <li>Elevation of hepatic aminotransferases </li> <li>Positive blood culture </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Localized infections</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Osteomyelitis and septic arthritis</td> <td> <ul> <li>Bone pain </li> <li>Limp </li> </ul> </td> <td> <ul> <li>Bone tenderness or joint tenderness </li> </ul> </td> <td> <ul> <li>Elevated ESR/CRP </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Infective endocarditis</td> <td> <ul> <li>Pre-existing cardiac lesion </li> </ul> </td> <td> <ul> <li>New onset cardiac murmur </li> <li>Conjunctival hemorrhage </li> <li>Hepatomegaly </li> <li>Splenomegaly </li> <li>Petechiae </li> </ul> </td> <td> <ul> <li>Anemia </li> <li>Leukocytosis </li> <li>Elevated ESR/CRP </li> <li>Positive blood culture </li> <li>Hematuria </li> <li>Proteinuria </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Intraabdominal abscess (subphrenic, perinephric, pelvic)</td> <td> <ul> <li>Previous intraabdominal disease or surgery </li> <li>Vague abdominal pain </li> </ul> </td> <td> <ul> <li>Abdominal tenderness (may be absent) </li> </ul> </td> <td> <ul> <li>Sterile pyuria </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Liver abscess/hepatic infection</td> <td> <ul> <li>Possible jaundice (jaundice is not common with a single pyogenic liver abscess) </li> <li>Most often in immunocompromised patients </li> </ul> </td> <td> <ul> <li>Hepatomegaly </li> <li>Right upper quadrant pain </li> </ul> </td> <td> <ul> <li>Abnormal hepatic aminotransferases (not always present; more likely with multiple abscesses or hepatic infection) </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Urinary tract infection</td> <td> <ul> <li>Dysuria </li> <li>Urgency </li> <li>Frequency </li> <li>Incontinence </li> <li>Abdominal pain </li> </ul> </td> <td> <ul> <li>Suprapubic tenderness </li> <li>Costovertebral angle tenderness </li> </ul> </td> <td> <ul> <li>Pyuria </li> <li>Bacteriuria </li> <li>Hematuria </li> <li>Positive urine culture </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Rheumatologic diseases</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Juvenile idiopathic arthritis</td> <td> <ul> <li>Intermittent fever pattern (&#8805;1 fever spike per day with return to normal temperature between fevers) </li> <li>Arthralgias </li> <li>Ill-appearing with fever </li> </ul> </td> <td> <ul> <li>Salmon-pink rash with fever </li> <li>Erythema nodosum </li> <li>Lymphadenopathy </li> <li>Hepatomegaly </li> <li>Splenomegaly </li> <li>Arthritis </li> </ul> </td> <td> <ul> <li>Leukocytosis </li> <li>Thrombocytosis </li> <li>Anemia </li> <li>Elevated ESR </li> <li>Mild elevation of aminotransferases </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> <td> <ul> <li>Malaise </li> <li>Headache </li> <li>Anterior chest pain </li> <li>Dyspnea </li> <li>Neuropsychiatric complaints (eg, depression, decreased academic performance) </li> </ul> </td> <td> <ul> <li>Tachycardia </li> <li>Tachypnea </li> <li>Weight loss </li> <li>Oral ulcers </li> <li>Malar rash </li> <li>Erythema nodosum </li> <li>Pericardial rub </li> <li>Small joint arthritis </li> </ul> </td> <td> <ul> <li>Anemia </li> <li>Neutropenia </li> <li>Thrombocytopenia </li> <li>Hematuria </li> <li>Proteinuria </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Vasculitis (eg, polyarteritis nodosa)</td> <td> <ul> <li>Malaise </li> <li>Abdominal pain </li> <li>Myalgia </li> <li>Muscle weakness </li> </ul> </td> <td> <ul> <li>Weight loss </li> <li>Hypertension </li> <li>Palpable purpura </li> <li>Subcutaneous nodules </li> <li>Asymmetric neuropathy </li> <li>Testicular tenderness </li> <li>Funduscopic examination: Perivascular sheathing </li> </ul> </td> <td> <ul> <li>Positive stool guaiac </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Neoplasms</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Leukemia</td> <td> <ul> <li>Limb or bone pain </li> </ul> </td> <td> <ul> <li>Gingival hypertrophy </li> <li>Hepatosplenomegaly </li> <li>Lymphadenopathy </li> <li>Testicular enlargement </li> </ul> </td> <td> <ul> <li>Cytopenia in &#8805;1 cell line </li> <li>Bizarre/immature WBCs </li> <li>Neutropenia </li> <li>Mediastinal mass </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lymphoma</td> <td> <ul> <li>Intermittent, remittent, or relapsing fever pattern </li> <li>Fatigue </li> <li>Night sweats </li> </ul> </td> <td> <ul> <li>Weight loss </li> <li>Lymphadenopathy </li> <li>Hepatosplenomegaly </li> </ul> </td> <td> <ul> <li>Mediastinal mass or lymphadenopathy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Other causes</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Altered thermoregulation</td> <td> <ul> <li>History of brain damage or CNS dysfunction </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Normal ESR/CRP </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diabetes insipidus (central or nephrogenic)</td> <td> <ul> <li>Polyuria </li> <li>Polydipsia </li> <li>More common in Ulster Scots (nephrogenic) </li> </ul> </td> <td> <ul> <li>Weight loss </li> <li>Lack of sweat with fever </li> <li>Decreased peripheral perfusion </li> </ul> </td> <td> <ul> <li>Hypernatremia </li> <li>Normal ESR/CRP </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Drug fever</td> <td> <ul> <li>Resolution with discontinuation of offending drug </li> </ul> <br /> <strong>Exposures:</strong> Virtually any drug or complementary and alternative agent</td> <td> <ul> <li>Rash </li> </ul> </td> <td> <ul> <li>Leukocytosis </li> <li>Eosinophilia </li> <li>Elevated ESR </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Factitious fever</td> <td> <ul> <li>Absence of nonspecific symptoms (malaise, discomfort) during fever </li> <li>Discrepancy between temperatures recorded or reported by the patient or caregiver and those obtained rectally under direct observation </li> </ul> </td> <td> <ul> <li>Rapid defervescence without diaphoresis </li> </ul> </td> <td> <ul> <li>Normal ESR/CRP </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Familial dysautonomia</td> <td> <ul> <li>Lack of sweat during fever </li> <li>More common in patients of Ashkenazi Jewish descent </li> </ul> </td> <td> <ul> <li>Labile blood pressure </li> <li>Decreased/absent tears </li> <li>Absent corneal reflex </li> <li>Hypodontia, adontia, or conical teeth </li> <li>Smooth tongue </li> <li>Erythematous or blotchy skin </li> <li>Decreased DTR </li> </ul> </td> <td> <ul> <li>Normal ESR/CRP </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hemophagocytic lymphohistiocytosis</td> <td> <ul> <li>May have positive family history </li> </ul> <br /> <strong>Exposures:</strong> Infection, immunologic disorder, malignancy, drugs</td> <td> <ul> <li>Lymphadenopathy </li> <li>Hepatosplenomegaly </li> <li>Skin lesions (generalized rash, erythroderma, edema, petechiae, purpura) </li> <li>Neurologic symptoms </li> </ul> </td> <td> <ul> <li>Cytopenias in &#8805;1 cell line (especially anemia and thrombocytopenia) </li> <li>Coagulopathy </li> <li>Liver dysfunction </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Infantile cortical hyperostosis</td> <td> <ul> <li>Limb or bone pain </li> </ul> </td> <td> <ul> <li>Bony tenderness </li> <li>Swelling of overlying tissues </li> </ul> </td> <td> <ul> <li>Leukocytosis </li> <li>Elevated ESR </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> <td> <ul> <li>Gastrointestinal complaints </li> <li>Delayed sexual maturation </li> <li>More common in adolescents </li> </ul> </td> <td> <ul> <li>Weight loss </li> <li>Short stature or decreased height velocity </li> <li>Oral ulcers </li> <li>Perianal fistulae, skin tags, or fissures </li> <li>Erythema nodosum </li> </ul> </td> <td> <ul> <li>Anemia </li> <li>Positive stool guaiac </li> <li>Elevated ESR/CRP </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Kawasaki disease</td> <td>&nbsp;</td> <td> <ul> <li>Bulbar conjunctivitis </li> <li>Strawberry tongue, cracked lips </li> <li>Rash </li> <li>Edema and periungual desquamation of hands and feet </li> <li>Cervical lymphadenopathy </li> </ul> </td> <td> <ul> <li>Thrombocytosis </li> <li>Sterile pyuria </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Kikuchi-Fujimoto disease</td> <td> <ul> <li>Fatigue </li> <li>Gastrointestinal complaints </li> <li>Joint pain </li> <li>More common in females and patients &#60;40 years of age </li> </ul> </td> <td> <ul> <li>Cervical lymphadenopathy </li> <li>Hepatosplenomegaly </li> <li>Arthritis </li> <li>Rash </li> </ul> </td> <td> <ul> <li>Leukopenia </li> <li>Atypical lymphocytes </li> <li>Thrombocytopenia </li> <li>Pancytopenia </li> <li>Elevated ESR </li> <li>Mildly elevated hepatic transferases </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Periodic fever disorders: <ul class=\"decimal_heading\"> <li>Cyclic neutropenia </li> <li>Hyperimmunoglobulin D syndrome </li> <li>PFAPA syndrome </li> <li>Deficiency of IL-1 or IL-36 receptor antagonist </li> </ul> </td> <td> <ul> <li>Recurrent fever pattern </li> </ul> </td> <td> <ul> <li>Refer to UpToDate content on periodic fever syndromes </li> </ul> </td> <td> <ul> <li>Elevated ESR/CRP during episodes </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FUO: fever of unknown origin; CXR: chest radiography; TST: tuberculin skin test; IGRA: interferon gamma release assay; TB: tuberculosis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; WBC: white blood cell; CNS: central nervous system; DTR: deep tendon reflexes; PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis; IL: interleukin.<br />* Relative bradycardia: For patients ≥13 years with temperature ≥38.9°C (102°F), failure of the pulse to increase as expected with fever (approximately 10 beats per minute for each 0.6°C [1°F]).</div><div id=\"graphicVersion\">Graphic 111282 Version 2.0</div></div></div>"},"111285":{"type":"graphic_table","displayName":"Examination FUO children","title":"Clinical significance of physical examination findings* in children with fever of unknown origin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical significance of physical examination findings* in children with fever of unknown origin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Possible causes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General assessment</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Labile blood pressure</td> <td> <ul> <li>Familial dysautonomia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tachypnea</td> <td> <ul> <li>Pneumonia </li> <li>Systemic lupus erythematosus </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Relative bradycardia<sup>&#182;</sup></td> <td> <ul> <li>Babesiosis </li> <li>Dengue fever </li> <li>Legionella </li> <li>Leptospirosis </li> <li>Malaria </li> <li>Psittacosis </li> <li>Q fever </li> <li>Rocky Mountain spotted fever </li> <li>Typhoid fever </li> <li>Typhus </li> <li>Viral hemorrhagic fever </li> <li>Yellow fever </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Weight loss</td> <td> <ul> <li>Diabetes insipidus </li> <li>Inflammatory bowel disease </li> <li>Malignancy </li> <li>Systemic illness </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Short stature or deceleration of linear growth</td> <td> <ul> <li>Endocrine disorder </li> <li>Inflammatory bowel disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin and scalp</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Petechiae</td> <td> <ul> <li>Bacteremia </li> <li>Infective endocarditis </li> <li>Rickettsial infection (eg, Rocky Mountain spotted fever) </li> <li>Viral infection </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Papular lesions</td> <td> <ul> <li>Cat scratch disease </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Eschar</td> <td> <ul> <li>Tularemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Erythema migrans or erythema migrans-like rashes</td> <td> <ul> <li>Lyme disease, Southern tick-associated rash illness </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Rose spots</td> <td> <ul> <li>Typhoid fever </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Salmon-pink rash with fever</td> <td> <ul> <li>Juvenile idiopathic arthritis </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Malar erythema</td> <td> <ul> <li>Systemic lupus erythematosus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Palpable purpura</td> <td> <ul> <li>Vasculitis (eg, polyarteritis nodosa) </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Erythema nodosum</td> <td> <ul> <li>Infection </li> <li>Inflammatory bowel disease </li> <li>Juvenile idiopathic arthritis </li> <li>Malignancy </li> <li>Systemic lupus erythematosus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Urticarial and/or serpiginous macular rash or band of erythema on the sides of the hands and feet</td> <td> <ul> <li>Serum sickness </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Seborrheic rash or scalp lesions</td> <td> <ul> <li>Langerhans cell histiocytosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lack of sweat during fever</td> <td> <ul> <li>Dehydration (possibly related to diabetes insipidus) </li> <li>Ectodermal dysplasia </li> <li>Familial dysautonomia (Riley-Day syndrome) </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Sparse hair</td> <td> <ul> <li>Hypohidrotic ectodermal dysplasia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Blotchy skin with multiple areas of trauma</td> <td> <ul> <li>Familial dysautonomia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Eyes</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Conjunctivitis</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\">Palpebral conjunctivitis</td> <td> <ul> <li>Coxsackievirus infection </li> <li>Infectious mononucleosis </li> <li>Measles </li> <li>Newcastle disease<sup>&#916;</sup> </li> <li>Tularemia </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Bulbar conjunctivitis</td> <td> <ul> <li>Kawasaki disease </li> <li>Leptospirosis </li> <li>Tularemia </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\">Phlyctenular conjunctivitis</td> <td> <ul> <li>Tuberculosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Abnormal funduscopic examination</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\">Ischemic retinopathy<br /> Ischemic optic neuropathy</td> <td> <ul> <li>Polyarteritis nodosa </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Choroid tubercles</td> <td> <ul> <li>Miliary tuberculosis </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\">Raised yellow-white cottony lesions in nonvascular distribution</td> <td> <ul> <li>Toxoplasmosis </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Perivascular sheathing</td> <td> <ul> <li>Vasculitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Other findings</strong></td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent2\">Conjunctival hemorrhage</td> <td> <ul> <li>Infective endocarditis </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Absent pupillary constrictor response</td> <td> <ul> <li>Autonomic dysfunction </li> <li>Hypothalamic dysfunction </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent2\">Absent tears, absent corneal reflex</td> <td> <ul> <li>Familial dysautonomia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sinuses</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Tenderness</td> <td> <ul> <li>Rhinosinusitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oropharynx</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Oral ulcers</td> <td> <ul> <li>Inflammatory bowel disease </li> <li>Systemic lupus erythematosus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pharyngeal hyperemia without exudate</td> <td> <ul> <li>Infectious mononucleosis (EBV or CMV) </li> <li>Leptospirosis </li> <li>Toxoplasmosis </li> <li>Tularemia </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Dental abscess</td> <td> <ul> <li>May be complicated by other infections (eg, sinusitis, brain abscess, etc) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypodontia, adontia, or conical (\"peg\") teeth</td> <td> <ul> <li>Anhidrotic ectodermal dysplasia </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Smooth tongue without fungiform papillae and/or excessive salivation</td> <td> <ul> <li>Familial dysautonomia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gingival hypertrophy or inflammation</td> <td> <ul> <li>Langerhans cell histiocytosis </li> <li>Leukemia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lymph nodes</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Lymphadenopathy/lymphadenitis</td> <td> <ul> <li>Refer to UpToDate content on peripheral lymphadenopathy in children </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chest</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Crackles (rales) decreased or bronchial breath sounds, bronchophony, whispered pectoriloquy, tactile fremitus, dullness to percussion</td> <td> <ul> <li>Pneumonia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cardiac murmur (new onset)</td> <td> <ul> <li>Infective endocarditis </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Pericardial rub</td> <td> <ul> <li>Pericarditis (a manifestation of systemic lupus erythematosus) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Hepatomegaly or splenomegaly</td> <td> <ul> <li>Brucellosis </li> <li>Cat scratch disease </li> <li>Hemophagocytic lymphohistiocytosis &nbsp;</li> <li>Infectious mononucleosis </li> <li>Infective endocarditis </li> <li>Leukemia/lymphoma&nbsp;</li> <li>Malaria </li> <li>Salmonellosis&nbsp;</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tenderness with palpation of the liver edge</td> <td> <ul> <li>Cat scratch disease </li> <li>Liver abscess </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Musculoskeletal</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Bony tenderness</td> <td> <ul> <li>Infantile cortical hyperostosis </li> <li>Osteomyelitis </li> <li>Malignant infiltration of the bone marrow </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Muscle tenderness</td> <td> <ul> <li>Arboviral infection </li> <li>Dermatomyositis </li> <li>Polyarteritis nodosa </li> <li>Trichinellosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Abnormal deep tendon reflexes</td> <td> <ul> <li>Hyperactive: Hyperthyroidism </li> <li>Hypoactive: Familial dysautonomia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genitourinary</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Perirectal tenderness or mass</td> <td> <ul> <li>Pelvic mass or tumor </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Genital ulcers, urethral discharge</td> <td> <ul> <li>Sexually transmitted infection </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Perianal fistulae, skin tags, or fissures</td> <td> <ul> <li>Inflammatory bowel disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">For females: Cervical motion tenderness, uterine or adnexal tenderness</td> <td> <ul> <li>Pelvic inflammatory disease </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">For males: Testicular tenderness</td> <td> <ul> <li>Brucellosis </li> <li>Polyarteritis nodosa </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBV: Epstein-Barr virus; CMV: cytomegalovirus.<br />* Repeating the examination on multiple occasions is necessary to detect findings that develop or evolve after the initial assessment.<br />&para; Relative bradycardia: For patients &ge;13 years with temperature &ge;38.9&deg;C (102&deg;F), failure of the pulse to increase as expected with fever (approximately 10 beats per minute for each 0.6&deg;C [1&deg;F]).<br />&Delta; Newcastle disease is a viral infection associated with exposure to chickens or other birds.</div><div id=\"graphicVersion\">Graphic 111285 Version 2.0</div></div></div>"},"111286":{"type":"graphic_table","displayName":"History FUO children","title":"Clinical significance of historical findings* in children with fever of unknown origin<sup>¶</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical significance of historical findings* in children with fever of unknown origin<sup>&para;</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Fever history</td> <td class=\"subtitle1_single\">Potential significance</td> </tr> <tr> <td class=\"indent1\">What is the fever pattern?</td> <td class=\"indent1\"> <ul> <li>Refer to UpToDate topic on FUO in children for details </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Is the fever associated with ill-appearance or symptoms (eg, malaise)?</td> <td class=\"indent1\"> <ul> <li>Absence of malaise or other generalized symptoms with high fever may suggest factitious fever </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Does the fever respond to antipyretic agents?</td> <td class=\"indent1\"> <ul> <li>Lack of response to antiinflammatory antipyretics may suggest a cause other than infection or rheumatologic disease (eg, familial dysautonomia, ectodermal dysplasia) </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Persistence of constitutional symptoms after fever abates?</td> <td class=\"indent1\"> <ul> <li>Persistence is worrisome for systemic disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Is there associated sweating with fever?</td> <td class=\"indent1\"> <ul> <li>Yes: Hyperthyroidism </li> <li>No: Ectodermal dysplasia </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Is there associated sweating with defervescence?</td> <td class=\"indent1\"> <ul> <li>No: Factitious fever </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\">Associated complaints</td> <td class=\"subtitle1_single\">Possible cause(s)</td> </tr> <tr> <td class=\"indent1\">Red eyes</td> <td class=\"indent1\"> <ul> <li>Kawasaki disease </li> <li>Leptospirosis </li> <li>Tuberculosis </li> <li>Infectious mononucleosis </li> <li>Tularemia </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Nasal discharge</td> <td class=\"indent1\"> <ul> <li>Rhinosinusitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recurrent pharyngitis with ulcerations</td> <td class=\"indent1\"> <ul> <li>PFAPA syndrome </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Gastrointestinal complaints</td> <td class=\"indent1\"> <ul> <li>Salmonellosis </li> <li>Intra-abdominal abscess </li> <li>Hepatic cat scratch disease </li> <li>Inflammatory bowel disease </li> <li>Leptospirosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Limb or bone pain</td> <td class=\"indent1\"> <ul> <li>Brucellosis </li> <li>Leukemia </li> <li>Lymphoma </li> <li>Osteomyelitis </li> <li>Infantile cortical hyperostosis </li> <li>Kikuchi-Fujimoto disease </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\">Exposures</td> <td class=\"subtitle1_single\">Possible cause(s)/potential significance</td> </tr> <tr> <td class=\"indent1\">Medications (prescription or nonprescription, including topical agents)</td> <td class=\"indent1\"> <ul> <li>Drug fever </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Surgery</td> <td class=\"indent1\"> <ul> <li>Abdominal surgery: Intra-abdominal abscess </li> <li>Tracheotomy or gastric tube, cochlear implant or other implantable devices: Expanded list of potential pathogens </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ill-contacts</td> <td class=\"indent1\"> <ul> <li>FUO is usually caused by unusual presentations of common illnesses </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Travel history, extending back to birth (including tick and insect exposure)</td> <td class=\"indent1\"> <ul> <li>Endemic pathogens, for example: <ul> <li>Histoplasmosis </li> <li>Coccidioidomycosis </li> <li>Blastomycosis </li> <li>Leishmaniasis </li> <li>Malaria </li> <li>Tuberculosis </li> <li>Typhoid fever </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Animals (household pets, domestic animals, or wild animals)</td> <td class=\"indent1\"> <ul> <li>Refer to UpToDate topics on zoonoses for details </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Ticks</td> <td class=\"indent1\"> <ul> <li>Rocky Mountain spotted fever </li> <li>Human ehrlichiosis or anaplasmosis </li> <li>Tularemia </li> <li>Tick-borne relapsing fever </li> <li>Lyme disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mosquitos</td> <td class=\"indent1\"> <ul> <li>Arboviruses (eg, West Nile virus) </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Sand flies</td> <td class=\"indent1\"> <ul> <li>Leishmaniasis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diet</td> <td class=\"indent1\"> <ul> <li>Game meat: Toxoplasmosis, tularemia </li> <li>Raw/undercooked meat: Tularemia, brucellosis </li> <li>Raw shellfish: Hepatitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Pica (specifically eating dirt)</td> <td class=\"indent1\"> <ul> <li>Visceral larva migrans </li> <li>Toxoplasmosis </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\">Ethnic or genetic background</td> <td class=\"subtitle1_single\">Possible cause</td> </tr> <tr> <td class=\"indent1\">Ulster Scot descent</td> <td class=\"indent1\"> <ul> <li>Nephrogenic diabetes insipidus </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td class=\"indent1\">Turkish, Armenian, North African Jewish, Arab descent</td> <td class=\"indent1\"> <ul> <li>Familial Mediterranean fever<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ashkenazi Jewish descent</td> <td class=\"indent1\"> <ul> <li>Familial dysautonomia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FUO: fever of unknown origin; PFAPA: periodic fever, aphthous stomatitis, pharyngitis, and adenitis.<br />* Repeating the history on multiple occasions and rephrasing questions may be necessary to elicit important information. Repeating the history may help the patient or parent remember information that was omitted, forgotten, or deemed unimportant in the initial history.<br />&para; We define FUO as fever &gt;38.3&deg;C (101&deg;F) for &ge;8 days.<br />&Delta; Familial Mediterranean fever is not restricted to these ethnic/racial groups.</div><div id=\"graphicVersion\">Graphic 111286 Version 3.0</div></div></div>"},"111287":{"type":"graphic_table","displayName":"Initial laboratory and imaging evaluation FUO children","title":"Suggested approach to initial laboratory and imaging evaluation for fever of unknown origin in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested approach to initial laboratory and imaging evaluation for fever of unknown origin in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnostic test</td> <td class=\"subtitle1\">Potential significance of results</td> </tr> <tr class=\"divider_bottom\"> <td>Complete blood count, differential and smear</td> <td> <ul> <li>Anemia: Malaria, tuberculosis, infective endocarditis, JIA, SLE, IBD </li> <li>Cytopenia in &#8805;1 cell line and/or bizarre or immature WBCs: Leukemia, hemophagocytic lymphohistiocytosis, SLE, Kikuchi-Fujimoto disease </li> <li>Leukocytosis or bandemia: Increased risk of bacterial infection, infective endocarditis, JIA, drug fever, infantile cortical hyperostosis </li> <li>Neutropenia: Tuberculosis, Dengue fever, EBV, CMV, HIV, SLE, leukemia, human granulocytic anaplasmosis&nbsp; </li> <li>Atypical lymphocytes: Viral infections (eg, EBV, CMV), Kikuchi-Fujimoto disease </li> <li>Lymphocytosis: Cat scratch disease, EBV, toxoplasmosis </li> <li>Lymphocytopenia: Brucellosis, malaria, tuberculosis, typhoid fever, HIV, SLE </li> <li>Eosinophilia: Parasitic or fungal infection; allergic disorder; neoplasm; immunodeficiency </li> <li>Thrombocytosis: JIA, Kawasaki disease </li> <li>Thrombocytopenia: EBV, CMV, HIV, parvovirus, varicella, leptospirosis, tularemia, rickettsial infection, SLE, Kikuchi-Fujimoto disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>ESR<sup>&#182;</sup> and CRP</td> <td> <ul> <li>Elevated: Nonspecific indication of inflammation; may warrant more rapid evaluation; factitious fever unlikely </li> <li>Normal: Reassuring; evaluation can proceed at deliberate pace; does not exclude noninflammatory conditions (eg, familial dysautonomia, ectodermal dysplasia, etc) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Aerobic and anaerobic blood cultures<sup>&#916;</sup></td> <td> <ul> <li>Bacteremia; infective endocarditis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Urinalysis and urine culture</td> <td> <ul> <li>Pyuria and bacteriuria: Urinary tract infection </li> <li>Sterile pyuria: Intra-abdominal infection, genitourinary tuberculosis, Kawasaki disease </li> <li>Hematuria and/or proteinuria: Infective endocarditis, leptospirosis, SLE </li> <li>Low specific gravity or osmolality: Diabetes insipidus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Chest radiograph</td> <td> <ul> <li>Infiltrate: Pneumonia </li> <li>Lymphadenopathy: Tuberculosis </li> <li>Mediastinal mass: Leukemia, lymphoma, neurogenic tumor, rhabdomyosarcoma </li> <li>Small nodular densities: Leptospirosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Tuberculin skin testing/IGRA</td> <td> <ul> <li>Tuberculosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Serum electrolytes, BUN, and creatinine</td> <td> <ul> <li>Hypernatremia: Diabetes insipidus, dehydration </li> <li>Hyponatremia: Leptospirosis, tularemia </li> <li>Elevated BUN/Cr: Renal impairment (SLE), dehydration </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Elevated hepatic aminotransferases</td> <td> <ul> <li>Elevated: Brucellosis, tularemia, hepatitis, JIA, Kikuchi-Fujimoto disease, adenovirus, EBV </li> </ul> </td> </tr> <tr> <td>Combination antigen/antibody HIV immunoassay</td> <td> <ul> <li>HIV infection </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FUO: fever of unknown origin; JIA: juvenile idiopathic arthritis; SLE: systemic lupus erythematosus; IBD: inflammatory bowel disease; WBC: white blood cell; EBV: Epstein-Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IGRA: interferon gamma release assay; BUN: blood urea nitrogen; Cr: creatinine ratio.<br />* Additional tests may be indicated if the history, examination, or initial diagnostic tests suggest a diagnosis or diagnoses.<br />¶ ESR may be lowered artifactually in conditions involving consumption of fibrinogen; ESR may be artifactually raised in hypergammaglobulinemia.<br />Δ Special media or environmental conditions, or longer incubation, may be necessary for specific pathogens (eg, <EM>Brucella</EM>, <EM>Leptospira</EM>, <EM>Spirillum</EM>).</div><div id=\"graphicVersion\">Graphic 111287 Version 2.0</div></div></div>"},"111290":{"type":"graphic_table","displayName":"Fever patterns","title":"Potential clinical significance of fever pattern*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential clinical significance of fever pattern*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pattern</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Possible causes</td> </tr> <tr class=\"divider_bottom\"> <td>Intermittent (also called hectic or spiking)</td> <td>High spike and rapid defervescence</td> <td> <ul> <li>Pyogenic infection (most common)</li> <li>Tuberculosis</li> <li>Lymphoma</li> <li>JIA</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Remittent<sup>&#182;</sup></td> <td>Fluctuating peaks, but baseline remains elevated</td> <td> <ul> <li>Viral infections (most common)</li> <li>Bacterial infection (particularly infective endocarditis)</li> <li>Sarcoidosis</li> <li>Lymphoma</li> <li>Atrial myxoma</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Sustained<sup>&#182;</sup></td> <td>Little or no fluctuation</td> <td> <ul> <li>Typhoid fever</li> <li>Typhus</li> <li>Brucellosis</li> <li>Other infections</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Relapsing</td> <td>Febrile episodes followed by afebrile periods of &#8805;1 day</td> <td> <ul> <li>Malaria</li> <li>Rat-bite fever</li> <li><em>Borrelia</em> infection (eg, tick-borne relapsing fever and louse-borne relapsing fever)</li> <li>Lymphoma</li> </ul> </td> </tr> <tr> <td>Recurrent</td> <td>Recurrent episodes of fever over &#8805;6 months' duration</td> <td> <ul> <li>Metabolic defects</li> <li>CNS dysregulation of temperature control</li> <li>Periodic disorders <ul> <li>Cyclic neutropenia</li> <li>Hyperimmunoglobulin D syndrome</li> <li>PFAPA</li> <li>Deficiency of IL-1 or IL-36 receptor antagonist</li> </ul> </li> <li>Immunodeficiency</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JIA: juvenile idiopathic arthritis; CNS: central nervous system; PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis; IL: interleukin.<br />* The fever pattern is best documented by asking the family to keep a fever diary.<br />&para; May appear to be intermittent if antipyretic agents are administered.</div><div id=\"graphicVersion\">Graphic 111290 Version 1.0</div></div></div>"},"111299":{"type":"graphic_figure","displayName":"Hemostatic controls","title":"Hemostatic control mechanisms and termination of clotting","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Hemostatic control mechanisms and termination of clotting</div><div class=\"cntnt\"><img style=\"width:586px; height:497px;\" src=\"images/HEME/111299_Hemostatic_controls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate for an overview of hemostasis regulation and the roles of specific procoagulant and anticoagulant factors in clinical thrombosis and hemostasis.</div><div class=\"graphic_footnotes\">APC: activated protein C; TM: thrombomodulin.</div><div class=\"graphic_reference\">Courtesy of Lawrence LK&nbsp;Leung, MD</div><div id=\"graphicVersion\">Graphic 111299 Version 1.0</div></div></div>"},"111307":{"type":"graphic_table","displayName":"ECG features of ventricular tachycardia","title":"ECG features of ventricular tachycardia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG features of ventricular tachycardia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>QRS width &#62;120 milliseconds </li> </ul> </td> </tr> <tr> <td> <ul> <li>Shift in QRS axis, particularly to a \"northwest\" axis (between &ndash;90 and &ndash;180 degrees) </li> </ul> </td> </tr> <tr> <td> <ul> <li>AV dissociation (including the presence of fusion complexes and/or capture beats) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Negative concordance in leads V1 to V6 </li> </ul> </td> </tr> <tr> <td> <ul> <li>RS &#62;100 milliseconds in any of leads V1 to V6 </li> </ul> </td> </tr> <tr> <td> <ul> <li>Morphology: </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>VT with RBBB like morphology in V1: R/S &#60;1 in V6 </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>VT with LBBB like morphology in V1: Any Q wave in V6 </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; AV: atrioventricular; VT: ventricular tachycardia; RBBB: right bundle branch block; LBBB: left bundle branch block.</div><div id=\"graphicVersion\">Graphic 111307 Version 1.0</div></div></div>"},"111319":{"type":"graphic_figure","displayName":"Lymph node maps for esophageal cancer","title":"Regional lymph node stations for staging esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Regional lymph node stations for staging esophageal cancer</div><div class=\"cntnt\"><img style=\"width:763px; height:439px;\" src=\"images/ONC/111319_Lymphnodemapsesophageal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(A-C)</strong> Lymph node maps for esophageal cancer. Regional lymph node stations for staging esophageal cancer from left <strong>(A)</strong>, right <strong>(B)</strong>, and anterior <strong>(C)</strong>.<br /><strong>1R:</strong> Right lower cervical paratracheal nodes, between the supraclavicular paratracheal space and apex of the lung. <strong>1L:</strong> Left lower cervical paratracheal nodes, between the supraclavicular paratracheal space and apex of the lung. <strong>2R:</strong> Right upper paratracheal nodes, between the intersection of the caudal margin of the brachiocephalic artery with the trachea and the apex of the lung. <strong>2L:</strong> Left upper paratracheal nodes, between the top of the aortic arch and the apex of the lung. <strong>4R:</strong> Right lower paratracheal nodes, between the intersection of the caudal margin of the brachiocephalic artery with the trachea and cephalic border of the azygos vein. <strong>4L:</strong> Left lower paratracheal nodes, between the top of the aortic arch and the carina. <strong>7:</strong> Subcarinal nodes, caudal to the carina of the trachea. <strong>8U:</strong> Upper thoracic paraesophageal lymph nodes, from the apex of the lung to the tracheal bifurcation. <strong>8M:</strong> Middle thoracic paraesophageal lymph nodes, from the tracheal bifurcation to the caudal margin of the inferior pulmonary vein. <strong>8Lo:</strong> Lower thoracic paraesophageal lymph nodes, from the caudal margin of the inferior pulmonary vein to the EGJ. <strong>9R:</strong> Pulmonary ligament nodes, within the right inferior pulmonary ligament. <strong>9L:</strong> Pulmonary ligament nodes, within the left inferior pulmonary ligament. <strong>15:</strong> Diaphragmatic nodes, lying on the dome of the diaphragm and adjacent or to behind its crura. <strong>16:</strong> Paracardial nodes, immediately adjacent to the gastroesophageal junction. <strong>17:</strong> Left gastric nodes, along the course of the left gastric artery. <strong>18:</strong> Common hepatic nodes, immediately on the proximal common hepatic artery. <strong>19:</strong> Splenic nodes, immediately on the proximal common hepatic artery. <strong>20:</strong> Celiac nodes, at the base of the celiac artery.</div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111319 Version 2.0</div></div></div>"},"111321":{"type":"graphic_algorithm","displayName":"Treatment of sarcoid arthropathy","title":"Treatment of sarcoid arthropathy","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Treatment of sarcoid arthropathy</div><div class=\"cntnt\"><img style=\"width:662px; height:725px;\" src=\"images/RHEUM/111321_Trtmnt_act_srcd_arthrpthy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs.<br />* Refer to UpToDate topic on sarcoid arthropathy for details of drug choice, dosing, and duration of therapy.<br />¶ A response to treatment is characterized by control of symptoms and signs of joint inflammation, with resolution of joint tenderness, swelling, and pain.</div><div id=\"graphicVersion\">Graphic 111321 Version 1.0</div></div></div>"},"111332":{"type":"graphic_figure","displayName":"Orientation for patient placement on operating table","title":"Usual and reverse orientation for patient placement on operating table","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Usual and reverse orientation for patient placement on operating table</div><div class=\"cntnt\"><img style=\"width:459px; height:540px;\" src=\"images/ANEST/111332_Orientation_for_patient_placement_on_operating_table.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient may be placed on the operating table in reverse orientation (ie, head placed at the foot of the table), as shown in&nbsp;figure B in this graphic. Weight limits are lower in reverse orientation because the patient’s weight is no longer centered over the base, and the risk of tipping is increased.</div><div id=\"graphicVersion\">Graphic 111332 Version 1.0</div></div></div>"},"111333":{"type":"graphic_table","displayName":"PCOS etiology two hits","title":"PCOS etiology as a complex trait involving two hits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PCOS etiology as a complex trait involving two hits</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Congenital predisposing \"hit\"</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Heritable traits and gene variants affecting ovarian function </li> <li>Heritable traits and gene variants predisposing to insulin resistance, obesity, and type 2 diabetes mellitus </li> <li>Congenital virilization </li> <li>Disturbed fetal nutrition </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Postnatal provocative \"hit\"</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Insulin-resistant hyperinsulinemia <ul> <li>Metabolic syndrome </li> <li>Postnatal obesity </li> </ul> </li> <li>Puberty </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews 2016; 37:467, by permission of Oxford University Press on behalf of The Endocrine Society. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 111333 Version 2.0</div></div></div>"},"111336":{"type":"graphic_picture","displayName":"Multilobed PMNs in heatstroke","title":"Multilobed neutrophils in a patient with heatstroke and amphetamine use","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Multilobed neutrophils in a patient with heatstroke and amphetamine use</div><div class=\"cntnt\"><img style=\"width:762px; height:765px;\" src=\"images/HEME/111336_MultilobedPMNsheatstroke.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heat stroke can cause neutrophils (PMNs)&nbsp;to become multilobed with a grape-like (botyroid) pattern. Panel A shows multilobed PMNs&nbsp;from a patient with heatstroke in the setting of amphetamine use. The white blood cell count was 17,800/microL, and 65 percent of PMNs showed the abnormality. Panel B shows the patient's monocytes, which demonstrate similar changes. Refer to the&nbsp;UpToDate topic on the peripheral blood smear for further information on this and other abnormal neutrophil findings.</div><div class=\"graphic_footnotes\">PMN: polymorphonuclear neutrophil.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from Nolte DA, Proytcheva MA. Flowers blossoming in the desert heat. Blood 2016; 128:2868; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 111336 Version 2.0</div></div></div>"},"111337":{"type":"graphic_figure","displayName":"Unified model of PCOS pathophysiology","title":"Unified minimal model of PCOS pathophysiology","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Unified minimal model of PCOS pathophysiology</div><div class=\"cntnt\"><img style=\"width:492px; height:728px;\" src=\"images/PEDS/111337_UnifdmodelPCOSpthphyslgy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Functional ovarian hyperandrogenism (FOH) is nearly universal in PCOS and can account for all the cardinal clinical features of the syndrome: Hyperandrogenemia, oligo-anovulation, and polycystic ovaries (step 1). Pituitary LH secretion is necessary to sustain the ovarian androgen excess, but is not sufficient to cause it.<br />(Panel B) About one-half of patients with FOH have an abnormal degree of insulin-resistant hyperinsulinism (step 2). Insulin-resistant hyperinsulinism acts on theca cells to aggravate hyperandrogenism, synergizes with androgen to prematurely luteinize granulosa cells, and stimulates fat accumulation. The increased hyperandrogenemia provokes LH excess, which then acts on both theca and luteinized granulosa cells to worsen hyperandrogenism (step 3). LH also stimulates luteinized granulosa cells to secrete estradiol (step 4), which suppresses FSH secretion. These hyperinsulinism-initiated changes in granulosa cell function further exacerbate polycystic ovary morphology (PCOM) and further hinder ovulation. Obesity increases insulin-resistance, and the resultant increased hyperinsulinism further aggravates hyperandrogenism (step 5). Bold and enlarged fonts represent greater severity.<br />Both FOH and insulin resistance typically have an intrinsic basis. This model does not exclude the possibility that the unknown intrinsic ovarian defects that underpin the ovarian steroidogenic dysfunction also involve granulosa cell folliculogenesis and other systems as well. The figure also does not depict other associated defects, such as the functional adrenal hyperandrogenism that often accompanies the ovarian hyperandrogenism and the contribution of excess adiposity to peripheral androgen production and gonadotropin suppression.</div><div class=\"graphic_reference\">Reproduced from: Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews 2016; 37:467, by permission of Oxford University Press on behalf of The Endocrine Society. Copyright © 2016.</div><div id=\"graphicVersion\">Graphic 111337 Version 2.0</div></div></div>"},"111347":{"type":"graphic_algorithm","displayName":"Neonatal erythroderma differential diagnosis 2","title":"Diagnostic approach to the erythrodermic newborn or infant presenting with bullae/pustules and/or areas of denuded skin","html":"<div class=\"graphic\"><div style=\"width: 1248px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the erythrodermic newborn or infant presenting with bullae/pustules and/or areas of denuded skin</div><div class=\"cntnt\"><img style=\"width:1228px; height:508px;\" src=\"images/DERM/111347_Neonatal_erythroderm_diag_2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBC: complete blood count; SSSS: staphylococcal scalded skin syndrome; TSS: toxic shock syndrome; HSV: herpes simplex virus; HTLV-1: human T-lymphotropic virus type I; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis; GVHD: graft-versus-host disease; SCID: severe combined immunodeficiency.<br />* Refer to UpToDate topics on the diagnosis of epidermolysis bullosa.<br />¶ Refer to UpToDate topics on cutaneous and systemic mastocytosis in children.</div><div id=\"graphicVersion\">Graphic 111347 Version 1.0</div></div></div>"},"111349":{"type":"graphic_table","displayName":"Framework for STI risk reduction counseling","title":"Framework for sexually transmitted infection risk reduction counseling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framework for sexually transmitted infection risk reduction counseling</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Ask</strong></td> <td> <p>Routinely obtain a sexual and substance use history for all patients to assess risk.</p> <em>Reinforce confidentiality; be tactful, clear, and nonjudgmental; check assumptions.</em> <ul class=\"decimal_heading\"> <li>\"To provide the best care, I ask all my patients about their sexual activity - so tell me about your sex life.\" </li> <li>\"Tell me about your partners.\" (gender, number, new partners, partners with other partners) </li> <li>\"What types of sex have you been having?\" (vaginal, anal, oral) </li> <li>\"How do you protect your partners and yourself during sex?\" </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intervene</strong></td> <td>Provide patients with brief, tailored, behavioral interventions for risk reduction. <ul class=\"decimal_heading\"> <li>Discuss risk with patients: <ul> <li>Unprotected sexual activity </li> <li>Anonymous partners </li> <li>Patient or partners with recent STI </li> <li>History of recreational or intravenous drug use (party drugs, methamphetamines) </li> <li>Exchange of sex for money or drugs </li> <li>Recent incarceration </li> </ul> </li> <li>Assess patient's knowledge and misconceptions about STI transmission and assess attitudes and beliefs: <ul> <li>\"What are your concerns about giving or getting an STI?\" </li> </ul> </li> <li>Assess circumstances affecting behaviors (what, where, and with whom; triggers): <ul> <li>\"What makes it difficult to use condoms with your partners?\" </li> <li>\"How do you tell your partner about your HIV status/your STI infection?\" </li> </ul> </li> <li>Assess patient's readiness to change </li> <li>Negotiate a behavioral goal: <ul> <li>\"What is one thing you can do to reduce your risk of getting HIV or another STI?\" </li> </ul> </li> <li>Identify a first step toward the goal that is: <ul> <li>Concrete </li> <li>Incremental </li> <li>Individualized </li> <li>Realistic </li> </ul> </li> </ul> </td> </tr> <tr> <td colspan=\"2\">Know the resources in your community that provide support and care for social and mental health, substance abuse, or reproductive concerns.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STI: sexually transmitted infection.</div><div class=\"graphic_reference\">Adapted from: National Network of STD/HIV Prevention Training Center. Ask, Screen, Intervene Pocket Guide. <a href=\"http://nnptc.org/resources/ask-screen-intervene-pocket-guide/\" target=\"_blank\">http://nnptc.org/resources/ask-screen-intervene-pocket-guide/</a> (Accessed on December 16, 2016).</div><div id=\"graphicVersion\">Graphic 111349 Version 1.0</div></div></div>"},"111350":{"type":"graphic_table","displayName":"Biologic therapies used in immunodeficient patients","title":"Biologic therapies used in immunodeficient patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biologic therapies used in immunodeficient patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug name</td> <td class=\"subtitle1\">Molecular target</td> <td class=\"subtitle1\">Molecular form</td> <td class=\"subtitle1\">Immunodeficiency or condition</td> </tr> <tr> <td>Abatacept</td> <td> <p>B7-1 (CD80)</p> B7-2 (CD86) </td> <td>CTLA4-human IgG1 fusion protein</td> <td>CTLA4 or LRBA deficiency</td> </tr> <tr> <td>Anti-TNF (adalimumab, certolizumab, etanercept, golimumab, infliximab)</td> <td>TNF-alpha</td> <td>Various monoclonal antibodies or fusion proteins</td> <td>Autoimmune/inflammatory complications, autoinflammatory disorders</td> </tr> <tr> <td>Anakinra</td> <td>Interleukin-1 type I receptor (IL-1RI)</td> <td>Recombinant human interleukin-1 receptor antagonist (IL-1Ra)</td> <td>Autoinflammatory disorders</td> </tr> <tr> <td>Canakinumab, rilonacept</td> <td>Interleukin-1-beta (IL-1-beta)</td> <td>Monoclonal antibody, fusion protein</td> <td>Autoinflammatory disorders</td> </tr> <tr> <td><span style=\"color: black;\">Eculizumab</span><span style=\"color: black;\">&nbsp;</span></td> <td><span style=\"color: black;\">C5</span></td> <td><span style=\"color: black;\">Humanized monoclonal antibody&nbsp;</span></td> <td><span style=\"color: black;\">Atypical&nbsp;HUS&nbsp;caused by genetic defects in<em> CFH, CFI, C3 </em>or <em>CF</em><em>B</em>&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Interferon-gamma</span></td> <td><span style=\"color: black;\">Type II interferon receptors</span></td> <td><span style=\"color: black;\">Recombinant, human</span></td> <td><span style=\"color: black;\">Chronic granulomatous disease; partial defects of interferon-gamma receptors</span></td> </tr> <tr> <td><span style=\"color: black;\">Palivizumab</span></td> <td><span style=\"color: black;\">Respiratory syncytial virus (RSV)</span></td> <td><span style=\"color: black;\">Humanized monoclonal antibody&nbsp;</span></td> <td><span style=\"color: black;\">Prevention of RSV infection in high-risk groups</span>&nbsp;</td> </tr> <tr> <td>Rituximab</td> <td>CD20</td> <td>Chimeric IgG1-kappa, recombinant</td> <td>Autoantibody-mediated complications</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTLA4: cytotoxic T lymphocyte-associated antigen 4; IgG1: immunoglobulin G1; LRBA: lipopolysaccharide (LPS)-responsive beige-like anchor; TNF: tumor necrosis factor; C5: complement component 5; HUS: hemolytic uremic syndrome; <EM>CFH</EM>: complement factor H gene; <EM>CFI</EM>: complement factor I gene; <EM>C3</EM>: complement component 3;<EM>&nbsp;CFB</EM>: complement factor B gene.</div><div id=\"graphicVersion\">Graphic 111350 Version 1.0</div></div></div>"},"111351":{"type":"graphic_table","displayName":"Esoph CA site TNM 2017","title":"Anatomy of esophageal cancer primary site by ICD-O-3 topography codes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomy of esophageal cancer primary site by ICD-O-3 topography codes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"13%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Anatomic name</td> <td class=\"subtitle1\" rowspan=\"2\">Compartment<br /> ICD-O-3</td> <td class=\"subtitle1\" colspan=\"2\">Esophageal location</td> <td class=\"subtitle1\" rowspan=\"2\">Anatomic boundaries</td> <td class=\"subtitle1\" rowspan=\"2\">Typical esophagectomy<br /> (cm)</td> </tr> <tr> <td class=\"subtitle2\">ICD-O-3</td> <td class=\"subtitle2\">Name</td> </tr> <tr class=\"divider_bottom\"> <td>Cervical</td> <td>C15.0</td> <td>C15.3</td> <td>Upper</td> <td>Hypopharynx to sternal notch</td> <td>15 to &#60;20</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Thoracic</td> <td class=\"divider_bottom\" rowspan=\"3\">C15.1</td> <td>C15.3</td> <td>Upper</td> <td>Sternal notch to azygos vein</td> <td>20 to &#60;25</td> </tr> <tr> <td>C15.4</td> <td>Middle</td> <td>Lower border of azygos vein to inferior pulmonary vein</td> <td>25 to &#60;30</td> </tr> <tr class=\"divider_bottom\"> <td>C15.5</td> <td>Lower</td> <td>Lower border of inferior pulmonary vein to esophagogastric junction</td> <td>30 to &#60;40</td> </tr> <tr> <td rowspan=\"2\">Abdominal</td> <td rowspan=\"2\">C15.2</td> <td>C15.5</td> <td>Lower</td> <td>Esophagogastric junction to 2 cm below esophagogastric junction</td> <td>40 to 45</td> </tr> <tr> <td>C16.0</td> <td>Esophagogastric junction/cardia</td> <td>Esophagogastric junction to 2 cm below esophagogastric junction</td> <td>40 to 45</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICD-O-3: International Classification of Diseases for Oncology, 3rd Edition.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111351 Version 2.0</div></div></div>"},"111353":{"type":"graphic_table","displayName":"Neuroendocrine tumors stomach TNM 2017","title":"Neuroendocrine tumors of the stomach TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroendocrine tumors of the stomach TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1*</td> <td colspan=\"3\">Invades lamina propria or submucosa and less than or equal to 1 cm in size</td> </tr> <tr> <td class=\"indent1\">T2*</td> <td colspan=\"3\">Invades muscularis propria or greater than 1 cm in size</td> </tr> <tr> <td class=\"indent1\">T3*</td> <td colspan=\"3\">Invades through the muscularis propria into subserosal tissue without penetration of overlying serosa</td> </tr> <tr> <td class=\"indent1\">T4*</td> <td colspan=\"3\">Invades visceral peritoneum (serosal) or other organs or adjacent structures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> For any T, add (m) for multiple tumors [TX(#) or TX(m), where X = 1 to 4 and # = number of primary tumors identified<sup>&#182;</sup>]; for multiple tumors with different Ts, use the highest.<br /> &#182; <em>Example:</em> If there are two primary tumors, one of which penetrates only the subserosa, we define the primary tumor as either T3(2) or T3(m).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastsis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis confined to liver</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastases in at least one extrahepatic site (eg, lung, ovary, nonregional lymph node, peritoneum, bone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Both hepatic and extrahepatic metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0, N1</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111353 Version 2.0</div></div></div>"},"111354":{"type":"graphic_table","displayName":"Neuroendocrine tumors of colon and rectum TNM 2017","title":"Neuroendocrine tumors of the colon and rectum TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroendocrine tumors of the colon and rectum TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong>*</td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the lamina propria or submucosa and is &#8804;2 cm</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor &#60;1 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor 1 to 2 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the muscularis propria or is &#62;2 cm with invasion of the lamina propria or submucosa</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades through the muscularis propria into subserosal tissue without penetration of overlying serosa</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades the visceral peritoneum (serosa) or other organs or adjacent structures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> For any T, add (m) for multiple tumors [TX(#) or TX(m), where X = 1 to 4 and # = number of primary tumors identified<sup>&#182;</sup>]; for multiple tumors with different Ts, use the highest.<br /> &#182; <em>Example:</em> If there are two primary tumors, only one of which invades through the muscularis propria into the subserosal tissue without penetration of the overlying serosa, we define the primary tumor as either T3(2) or T3(m).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis has occurred</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis confined to liver</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastases in at least one extrahepatic site (eg, lung, ovary, nonregional lymph node, peritoneum, bone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Both hepatic and extrahepatic metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><em>NOTE:</em> For multiple synchronous tumors, the highest T category should be used and the multiplicity or the number of tumors should be indicated in parenthesis, eg, T3(2) or T3(m).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111354 Version 3.0</div></div></div>"},"111355":{"type":"graphic_table","displayName":"Neuroendocrine tumors of the pancreas TNM 2017","title":"Neuroendocrine tumors of the pancreas TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuroendocrine tumors of the pancreas TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor limited to the pancreas,* &#60;2 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor limited to the pancreas,* 2-4 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor limited to the pancreas,* &#62;4 cm; or tumor invading the duodenum or bile duct</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>Limited to the pancreas</em> means there is no invasion of adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). Extension of tumor into peripancreatic adipose tissue is NOT a basis for staging.<br /> <em>NOTE:</em> Multiple tumors should be designated as such (the largest tumor should be used to assign T category): <ul class=\"decimal_heading\"> <li>If the number of tumors is known, use T(#); eg, pT3(4) N0 M0. </li> <li>If the number of tumors is unavailable or too numerous, use the m suffix, T(m); eg, pT3(m) N0 M0. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node involvement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node involvement</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis confined to liver</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastases in at least one extrahepatic site (eg, lung, ovary, nonregional lymph node, peritoneum, bone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Both hepatic and extrahepatic metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111355 Version 2.0</div></div></div>"},"111359":{"type":"graphic_figure","displayName":"Overall survival by pathologic stage group for colorectal NETs","title":"Overall survival stratified pathological stage group for colorectal primary neuroendocrine tumors","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Overall survival stratified pathological stage group for colorectal primary neuroendocrine tumors</div><div class=\"cntnt\"><img style=\"width:712px; height:534px;\" src=\"images/ONC/111359_PathstggrcolorectalNETs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival for each pathological stage group for colorectal primary neuroendocrine tumors. Kaplan-Meier survival curves, with a follow-up time of three years (2010 to 2013) and adjusted for patient age, for a total of 1414 patients included in the pathological stage survival calculation.</div><div class=\"graphic_footnotes\">Path stage: pathological stage.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111359 Version 2.0</div></div></div>"},"111360":{"type":"graphic_figure","displayName":"Overall survival by pathologic stage group jejunoileal NETs","title":"Overall survival stratified by pathologic stage group for jejunoileal neuroendocrine tumors","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Overall survival stratified by pathologic stage group for jejunoileal neuroendocrine tumors</div><div class=\"cntnt\"><img style=\"width:712px; height:588px;\" src=\"images/ONC/111360_PthstggrsmallbowelNETs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier survival curves for each 8th edition pathological stage for small bowel primary neuroendocrine tumors, with a follow-up time of three years (2010 to 2013) and adjusted for patient age. A total of 3366 patients were included in the pathological stage survival calculation. Data from the National Cancer Data Base.</div><div class=\"graphic_footnotes\">Path stage: pathologic stage.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111360 Version 3.0</div></div></div>"},"111363":{"type":"graphic_table","displayName":"Rule of 8s","title":"Rule of 8s for determining the need for referral in childhood vision screening*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rule of 8s for determining the need for referral in childhood vision screening*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Rule of 8s</td> <td class=\"subtitle1\">\"Critical line\" for normal visual acuity<sup>&#182;</sup></td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">2 + <strong>6</strong> = 8</td> <td class=\"centered\">20/<strong>6</strong>0</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">3 + <strong>5</strong> = 8</td> <td class=\"centered\">20/<strong>5</strong>0</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">4 + <strong>4</strong> = 8</td> <td class=\"centered\">20/<strong>4</strong>0</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">5 + <strong>3</strong> = 8</td> <td class=\"centered\">20/<strong>3</strong>0</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">6 + <strong>2</strong> = 8</td> <td class=\"centered\">20/<strong>2</strong>0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The patient's age plus the tens digit of the denominator of his or her visual acuity should be &le;8.<br />\"If it equals eight, vision is great! Nine or more, vision is poor.\"</div><div class=\"graphic_footnotes\">* Poor visual acuity is one reason for referral to an eye specialist. Other important indications for referral include abnormal red reflex, abnormal ocular alignment, eye preference, pupillary asymmetry, and abnormal instrument-based vision screening. Refer to UpToDate's content on vision screening in children for further details.<br />¶ The \"critical line\" is the line a child is expected to see normally and pass. Visual acuity at or better than this value is considered normal and referral is not necessary. If visual acuity is worse that this level, referral is generally warranted.</div><div class=\"graphic_reference\">Source: Bhatt AR, Baylor College of Medicine, Texas Children's Hospital, 2016, personal communication.</div><div id=\"graphicVersion\">Graphic 111363 Version 1.0</div></div></div>"},"111369":{"type":"graphic_figure","displayName":"Prone position","title":"Prone position","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Prone position</div><div class=\"cntnt\"><img style=\"width:715px; height:400px;\" src=\"images/ANEST/111369_Prone_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 111369 Version 3.0</div></div></div>"},"111370":{"type":"graphic_figure","displayName":"Lithotomy position","title":"Lithotomy position","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Lithotomy position</div><div class=\"cntnt\"><img style=\"width:710px; height:450px;\" src=\"images/ANEST/111370_Lithotomy_positn_ansthslgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Illustration by Kiran Guthikonda, MD, PhD, Dartmouth-Hitchcock Medical Center.</div><div id=\"graphicVersion\">Graphic 111370 Version 4.0</div></div></div>"},"111371":{"type":"graphic_algorithm","displayName":"Overview of initial immunosuppressive therapy in GPA or MPA","title":"Overview of initial (induction) immunosuppressive therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Overview of initial (induction) immunosuppressive therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)</div><div class=\"cntnt\"><img style=\"width:680px; height:588px;\" src=\"images/NEPH/111371_Immnspprssv_thrpy_GPA_MPA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ANCA: antineutrophil cytoplasmic autoantibody.<br />* Cyclophosphamide (intravenous or oral) and rituximab are both effective immunosuppressive agents for the treatment of organ-threatening or life-threatening ANCA-associated vasculitis. The choice is based upon clinician experience, patient preference, and the toxicities and adverse effects associated with each drug (refer to UpToDate topic on initial immunosuppressive therapy in GPA and MPA, as well as topics on toxicities and side effects of cyclophosphamide and rituximab).<br />​¶ Some clinicians treat patients with organ-threatening or life-threatening GPA or MPA by sequentially using both cyclophosphamide (for the first two to three months) and rituximab (after discontinuation of cyclophosphamide). This induction strategy is controversial.<br />Δ Contraindications to methotrexate include, but are not limited to, heavy alcohol use and chronic liver disease. For more information, refer to the UpToDate topics on toxicity and side effects of methotrexate.<br /><FONT class=lozenge>◊</FONT> The three major indications for plasma exchange in patients with GPA or MPA are as follows: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Advanced kidney dysfunction as a result of glomerulonephritis due to GPA or MPA (for example, need for dialysis or a serum creatinine of &gt;4.0 mg/dL [&gt;350 micromol/L]) or rapidly declining kidney function </LI>&#xD;&#xA;<LI>Positive anti-glomerular basement membrane (anti-GBM) autoantibody</LI>&#xD;&#xA;<LI>Pulmonary hemorrhage complicated by respiratory compromise or pulmonary hemorrhage that does not respond rapidly to intravenous glucocorticoids (although some experts prescribe plasma exchange to all patients with GPA or MPA who have pulmonary hemorrhage)</LI></UL>§ Some clinicians treat all patients with organ-threatening or life-threatening GPA or MPA with three days of high-dose intravenous pulse methylprednisolone before initiating oral glucocorticoids, whereas others only give pulse methylprednisolone to patients with necrotizing or crescentic glomerulonephritis or pulmonary hemorrhage.</div><div id=\"graphicVersion\">Graphic 111371 Version 2.0</div></div></div>"},"111372":{"type":"graphic_table","displayName":"History in a malnourished child","title":"Clinical history in a malnourished child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical history in a malnourished child</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History of presenting illness</td> </tr> <tr> <td class=\"indent1\"><strong>Nutrition history</strong></td> </tr> <tr> <td class=\"indent2\">Dietary history - Including changes in appetite and recent oral intake (quantity and quality of diet)</td> </tr> <tr> <td class=\"indent2\">Recent change in weight</td> </tr> <tr> <td class=\"indent2\">Recent swelling of feet</td> </tr> <tr> <td class=\"indent1\"><strong>Associated symptoms</strong></td> </tr> <tr> <td class=\"indent2\">Stool pattern, especially diarrhea (increased volume and watery, frequency,&nbsp;presence of blood)</td> </tr> <tr> <td class=\"indent2\">Fever</td> </tr> <tr> <td class=\"indent2\">Cough (acute or chronic)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Decrease in urine output</td> </tr> <tr> <td class=\"subtitle1_single\">Past medical history</td> </tr> <tr> <td class=\"indent1\"><strong>Neonatal history</strong></td> </tr> <tr> <td class=\"indent2\">Prematurity</td> </tr> <tr> <td class=\"indent2\">Low birth weight</td> </tr> <tr> <td class=\"indent2\">Twin birth</td> </tr> <tr> <td class=\"indent2\">Birth asphyxia</td> </tr> <tr> <td class=\"indent1\"><strong>Infant feeding history</strong></td> </tr> <tr> <td class=\"indent2\">Duration of breastfeeding</td> </tr> <tr> <td class=\"indent2\">Use of breast milk substitutes</td> </tr> <tr> <td class=\"indent2\">Age and diet at weaning</td> </tr> <tr> <td class=\"indent1\"><strong>Other</strong></td> </tr> <tr> <td class=\"indent2\">Recurrent diarrhea or pneumonia</td> </tr> <tr> <td class=\"indent2\">Recurrent or recent thrush (suggests possible immunosuppression)&nbsp;</td> </tr> <tr> <td class=\"indent2\">Other chronic disease, such as cancer</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Recent history of or contact with infectious disease, such as tuberculosis or measles</td> </tr> <tr> <td class=\"subtitle1_single\">Preventive health care</td> </tr> <tr> <td class=\"indent1\">Immunizations received</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin A supplementation</td> </tr> <tr> <td class=\"subtitle1_single\">Family history</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">History of tuberculosis or HIV</td> </tr> <tr> <td class=\"subtitle1_single\">Social history</td> </tr> <tr> <td class=\"indent1\"><strong>Family structure</strong></td> </tr> <tr> <td class=\"indent2\">Number of living parents or other caregivers</td> </tr> <tr> <td class=\"indent2\">Number of siblings</td> </tr> <tr> <td class=\"indent2\">Birth order of this patient</td> </tr> <tr> <td class=\"indent1\"><strong>Economics</strong></td> </tr> <tr> <td class=\"indent2\">Parents' occupation</td> </tr> <tr> <td class=\"indent2\">Household income</td> </tr> <tr> <td class=\"indent2\">Availability of food</td> </tr> <tr> <td class=\"indent1\"><strong>Accommodation</strong></td> </tr> <tr> <td class=\"indent2\">Crowding</td> </tr> <tr> <td class=\"indent2\">Water source</td> </tr> <tr> <td class=\"indent2\">Sanitary facilities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Original figure modified for this publication. Walton E, Allen S. Malnutrition in developing countries. Paediatrics and Child Health, 2011; 21:418. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111372 Version 4.0</div></div></div>"},"111373":{"type":"graphic_table","displayName":"Physical examination in a malnourished child","title":"Physical examination in a malnourished child","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination in a malnourished child</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Anthropometric assessment</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Measure mid-upper arm circumference (MUAC)&nbsp; </li> <li>Assess for edema&nbsp; </li> <li>Measure weight and length or height </li> <li>Calculate Z-scores for each of the following:* <ul> <li>Weight-for-length </li> <li>Length/height </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Vital signs</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Temperature <ul> <li>Assess for fever or hypothermia </li> </ul> </li> <li>Signs of shock <ul> <li>Cold hands with capillary refill time greater than 3 seconds; weak, fast pulse; lethargic or unconscious </li> </ul> </li> <li>Signs of dehydration <ul> <li>Usual signs may be unreliable in the malnourished child </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Remainder of the&nbsp;examination</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Skin <ul> <li>In kwashiorkor, there may be areas of hypo- or hyperpigmentation, hyperkeratosis, shedding of the skin, cracks and fissures, extensive desquamation. In marasmus, skin is often thin and flaccid. </li> <li>Evidence of measles suggests higher risk for poor outcome. </li> <li>Bullous pustular dermatitis (moist erythematous plaques) around mouth and anus suggests zinc deficiency.</li> </ul> </li> <li>Hair <ul> <li>Lightly colored to shades of brown/red; lack of luster; sparsely distributed to alopecia; thin and easily pluckable; 'flag sign' </li> </ul> </li> <li>Mouth <ul> <li>Ulcers, angular stomatitis, oral thrush (thrush suggests possible immunosuppression) </li> </ul> </li> <li>Central nervous system <ul> <li>Apathetic face and irritability </li> </ul> </li> <li>Muscles <ul> <li>Signs of severe wasting: 'old man' face, emaciated limbs, increased axillary skin folds, buttock wasting, visible ribs and scapula, over-hanging skin and flabby muscles </li> <li>In patients with kwashiorkor, muscle wasting may be masked by edema, but is often apparent as loose inguinal skin folds. </li> </ul> </li> <li>Other <ul> <li>Pallor </li> <li>Localizing signs of infection (ear, throat, skin, chest) </li> <li>Abdominal distention </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The Z-scores are used to determine the category (wasting, stunting) and severity of malnutrition.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Walton E, Allen S. Malnutrition in developing countries. Paediatrics and Child Health, 2011; 21:418.</li>&#xD;&#xA;    <li>Antwi A. Assessment and management of severe malnutrition in children. West Afr J Med 2011; 30:11.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 111373 Version 4.0</div></div></div>"},"111374":{"type":"graphic_table","displayName":"Characteristics of grade 3 well-differentiated NET versus NEC","title":"Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of patients with grade 3 neuroendocrine neoplasms in studies comparing grade 3 well to moderately differentiated neuroendocrine tumors and neuroendocrine carcinomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">NET G-3</td> <td class=\"subtitle1\">NEC</td> </tr> <tr> <td>Number of patients, n (%)</td> <td class=\"centered\">89 (23)<sup>[1,2,3,4]</sup></td> <td class=\"centered\">298 (77)<sup>[1,2,3,4]</sup></td> </tr> <tr> <td>Distribution of patients (%)</td> <td class=\"centered\">18 to 32<sup>[1,2,4]</sup></td> <td class=\"centered\">68 to 79<sup>[1,2,4]</sup></td> </tr> <tr> <td>Age (median)</td> <td class=\"centered\">52 to 56<sup>[1,4]</sup></td> <td class=\"centered\">55 to 64<sup>[1,4]</sup></td> </tr> <tr> <td colspan=\"3\">Primary tumor location (%)</td> </tr> <tr> <td class=\"indent1\">Esophagus</td> <td class=\"centered\">0<sup>[1,2]</sup></td> <td class=\"centered\">5 to 8<sup>[1,5]</sup></td> </tr> <tr> <td class=\"indent1\">Stomach</td> <td class=\"centered\">8 to 24<sup>[1,2]</sup></td> <td class=\"centered\">7 to 8<sup>[1,5]</sup></td> </tr> <tr> <td class=\"indent1\">Pancreas</td> <td class=\"centered\">33 to 65<sup>[1,2,3]</sup></td> <td class=\"centered\">13 to 25<sup>[1,3,5]</sup></td> </tr> <tr> <td class=\"indent1\">Colon-rectum</td> <td class=\"centered\">8 to 29<sup>[1,2]</sup></td> <td class=\"centered\">24 to 32<sup>[1,5]</sup></td> </tr> <tr> <td class=\"indent1\">Small-bowel</td> <td class=\"centered\">0 to 5<sup>[1,2]</sup></td> <td class=\"centered\">3 to 5<sup>[1,5]</sup></td> </tr> <tr> <td>Functional tumors (%)</td> <td class=\"centered\">14 to 25<sup>[1,3]</sup></td> <td class=\"centered\">0 to 6<sup>[1,3,4,5]</sup></td> </tr> <tr> <td>Genetic syndrome</td> <td class=\"centered\">0 to 5<sup>[3,4]</sup></td> <td class=\"centered\">0<sup>[3,4,5]</sup></td> </tr> <tr> <td>Stage IV (%)</td> <td class=\"centered\">62 to 100<sup>[1,3,4]</sup></td> <td class=\"centered\">44 to 75<sup>[1,3,4]</sup></td> </tr> <tr> <td>Percentage of elevated plasma marker (CgA, NSE)</td> <td class=\"centered\">CgA&#62;NSE<sup>[3]</sup></td> <td class=\"centered\">NSE&#62;CgA<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">CgA (%)</td> <td class=\"centered\">42<sup>[3]</sup></td> <td class=\"centered\">31<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">NSE (%)</td> <td class=\"centered\">25<sup>[3]</sup></td> <td class=\"centered\">50<sup>[3]</sup></td> </tr> <tr> <td>Uptake on 18-FDG PET/CT (%)</td> <td class=\"centered\">25 to 75<sup>[1,3]</sup></td> <td class=\"centered\">19 to 89<sup>[1,3,5]</sup></td> </tr> <tr> <td>Uptake on somatostatin receptor scintigraphy (%)</td> <td class=\"centered\">88 to 92<sup>[1,3]</sup></td> <td class=\"centered\">40 to 50<sup>[1,3]</sup></td> </tr> <tr> <td>Ki-67 (median, %)</td> <td class=\"centered\">21 to 40<sup>[1,2,3,4]</sup></td> <td class=\"centered\">30 to 80<sup>[1,2,3,4,5]</sup></td> </tr> <tr> <td>Mitotic index</td> <td class=\"centered\">8 to 17<sup>[3,4]</sup></td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Necrosis (%)</td> <td class=\"centered\">42<sup>[3]</sup></td> <td class=\"centered\">75 to 76<sup>[3,5]</sup></td> </tr> <tr> <td>Surgery of primary tumor (%)</td> <td class=\"centered\">60 to 83<sup>[1,3]</sup></td> <td class=\"centered\">14 to 36<sup>[1,3,5]</sup></td> </tr> <tr> <td>Overall survival in months from diagnosis</td> <td class=\"centered\">41 to 99<sup>[1,3,4]</sup></td> <td class=\"centered\">11 to 17<sup>[1,2,3,4,5]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NET G-3: well-differentiated grade 3 neuroendocrine tumor; NEC: neuroendocrine carcinoma; CgA: chromogranin A; NSE: neuron-specific enolase; 18-FDG: 18-fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22:657.</li>&#xD;&#xA;    <li>Scoazec JY, Couvelard A, Monges F, et al. Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality&mdash;The PRONETstudy group. J Clin Oncol 2012; 30(suppl):4129a.</li>&#xD;&#xA;    <li>V&eacute;layoudom-C&eacute;phise, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 2013; 20:649.</li>&#xD;&#xA;    <li>Basturk O,Yang Z,Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39:683.</li>&#xD;&#xA;    <li>Walter T, Tougeron D, Baudin E, et al. Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort. J Clin Oncol 2015; 33(suppl):4095a.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Coriat R, Walter T, Terris B, et al. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 2016; 21:1191. <a href=\"http://theoncologist.alphamedpress.org/content/21/10/1191.abstract\" spellcheck=\"true\" target=\"_blank\">http://theoncologist.alphamedpress.org/content/21/10/1191.abstract</a>. Copyright &copy; 2016 Society for Translational Oncology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 111374 Version 3.0</div></div></div>"},"111376":{"type":"graphic_algorithm","displayName":"Primary aldosteronism: Case-detection testing","title":"Case-detection testing for diagnosis of primary aldosteronism","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Case-detection testing for diagnosis of primary aldosteronism</div><div class=\"cntnt\"><img style=\"width:500px; height:478px;\" src=\"images/ENDO/111376_Prmry_aldosternsm_case_dtct.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HTN: hypertension; BP: blood pressure; PAC: plasma aldosterone concentration; PRA: plasma renin activity; PRC: plasma renin concentration; CAH: congenital adrenal hyperplasia; DOC: deoxycorticosterone.<br />* Patient out of bed for at least two hours and seated for at least 5 to 15 minutes before sample is drawn.<br />&para; Direct PRC can be measured instead of PRA. However, UpToDate authors prefer PRA. Refer to topic text for interpretation of PRC cutoffs and normal values.<br />&Delta; Oral sodium loading over three days is one confirmation test that many experts use. An alternative is the saline infusion test. Details of both are reviewed in the accompanying topic.</div><div id=\"graphicVersion\">Graphic 111376 Version 1.0</div></div></div>"},"111378":{"type":"graphic_picture","displayName":"IBD pseudopolyps","title":"Pseudopolyps in IBD","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Pseudopolyps in IBD</div><div class=\"cntnt\"><img style=\"width:756px; height:595px;\" src=\"images/GAST/111378_IBD_pseudopolyps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the colon&nbsp;with&nbsp;multiple pseudopolyps</div><div class=\"graphic_footnotes\">IBD: Inflammatory bowel disease</div><div id=\"graphicVersion\">Graphic 111378 Version 1.0</div></div></div>"},"111380":{"type":"graphic_table","displayName":"Clinical features functioning pancreatic neuroendocrine tumors","title":"Clinical features of functional pancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of functional pancreatic neuroendocrine tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Biologically active peptide(s)</td> <td class=\"subtitle1\">Incidence<br /> (new cases/10<sup>6</sup> population/year)</td> <td class=\"subtitle1\">Tumor location</td> <td class=\"subtitle1\">Most common symptoms/signs</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Most common syndromes</td> </tr> <tr> <td class=\"indent1\">Insulinoma</td> <td>Insulin</td> <td>1 to 3</td> <td> <ul> <li>Pancreas (&#62;99%) </li> </ul> </td> <td>Hypoglycemic syndromes (Whipple's triad)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zollinger-Ellison syndrome</td> <td>Gastrin</td> <td>0.5 to 2</td> <td> <ul> <li>Duodenum (70%) </li> <li>Pancreas (25%) </li> <li>Other sites (5%) </li> </ul> </td> <td>Abdominal pain, gastroesophageal reflux, diarrhea, duodenal ulcers, PUD/GERD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Less common syndromes (additional, rarer syndromes also exist)</td> </tr> <tr> <td class=\"indent1\">VIPoma (Verner-Morrison syndrome, pancreatic cholera, WDHA syndrome)</td> <td>Vasoactive intestinal peptide</td> <td>0.05 to 0.2</td> <td> <ul> <li>Pancreas (90%, adult) </li> <li>Other (10%, neural, adrenal, periganglionic) </li> </ul> </td> <td>Diarrhea, hypokalemia, dehydration</td> </tr> <tr> <td class=\"indent1\">Glucagonoma</td> <td>Glucagon</td> <td>0.01 to 0.1</td> <td> <ul> <li>Pancreas (100%) </li> </ul> </td> <td>Rash, glucose intolerance, necrolytic migratory erythema, weight loss</td> </tr> <tr> <td class=\"indent1\">Somatostatinoma</td> <td>Somatostatin</td> <td>Rare</td> <td> <ul> <li>Pancreas (55%) </li> <li>Duodenum/jejunum (44%) </li> </ul> </td> <td>Diabetes mellitus, cholelithiasis, diarrhea</td> </tr> <tr> <td class=\"indent1\">ACTHoma/Cushing's syndrome</td> <td>ACTH</td> <td>Rare</td> <td> <ul> <li>Pancreas (4 to 16% all ectopic Cushing's) </li> </ul> </td> <td>Cushing's syndrome</td> </tr> <tr> <td class=\"indent1\">Pancreatic NET causing carcinoid syndrome</td> <td>Serotonin</td> <td>Rare</td> <td> <ul> <li>Pancreas (&#60;1% all carcinoid syndrome) </li> </ul> </td> <td>Flushing, diarrhea</td> </tr> <tr> <td class=\"indent1\">PTHrp-oma (hypercalcemia)</td> <td>PTHrp, others unknown</td> <td>Rare</td> <td> <ul> <li>Pancreas </li> </ul> </td> <td>Symptoms due to hypercalcemia (mimics primary hyperparathyroidism)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PUD: peptic ulcer disease; GERD: gastroesophageal reflux disease; WDHA: watery diarrhea, hypokalemia, and achlorhydria; NET: neuroendocrine tumor; PTHrp: parathyroid hormone-related protein.</div><div class=\"graphic_reference\">Adapted with permission from: Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95:98. Copyright &copy; 2012 S. Karger AG, Basel.</div><div id=\"graphicVersion\">Graphic 111380 Version 3.0</div></div></div>"},"111381":{"type":"graphic_figure","displayName":"Pathophysiology of malnutrition","title":"Pathophysiology of childhood malnutrition","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of childhood malnutrition</div><div class=\"cntnt\"><img style=\"width:542px; height:468px;\" src=\"images/PEDS/111381_Pathophysiology_of_malnutrition.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A;&nbsp;IL6: interleukin 6;&nbsp;CRP: C-reactive protein;&nbsp;GFR: glomerular filtration rate;&nbsp;UTI: urinary tract infection; GH: growth hormone; IGF-1: insulin-like growth factor 1; BMR: basal metabolic rate.<br />* Cardiac output is decreased in proportion to lean body mass. Cardiac index (which relates cardiac output to body surface area) is normal.<br />¶ Children with either marasmus or kwashiorkor (edematous malnutrition) have precarious fluid balance: Fluid overload may cause acute congestive heart failure, while hypovolemia quickly compromises tissue perfusion. </div><div id=\"graphicVersion\">Graphic 111381 Version 2.0</div></div></div>"},"111386":{"type":"graphic_picture","displayName":"FES rash","title":"Classic petechial rash associated with fat embolism","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Classic petechial rash associated with fat embolism</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PULM/111386_FES_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows the classic petechial rash associated with fat embolism. Emboli traveling through the arterial circulation are thought to obstruct dermal vessels resulting in petechiae of the nondependent regions of the body such as the anterior thorax depicted in this image.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111386 Version 1.0</div></div></div>"},"111387":{"type":"graphic_diagnosticimage","displayName":"FES chest radiography","title":"Airspace disease from fat embolism on chest radiography","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Airspace disease from fat embolism on chest radiography</div><div class=\"cntnt\"><img style=\"width:766px; height:405px;\" src=\"images/PULM/111387_FESchestradiography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial imaging. (A) Radiograph of the left lower extremity demonstrating a closed, oblique fracture of the left femur with displacement of the distal femoral fragment. (B) Chest radiograph obtained shortly after endotracheal intubation showing bilateral patchy infiltrates consistent with acute respiratory distress syndrome (ARDS).</div><div class=\"graphic_reference\">From: Kosova E, Bergmark B, Piazza G. Fat embolism syndrome. Circulation 2015; 131(3):317-20. DOI: <A href=\"http://circ.ahajournals.org/content/131/3/317.long\" target=_blank>10.1161/CIRCULATIONAHA.114.010835</A>. Copyright © 2015 American Heart Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111387 Version 2.0</div></div></div>"},"111388":{"type":"graphic_diagnosticimage","displayName":"MRI FES","title":"Magnetic resonance image of a cerebral fat embolism","html":"<div class=\"graphic\"><div style=\"width: 711px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of a cerebral fat embolism</div><div class=\"cntnt\"><img style=\"width:691px; height:442px;\" src=\"images/PULM/111388_MRIFES.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 25-year-old man with a traumatic tibial bone fracture. Rapid consciousness decline was noted at postfracture day 1, and the brain MRI was performed at postfracture day 2. Axial DWI (A) and corresponding axial ADC image (B) demonstrate scattered spot diffusion-restricted lesions in the bilateral striatum, left posterior internal capsule, insula, operculum, and periventricular white matter (type 1 pattern).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; DWI: diffusion weighted image; ADC: apparent diffusion coefficient. </div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Neuroradiology, from: Kuo KH, Pan YJ, Lai YJ, et al. Dynamic MR imaging patterns of cerebral fat embolism: a systematic review with illustrative cases. AJNR Am J Neuroradiol 2014; 35:1052; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2014.</div><div id=\"graphicVersion\">Graphic 111388 Version 2.0</div></div></div>"},"111391":{"type":"graphic_picture","displayName":"Light microscopy in endocarditis-associated glomerulonephritis","title":"Light microscopy findings in endocarditis-associated glomerulonephritis","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Light microscopy findings in endocarditis-associated glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:716px; height:766px;\" src=\"images/NEPH/111391_Lghtmcrscpyendcrdtsasscd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cellular crescents with necrotizing foci (Jones methenamine silver; original magnification 400x). <br />(B) Segmental cellular crescent with no underlying proliferation (periodic acid-Schiff; original magnification 400x). <br />(C) Diffuse crescentic glomerulonephritis (Jones methenamine silver; original magnification 400x). <br />(D) Acute focal proliferative glomerulonephritis (hematoxylin and eosin; original magnification 400x). <br />(E) Diffuse proliferative glomerulonephritis (periodic acid-Schiff; original magnification 400x).&nbsp;<br />(F) Mesangial proliferative glomerulonephritis (periodic acid-Schiff; original magnification 400x).<br /></div><div class=\"graphic_reference\">Reproduced from: Boils CL, Nasr SH, Walker PD, et al. Update on endocarditis-associated glomerulonephritis. Kidney Int 2015; 87:1241. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111391 Version 1.0</div></div></div>"},"111393":{"type":"graphic_figure","displayName":"Clinical course IPF","title":"Clinical course of idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Clinical course of idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:718px; height:570px;\" src=\"images/PULM/111393_Clinical_course_IPF.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 111393 Version 1.0</div></div></div>"},"111399":{"type":"graphic_table","displayName":"Thymic tumors TNM 2017","title":"Tumors of the thymus TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumors of the thymus TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)*<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T description</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor encapsulated or extending into the mediastinal fat; may involve the mediastinal pleura</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor with no mediastinal pleura involvement</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor with direct invasion of mediastinal pleura</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor with direct invasion of the pericardium (either partial or full thickness)</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor with direct invasion into any of the following: Lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor with invasion into any of the following: Aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* Involvement must be microscopically confirmed in pathological staging, if possible.<br /> &#182; T categories are defined by \"levels\" of invasion; they reflect the highest degree of invasion regardless of how many other (lower-level) structures are invaded. T1, level 1 structures: thymus, anterior mediastinal fat, mediastinal pleura; T2, level 2 structures: pericardium; T3, level 3 structures: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, hilar pulmonary vessels; T4, level 4 structures: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N description</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in anterior (perithymic) lymph nodes</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in deep intrathoracic or cervical lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">&#916; Involvement must be microscopically confirmed in pathological staging, if possible.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M description</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No pleural, pericardial, or distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Pleural, pericardial, or distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Separate pleural or pericardial nodule(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Pulmonary intraparenchymal nodule or distant organ metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">The T, N, and M categories are organized into stage groups, as shown in the table. This schema was developed based primarily on outcomes; in the lower stages, recurrence rates in patients with complete resections were judged most relevant, whereas in higher stages, survival in all patients, regardless of resection status, was weighed more heavily. Practical applicability and clinical implications also were considered. Differences among the stage groups were subjected to statistical analysis and generally were found to have a stepwise progression toward worse survival in multiple patient cohorts (eg, R0, R-any<sup>&#9674;</sup>).</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1a,b</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N0, N1</td> <td>M1a</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0, M1a</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#9674; R0: no residual tumor; R-any: any type of resection (no residual tumor, microscopic residua<span style=\"font-family: Calibri;\">l&nbsp;</span>tumor, or macroscopic residual tumor at the primary cancer site or regional nodal sites).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111399 Version 2.0</div></div></div>"},"111404":{"type":"graphic_algorithm","displayName":"Evaluation of transient monocular blindness","title":"Evaluation of transient monocular blindness","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Evaluation of transient monocular blindness</div><div class=\"cntnt\"><img style=\"width:510px; height:361px;\" src=\"images/NEURO/111404_Evltrnsntmnclrblndnsed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate.<br />* Vascular risk factors include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Hypertension</LI>&#xD;&#xA;<LI>Smoking</LI>&#xD;&#xA;<LI>Diabetes</LI>&#xD;&#xA;<LI>Hypercholesterolemia</LI>&#xD;&#xA;<LI>Patient or family history of vascular or thrombotic disease</LI></UL>¶ Details provided in UpToDate topic reviews discussing giant cell arteritis.<br />Δ Details provided in UpToDate topic reviews discussing transient monocular blindness.</div><div id=\"graphicVersion\">Graphic 111404 Version 1.0</div></div></div>"},"111406":{"type":"graphic_algorithm","displayName":"Subsequent-line treatment for small cell lung cancer","title":"Subsequent-line treatment for small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Subsequent-line treatment for small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:532px; height:472px;\" src=\"images/ONC/111406_Sub_line_tx_small_cell_lung.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">*&nbsp;In this setting, a clinical trial or palliative management are also appropriate alternatives.&nbsp;<br />¶ Alternatively, patients may be treated instead with single-agent therapy using a camptothecin, particularly those with poor performance status.<br />Δ Treatment is at the discretion of the patient and treating provider. For those receiving systemic therapy, our preference is to proceed with paclitaxel as a next-line option after progression on a camptothecin. However, no therapies are approved in this setting and one may reasonably proceed with another agent (eg, gemcitabine, temozolomide, or vinorelbine). A choice among agents should take into account their side effect profiles. </div><div id=\"graphicVersion\">Graphic 111406 Version 1.0</div></div></div>"},"111409":{"type":"graphic_table","displayName":"Lab testing for neonate or infant with cholestatic liver disease","title":"Laboratory testing for evaluating a neonate or young infant with suspected cholestatic liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory testing for evaluating a neonate or young infant with suspected cholestatic liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Implications</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Initial tests for all infants</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Comprehensive metabolic panel </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Total and conjugated bilirubin </li> </ul> </td> <td>To evaluate for conjugated hyperbilirubinemia (cholestasis) versus unconjugated hyperbilirubinemia.</td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>ALT and AST </li> </ul> </td> <td>To assess for hepatocyte injury.</td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Alkaline phosphatase and GGTP </li> </ul> </td> <td>To assess for biliary injury. Furthermore, several genetic/metabolic disorders can be divided into high and low GGTP categories.*</td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Total protein and albumin </li> </ul> </td> <td>To assess hepatocyte function. Low albumin suggests poor nutrition, renal losses or poor hepatic synthetic function.</td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Electrolytes, bicarbonate, glucose </li> </ul> </td> <td>To assess for metabolic disease. Abnormalities in these results are often seen in infants with metabolic disease.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>CBC with differential </li> </ul> </td> <td> <p>To assess for infection and/or splenic sequestration. Elevated WBC is suggestive of infection. Low WBC and platelet count could indicate portal hypertension (with splenic sequestration).</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>PT/INR and PTT </li> </ul> </td> <td>To assess hepatocyte function and/or vitamin K deficiency. Abnormal results indicate impaired liver synthetic function and/or vitamin K deficiency.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Additional tests to evaluate for systemic illness of specific liver diseases<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Urinalysis and urine culture </li> </ul> </td> <td>Appropriate for most infants with cholestasis, to exclude urinary tract infection and to evaluate possible renal involvement.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Blood culture </li> </ul> </td> <td>If clinical presentation suggests sepsis.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Urine reducing substances </li> </ul> </td> <td>Screen for galactosemia (in infants ingesting lactose).<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Serum bile acids </li> </ul> </td> <td>Elevations are diagnostic of cholestasis.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Alpha 1 antitrypsin concentration </li> </ul> </td> <td>Low levels suggest AAT deficiency. Normal levels do not exclude AAT deficiency because this is an acute phase reactant.</td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>And protease inhibitor phenotype (PI type) </li> </ul> </td> <td>The primary alleles associated with liver disease are PI*ZZ homozygosity or PI*SZ heterozygosity.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>TSH, T4 </li> </ul> </td> <td>Screen for congenital hypothyroidism (primary or central).</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Urine bile acid analysis by FAB-MS </li> </ul> </td> <td>Used to diagnose bile acid synthetic disorders (BASD), which may present with low-GGT cholestasis.<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Metabolic testing </li> </ul> </td> <td>If a metabolic disorder is suspected, initial screening includes plasma amino acids, urine organic acids, acylcarnitine profile, ammonia, lactate/pyruvate ratio.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Genetic testing </li> </ul> </td> <td>Genetic testing is rapidly evolving with the availability of new technologies.<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGTP: gamma glutamyl transpeptidase; CBC: complete blood count; WBC: white blood cell count; PT: prothrombin time; INR: international normalized ratio; PTT: partial thromboplastin time; AAT: alpha-1 antitrypsin; TSH: thyroid stimulating hormone (thyrotropin); T4: thyroxine; FAB-MS: fast atom bombardment-mass spectrometry; GGT: gamma glutamyl transferase.<br />* GGTP is disproportionately elevated (compared with AST and ALT) in the most common types of neonatal cholestasis, including biliary atresia and Alagille syndrome, while a normal or low GGTP is seen in most forms of progressive familial intrahepatic cholestasis (PFIC), BASD, and arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome.<br />&#182; These tests are selected based upon the clinical presentation and results of initial tests.<br />&#916; Urine reducing substances is only valid as a screen for galactosemia if the infant is fed breast milk or a cow's milk-based formula (which contains lactose, then hydrolyzed to galactose).<br /><FONT class=lozenge>&#9674;</FONT> Infants must be off of ursodeoxycholic acid for at least five days prior to urine collection for bile acid analysis, because the FAB-MS signature of the drug overlaps with some of the abnormal bile acid metabolites seen in BASD.<br />&#167; Individual gene sequencing can be done if the clinical presentation suggests a specific diagnosis, such as Alagille syndrome. For screening of multiple genes associated with inherited cholestasis, next generation sequencing panels are available. Each panel interrogates about 20 to 50 genes. Up to date information is available at <A href=\"http://www.genetests.org/\" target=_blank>http://www.GeneTests.org</A>.</div><div id=\"graphicVersion\">Graphic 111409 Version 3.0</div></div></div>"},"111410":{"type":"graphic_table","displayName":"Physical exam for neonate or young infant with cholestatic liver","title":"Important elements of the physical examination for evaluating a neonate or young infant with cholestatic liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important elements of the physical examination for evaluating a neonate or young infant with cholestatic liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Implications</td> </tr> <tr> <td><strong>Vital signs</strong></td> <td>Infants with biliary atresia typically have normal vital signs. Abnormal vital signs are more likely in infants with an underlying infectious or metabolic disease.</td> </tr> <tr> <td><strong>General health and vigor</strong></td> <td>Infants with biliary atresia typically appear well; ill-appearance may indicate infection or metabolic disease.</td> </tr> <tr> <td><strong>Growth parameters</strong></td> <td>Infants with biliary atresia typically have normal growth initially, but poor weight gain after becoming cholestatic.</td> </tr> <tr> <td><strong>Facies and appearance</strong></td> <td>Infants with Alagille syndrome may have a characteristic facial appearance with a broad nasal bridge, triangular facies, and deep set eyes. This and other facial malformations or dysmorphism should prompt further evaluation for genetic disorders, such as cleft lip or palate (Hardikar syndrome), or other syndromic features.</td> </tr> <tr> <td><strong>Ophthalmologic examination</strong></td> <td>Cataracts suggest congenital infection or galactosemia; macular cherry red spot suggests Niemann-Pick; posterior embryotoxon suggests Alagille syndrome; optic nerve hypoplasia suggests septo-optic dysplasia.</td> </tr> <tr> <td><strong>Cardiac examination</strong></td> <td>Congenital heart disease may be present in patients with biliary atresia or Alagille syndrome.</td> </tr> <tr> <td colspan=\"2\"><strong>Abdominal examination</strong></td> </tr> <tr> <td class=\"indent1\">Ascites</td> <td>Suggests portal hypertension.*</td> </tr> <tr> <td class=\"indent1\">Abdominal wall veins</td> <td>Prominent abdominal wall veins suggest portal hypertension.*</td> </tr> <tr> <td class=\"indent1\">Liver size</td> <td>Hepatomegaly suggests a storage disorder. Hepatomegaly may also be present in biliary atresia or other cholestatic disorders.</td> </tr> <tr> <td class=\"indent1\">Liver consistency</td> <td>Firm liver texture suggests fibrosis and may be present in biliary atresia.</td> </tr> <tr> <td class=\"indent1\">Spleen</td> <td>Splenomegaly suggests portal hypertension or storage disorder.*</td> </tr> <tr> <td><strong>Skin</strong></td> <td>Bruising or petechiae suggest coagulopathy or thrombocytopenia. Jaundice confirms hyperbilirubinemia (which may be either conjugated or unconjugated).</td> </tr> <tr> <td><strong>Urine</strong></td> <td>Dark urine suggests conjugated hyperbilirubinemia.</td> </tr> <tr> <td><strong>Stool</strong></td> <td>Acholic (very pale) stools suggest absent bile flow.<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Portal hypertension is unusual at the time of diagnosis in biliary atresia, unless the presentation is late.<br />&para; Stool color cards provide examples of normal and abnormal infant stool colors. An example is available at: <a href=\"http://www.perinatalservicesbc.ca/Documents/Screening/BiliaryAtresia/StoolColourCard_English.pdf\" target=\"_blank\">http://www.perinatalservicesbc.ca/Documents/Screening/BiliaryAtresia/StoolColourCard_English.pdf</a>.</div><div id=\"graphicVersion\">Graphic 111410 Version 2.0</div></div></div>"},"111411":{"type":"graphic_table","displayName":"Clinical history for neonate or infant with cholestatic liver","title":"Important elements of the clinical history for evaluating a neonate or young infant with cholestatic liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important elements of the clinical history for evaluating a neonate or young infant with cholestatic liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Implications</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Birth history</td> </tr> <tr> <td class=\"indent1\">Prenatal ultrasonography and results</td> <td>Evaluate for choledochal cyst or bowel anomalies.</td> </tr> <tr> <td class=\"indent1\">Birth weight and gestational age</td> <td>Infants with biliary atresia typically have normal prenatal history and normal birth weight. Many genetic and metabolic causes of neonatal liver disease are associated with poor fetal growth.</td> </tr> <tr> <td class=\"indent1\">Newborn screen results</td> <td>Disorders on the newborn screen that can present with cholestasis include cystic fibrosis; galactosemia; tyrosinemia or other disorders of amino acid metabolism; and disorders of fatty acid oxidation or organic acid metabolism.*</td> </tr> <tr> <td class=\"indent1\">Isoimmune hemolysis</td> <td>In infants with severe ABO incompatibility, conjugated hyperbilirubinemia occasionally persists until two weeks of age.<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Maternal infections (TORCH)</td> <td>Among the TORCH infections, herpes simplex virus infection and syphilis are particularly likely to be associated with liver injury in the neonate.</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Complications of pregnancy</td> <td>Intrahepatic cholestasis of pregnancy in the mother (which may manifest as pruritus without jaundice) suggests the possibility of PFIC in the infant.</td> </tr> <tr class=\"divider_bottom\"> <td>Acute fatty liver of pregnancy in the mother suggests the possibility of a fatty acid oxidation defect in the infant.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td class=\"indent1\">Consanguinity</td> <td>Increases the risk of an autosomal recessive disorder.<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">History of similar problems in the family</td> <td>Suggests a heritable disorder, particularly those with dominant or co-dominant inheritance.<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Stool characteristics</td> </tr> <tr> <td class=\"indent1\">Stool color</td> <td>Persistent acholic (clay colored) stools are a sign of cholestasis, which could be the result of biliary obstruction (eg, biliary atresia) or other causes.<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Stooling pattern</td> <td>Delayed stooling may occur in cystic fibrosis or hypothyroidism; diarrhea may occur in infection, metabolic disease, or PFIC.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Diet and gastrointestinal symptoms</td> </tr> <tr> <td class=\"indent1\">Dietary history</td> <td>Galactosemia is only expressed if the infant is taking breastmilk or a cow's milk-based formula (contains lactose, which is hydrolyzed to galactose).</td> </tr> <tr> <td class=\"indent1\">Weight gain</td> <td>Severe cholestasis, genetic disease, or metabolic disease may cause failure to thrive.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vomiting</td> <td>May occur in metabolic disease, bowel obstruction, and pyloric stenosis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other symptoms</td> </tr> <tr> <td class=\"indent1\">Urine color</td> <td>Dark urine suggests conjugated hyperbilirubinemia.</td> </tr> <tr> <td class=\"indent1\">Excessive bleeding (eg, after circumcision)</td> <td>May indicate coagulopathy (eg, due to vitamin K deficiency or poor hepatocellular function).</td> </tr> <tr> <td class=\"indent1\">Infant's behavior</td> <td>Irritability may indicate metabolic disease or sepsis; lethargy may indicate metabolic disease, sepsis, hypothyroidism, or panhypopituitarism.</td> </tr> <tr> <td class=\"indent1\">Neonatal infection</td> <td>Infections, particularly urinary tract infections, may be associated with transient cholestasis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFIC: progressive familial intrahepatic cholestasis; TORCH: toxoplasmosis, other (syphilis), rubella, cytomegalovirus, herpes simplex virus.<br />* All US states routinely perform newborn screening for cystic fibrosis, galactosemia, and several fatty acid and organic acid disorders. Most states also include screening for tyrosinemia. Details are available at the National Newborn Screening and Global Resource Center (http://genes-r-us.uthscsa.edu/).<br />¶ Isoimmune hemolysis causes a hyperbilirubinemia that is predominantly unconjugated, but may have a significant conjugated component, due to immaturity of the liver and enterohepatic circulation.<br />Δ Disorders with an autosomal recessive pattern of inheritance include cystic fibrosis, alpha-1 antitrypsin deficiency, galactosemia, tyrosinemia, and progressive familial intrahepatic cholestasis (PFIC).<br /><FONT class=lozenge>◊</FONT> Disorders with dominant or co-dominant inheritance include Alagille syndrome.<br />§ Stool color cards provide examples of normal and abnormal infant stool colors. An example is available at: <A spellcheck=true href=\"http://www.perinatalservicesbc.ca/Documents/Screening/BiliaryAtresia/StoolColourCard_English.pdf\">http://www.perinatalservicesbc.ca/Documents/Screening/BiliaryAtresia/StoolColourCard_English.pdf. </A></div><div id=\"graphicVersion\">Graphic 111411 Version 1.0</div></div></div>"},"111413":{"type":"graphic_algorithm","displayName":"Admission and discharge criteria for malnutrition in children","title":"Admission and discharge criteria for children 6 to 59 months of age with severe acute malnutrition in a resource-limited setting","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Admission and discharge criteria for children 6 to 59 months of age with severe acute malnutrition in a resource-limited setting</div><div class=\"cntnt\"><img style=\"width:530px; height:860px;\" src=\"images/PEDS/111413_Admssn_dschrg_mlntrtn_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MUAC: mid-upper arm circumference; SAM: severe acute malnutrition; IMCI: integrated management of childhood illness.<br />* Severe edema is defined as generalized edema including both feet, legs, hands, arms, and face. Moderate edema involves both feet plus lower legs, hands, or lower arms. Mild edema involves both feet only.<br />&para; Admit if the child is having a convulsion now, or if there is a history of more than one convulsion, or of a prolonged convulsion (&gt;15 min).<br />&Delta; The decision to transfer a child from inpatient to outpatient care should be determined by the clinical condition, and not on the basis of specific anthropometric outcomes such as a specific MUAC or weight-for-height/length Z-score.<br /><span class=\"lozenge\">&loz;</span> The anthropometric indicator that is used to confirm severe acute malnutrition should also be used to assess whether a child has reached nutritional recovery, ie, if MUAC was used to identify that a child has SAM, then MUAC should be used to assess and confirm nutritional recovery. Similarly, if weight-for-height is used to identify that a child has SAM, then weight-for-height should be used to assess and confirm nutritional recovery. Percentage weight gain should not be used as a discharge criterion.</div><div id=\"graphicVersion\">Graphic 111413 Version 2.0</div></div></div>"},"111414":{"type":"graphic_algorithm","displayName":"Admission and discharge criteria for malnutrition in infants","title":"Admission and discharge criteria for infants less than 6 months of age with severe acute malnutrition in a resource-limited setting","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Admission and discharge criteria for infants less than 6 months of age with severe acute malnutrition in a resource-limited setting</div><div class=\"cntnt\"><img style=\"width:580px; height:872px;\" src=\"images/PEDS/111414_Admssn_dschrg_mlntrtn_infnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SAM: severe acute malnutrition; IMCI: integrated management of childhood illness; WHO: World Health Organization.<br />* Admit if the child is having a convulsion now, or if there is a history of more than one convulsion, or of a prolonged convulsion (&gt;15 min).<br />&para; Ineffective feeding is difficulty with attachment, positioning or suckling, determined by direct observation of a feed for 15 to 20 minutes, ideally in a supervised and separated area.<br />&Delta; Issues may include disability or depression of the caregiver, or other adverse social circumstances.<br /><span class=\"lozenge\">&loz;</span> The infant should be transferred from inpatient to outpatient care only if all of the following conditions are met:&#xD;&#xA;<ul>&#xD;&#xA;    <li>All clinical conditions or medical complications are resolved.</li>&#xD;&#xA;    <li>Has good appetite and is clinically well and alert.</li>&#xD;&#xA;    <li>Weight gain on exclusive breastfeeding or replacement feeding is satisfactory.<sup>&sect;</sup></li>&#xD;&#xA;    <li>Immunizations and other routine interventions are up to date.</li>&#xD;&#xA;    <li>Mother or caregiver(s) are linked with appropriate community-based services for follow up and support.</li>&#xD;&#xA;</ul>&#xD;&#xA;&sect; Adequate weight is defined as growth velocity more than 5 g/kg per day for at least three successive days, or above the median for World Health Organization (WHO) standards.</div><div id=\"graphicVersion\">Graphic 111414 Version 2.0</div></div></div>"},"111417":{"type":"graphic_figure","displayName":"Dental/oral complications of immunodeficiency","title":"Dental/oral complications of immunodeficiency","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dental/oral complications of immunodeficiency</div><div class=\"cntnt\"><img style=\"width:756px; height:1039px;\" src=\"images/ALLRG/111417_Dntl_orl_cmplctns_immndfncy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A; IgG: immunoglobulin G.<br />* The failure of up to five permanent teeth to develop (also called tooth agenesis).<br />¶ An abnormal tooth shape in which the roots are reduced in size and the body of the tooth is enlarged, most often affecting molars.<br />Δ Also bleeding and petechiae.</div><div class=\"graphic_reference\">Adapted from: Peacock ME, Arce RM, Cutler CW. Periodontal and other oral manifestations of immunodeficiency diseases. Oral Dis 2016. DOI: 10.1111/odi.12584.</div><div id=\"graphicVersion\">Graphic 111417 Version 1.0</div></div></div>"},"111424":{"type":"graphic_picture","displayName":"Endobronchial sarcoidosis","title":"Endobronchial sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 647px\" class=\"figure\"><div class=\"ttl\">Endobronchial sarcoidosis</div><div class=\"cntnt\"><img style=\"width:627px; height:359px;\" src=\"images/PULM/111424_Endobronchial_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endobronchial views of airways showing erythema and a nodular, cobblestone appearance, indicated by the arrows,&nbsp;due to mucosal sarcoidosis.</div><div class=\"graphic_footnotes\">RML: right middle lobe; RLL: right lower lobe.</div><div class=\"graphic_reference\">Reproduced from: Barreiro TJ. Cobblestone Airways. Mayo Clin Proc 2016; 91:1849. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111424 Version 1.0</div></div></div>"},"111425":{"type":"graphic_table","displayName":"Causes of crazy-paving pattern on HRCT","title":"Causes of crazy-paving pattern on high resolution computed tomography (HRCT)*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of crazy-paving pattern on high resolution computed tomography (HRCT)*<SUP>¶</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td>Acute respiratory distress syndrome</td> </tr> <tr> <td>Adenocarcinoma of the lung (eg, lepidic predominant, formerly known as bronchioloalveolar carcinoma)</td> </tr> <tr> <td>Alveolar hemorrhage</td> </tr> <tr> <td>Amiodarone lung toxicity</td> </tr> <tr> <td>Bacterial (eg, <em>Streptococcus pneumoniae</em>, leptospirosis, <em>Mycoplasma</em>, <em>Nocardia</em>), and viral (eg, influenza, cytomegalovirus, hantavirus, HTLV-1, SARS-coronavirus) pneumonia </td> </tr> <tr> <td>Cardiogenic pulmonary edema</td> </tr> <tr> <td>Exogenous lipoid pneumonia</td> </tr> <tr> <td>Nonspecific interstitial pneumonitis</td> </tr> <tr> <td>Organizing pneumonia</td> </tr> <tr> <td>Pulmonary alveolar proteinosis</td> </tr> <tr> <td><em>Pneumocystis jirovecii</em> pneumonia</td> </tr> <tr> <td>Sarcoidosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HTLV-1: human T-cell lymphotropic virus type 1; SARS: severe acute respiratory syndrome (due to coronavirus).<br />* \"Crazy-paving\" describes a ground-glass pattern of opacification with thickening of the intralobular and interlobular septa to produce polygonal shapes.<br />¶ Many of these diagnoses have other more common presentations on HRCT but can occasionally be associated with crazy-paving.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rossi SE, Erasmus JJ, Volpacchio M et al. \"Crazy-paving\" pattern at thin-section CT of the lungs: radiologic-pathologic overview. Radiographics 2003; 23:1509.</LI>&#xD;&#xA;<LI>Feng Y, Zhao J, Yang Q, et al. Pulmonary melanoma and \"crazy paving\" patterns in chest images: a case report and literature review. BMC Cancer 2016; 16:592.</LI>&#xD;&#xA;<LI>For additional information, refer to the UpToDate topic on high resolution computed tomography of the lungs.</LI></OL></div><div id=\"graphicVersion\">Graphic 111425 Version 1.0</div></div></div>"},"111428":{"type":"graphic_algorithm","displayName":"Algorithm for the diagnosis of PAP","title":"Diagnostic algorithm for pulmonary alveolar proteinosis (PAP) in adults*","html":"<div class=\"graphic\"><div style=\"width: 866px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for pulmonary alveolar proteinosis (PAP) in adults*</div><div class=\"cntnt\"><img style=\"width:846px; height:762px;\" src=\"images/PULM/111428_Algorithm_diagnosis_PAP.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography; CBC: complete blood count; MARS: methionyl-tRNA synthetase; BAL: bronchoalveolar lavage; TBLB: transbronchial lung biopsy; GM-CSF: granulocyte monocyte-colony stimulating factor; PAS: periodic acid-Schiff.<br />* Surfactant-related genetic variants typically present in infancy or childhood.<br />¶ \"Crazy-paving\" pattern on HRCT is due to thickening of interlobular and intralobular septa. While crazy-paving is often present in autoimmune PAP, it is seen less often in secondary causes of PAP. Crazy-paving is not specific to PAP.<br />Δ Depending on test availability, can test for antibodies to GM-CSF before or after BAL. Testing is usually performed before surgical lung biopsy, as a confident diagnosis of autoimmune PAP can be made with compatible HRCT and BAL in combination with antibodies to GM-CSF.<br /><FONT class=lozenge>◊</FONT> Typical cytologic/histopathologic findings of PAP: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Copious amorphous PAS positive material</LI>&#xD;&#xA;<LI>Alveolar macrophages engorged with PAS positive material</LI>&#xD;&#xA;<LI>Few inflammatory cells</LI>&#xD;&#xA;<LI>Stains and cultures for <EM>Pneumocystis jirovecii</EM> and other organisms negative</LI></UL></div><div id=\"graphicVersion\">Graphic 111428 Version 1.0</div></div></div>"},"111429":{"type":"graphic_picture","displayName":"Ichthyosis hystrix","title":"Ichthyosis hystrix","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Ichthyosis hystrix</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/111429_Ichthyosis_hystrix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized verrucous plaques with accentuation over the extensor surfaces in a child with ichthyosis hystrix.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111429 Version 1.0</div></div></div>"},"111430":{"type":"graphic_table","displayName":"Baseline and follow-up tests for IMWG response assessment","title":"Baseline and follow-up tests for response assessment in multiple myeloma using IMWG consensus criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Baseline and follow-up tests for response assessment in multiple myeloma using IMWG consensus criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">&nbsp;</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">Every response assessment timepoint (every cycle)</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">If electrophoresis shows no measurable protein</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">At suspected CR</td> <td class=\"subtitle1_left\" style=\"border-bottom: black 3px solid;\">At suspected progression (clinical or biochemical)</td> </tr> <tr class=\"divider_bottom\"> <td>SPEP (serum M-spike &#8805;1 g/dL<sup>[1]</sup>)*</td> <td>X</td> <td>&#9674;&#9674;</td> <td>X</td> <td>X</td> </tr> <tr class=\"divider_bottom\"> <td>Serum immunofixation (any)</td> <td>&#9674;&#9674;</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr class=\"divider_bottom\"> <td>UPEP (urine M-spike &#8805;200 mg/24 hours)</td> <td>X</td> <td>&#9674;&#9674;</td> <td>X</td> <td>X</td> </tr> <tr class=\"divider_bottom\"> <td>Urine immunofixation (any)</td> <td>&#9674;&#9674;</td> <td>X</td> <td>X</td> <td>&#9674;&#9674;</td> </tr> <tr> <td colspan=\"5\">Serum FLC</td> </tr> <tr> <td class=\"indent1\">Serum M-spike &#60;1 g/dL, urine M-spike &#60;200 mg/24 hours, but involved immunoglobulin FLC is &#8805;10 mg/dL</td> <td>X</td> <td>&#9674;&#9674;</td> <td>X</td> <td>X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any</td> <td>&#9674;&#9674;</td> <td>&#9674;&#9674;</td> <td>X</td> <td>X</td> </tr> <tr> <td colspan=\"5\">Bone marrow aspirate/biopsy</td> </tr> <tr> <td class=\"indent1\">Serum M-spike, urine M-spike, or involved immunoglobulin FLC not meeting above criteria but bone marrow plasma cell percentage &#8805;30%</td> <td>X<br /> (to be done every three or four cycles till a plateau or complete response, or as clinically indicated and then at suspected progression)</td> <td>&#9674;&#9674;</td> <td>X</td> <td>&#9674;&#9674;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any</td> <td>&#9674;&#9674;</td> <td>&#9674;&#9674;</td> <td>X</td> <td>&#9674;&#9674;</td> </tr> <tr> <td colspan=\"5\">Plasmacytoma (PET imaging)</td> </tr> <tr> <td class=\"indent1\">Serum M-spike, urine M-spike, involved Ig FLC or bone marrow not meeting above criteria, but at least one lesion that has a single diameter of &#8805;2 cm</td> <td>X<br /> (to be done every three or four cycles till a plateau or complete response, or as clinically indicated, and then at suspected progression)</td> <td>&#9674;&#9674;</td> <td>X</td> <td>&#9674;&#9674;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any</td> <td>&#9674;&#9674;</td> <td>&#9674;&#9674;</td> <td>X</td> <td>&#9674;&#9674;</td> </tr> <tr> <td>Hemoglobin, serum calcium, creatinine (any)</td> <td>X</td> <td>&#9674;&#9674;</td> <td>&#9674;&#9674;</td> <td>X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IMWG: International Myeloma Working Group; CR: complete response; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; FLC: free light chain; X: test performed; &#9674;&#9674;: test not performed.<br />* A baseline M-spike of &ge;0.5 g/dL is acceptable if very good partial response or higher is the response endpoint to be measured and in situations where progression-free survival or time to progression are the endpoints of interest.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013; 28: 1122-08.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17:e328. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111430 Version 1.0</div></div></div>"},"111435":{"type":"graphic_table","displayName":"Causes of thrombocytopenia in pregnancy","title":"Causes of thrombocytopenia in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thrombocytopenia in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age</td> <td class=\"subtitle1\">Incidental finding of asymptomatic thrombocytopenia<br /> (platelet count 80,000 to 149,000/microL)</td> <td class=\"subtitle1\">Platelet count &#60;80,000/microL</td> </tr> <tr class=\"divider_bottom\"> <td>&#8804;20 weeks</td> <td> <ul> <li>Most often GT </li> <li>ITP cannot be excluded, but no evaluation or management would be required </li> <li>Occurrence of other disorders not different from non-pregnant patients </li> </ul> </td> <td> <ul> <li>Not GT </li> <li>May be ITP </li> <li>Occurrence of other disorders not different from non-pregnant patients </li> </ul> </td> </tr> <tr> <td>&#62;20 weeks, at delivery, and postpartum</td> <td> <ul> <li>Almost always GT </li> <li>ITP cannot be excluded, but no evaluation or management would be required </li> <li>Occurrence of other disorders not different from non-pregnant patients </li> </ul> </td> <td> <ul> <li>Almost never GT </li> <li>If asymptomatic, ITP likely </li> <li>If hypertension, preeclampsia </li> <li>If symptoms of systemic illness as well as MAHA: <ul> <li>HELLP syndrome, if LFTs increased </li> <li>DIC, if coagulation abnormalities present; suspect sepsis </li> <li>C-TMA, if AKI is severe </li> <li>TTP, if transient focal neurologic abnormalities occur </li> </ul> </li> </ul> <ul style=\"list-style-type: none;\"> <li>The frequency of these disorders increases with gestation, with a peak occurrence at delivery and the first postpartum week. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Some disorders are listed in both columns because patients with these disorders may have mild or severe thrombocytopenia. Refer to UpToDate topics for details of the diagnostic evaluation and immediate management interventions while determining the diagnosis.</div><div class=\"graphic_footnotes\">GT: gestational thrombocytopenia; ITP: immune thrombocytopenia; TTP: thrombotic thrombocytopenic purpura; MAHA: microangiopathic hemolytic anemia; HELLP: hemolysis, elevated liver function tests, and low platelets; LFTs: liver function tests; DIC: disseminated intravascular coagulation; C-TMA: complement-mediated thrombotic microangiopathy; AKI: acute kidney injury.</div><div id=\"graphicVersion\">Graphic 111435 Version 1.0</div></div></div>"},"111437":{"type":"graphic_table","displayName":"Symptoms of febrile illness versus neurologic illness in ARF","title":"Symptoms of febrile illness versus neurologic illness in patients with acute rheumatic fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of febrile illness versus neurologic illness in patients with acute rheumatic fever</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Acute febrile illness</td> <td class=\"subtitle1\">Neurologic illness (25 to 30%)</td> </tr> <tr> <td> <ul> <li>Onset two to four weeks after GAS infection </li> <li>Fever is common </li> <li>Acute joint symptoms and signs </li> <li>Carditis <ul> <li>Clinical and subclinical </li> </ul> </li> <li>Skin manifestations and subcutaneous nodules (both are rare)&nbsp;</li> <li>Raised inflammatory markers </li> <li>Evidence of preceding GAS infection (elevated ASO and anti-DNase B titers) </li> <li>Dramatic symptomatic response to aspirin and NSAIDS </li> <li>Duration usually &#60;6 weeks </li> <li>Followed by RHD in approximately 75% </li> </ul> </td> <td> <ul> <li>Later onset <ul> <li>Two to six months after GAS infection </li> </ul> </li> <li>No fever </li> <li>Joint manifestations are not a feature </li> <li>Behavioral disorder and distinctive chorea </li> <li>Carditis &#62;30% <ul> <li>Often subclinical </li> </ul> </li> <li>Often normal inflammatory markers </li> <li>ASO often unhelpful,&nbsp;anti-DNase B&nbsp;may be raised </li> <li>Followed by RHD in approximately 50% </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GAS: group A <EM>Streptococcus</EM>; ASO: antistreptolysin; NSAID: nonsteroidal anti-inflammatory drug; anti-DNase B: antideoxyribonuclease B; RHD: rheumatic heart disease.</div><div id=\"graphicVersion\">Graphic 111437 Version 1.0</div></div></div>"},"111438":{"type":"graphic_table","displayName":"Colorectal cancer TNM 2017","title":"Colorectal cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Colorectal cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em>, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae)</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria)</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the muscularis propria</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades through the muscularis propria into pericolorectal tissues</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades the visceral peritoneum or invades or adheres to adjacent organ or structure</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Tumor directly invades or adheres to adjacent organs or structures</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">One to three regional lymph nodes are positive (tumor in lymph nodes measuring &#8805;0.2 mm), or any number of tumor deposits are present and all identifiable lymph nodes are negative</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td colspan=\"3\">One regional lymph node is positive</td> </tr> <tr> <td class=\"indent2\">N1b</td> <td colspan=\"3\">Two or three regional lymph nodes are positive</td> </tr> <tr> <td class=\"indent2\">N1c</td> <td colspan=\"3\">No regional lymph nodes are positive, but there are tumor deposits in the <ul class=\"decimal_heading\"> <li>subserosa </li> <li>mesentery </li> <li>or nonperitonealized pericolic, or perirectal/mesorectal tissues. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Four or more regional nodes are positive</td> </tr> <tr> <td class=\"indent2\">N2a</td> <td colspan=\"3\">Four to six regional lymph nodes are positive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N2b</td> <td colspan=\"3\">Seven or more regional lymph nodes are positive</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis by imaging, etc, no evidence of tumor in distant sites or organs. (This category is not assigned by pathologists.)</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Metastasis to one or more distant sites or organs or peritoneal metastasis is identified</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Metastasis to one site or organ is identified without peritoneal metastasis</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Metastasis to two or more sites or organs is identified without peritoneal metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1c</td> <td colspan=\"3\">Metastasis to the peritoneal surface is identified alone or with other site or organ metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1, T2</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N0</td> <td>M0</td> <td>IIC</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N1/N1c</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N2a</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3-T4a</td> <td>N1/N1c</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T2-T3</td> <td>N2a</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N2b</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N2a</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T3-T4a</td> <td>N2b</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N1-N2</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1a</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1c</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111438 Version 2.0</div></div></div>"},"111439":{"type":"graphic_table","displayName":"Tumor regression score for rectal cancer","title":"Modified Ryan scheme for tumor regression scoring in rectal cancer treated preoperatively","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Ryan scheme for tumor regression scoring in rectal cancer treated preoperatively</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"75%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Tumor regression score</td> </tr> <tr> <td>No viable cancer cells (complete response)</td> <td class=\"centered\">0</td> </tr> <tr> <td>Single cells or rare small groups of cancer cells (near-complete response)</td> <td class=\"centered\">1</td> </tr> <tr> <td>Residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response)</td> <td class=\"centered\">2</td> </tr> <tr> <td>Extensive residual cancer with no evident tumor regression (poor or no response)</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47:141. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2005.02176.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2005.02176.x/abstract</a>. Copyright &copy; 2005. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 111439 Version 1.0</div></div></div>"},"111440":{"type":"graphic_table","displayName":"2015 classification of vulvar pain","title":"2015 international consensus of sexual medicine classification of vulvar pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2015 international consensus of sexual medicine classification of vulvar pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Vulvar pain caused by a specific disorder*</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Infectious (eg, recurrent candidiasis, herpes) </li> <li>Inflammatory (eg, lichen sclerosus, lichen planus, immunobullous disorders) </li> <li>Neoplastic (eg, Paget disease, squamous cell carcinoma) </li> <li>Neurologic (eg, post-herpetic neuralgia, nerve compression or injury, neuroma) </li> <li>Trauma (eg, female genital cutting, obstetrical) </li> <li>Iatrogenic (eg, postoperative, chemotherapy, radiation) </li> <li>Hormonal deficiencies (eg, genitourinary syndrome of menopause [vulvovaginal atrophy], lactational amenorrhea) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Vulvodynia - Vulvar pain of at least three months duration, without clear identifiable cause, which may have potential associated factors</td> </tr> <tr> <td> <ul> <li>Localized (eg, vestibulodynia, clitorodynia) <strong>or</strong> generalized <strong>or</strong> mixed (localized and generalized) </li> <li>Provoked (eg, insertional, contact) <strong>or</strong> spontaneous <strong>or</strong> mixed (provoked and spontaneous) </li> <li>Onset (primary or secondary) </li> <li>Temporal pattern (intermittent, persistent, constant, immediate, delayed) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Women may have both a specific disorder (eg, lichen sclerosus) and vulvodynia.</div><div class=\"graphic_reference\">Reproduced with permission from: The International Society for the Study of Vulvovaginal Disease (ISSVD), the International Society for the Study of Women's Sexual Health (ISSWSH), and the International Pelvic Pain Society (IPPS). 2015 consensus terminology and classification of persistent vulvar pain. Available from: <a href=\"http://www.issvd.org/wp-content/uploads/2015/09/consensus-terminology-of-Vulvar-Pain-V5.pdf\" target=\"_blank\">http://www.issvd.org/wp-content/uploads/2015/09/consensus-terminology-of-Vulvar-Pain-V5.pdf</a> (Accessed on January 12, 2017).</div><div id=\"graphicVersion\">Graphic 111440 Version 1.0</div></div></div>"},"111441":{"type":"graphic_table","displayName":"Approach to vulvar hygiene","title":"Approach to vulvar hygiene","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to vulvar hygiene</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Clothing and laundry</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Wear white cotton underwear </li> <li>Do not wear pantyhose (wear thigh-high or knee-high hose instead) </li> <li>Wear loose-fitting pants or skirts </li> <li>Remove wet bathing suits and exercise clothing promptly </li> <li>Use dermatologically approved detergent </li> <li>Do not use fabric softener on undergarments </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Hygiene</td> </tr> <tr> <td> <ul> <li>Use soft, white, unscented toilet paper </li> <li>Use lukewarm or cool sitz baths to relieve burning and irritation </li> <li>Avoid getting shampoo on the vulvar area </li> <li>Do not use bubble bath, feminine hygiene products, or any perfumed creams or soaps </li> <li>Wash the vulva with cool to lukewarm water only </li> <li>Rinse the vulva with water after urination </li> <li>Urinate before the bladder is full </li> <li>Prevent constipation by adding fiber to your diet (if necessary, use a psyllium product) and drinking at least eight glasses of water daily </li> <li>Use 100% cotton menstrual pads and tampons </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: National Vulvodynia Association. Self-help tips. <a href=\"http://www.nva.org/for-patients/self-help-tips\" target=\"_blank\">www.nva.org/for-patients/self-help-tips</a> (Accessed on January 12, 2017).</div><div id=\"graphicVersion\">Graphic 111441 Version 1.0</div></div></div>"},"111443":{"type":"graphic_table","displayName":"Prognostic outcomes path stage after CRT rectal CA","title":"Five- and 10-year disease-free survival (DFS) according to posttreatment pathologic (yp) stage and tumor regression grade (TRG) at resection after neoadjuvant chemoradiotherapy in the German Rectal Cancer Study Group (CAO/ARO/AIO-94) trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five- and 10-year disease-free survival (DFS) according to posttreatment pathologic (yp) stage and tumor regression grade (TRG) at resection after neoadjuvant chemoradiotherapy in the German Rectal Cancer Study Group (CAO/ARO/AIO-94) trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">yp category</td> <td class=\"subtitle1_left\">Five-year DFS (%)</td> <td class=\"subtitle1_left\">10-year DFS (%)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ypT</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>86</td> <td>90</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>95</td> <td>95</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>81</td> <td>78</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>65</td> <td>66</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td>42</td> <td>40</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">ypN</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>85</td> <td>84</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>65</td> <td>59</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td>18</td> <td>28</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">TRG</td> <td class=\"subtitle1_left\">Five-year DFS (%)</td> <td class=\"subtitle1_left\">10-year DFS (%)</td> </tr> <tr> <td class=\"indent1\">4</td> <td>86</td> <td>90</td> </tr> <tr> <td class=\"indent1\">2-3</td> <td>75</td> <td>74</td> </tr> <tr> <td class=\"indent1\">0-1</td> <td>63</td> <td>63</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Five-tier system for TRG. Complete regression = TRG 4; intermediate regression = TRG 2-3; poor or no regression = TRG 0-1.</div><div class=\"graphic_reference\">Data from: R&ouml;del C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688 and Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014; 32:1554.</div><div id=\"graphicVersion\">Graphic 111443 Version 1.0</div></div></div>"},"111447":{"type":"graphic_table","displayName":"Benefit of postop chemo after preop CRT rectal CA Eur trials","title":"Estimates of the benefit of adjuvant chemotherapy in responders versus nonresponders after chemoradiotherapy for rectal cancer, from an analysis of five European randomized trials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimates of the benefit of adjuvant chemotherapy in responders versus nonresponders after chemoradiotherapy for rectal cancer, from an analysis of five European randomized trials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Estimates at five years</td> <td class=\"subtitle1\" colspan=\"2\">Responders (ie, ypT0N0)</td> <td class=\"subtitle1\" colspan=\"2\">Nonresponders (ie, ypT3N1)</td> </tr> <tr> <td class=\"subtitle2\">Adjuvant chemo negative</td> <td class=\"subtitle2\">Adjuvant chemo positive</td> <td class=\"subtitle2\">Adjuvant chemo negative</td> <td class=\"subtitle2\">Adjuvant chemo positive</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Local recurrence risk (%)</strong></td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> <td class=\"centered\">20</td> <td class=\"centered\">12</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Distant metastasis risk (%)</strong></td> <td class=\"centered\">11</td> <td class=\"centered\">9</td> <td class=\"centered\">51</td> <td class=\"centered\">36</td> </tr> <tr> <td><strong>Death (%)</strong></td> <td class=\"centered\">11.5</td> <td class=\"centered\">9.5</td> <td class=\"centered\">68</td> <td class=\"centered\">57</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011; 29:3163.</div><div id=\"graphicVersion\">Graphic 111447 Version 1.0</div></div></div>"},"111448":{"type":"graphic_algorithm","displayName":"Syphilis screening for asymptomatic, nonpregnant adults","title":"Syphilis screening for asymptomatic, nonpregnant adults","html":"<div class=\"graphic\"><div style=\"width: 1162px\" class=\"figure\"><div class=\"ttl\">Syphilis screening for asymptomatic, nonpregnant adults</div><div class=\"cntnt\"><img style=\"width:1142px; height:768px;\" src=\"images/ID/111448_Syphils_scrn_asympt_nnprgnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm addresses syphilis screening in asymptomatic, nonpregnant adults. It does <STRONG>not</STRONG> apply to patients who present with or develop symptoms consistent with syphilis. Refer to the UpToDate topic on screening and diagnostic testing for syphilis for a discussion of testing in patients with clinical signs and symptoms suggestive of infection.</div><div class=\"graphic_footnotes\">* Nontreponemal tests include the rapid plasma reagin (RPR), the Venereal Disease Research Laboratory (VDRL), and the toluidine red unheated serum test (TRUST).<br />¶ Treponemal tests include the fluorescent treponemal antibody absorption (FTA-ABS), the treponema pallidum particle agglutination (TPPA), the T. pallidum enzyme immunoassay (TP-EIA), or chemiluminescence immunoassay (CIA). These different tests target different antigens.<br />Δ Both treponemal and nontreponemal tests take time to convert (eg, approximately 2 to 4 weeks ) in the setting of a new infection. Thus, on rare occasion, asymptomatic patients who have had a recent exposure to syphilis (eg, sexually active men who have sex with men, those having condomless sex with unknown or multiple partners) may have a false-negative nontreponemal or treponemal screening test.<br /><FONT class=lozenge>◊</FONT> Treatment of syphilis depends upon the clinical manifestations and the stage of disease (eg, early, late, neurosyphilis). Asymptomatic patients are considered to have latent syphilis and should be treated for early latent (the patient was infected within the last 12 months) or late latent disease (the patient was infected more than 12 months ago). Refer to the UpToDate topics that discuss clinical manifestations, treatment, and monitoring of syphilis for specific information.<br />§ False-positive nontreponemal tests can be seen in the setting of pregnancy, an acute event (eg, febrile illness, endocarditis, Rickettsial disease), or recent immunization. Test abnormalities attributed to these conditions are usually transitory and typically last for six months or less. Other etiologies include chronic conditions, such as autoimmune disorders (particularly systemic lupus erythematosus), intravenous drug use, chronic liver disease, and underlying HIV disease.<br />¥ Refer to UpToDate topic on treatment and monitoring of syphilis to help guide management decisions.</div><div id=\"graphicVersion\">Graphic 111448 Version 1.0</div></div></div>"},"111452":{"type":"graphic_algorithm","displayName":"Guide to interpretation of synovial fluid analysis","title":"Guide to interpretation of synovial fluid analysis","html":"<div class=\"graphic\"><div style=\"width: 880px\" class=\"figure\"><div class=\"ttl\">Guide to interpretation of synovial fluid analysis</div><div class=\"cntnt\"><img style=\"width:860px; height:832px;\" src=\"images/RHEUM/111452_Intrprttn_synovl_fld_anlyss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WBC: white blood cell; MSU: monosodium urate; CPPD: calcium pyrophosphate crystal deposition.<br />* Crystal-induced arthritis may still be considered despite the absence of identified crystals; false-negative results occur, especially with CPPD.<br />¶ If treatment of crystal-induced arthritis does not result in clinical improvement, consider other inflammatory or infectious arthridites.</div><div id=\"graphicVersion\">Graphic 111452 Version 1.0</div></div></div>"},"111453":{"type":"graphic_algorithm","displayName":"Introducing peanut during infancy and early childhood","title":"Introduction of peanut into the diet during infancy/early childhood","html":"<div class=\"graphic\"><div style=\"width: 851px\" class=\"figure\"><div class=\"ttl\">Introduction of peanut into the diet during infancy/early childhood</div><div class=\"cntnt\"><img style=\"width:831px; height:539px;\" src=\"images/ALLRG/111453_Intropeanutinfancychild.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; PN-IgE: peanut-specific immunoglobulin E.<br />* Alternatively, the allergy specialist may chose to perform PN-IgE testing, or both skin prick and PN-IgE testing, for the initial evaluation.<br />&para; Prior to introduction of highly allergenic foods, the infant/child should:&#xD;&#xA;<ul class=\"decimal_heading\">&#xD;&#xA;    <li>Be at least four months of age.</li>&#xD;&#xA;    <li>Show developmental readiness to consume complementary foods.</li>&#xD;&#xA;    <li>Have tolerated a few of the more typical, initial complementary foods (eg, cereals, fruits, vegetables).</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; These skin prick test cutoffs for peanut are best estimates based upon limited data from two non-US study cohorts (Learning Early About Peanut Allergy [LEAP] and HealthNuts). A number of factors can affect the size of the skin test reaction, including test site chosen (back versus forearm), testing device used, and age of the patient. It is important that clinicians performing in-office feedings or graded challenges have the appropriate training and equipment to manage potential severe allergic reactions regardless of the test results.</div><div id=\"graphicVersion\">Graphic 111453 Version 2.0</div></div></div>"},"111458":{"type":"graphic_algorithm","displayName":"Management of women with known endometriosis and infertility","title":"Management of women with known endometriosis and infertility*","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Management of women with known endometriosis and infertility*</div><div class=\"cntnt\"><img style=\"width:710px; height:850px;\" src=\"images/OBGYN/111458_Mngmnt_wmn_endmtrsis_infert.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* This algorithm reflects a general approach to the woman with known endometriosis who presents with infertility. Specific treatment decisions may change based on patient preferences and availability of treatment options.<br />&para; Assisted reproductive technology includes in vitro fertilization, intracytoplasmic sperm injection, and assisted reproductive hatching.<br />&Delta; For more information on the surgical staging of endometriosis, refer to UpToDate topic on the clinical features of endometriosis.<br /><span class=\"lozenge\">&loz;</span> Treatable causes of infertility include intrauterine lesions, ovulatory disorders, and tubal disease. For more information, refer to UpToDate topics on the evaluation and treatment of female and male infertility.</div><div id=\"graphicVersion\">Graphic 111458 Version 1.0</div></div></div>"},"111459":{"type":"graphic_algorithm","displayName":"Algorithm for the management of pediatric HCM","title":"Algorithm for the management of pediatric HCM","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Algorithm for the management of pediatric HCM</div><div class=\"cntnt\"><img style=\"width:692px; height:790px;\" src=\"images/CARD/111459_Algo_mgmt_HCM_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content on HCM in children. Refer to UpToDate topics on the management of patients with HCM and the management of heart failure in children for additional details of our approach to treatment and the overall efficacy of these treatments.</div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; LVOT: left ventricular outflow tract; LV: left ventricle; ECG: electrocardiogram.<br />* For the purposes of this algorithm, \"greater than mild LVOT\" is defined as a gradient &gt;25 mmHg. This criterion is not standardized and other centers may use different criteria in determining when to initiate pharmacotherapy in children with HCM.<br />¶ Targets of therapy include reduction of symptoms (if present), reduction in the LVOT gradient (goal is &lt;25 mmHg), and preservation of LV function.<br />Δ Verapamil should be avoided in patients &lt;12 months old due to concerns for apnea, hypotension, and cardiac arrest.<br /><FONT class=lozenge>◊</FONT> Combined therapy with beta blocker and verapamil is frequently limited by symptomatic bradycardia, particularly in younger patients who are more dependent on calcium and less tolerant of bradycardia.<br />§ Adverse effects of the agents listed in this algorithm include bradycardia, hypotension, fatigue, decreased appetite, and feeding intolerance.<br />¥ Refer to separate UpToDate content for details of nonpharmacologic therapies.</div><div id=\"graphicVersion\">Graphic 111459 Version 1.0</div></div></div>"},"111461":{"type":"graphic_picture","displayName":"Tinea nigra PI","title":"Tinea nigra","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea nigra</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/111461_Tinea_nigra_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea nigra looks like a brown patch on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111461 Version 2.0</div></div></div>"},"111464":{"type":"graphic_picture","displayName":"Magill forceps","title":"Magill forceps","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Magill forceps</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ANEST/111464_Magill_forceps_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magill forceps are commonly used during nasal intubation, to grasp the endotracheal tube in the posterior pharynx, and to advance or direct the tube into the laryngeal inlet. They have bent handles, such that the handles are out of the line of sight when being used.</div><div id=\"graphicVersion\">Graphic 111464 Version 1.0</div></div></div>"},"111465":{"type":"graphic_table","displayName":"Prevention of periop peripheral neuropathies","title":"Summary of ASA Practice Advisory for prevention of perioperative peripheral neuropathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of ASA Practice Advisory for prevention of perioperative peripheral neuropathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Areas of interest</td> <td class=\"subtitle1\">Recommendations/statements</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Preoperative assessment</strong></td> <td> <ul> <li>Risk factors for perioperative nerve damage should be identified </li> <li>Patient's ability to tolerate the planned position should be assessed </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Positioning strategies UE, individual nerves</td> </tr> <tr> <td class=\"indent1\">Brachial plexus</td> <td> <ul> <li>Supine: Arm abduction should be limited to &#8804;90 degrees </li> <li>Prone: Abduction &#62;90 degrees may be tolerated </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ulnar nerve</td> <td> <ul> <li>Arms abducted: Avoid pressure on ulnar groove, forearm supinated or neutral </li> <li>Arms tucked: Forearm should be in neutral position </li> <li>When possible avoid elbow flexion, unknown acceptable degree of flexion </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Radial nerve</td> <td> <ul> <li>Avoid pressure on the nerve in spiral groove of humerus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Median nerve</td> <td> <ul> <li>Avoid extension of elbow beyond preoperative comfortable range </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Positioning strategies LE, individual nerves</td> </tr> <tr> <td class=\"indent1\">Sciatic</td> <td> <ul> <li>Avoid stretch of hamstring muscle group beyond preoperative comfortable range </li> <li>Consider extension and flexion of both hip and knee joints, as nerve crosses both joints </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Femoral</td> <td> <ul> <li>When possible avoid extension or flexion of the hip&nbsp;</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Peroneal</td> <td> <ul> <li>Avoid pressure on nerve at fibular head </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Protective padding</strong></td> <td> <ul> <li>Arm boards should be padded </li> <li>Use chest roll in lateral decubitus position </li> <li>Pad at elbow </li> <li>Pad fibular head </li> <li>Avoid tight padding </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Equipment</strong></td> <td> <ul> <li>When possible avoid use of shoulder braces in steep head down position</li> <li>When possible avoid blood pressure cuff below the antecubital fossa</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Postoperative assessment</strong></td> <td> <ul> <li>May lead to early recognition of neuropathy </li> </ul> </td> </tr> <tr> <td><strong>Documentation of positioning</strong></td> <td> <ul> <li>May focus attention on positioning </li> <li>May provide information that leads to improved patient care </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UE: upper extremity; LE: lower extremity.</div><div class=\"graphic_reference\">Adapted from: Practice Advisory for the Prevention of Perioperative Peripheral Neuropathies 2018: An Updated Report by the American Society of Anesthesiologists Task Force on Prevention of Perioperative Peripheral Neuropathies. Anesthesiology 2018; 128:11.</div><div id=\"graphicVersion\">Graphic 111465 Version 2.0</div></div></div>"},"111471":{"type":"graphic_table","displayName":"Normal levels of folic acid in pregnancy","title":"Normal levels of folic acid in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal levels of folic acid in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nutrient</td> <td class=\"subtitle1\">First trimester</td> <td class=\"subtitle1\">Second trimester</td> <td class=\"subtitle1\">Third trimester</td> </tr> <tr> <td>Folate, serum (ng/mL)</td> <td class=\"centered\">2.6 to 15.0</td> <td class=\"centered\">0.8 to 24.0</td> <td class=\"centered\">1.4 to 20.7</td> </tr> <tr> <td>Folate, red blood cell (ng/mL)</td> <td class=\"centered\">137 to 589</td> <td class=\"centered\">94 to 828</td> <td class=\"centered\">109 to 663</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: The World Health Organization recommends a minimum red blood cell folate level of 400 ng/mL prior to conception and in the first trimester.</div><div class=\"graphic_reference\">Data from: Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: A reference table for clinicians. Obstet Gynecol 2009; 114:1326.</div><div id=\"graphicVersion\">Graphic 111471 Version 1.0</div></div></div>"},"111472":{"type":"graphic_figure","displayName":"ScvO2 preceding intradialytic hypotension","title":"ScvO<SUB>2</SUB> preceding intradialytic hypotension","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">ScvO<SUB>2</SUB> preceding intradialytic hypotension</div><div class=\"cntnt\"><img style=\"width:538px; height:370px;\" src=\"images/NEPH/111472_ScvO2intradialytchypotnsn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had a history of cardiomyopathy and symptoms on hemodialysis ranging from hypotension to \"a funny feeling\" at various times during treatment. The patient had previously been identified as having a low ScvO<SUB>2</SUB> and used oxygen with each hemodialysis treatment, most often with a mask instead of a nasal cannula due to nostril irritation. This patient's fluid gains were typically 1 to 2 kg between dialysis sessions. On the example exhibit the patient had a stable ScvO<SUB>2</SUB> ranging from 55 to 58% with 2 liters of oxygen per minute, but, in the beginning of the third hour, there was a sharp decrease in the ScvO<SUB>2</SUB> along with symptoms of hypotension and lightheadedness. A 100 mL bolus of normal saline (NS)&nbsp;improved the symptoms and the ScvO<SUB>2</SUB> for the remaining hour and a half. This patient had a history of having unexplained symptoms, often in the middle of the treatment, and the estimated dry weight was raised several times. Symptoms were lessened when the staff reacted to the decreasing ScvO<SUB>2</SUB> by reducing the ultrafiltration.</div><div class=\"graphic_footnotes\">ScvO<SUB>2</SUB>: central venous oxygen saturation; SAT%: percent saturation; NS: normal saline; %BVΔ: percent change in blood volume; UF: ultrafiltration.</div><div class=\"graphic_reference\">From: Campos I, Chan L, Zhang H, et al. Intradialytic hypoxemia in chronic hemodialysis patients. Blood Purif 2016; 41:177. Copyright © 2016 Karger Publishers, Basel, Switzerland.</div><div id=\"graphicVersion\">Graphic 111472 Version 2.0</div></div></div>"},"111473":{"type":"graphic_table","displayName":"Folic acid supplementation guidelines by indication","title":"Folic acid supplementation guidelines by indication","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Folic acid supplementation guidelines by indication</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"17.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication for supplementation</td> <td class=\"subtitle1\">Dose (daily)</td> <td class=\"subtitle1\">Start (minimum)</td> <td class=\"subtitle1\">Duration*</td> <td class=\"subtitle1\">Recommended by</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">High risk</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Prior NTD or personal history in either parent<sup>[1-4]</sup></td> <td>4 mg</td> <td>One month PTC</td> <td>12 weeks</td> <td>ACOG, CDC, AAP</td> </tr> <tr> <td>4 mg</td> <td>Three months PTC</td> <td>12 weeks</td> <td>SOGC</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Moderate risk</td> </tr> <tr> <td class=\"indent1\">Personal or family history of folate-sensitive congenital anomaly other than NTD<sup>[4]</sup></td> <td>1 mg</td> <td>Three months PTC</td> <td>12 weeks</td> <td>SOGC</td> </tr> <tr> <td class=\"indent1\">Family history of NTD (first- or second-degree relative)<sup>[4]</sup></td> <td>1 mg</td> <td>Three months PTC</td> <td>12 weeks</td> <td>SOGC</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Type I or II diabetes<sup>[4]</sup></td> <td>1 mg</td> <td>Three months PTC</td> <td>12 weeks</td> <td>SOGC</td> </tr> <tr> <td>0.4 mg</td> <td>One month PTC</td> <td>12 weeks</td> <td>ADA, ACOG</td> </tr> <tr> <td class=\"indent1\">Maternal gastrointestinal malabsorption<sup>[4]</sup></td> <td>1 mg</td> <td>Three months PTC</td> <td>12 weeks</td> <td>SOGC</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Medical conditions associated with risk (advanced liver disease, dialysis, alcohol overuse)<sup>[4]</sup></td> <td>1 mg</td> <td>Three months PTC</td> <td>12 weeks</td> <td>SOGC</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Low risk</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Pregnancy or potential for pregnancy<sup>[1-4,6,7]</sup></td> <td>0.4 mg</td> <td>One to three months PTC</td> <td>Through pregnancy +/&ndash; lactation</td> <td>ACOG, CDC, AAP, NICE, SOGC, USPHS</td> </tr> <tr> <td>0.4 to 0.8 mg</td> <td>One month PTC</td> <td>First two to three months of pregnancy</td> <td>USPSTF</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Clinical guidelines vary regarding the dose of folic acid supplementation in women taking antiepileptic drugs. The SOGC recommends 1 mg of folic acid daily for women taking medications with secondary teratogenic effects related to folate inhibition<SUP>[4]</SUP>. The American Academy of Neurology and American Epilepsy Society guidelines state that data are insufficient to determine whether doses higher than 0.4 mg offer greater protective benefits<SUP>[8]</SUP>. ACOG recommends 4 mg of folic acid daily for women at high risk of having offspring with neural tube defects, and include women taking antiepileptic drugs in this category<SUP>[9]</SUP>.&nbsp;UpToDate&nbsp;suggests 4 mg/day for women on valproate or carbamazepine and 0.4 mg/day for women on other antiepileptic drugs.</div><div class=\"graphic_footnotes\">NTD: neural tube defect; PTC: prior to conception; ACOG: American College of Obstetricians and Gynecologists; CDC: Centers for Disease Control and Prevention; AAP: American Academy of Pediatrics; SOGC: Society of Obstetricians and Gynaecologists of Canada; ADA: American Diabetes Association; NICE: National Institute for Health and Care Excellence; USPHS: United States Public Health Service; USPSTF: United States Preventive Services Task Force.<br />* After 12 weeks, supplementation via routine prenatal vitamin is recommended through the remainder of pregnancy and lactation.<br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>ACOG Committee on Practice Bulletins. ACOG practice bulletin. Neural tube defects. Number 44, July 2003. Reaffirmed 2016.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects 1983-1991. MMWR Morb Mortal Wkly Rep 1991; 40:513.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics Committee on Genetics. Folic acid for the prevention of neural tube defects. Pediatrics 1999; 104:325.</LI>&#xD;&#xA;<LI>Wilson RD, Genetics Committee, Audibert F, et al. Preconceptional folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid sensitive congenital anomalies. J Obstet Gynaecol Can 2015; 37:534.</LI>&#xD;&#xA;<LI>Wald NJ. Folic acid and the prevention of neural tube defects. N Engl J Med 2004; 350:101.</LI>&#xD;&#xA;<LI>US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al.&nbsp;Folic acid for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement. JAMA 2017; 317:183.</LI>&#xD;&#xA;<LI>National Institute for Health and Care Excellence. Maternal and child nutrition, 2008. <A href=\"https://www.nice.org.uk/guidance/ph11/chapter/4-Recommendations#folic-acid-2\" target=_blank>https://www.nice.org.uk/guidance/ph11/chapter/4-Recommendations#folic-acid-2</A> (Accessed on August 18, 2016).</LI>&#xD;&#xA;<LI>Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73:142.</LI>&#xD;&#xA;<LI>American College of Obstetricians and Gynecologists. Preconception and interconception care. In: Guidelines for Women's Health Care, 4<SUP>th</SUP> ed, 2014. p.389.</LI></OL></div><div id=\"graphicVersion\">Graphic 111473 Version 3.0</div></div></div>"},"111476":{"type":"graphic_figure","displayName":"Creation of esophagojejunostomy with OrVil device","title":"Creation of esophagojejunostomy with OrVil device","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Creation of esophagojejunostomy with OrVil device</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/111476_Creation_of_esophagojejunostomy_with_OrVil_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The OrVil anvil is passed transorally to the stapled esophageal stump trailing a specially designed nasogastric tube. A small incision is made in the middle of the esophageal staple line to allow the nasogastric tube to pass. Once the tube is pulled into the abdominal cavity, it is disconnected from the anvil by cutting the connecting thread.<br />(B) An EEA stapler is advanced into the lumen of the loop of jejunum to be anastomosed to the esophagus. The spike, which punctures the jejunal wall, is connected with the anvil.<br />(C) The EEA stapler is closed and fired, creating a circular stapled esophagojejunal anastomosis. <br />(D) The EEA stapler is removed from the jejunum. The open end is closed with a linear endoscopic stapler. <br />(E) Detailed view of an EEA stapled esophagojejunostomy with the OrVil device.</div><div id=\"graphicVersion\">Graphic 111476 Version 1.0</div></div></div>"},"111477":{"type":"graphic_table","displayName":"Imaging in the evaluation of chronic dyspnea","title":"Imaging in the evaluation of chronic dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imaging in the evaluation of chronic dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Imaging</td> </tr> <tr> <td class=\"subtitle2\">Abnormality</td> <td class=\"subtitle2\">Interpretation</td> <td class=\"subtitle2\">Further testing</td> </tr> <tr class=\"divider_bottom\"> <td>Normal or increased reticular markings on chest radiograph</td> <td>Review PFTs re: evidence of restriction, abnormal DLCO, or low SpO<sub>2</sub> at rest or with exertion. If abnormalities suggest ILD, obtain HRCT.</td> <td>Review HRCT pattern to differentiate types of ILD; obtain appropriate tests for rheumatic diseases, HP, pneumoconiosis. Refer to UpToDate topics on evaluation of interstitial lung disease.</td> </tr> <tr class=\"divider_bottom\"> <td>Hyperinflation</td> <td>DDx includes COPD/emphysema, asthma, normal variant, bronchiolitis, lymphangioleiomyomatosis, Marfan syndrome, Birt-Hogg-Dube.</td> <td> <p>Correlate with PFTs.</p> <p>If airflow limitation, empiric bronchodilator therapy.</p> Consider HRCT.</td> </tr> <tr class=\"divider_bottom\"> <td>Pleural effusion or thickening on chest radiograph</td> <td>Pleural effusion, trapped lung, and fibrothorax can lead to dyspnea through altered pleural mechanics and compressive atelectasis.</td> <td>Evaluation usually requires thoracentesis of pleural effusion, sometimes with measurement of pleural pressures. In addition, chest computed tomography with contrast is frequently part of the evaluation.</td> </tr> <tr class=\"divider_bottom\"> <td>Abnormal spine, rib cage, or diaphragm</td> <td>Review PFTs to assess degree of functional impairment.</td> <td>For patients with chest wall disease and an FVC &#60;1 L, consider assessment for hypercapnia.</td> </tr> <tr> <td>Enlarged or abnormal heart contour on chest radiograph</td> <td>Obtain BNP and echocardiogram with Doppler assessment of PA pressures: Review pericardium, systolic/diastolic function, valvular function.</td> <td>If echocardiogram normal, consider MRI or CT scan to evaluate abnormal heart size/contour.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PFTs: pulmonary function tests; DLCO: diffusion capacity of the lungs for carbon monoxide; SpO<SUB>2</SUB>: pulse oxygen saturation; ILD: interstitial lung disease; HRCT: high resolution computed tomography; HP: hypersensitivity pneumonitis; DDx: differential diagnosis; COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; BNP: brain natriuretic peptide; PA: pulmonary artery; MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 111477 Version 1.0</div></div></div>"},"111478":{"type":"graphic_table","displayName":"Cardiac testing in the evaluation of chronic dyspnea","title":"Cardiac testing in the evaluation of chronic dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiac testing in the evaluation of chronic dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Cardiac evaluation</td> </tr> <tr> <td class=\"subtitle2\">Test</td> <td class=\"subtitle2\">Interpretation</td> <td class=\"subtitle2\">Follow-up</td> </tr> <tr class=\"divider_bottom\"> <td>ECG shows arrhythmia, conduction disturbance, or myocardial injury</td> <td>ECG abnormalities may be a clue to underlying coronary artery or myocardial disease. Obtain treadmill/other stress test and echocardiogram.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Treadmill or nuclear stress test can be helpful even in absence of chest pain</td> <td>Some patients are more aware of dyspnea than chest pressure. Patients with COPD may&nbsp;report dyspnea that is due to comorbid cardiac disease.</td> <td>Testing suggests CAD; evaluate and treat.</td> </tr> <tr> <td rowspan=\"3\">Transthoracic echocardiogram: Useful in the identification of systolic and diastolic ventricular dysfunction, hypertrophic cardiomyopathy, valvular disease, pericardial disease, and pulmonary hypertension</td> <td>Echocardiogram shows reduced left ventricular systolic function (HFrEF): Likely cardiomyopathy or CAD.</td> <td>Evaluate for risk factors. Initiate treatment.</td> </tr> <tr> <td>Echocardiogram shows preserved ejection fraction (HFpEF). Assess severity and potential risk factors; initiate treatment.</td> <td>Depending on response to treatment, may need right and/or left heart catheterization to confirm.</td> </tr> <tr> <td>Echocardiogram shows elevated PA pressure with normal systolic LV function. DDx includes pulmonary hypertension, CTEPH, HFpEF, others. Check BNP, assess for risk factors.</td> <td>Consider right heart catheterization to confirm diagnosis of PH (mean PAP &#8805;25 and PAWP &#60;15). Consider V/Q scan re: CTEPH. Obtain appropriate tests for secondary PH (eg, rheumatic diseases, HBV, HCV, HIV, PSG).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; PA: pulmonary artery; LV: left ventricular; DDx: differential diagnosis; CTEPH: chronic thromboembolic pulmonary hypertension; BNP: brain natriuretic peptide; PH: pulmonary hypertension; PAP: pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; V/Q: ventilation perfusion; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; PSG: polysomnography.</div><div id=\"graphicVersion\">Graphic 111478 Version 1.0</div></div></div>"},"111489":{"type":"graphic_diagnosticimage","displayName":"Benign extra-axial fluid of infancy","title":"Benign extra-axial fluid of infancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign extra-axial fluid of infancy</div><div class=\"cntnt\"><img style=\"width:262px; height:262px;\" src=\"images/PEDS/111489_Bngn_extra-axial_fld_infncy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T1-weighted image of a term infant who presented with increasing head circumference &gt;97<SUP>th</SUP> percentile for age. The infant was otherwise well-appearing, had no concerning symptoms, and was developing normally. The family history was positive for macrocephaly. Brain MRI demonstrates enlargement of the anterior subarachnoid space with mild ventriculomegaly consistent with benign extra-axial fluid of infancy (also called \"benign external hydrocephalus\").</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 111489 Version 1.0</div></div></div>"},"111490":{"type":"graphic_diagnosticimage","displayName":"Obliterated cavum septi pellucidi","title":"Obliterated cavum septi pellucidi at 20<SUP>3/7ths</SUP> weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Obliterated cavum septi pellucidi at 20<SUP>3/7ths</SUP> weeks of gestation</div><div class=\"cntnt\"><img style=\"width:617px; height:903px;\" src=\"images/OBGYN/111490_Oblitertd_cavum_septi_pellc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A normal hypoechoic corpus callosum is seen (arrow). The cavum septi is obliterated, with absence of its typical anechoic appearance.<br />(B) A normal pericallosal artery is seen (arrow) on color Doppler.</div><div id=\"graphicVersion\">Graphic 111490 Version 1.0</div></div></div>"},"111491":{"type":"graphic_diagnosticimage","displayName":"Dandy-Walker brainstem-vermis angle","title":"Dandy-Walker malformation at 21<SUP>2/7ths</SUP> weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">Dandy-Walker malformation at 21<SUP>2/7ths</SUP> weeks of gestation</div><div class=\"cntnt\"><img style=\"width:785px; height:404px;\" src=\"images/OBGYN/111491_Dandy-Walker_brainstm-verms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Median section of the fetal brain showing a large cisterna magna with a small and rotated vermis and elevated tentorium and torcular.<br />(B) The brainstem-vermis angle is measured by drawing a line tangentially to the dorsal aspect of the brainstem and a second line drawn tangentially to the ventral contour of the vermis.</div><div id=\"graphicVersion\">Graphic 111491 Version 1.0</div></div></div>"},"111496":{"type":"graphic_picture","displayName":"Major medical station Twin Cities Marathon","title":"Major medical station Twin Cities Marathon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Major medical station Twin Cities Marathon</div><div class=\"cntnt\"><img style=\"width:368px; height:825px;\" src=\"images/SM/111496_Majr_med_sttn_Twn_Cts_Mrthn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above show the outside appearance (photo A)&nbsp;and entryway (including signs) and primary medical treatment area (photos B and C)&nbsp;for the main medical tent located at the finish line of the Twin Cities Marathon.</div><div class=\"graphic_reference\">Courtesy of William Roberts, MD.</div><div id=\"graphicVersion\">Graphic 111496 Version 1.0</div></div></div>"},"111497":{"type":"graphic_figure","displayName":"Port placement for laparoscopic or robotic gastrectomy","title":"Port placement for laparoscopic or robotic gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Port placement for laparoscopic or robotic gastrectomy</div><div class=\"cntnt\"><img style=\"width:449px; height:540px;\" src=\"images/SURG/111497_Port_placement_for_laparoscopic_or_robotic_gastrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Minimally invasive gastrectomy can be performed with five ports, including three 12-mm ports and two either 8-mm (for robotic surgery) or 5-mm&nbsp;(for laparoscopic surgery) ports.&nbsp;We position the&nbsp;central 12-mm (camera) port at or just above the level of the umbilicus, depending upon the length of the torso.</div><div id=\"graphicVersion\">Graphic 111497 Version 1.0</div></div></div>"},"111498":{"type":"graphic_picture","displayName":"Dissection of the posterior wall of the stomach off pancreas","title":"Dissection of the posterior wall of the stomach off the pancreas","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dissection of the posterior wall of the stomach off the pancreas</div><div class=\"cntnt\"><img style=\"width:756px; height:608px;\" src=\"images/SURG/111498_Dssctn_pstr_wll_stmch_pncrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In laparoscopic total gastrectomy, the posterior wall of the stomach should be dissected off the anterior aspect of the pancreas until the gastroduodenal artery groove (arrow) can be visualized to ensure adequate mobilization of the stomach.</div><div class=\"graphic_reference\">Courtesy of Joyce Wong, MD.</div><div id=\"graphicVersion\">Graphic 111498 Version 1.0</div></div></div>"},"111499":{"type":"graphic_picture","displayName":"Distal esophagus being transected with Endo GIA stapler","title":"Distal esophagus being transected with Endo GIA stapler","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Distal esophagus being transected with Endo GIA stapler</div><div class=\"cntnt\"><img style=\"width:756px; height:589px;\" src=\"images/SURG/111499_Dstl_esphgs_Endo_GIA_staplr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal esophagus is transected with an Endo GIA stapler. The Penrose drain placed around the gastroesophageal junction provides caudal retraction.</div><div class=\"graphic_reference\">Courtesy of Joyce Wong, MD.</div><div id=\"graphicVersion\">Graphic 111499 Version 1.0</div></div></div>"},"111500":{"type":"graphic_picture","displayName":"Anvil grasper around anvil seated in the esophageal stump","title":"Anvil grasper around anvil seated in the esophageal stump","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Anvil grasper around anvil seated in the esophageal stump</div><div class=\"cntnt\"><img style=\"width:756px; height:581px;\" src=\"images/SURG/111500_Anvl_graspr_esophageal_stmp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anvil seated in the esophageal stump (secured with an anvil grasper) is being mated with the spike. The stapler handle is in the jejunum.</div><div class=\"graphic_reference\">Courtesy of Joyce Wong, MD.</div><div id=\"graphicVersion\">Graphic 111500 Version 1.0</div></div></div>"},"111501":{"type":"graphic_picture","displayName":"Circular esophagojejunal anastomosis","title":"Circular esophagojejunal anastomosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Circular esophagojejunal anastomosis</div><div class=\"cntnt\"><img style=\"width:756px; height:661px;\" src=\"images/SURG/111501_Circular_esophgjjnl_anstmss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Completed circular stapled esophagojejunal anastomosis (arrow).</div><div class=\"graphic_reference\">Courtesy of Joyce Wong, MD.</div><div id=\"graphicVersion\">Graphic 111501 Version 1.0</div></div></div>"},"111502":{"type":"graphic_picture","displayName":"Non-bullous impetigo PI","title":"Impetigo around the nose","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Impetigo around the nose</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/PI/111502_Non-bullous_impetigo_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When you have impetigo, your skin forms honey-colored crusts. It also turns red under the crusts.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright © 2014 Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111502 Version 2.0</div></div></div>"},"111503":{"type":"graphic_picture","displayName":"Bullous impetigo PI","title":"Impetigo sores","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Impetigo sores</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/PI/111503_Bullous_impetigo_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sometimes impetigo causes red-rimmed, painful sores on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111503 Version 2.0</div></div></div>"},"111504":{"type":"graphic_table","displayName":"WASHING mnemonic for perioperative risk factors","title":"WASHING mnemonic for perioperative risk factors for surgical site infection following gynecologic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WASHING mnemonic for perioperative risk factors for surgical site infection following gynecologic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"centered\"><strong>W</strong></td> <td>Weight</td> </tr> <tr> <td class=\"centered\"><strong>A</strong></td> <td>Antibiotic-resistant skin flora, methicillin-resistant <em>Staphylococcus</em> aureus</td> </tr> <tr> <td class=\"centered\"><strong>S</strong></td> <td>Smoking cessation</td> </tr> <tr> <td class=\"centered\"><strong>H</strong></td> <td>Hygiene (skin preparation)</td> </tr> <tr> <td class=\"centered\"><strong>I</strong></td> <td>Immune deficiency status</td> </tr> <tr> <td class=\"centered\"><strong>N</strong></td> <td>Nutritional status</td> </tr> <tr> <td class=\"centered\"><strong>G</strong></td> <td>Glycemic control</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Mnemonic to aid in identifying patient risk factors for surgical site infection.</div><div class=\"graphic_reference\">From: Pellegrini JE, Toledo P, Soper DE, et al. Consensus bundle on prevention of surgical site infections after major gynecologic surgery. Obstet Gynecol 2017; 129(1):50-61. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2017&amp;issue=01000&amp;article=00007&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000001751</A>. Copyright © 2017 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111504 Version 2.0</div></div></div>"},"111505":{"type":"graphic_picture","displayName":"Tinea versicolor neck PI","title":"Tinea versicolor on the neck","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor on the neck</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PI/111505_Tinea_versicolor_neck_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea versicolor can look like dark patches on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111505 Version 2.0</div></div></div>"},"111506":{"type":"graphic_picture","displayName":"Tinea versicolor face PI","title":"Tinea versicolor on the face and neck","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor on the face and neck</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PI/111506_Tinea_versicolor_face_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea versicolor can look like light patches on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111506 Version 2.0</div></div></div>"},"111507":{"type":"graphic_table","displayName":"Data collection for surgical site infection risk review","title":"Data collection for surgical site infection risk review","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Data collection for surgical site infection risk review</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Patient-level risk factors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Obesity </li> <li>Diabetes mellitus </li> <li>Smoking status </li> <li>Steroid use </li> <li>Nutritional status </li> <li>American Society of Anesthesiologists Physical Status </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Health care provider-level risk factors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adherence with hand-washing and use of proper surgical attire </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Surgical risk factors</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Preoperative skin antisepsis </li> <li>Preoperative hair removal </li> <li>Operating room temperature </li> <li>Type of surgery </li> <li>Duration of surgery </li> <li>Insertion of foreign material </li> <li>Appropriate redosing of antibiotics (eg, owing to prolonged duration of surgery, excessive blood loss) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Pellegrini JE, Toledo P, Soper DE, et al. Consensus bundle on prevention of surgical site infections after major gynecologic surgery. Obstet Gynecol 2017; 129(1):50-61. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2017&amp;issue=01000&amp;article=00007&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000001751</A>. Copyright © 2017 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111507 Version 2.0</div></div></div>"},"111509":{"type":"graphic_figure","displayName":"Atlantoaxial subluxation of the cervical spine in RA","title":"Atlantoaxial subluxation of the cervical spine in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atlantoaxial subluxation of the cervical spine in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:504px; height:612px;\" src=\"images/RHEUM/111509_AtlantoaxlsblxtnCspineRA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration demonstrating the forward subluxation of the atlas on the axis, pannus formation around the odontoid process, and osseous erosions. There is severe compression of the spinal cord between the pannus anteriorly and the arch of the atlas posteriorly.</div><div class=\"graphic_reference\">From: Boden SD, Dodge LD, Bohlman HH, Rechtine GR. Rheumatoid arthritis of the cervical spine. A long-term analysis with predictors of paralysis and recovery. J Bone Joint Surg Am 1993; 75(9):1282-97. <A href=\"http://journals.lww.com/jbjsjournal/pages/default.aspx\"target=_blank>http://journals.lww.com/jbjsjournal/pages/default.aspx</A>. Copyright © 1993 The Journal of Bone and Joint Surgery, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111509 Version 2.0</div></div></div>"},"111510":{"type":"graphic_figure","displayName":"Cranial settling of the odontoid process in RA","title":"Cranial settling of the odontoid process in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cranial settling&nbsp;of the odontoid process in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:504px; height:612px;\" src=\"images/RHEUM/111510_BslrinvgntnodntdprcssRA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of the lateral view of the upper cervical spine, demonstrating&nbsp;cranial settling&nbsp;(arrow) of the odontoid process into the foramen magnum. Note the compression of the spinal cord.</div><div class=\"graphic_reference\">From: Boden SD, Dodge LD, Bohlman HH, Rechtine GR. Rheumatoid arthritis of the cervical spine. A long-term analysis with predictors of paralysis and recovery. J Bone Joint Surg Am 1993; 75(9):1282-97. <A href=\"http://journals.lww.com/jbjsjournal/pages/default.aspx\"target=_blank>http://journals.lww.com/jbjsjournal/pages/default.aspx</A>. Copyright © 1993 The Journal of Bone and Joint Surgery, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111510 Version 2.0</div></div></div>"},"111513":{"type":"graphic_figure","displayName":"Central theta EEG rhythm in Rett syndrome","title":"Electroencephalography demonstrating rhythmic frontocentral theta activity in a patient with Rett syndrome","html":"<div class=\"graphic\"><div style=\"width: 799px\" class=\"figure\"><div class=\"ttl\">Electroencephalography demonstrating rhythmic frontocentral theta activity in a patient with Rett syndrome</div><div class=\"cntnt\"><img style=\"width:779px; height:730px;\" src=\"images/NEURO/111513_CentralthetaEEGRettsyn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythmic frontocentral theta in a patient with Rett syndrome.<br />(A) Electroencephalography demonstrated a prominent 50 to 100 microvolts, 4 to 5 Hz rhythmic, fluctuating central theta rhythm (asterisk) during wakefulness.<br />(B) After tactile stimulation (line), a blocking phenomenon occurred (arrow), during which the central theta rhythm abated. All data are presented in longitudinal bipolar montage, sensitivity 7 microvolts/mm.</div><div class=\"graphic_reference\">From: Weber AR, Ostendorf A. Teaching NeuroImages: A central theta EEG rhythm in Rett syndrome can masquerade as seizure. Neurology 2016; 87(3):e29-30. DOI: <A href=\"http://www.neurology.org/content/87/3/e29.extract\" target=_blank>10.1212/WNL.0000000000002866</A>. Copyright © 2016 American Academy of Neurology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111513 Version 2.0</div></div></div>"},"111516":{"type":"graphic_table","displayName":"NCI CTCAE v5 dehydration","title":"NCI CTCAE version 5.0 dehydration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE version 5.0 dehydration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Dehydration</td> <td>Increased oral fluids indicated; dry mucous membranes; diminished skin turgor</td> <td>IV fluids indicated</td> <td>Hospitalization indicated</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Dehydration is characterized by excessive loss of water from the body. It is usually caused by severe diarrhea, vomiting, or diaphoresis.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; IV: intravenous.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 111516 Version 4.0</div></div></div>"},"111517":{"type":"graphic_table","displayName":"Severe thrombocytopenia after 20 weeks gestation","title":"Comparison of typical clinical features and specific management of disorders associated with a platelet count <80,000/microL occurring after 20 weeks gestation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of typical clinical features and specific management of disorders associated with a platelet count &lt;80,000/microL occurring after 20 weeks gestation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Preeclampsia/HELLP</td> <td class=\"subtitle1\">TTP</td> <td class=\"subtitle1\">C-TMA</td> <td class=\"subtitle1\">ITP</td> <td class=\"subtitle1\">Hemorrhage/DIC</td> <td class=\"subtitle1\">Sepsis/DIC</td> </tr> <tr class=\"divider_bottom\"> <td>Incidence</td> <td>100 in 10,000 pregnancies</td> <td>1&nbsp;in 10,000 pregnancies</td> <td>Unknown. May be similar to TTP.</td> <td>3 in 10,000 pregnancies</td> <td>&nbsp;2 in 10,000 pregnancies</td> <td>&nbsp;1 in 10,000 pregnancies</td> </tr> <tr class=\"divider_bottom\"> <td>Time of occurrence</td> <td>By definition, occurs after 20 weeks of gestation; more common near term and within three days postpartum</td> <td>May occur throughout pregnancy, but most common near term and several weeks postpartum</td> <td>May occur throughout pregnancy, but most common postpartum</td> <td>Any time during pregnancy</td> <td>Most commonly at delivery and postpartum</td> <td>Most commonly at delivery and postpartum</td> </tr> <tr class=\"divider_bottom\"> <td>Vital signs</td> <td>Hypertension, by definition, BP &#8805;160/110</td> <td>Normal BP, fever may be present but is rare</td> <td>Hypertension due to AKI</td> <td>Normal, unless hypotension and tachycardia from bleeding</td> <td>Hypotension, tachycardia (may have been transient)</td> <td>Fever, hypotension, tachycardia</td> </tr> <tr class=\"divider_bottom\"> <td>Neurologic abnormalities</td> <td>Headache, vision changes. Less commonly eclamptic seizures, PRES, stroke.</td> <td>Severe in 41% (transient focal defects, seizure, stroke); minor in 30%</td> <td>None</td> <td>None</td> <td>Probably none</td> <td>Probably none</td> </tr> <tr class=\"divider_bottom\"> <td>Microangiopathic hemolysis/schistocytes</td> <td>Moderate</td> <td>Severe</td> <td>Moderate</td> <td>None</td> <td>Variable</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td>Kidney injury</td> <td>Usually mild, but severe AKI is possible. Dialysis is rarely required.</td> <td>Usually mild or absent; severe AKI requiring dialysis in &#60;5%</td> <td>Severe, typically dialysis is required</td> <td>None</td> <td>Severe ATN, reversible</td> <td>May have ATN, reversible</td> </tr> <tr class=\"divider_bottom\"> <td>Liver function tests: ALT, AST</td> <td>From normal to markedly increased</td> <td>Normal or slightly increased</td> <td>Normal</td> <td>Normal</td> <td>May be markedly increased</td> <td>May be increased</td> </tr> <tr class=\"divider_bottom\"> <td>Typical course following delivery</td> <td>Stabilization or improvement within 48 hours</td> <td>No stabilization or improvement within 48 hours</td> <td>Increasing serum creatinine</td> <td>Most unchanged, but may improve after delivery</td> <td>Recovery after source of hemorrhage corrected</td> <td>Recovery after appropriate treatment</td> </tr> <tr> <td>Specific management</td> <td>Delivery of infant is curative</td> <td>Plasma exchange, immunosuppression if acquired autoimmune TTP suspected. If hereditary TTP is strongly suspected, plasma infusion is sufficient</td> <td>Anti-complement agent</td> <td>Glucocorticoids, IVIG, and maybe additional immunosuppressive agents</td> <td>Identify and correct source of hemorrhage. May require additional laparotomy.</td> <td>Antibiotics</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The incidence of preeclampsia with severe features is 1 case per 100 pregnancies. The incidence of TTP during pregnancy is estimated from data from the Oklahoma TTP Registry (frequency of TTP during pregnancy), and the CDC (birth rate per population). </div><div class=\"graphic_footnotes\">PE/HELLP: preeclampsia/hemolysis, elevated liver enzymes, low platelets; TTP: thrombotic thrombocytopenic purpura; C-TMA: complement-mediated thrombotic microangiopathy; ITP: immune thrombocytopenia; DIC: disseminated intravascular coagulation; PRES: posterior reversible encephalopathy syndrome; AKI: acute kidney injury; ATN: acute tubular necrosis; AST: aspartate aminotransferase; ALT: alanine aminotransferase; IVIG: intravenous immune globulin; CDC: US Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">Courtesy of James N George, MD and Jennifer J McIntosh, DO, MS.</div><div id=\"graphicVersion\">Graphic 111517 Version 4.0</div></div></div>"},"111524":{"type":"graphic_waveform","displayName":"ECG bifascicular block RBBB and LPFB","title":"ECG bifascicular block RBBB and LPFB","html":"<div class=\"graphic\"><div style=\"width: 865px\" class=\"figure\"><div class=\"ttl\">ECG bifascicular block RBBB and LPFB</div><div class=\"cntnt\"><img style=\"width:845px; height:452px;\" src=\"images/CARD/111524_ECG_bifscclr_blck_RBBB_LPFB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG from a patient with bifascicular block with RBBB and LPFB.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; RBBB: right bundle branch block; LPFB: left posterior fascicular block.</div><div class=\"graphic_reference\">Reproduced with permission from: Nathanson LA, McClennen S, Safran C, Goldberger AL. ECG Wave-Maven: Self-Assessment Program for Students and Clinicians. Available at: <A href=\"http://ecg.bidmc.harvard.edu/\" target=_blank>http://ecg.bidmc.harvard.edu</A> (Accessed on January 11, 2017).</div><div id=\"graphicVersion\">Graphic 111524 Version 2.0</div></div></div>"},"111525":{"type":"graphic_table","displayName":"Signs symptoms Cushing's syndrome","title":"Signs and symptoms of Cushing's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and&nbsp;symptoms of Cushing's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">More common</td> <td class=\"subtitle1\">Less common</td> </tr> <tr> <td> <ul> <li>Decreased libido </li> <li>Obesity/weight gain </li> <li>Plethora </li> <li>Round face </li> <li>Menstrual changes </li> <li>Hirsutism </li> <li>Hypertension </li> <li>Ecchymoses </li> <li>Lethargy, depression </li> <li>Dorsal fat pad </li> <li>Abnormal glucose tolerance </li> </ul> </td> <td> <ul> <li>ECG abnormalities or atherosclerosis </li> <li>Striae </li> <li>Edema </li> <li>Proximal muscle weakness </li> <li>Osteopenia or fracture </li> <li>Headache </li> <li>Backache </li> <li>Recurrent infections </li> <li>Abdominal pain </li> <li>Acne </li> <li>Female balding </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Reproduced with permission from: Nieman LK. Cushing's syndrome: Update on signs, symptoms and biochemical screening. Eur J Endocrin 2015; 173:M33. Copyright © 2015 BioScientifica Ltd.</div><div id=\"graphicVersion\">Graphic 111525 Version 3.0</div></div></div>"},"111542":{"type":"graphic_picture","displayName":"Tuberous xanthomas in HoFH","title":"Tuberous xanthomas in a child with homozygous familial hypercholesterolemia","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Tuberous xanthomas in a child with homozygous familial hypercholesterolemia</div><div class=\"cntnt\"><img style=\"width:566px; height:756px;\" src=\"images/PEDS/111542_Tuberous_xanthomas_HoFH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of a child with homozygous familial hypercholesterolemia showing tuberous xanthomas on both knees. These are due to abnormal deposits of cholesterol in the skin.</div><div id=\"graphicVersion\">Graphic 111542 Version 1.0</div></div></div>"},"111545":{"type":"graphic_figure","displayName":"Regional lymph nodes of the large bowel","title":"Regional lymph nodes of the colon and rectum","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Regional lymph nodes of the colon and rectum</div><div class=\"cntnt\"><img style=\"width:586px; height:808px;\" src=\"images/ONC/111545_Regnllymphnodeslrgbowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111545 Version 2.0</div></div></div>"},"111546":{"type":"graphic_figure","displayName":"Prognostic impact total resected involved nodes T stage rect ca","title":"Prognostic impact of the number of positive nodes, total number of nodes examined, and depth of the primary tumor for patients in a population-based cohort of 30,202 patients with rectal cancer","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Prognostic impact of the number of positive nodes, total number of nodes examined, and depth of the primary tumor for patients in a population-based cohort of 30,202 patients with rectal cancer</div><div class=\"cntnt\"><img style=\"width:628px; height:696px;\" src=\"images/ONC/111546_ProgimpctrescnodesTstg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impact of positive nodes, the total number of nodes examined, and the depth of primary tumor invasion in a population-based cohort of rectal carcinoma. Data from 30,202 patients diagnosed with rectal carcinoma between 2004 and 2010 and included in the population-based SEER database were analyzed for five-year relative survival. Each T category is presented separately. The N categories are color-coded as follows: green, N0 (all nodes negative); red, N1a (one positive node); orange, N1b (two or three positive nodes); light blue, N2a (four to six positive nodes); and purple, N2b (seven or more positive nodes). The N1c category is not represented because there is not yet a mature cohort in SEER with five-year relative survival. The lines for N category levels spread across the numbers of nodes examined. All patients were free of clinical metastases by surgical and clinical staging; that is, they were in stage groups I to III. Results are mean±SEM of five-year relative survival except for T4a and T4b, for which the number of patients is small and the error is large. The results suggest that the examination of more nodes for a given N category is associated with increasing survival. N0(i+) and N0mi are not included because they were not recorded previously for colorectal carcinoma.</div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology, and End Results; SEM: standard error of the mean.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111546 Version 2.0</div></div></div>"},"111547":{"type":"graphic_figure","displayName":"Prognost impact resected and involved nodes T stage colon ca","title":"Prognostic impact of the number of positive nodes, total number of nodes examined, and depth of the primary tumor for patients in a population-based cohort of 144,744 patients with colon cancer","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Prognostic impact of the number of positive nodes, total number of nodes examined, and depth of the primary tumor for patients in a population-based cohort of 144,744 patients with colon cancer</div><div class=\"cntnt\"><img style=\"width:650px; height:700px;\" src=\"images/ONC/111547_ProgimpctrscndesTcolon.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impact of positive nodes, the total number of nodes examined, and the depth of primary tumor invasion in a population-based cohort of colon carcinoma. Data from 144,744 patients diagnosed with colon carcinoma between 2004 and 2011 and included in the population-based SEER database were analyzed for five-year relative survival. Each T category is presented separately. The N categories are color-coded as follows: green, N0 (all nodes negative); red, N1a (one positive node); orange, N1b (two or three positive nodes); light blue, N2a (four to six positive nodes); and purple, N2b (seven or more positive nodes). N1c category is not represented because there is not yet a mature cohort in SEER with five-year relative survival. The lines for N category levels spread across the numbers of nodes examined. All patients were free of clinical metastases by surgical and clinical staging; that is, they were in stage groups I to III. Results are mean&plusmn;SEM of five-year relative survival. Results suggest that the examination of more nodes for a given N category is associated with increasing survival. N0(i+) and N0mi are not included because they were not recorded previously for colorectal carcinoma.</div><div class=\"graphic_footnotes\">SEER: Surveilance, Epidemiology, and End Results; SEM: standard error of the mean.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111547 Version 2.0</div></div></div>"},"111548":{"type":"graphic_table","displayName":"Non-traumatic knee pain with effusion in adults: Common causes","title":"Non-traumatic knee pain associated with joint effusion in adults: Common causes and features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-traumatic knee pain associated with joint effusion in adults: Common causes and features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Mechanism &#38; historical features</td> <td class=\"subtitle1\">Common symptoms</td> <td class=\"subtitle1\">Key examination findings</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Activity related</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Chronic osteochondral defect </li> </ul> </td> <td> <ul> <li>Mild repetitive trauma (running/jumping) </li> </ul> </td> <td> <ul> <li>Diffuse knee pain worse with and after activity </li> </ul> </td> <td> <ul> <li>Activity related effusion </li> </ul> </td> <td> <ul> <li>Radiographs or advanced imaging (MRI) needed for diagnosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Knee osteoarthritis </li> </ul> </td> <td> <ul> <li>Usually adults 50 years or older </li> <li>Activity-related pain; brief stiffness after inactivity </li> </ul> </td> <td> <ul> <li>Diffuse knee pain </li> <li>Delayed swelling (12 to 24 hours post activity) </li> </ul> </td> <td> <ul> <li>Effusion present </li> <li>Ligaments stable; meniscus testing equivocal </li> <li>Inability to fully flex or extend knee common </li> </ul> </td> <td> <ul> <li>Weight bearing radiographs show sclerosis, osteophytes, and joint space narrowing </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Not activity related</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Crystal arthropathy </li> </ul> </td> <td> <ul> <li>Acute knee pain and effusion </li> <li>No trauma or recent activity </li> </ul> </td> <td> <ul> <li>Diffuse knee pain and swelling </li> <li>Weight bearing can be difficult </li> </ul> </td> <td> <ul> <li>Erythema, warmth, tenderness, and swelling of knee </li> <li>Knee flexion limited by effusion and pain </li> </ul> </td> <td> <ul> <li>Joint aspiration required for diagnosis </li> <li>Serum uric acid level should not be used for diagnosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Infectious arthritis </li> </ul> </td> <td> <ul> <li>Acute knee pain and effusion </li> <li>No trauma or recent activity </li> </ul> </td> <td> <ul> <li>Diffuse knee pain and swelling </li> <li>Weight bearing can be difficult </li> </ul> </td> <td> <ul> <li>Erythema, warmth, tenderness, and swelling of knee </li> <li>Knee flexion limited by effusion and pain </li> </ul> </td> <td> <ul> <li>Medical emergency </li> <li>Joint aspiration critical for diagnosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Systemic rheumatic disease </li> </ul> </td> <td> <ul> <li>Include RA, SLE, Sj&#246;gren's syndrome, systemic sclerosis, spondyloarthropathy, polymyositis, and dermatomyositis </li> <li>RA is most prevalent </li> </ul> </td> <td> <ul> <li>Systemic symptoms (fever, night sweats, fatigue, weight loss) and polyarthralgia common </li> </ul> </td> <td> <ul> <li>Examination findings highly variable </li> </ul> </td> <td> <ul> <li>Consider in oligoarticular or polyarticular joint disease, pain with swelling, systemic symptoms, or a positive family history </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 111548 Version 1.0</div></div></div>"},"111549":{"type":"graphic_diagnosticimage","displayName":"Pulmonary contusion in a child","title":"Pulmonary contusion in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary contusion in a child</div><div class=\"cntnt\"><img style=\"width:440px; height:839px;\" src=\"images/EM/111549_Pulmonary_contusion_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This chest radiograph from a 2-year-old boy, who sustained chest trauma and surface burns from an explosion of a cache of fireworks, demonstrates a right upper lobe opacity consistent with a pulmonary contusion. The patient was endotracheally intubated emergently.<br />(B) Post-intubation radiography, one hour after the initial film, shows an interval increase in the size of the contusion.</div><div class=\"graphic_reference\">Courtesy of Matthew Eisenberg, MD.</div><div id=\"graphicVersion\">Graphic 111549 Version 1.0</div></div></div>"},"111550":{"type":"graphic_figure","displayName":"T4a colorectal cancer and the importance of the CRM","title":"Depiction of T4a lesions and the importance of the circumferential margin*","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Depiction of T4a lesions and the importance of the circumferential margin*</div><div class=\"cntnt\"><img style=\"width:536px; height:554px;\" src=\"images/ONC/111550_T4acolorectalimportCRM.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* In portions of the colorectum that are not peritonealized (eg, posterior aspects of the ascending and descending colon, lower portion of the rectum), the pT4a category is not applicable.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111550 Version 2.0</div></div></div>"},"111551":{"type":"graphic_table","displayName":"Quality and completeness of the mesorectum in TME","title":"Grading of quality and completeness of the mesorectum in a total mesorectal excision (TME)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of quality and completeness of the mesorectum in a total mesorectal excision (TME)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mesorectum</td> <td class=\"subtitle1\">Defects</td> <td class=\"subtitle1\">Coning</td> <td class=\"subtitle1\">CRM</td> </tr> <tr> <td><strong>Complete</strong></td> <td>Intact, smooth</td> <td>Not deeper than 5 mm</td> <td>None</td> <td>Smooth, regular</td> </tr> <tr> <td><strong>Nearly complete</strong></td> <td>Moderate bulk, irregular</td> <td>No visible muscularis propria</td> <td>Moderate</td> <td>Irregular</td> </tr> <tr> <td><strong>Incomplete</strong></td> <td>Little bulk</td> <td>Down to muscularis propria</td> <td>Moderate/marked</td> <td>Irregular</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Both the specimen as a whole (fresh) and cross-sectional slices (fixed) are examined to make an adequate interpretation.</div><div class=\"graphic_footnotes\">CRM: circumferential resection margin.</div><div class=\"graphic_reference\">From: Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol 2007; 60:849. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2007.</div><div id=\"graphicVersion\">Graphic 111551 Version 1.0</div></div></div>"},"111552":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis 1","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:640px; height:756px;\" src=\"images/DERM/111552_Erythrodermic_psoriasis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent, generalized erythema with prominent scale.</div><div class=\"graphic_reference\">Courtesy of Kristina Callis Duffin, MD.</div><div id=\"graphicVersion\">Graphic 111552 Version 1.0</div></div></div>"},"111553":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis 2","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/111553_Erythrodermic_psoriasis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent generalized erythema with prominent scale.</div><div class=\"graphic_reference\">Courtesy of Kristina Callis Duffin, MD.</div><div id=\"graphicVersion\">Graphic 111553 Version 2.0</div></div></div>"},"111554":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis 3","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 709px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:689px; height:756px;\" src=\"images/DERM/111554_Erythrodermic_psoriasis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized erythema with scattered areas of exfoliation.</div><div class=\"graphic_reference\">Courtesy of Jason E. Hawkes, MD.</div><div id=\"graphicVersion\">Graphic 111554 Version 1.0</div></div></div>"},"111555":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis with pustules on chest","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:569px;\" src=\"images/DERM/111555_Erythrodrmc_psoriasis_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized pustules arranged in clusters on erythematous skin.</div><div class=\"graphic_reference\">Courtesy of Kristina Callis Duffin, MD.</div><div id=\"graphicVersion\">Graphic 111555 Version 2.0</div></div></div>"},"111556":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis with pustules","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:676px; height:756px;\" src=\"images/DERM/111556_Erythroderm_psoriasis_pstls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial pustules that coalesce to form \"lakes of pus\" on erythematous skin.</div><div class=\"graphic_reference\">Courtesy of Jason E. Hawkes, MD.</div><div id=\"graphicVersion\">Graphic 111556 Version 1.0</div></div></div>"},"111557":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis with exfoliation","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:485px;\" src=\"images/DERM/111557_Erythroderm_psorias_exfltn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large patches of erythema with areas of exfoliation.</div><div class=\"graphic_reference\">Courtesy of Jason E. Hawkes, MD.</div><div id=\"graphicVersion\">Graphic 111557 Version 1.0</div></div></div>"},"111558":{"type":"graphic_picture","displayName":"Erythrodermic psoriasis with exfoliation 2","title":"Erythrodermic psoriasis","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Erythrodermic psoriasis</div><div class=\"cntnt\"><img style=\"width:536px; height:756px;\" src=\"images/DERM/111558_Erythroderm_psorias_exfltn2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macules and patches of erythema with areas of exfoliation.</div><div class=\"graphic_reference\">Courtesy of Jason E Hawkes, MD.</div><div id=\"graphicVersion\">Graphic 111558 Version 1.0</div></div></div>"},"111560":{"type":"graphic_table","displayName":"Forms of agammaglobulinemia","title":"Forms of agammaglobulinemia by genetic defect, mode of transmission, and clinical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Forms of agammaglobulinemia by genetic defect, mode of transmission, and clinical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup span=\"3\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene defect</td> <td class=\"subtitle1\">Mode of transmission</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr class=\"divider_bottom\"> <td><em>BTK</em><sup>[1-10]</sup></td> <td>X linked</td> <td> <ul> <li>Chronic enteroviral encephalomeningitis </li> <li><em>Giardia lamblia</em> gastroenteritis </li> <li><em>Haemophilus</em> conjunctivitis </li> <li><em>Mycoplasma</em> septic arthritis </li> <li>Recurrent otitis media </li> <li>Recurrent pneumonia </li> <li>Recurrent sinusitis </li> <li>Pseudomonal sepsis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>IGHM</em><sup>[11,12]</sup></td> <td>Autosomal recessive</td> <td> <ul> <li>Bronchiectasis, enteroviral infections </li> <li>Failure to thrive </li> <li>Neutropenia </li> <li>Pseudomonal sepsis </li> <li>Recurrent otitis media </li> <li>Recurrent pneumonia </li> <li>Recurrent sinusitis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>CD79A</em><sup>[11,13,14]</sup></td> <td>Autosomal recessive</td> <td> <ul> <li>Enteroviral infections </li> <li>Failure to thrive </li> <li>Neutropenia </li> <li>Pseudomonal sepsis </li> <li>Recurrent bronchitis </li> <li>Recurrent diarrhea </li> <li>Recurrent otitis media </li> <li>Vaccine-associated polio </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>PIK3R1</em><sup>[15,16]</sup></td> <td>Autosomal recessive</td> <td> <ul> <li>Arthritis </li> <li>Colitis </li> <li>Chronic <em>Campylobacter </em>enteritis</li> <li>EBV viremia </li> <li>Erythema nodosum </li> <li>Inflammatory bowel disease </li> <li>Neutropenia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>BLNK</em><sup>[11,17]</sup></td> <td>Autosomal recessive</td> <td> <ul> <li>Chronic sinusitis </li> <li>Enteroviral infections </li> <li>Neutropenia </li> <li>Pneumonia </li> <li>Protein-losing enteropathy </li> <li>Pseudomonal sepsis </li> <li>Recurrent otitis media </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>TCF3</em><sup>[18]</sup></td> <td>Autosomal dominant</td> <td> <ul> <li>Arthritis </li> <li>Pneumococcal meningitis </li> <li>Recurrent otitis media </li> <li>Vaccine-associated polio </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>CD79B</em><sup>[19,20]</sup></td> <td>Autosomal recessive</td> <td> <ul> <li>Bacterial conjunctivitis </li> <li>Chronic sinusitis </li> <li>Neutropenia </li> <li>Pneumonia </li> <li>Recurrent bronchitis </li> <li>Recurrent otitis media </li> <li><em>Salmonella</em> enteritis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><em>IGLL1</em><sup>[11,21,22]</sup></td> <td>Autosomal recessive</td> <td> <ul> <li><em>Haemophilus</em> meningitis </li> <li>Pneumococcal pneumonia </li> <li>Recurrent otitis media </li> </ul> </td> </tr> <tr> <td><em>LRR8C8</em><sup>[23]</sup></td> <td>Autosomal dominant</td> <td> <ul> <li>Epicanthal folds </li> <li>High arched palate </li> <li>Hypertelorism </li> <li>Low ears </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The forms of autosomal agammaglobulinemia are listed in the table in order from most to least common. The characteristic features are listed in alphabetical order.</div><div class=\"graphic_footnotes\"><EM>BTK</EM>: Bruton tyrosine kinase; <EM>IGHM</EM>: immunoglobulin heavy constant mu; <EM>CD79A</EM>: a cluster of differentiation molecule, also known as immunoglobulin-associated alpha or B cell antigen receptor complex-associated protein alpha chain; <EM>PIK3R1</EM>: phosphoinositide-3-kinase regulatory subunit 1; EBV: Epstein-Barr virus; <EM>BLNK</EM>: B cell linker; <EM>TCF3</EM>: transcription factor 3; <EM>CD79B</EM>: a cluster of differentiation molecule, also known as immunoglobulin-associated beta; <EM>IGLL1</EM>: immunoglobulin lambda like polypeptide 1; <EM>LRRC8</EM>: leucine-rich repeat-containing.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 1996; 75:287.</li>&#xD;&#xA;    <li>Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol 2000; 19:183.</li>&#xD;&#xA;    <li>Ochs HD, Stiehm ER, Winkelstein JA. Antibody deficiencies. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier/Sanders, Philadelphia 2004. p.356.</li>&#xD;&#xA;    <li>Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193.</li>&#xD;&#xA;    <li>Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9:722.</li>&#xD;&#xA;    <li>Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985; 64:145.</li>&#xD;&#xA;    <li>Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol 2002; 104:221.</li>&#xD;&#xA;    <li>Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002; 141:566.</li>&#xD;&#xA;    <li>Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.</li>&#xD;&#xA;    <li>Agarwal S, Mayer L. Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes. J Allergy Clin Immunol 2009; 124:658.</li>&#xD;&#xA;    <li>Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: Comparisons and contrasts. Annu Rev Immunol 2009; 27:199.</li>&#xD;&#xA;    <li>Yel L, Minegishi Y, Coustan-Smith E, et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med 1996; 335:1486.</li>&#xD;&#xA;    <li>Khalili A, Plebani A, Vitali M, et al. Autosomal recessive agammaglobulinemia: A novel non-sense mutation in CD79a. J Clin Immunol 2014; 34:138.</li>&#xD;&#xA;    <li>Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest 1999; 104:1115.</li>&#xD;&#xA;    <li>Conley ME, Dobbs AK, Quintana AM, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85a subunit of PI3K. J Exp Med 2012; 209:463.</li>&#xD;&#xA;    <li>Deau MC, Heurtier L, Frange P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest 2014; 124:3923.</li>&#xD;&#xA;    <li>Minegishi Y, Rohrer J, Coustan-Smith E, et al. An essential role for BLNK in human B cell development. Science 1999; 286:1954.</li>&#xD;&#xA;    <li>Boisson B, Wang YD, Bosompem A, et al. A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells. J Clin Invest 2013; 123:4781.</li>&#xD;&#xA;    <li>Lougaris V, Vitali M, Baronio M, et al. Autosomal recessive agammaglobulinemia: The third case of Ig&beta; deficiency due to a novel non-sense mutation. J Clin Immunol 2014; 34:425.</li>&#xD;&#xA;    <li>Ferrari S, Lougaris V, Caraffi S, et al. Mutations of the Igbeta gene cause agammaglobulinemia in man. J Exp Med 2007; 204:2047.</li>&#xD;&#xA;    <li>Gemayel KT, Litman GW, Sriaroon P. Autosomal recessive agammaglobulinemia associated with an IGLL1 gene missense mutation. Ann Allergy Asthma Immunol 2016; 117:439.</li>&#xD;&#xA;    <li>Minegishi Y, Coustan-Smith E, Wang YH, et al. Mutations in human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998; 187:71.</li>&#xD;&#xA;    <li>Kubota K, Kim JY, Sawada A, et al. LRRC8 involved in B cell development belongs to a novel family of leucine rich repeat proteins. FEBS Lett 2004; 564:147.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Vivian P Hernandez-Trujillo, MD.</div><div id=\"graphicVersion\">Graphic 111560 Version 1.0</div></div></div>"},"111562":{"type":"graphic_table","displayName":"Knee pain NOT associated with acute trauma or effusion in adults","title":"Knee pain NOT associated with acute trauma or joint effusion in adults: Causes and distinguishing features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Knee pain NOT associated with acute trauma or joint effusion in adults: Causes and distinguishing features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"5\" width=\"19%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Condition</td> <td class=\"subtitle1\">Mechanism &#38; historical features</td> <td class=\"subtitle1\">Common symptoms</td> <td class=\"subtitle1\">Key examination findings</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Anterior knee pain</td> </tr> <tr> <td class=\"indent1 divider_bottom\" colspan=\"6\"><strong>Conditions with focal pain</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Tibial tubercle apophysitis (Osgood Schlatter) </li> </ul> </td> <td> <p>Common in athletes in early to mid teens whose sports involve cutting and jumping.</p> <p>Often occurs during growth spurt while athlete is very active.</p> Pain increases with activity and decreases with rest.</td> <td>Pain around tibial tubercle or inferior pole of patella.</td> <td> <p>Tenderness at tibial tubercle or inferior pole of patella.</p> <p>Focal swelling &#38; warmth directly over apophysis.</p> Knee stable and motion normal.</td> <td> <p>Apophysitis at tibial tubercle (Osgood Schlatter) is far more common than apophysitis at inferior pole of patella (Sinding Larsen Johansson).</p> <p>Plain radiographs show open apophysis, often with fragmentation.</p> US shows open apophysis &#38; fluid over tuberosity.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Hoffa's fat pad syndrome </li> </ul> </td> <td>Caused by painful edema within fat pad.</td> <td> <p>Anterior knee pain.</p> Pain increases with kneeling, walking, squatting, or running.</td> <td> <p>Tenderness along either side of patella tendon (not tendon proper).</p> Asymmetric swelling adjacent to patellar tendon.</td> <td>May contribute to patellofemoral maltracking.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Quadriceps and patellar tendinopathy </li> </ul> </td> <td> <p>History of overuse, typically involving sports with jumping or sprinting and sudden direction change.</p> Gradual onset of pain that steadily increases over time if ballistic activity continues.</td> <td>Pain at tendon or inferior pole of patella (patellar tendinopathy) or superior pole of patella (quadriceps tendinopathy) with ballistic movements (eg, jumping, sprinting, cutting).</td> <td> <p>Tendon tender at inferior pole of patella (most common), along tendon, at tibial tuberosity, or at superior pole of patella.</p> <p>Tendon may feel thick compared to normal (contralateral) one.</p> <p>Often associated with tight quadriceps and/or hip flexors.</p> <p>Knee motion normal.</p> Squat or hop reproduces pain.</td> <td> <p>US shows characteristic changes of tendinopathy.</p> <p>Patellar tendinopathy more common than quadriceps.</p> In skeletally immature, consider apophysitis.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Prepatellar or infrapatellar bursitis </li> </ul> </td> <td> <p>Swelling develops over days just anterior or inferior to patella.</p> History of continual pressure on affected area (eg, laborer working while kneeling); not typically associated with acute trauma, but prior puncture wound may be reported.</td> <td>Pain and swelling just anterior to or below patella.</td> <td> <p>Swollen boggy bursa: Early swelling anterior to or below patella; gradually swelling increases.</p> <p>Overlying skin erythematous.</p> Knee motion normal.</td> <td> <p>US shows fluid collection; fluid extends into soft tissues as swelling increases.</p> Aspiration may be needed to rule out septic bursitis.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Plica syndrome </li> </ul> </td> <td> <p>History of trauma to medial peripatellar area or dislocation/subluxation of patella.</p> Runners with genu valgus (\"knock knees\") at risk.</td> <td>Pain around medial patella that increases with movement (knee flexion and extension).</td> <td> <p>Thickened plica palpable under medial patella.</p> <p>Patella tracks abnormally during knee flexion-extension.</p> Audible pop from medial patella area during flexion-extension.</td> <td>US shows thickened plica.</td> </tr> <tr> <td class=\"indent1 divider_bottom\" colspan=\"6\"><strong>Conditions without focal pain</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Chronic patella dislocation or subluxation </li> </ul> </td> <td>Pivoting or sudden change in direction produces acute episodes, which recur.</td> <td> <p>Knee \"out of place\" (typically lateral).</p> Many episodes reduce spontaneously prior to presentation.</td> <td> <p>Tenderness often present along medial patellar border.</p> Effusion may be present after acute dislocation.</td> <td> <p>Patients with hypermobility may have recurrent dislocation with milder symptoms and physical findings.</p> More common among young females.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Patellofemoral pain </li> </ul> </td> <td>History of overuse, often involving running.</td> <td> <p>Diffuse, anterior peri-patellar pain.</p> <p>Knee may feel \"unstable\".</p> Pain increases with squatting, prolonged sitting, running (especially downhill), climbing or descending stairs.</td> <td> <p>Patellar undersurface may be tender (medial or lateral).</p> <p>Weak terminal knee extension and VMO atrophy common.</p> <p>Weak hip flexion, abduction, &#38; external rotation common.</p> <p>Hamstring tightness common.</p> <p>Patellofemoral compression test may be positive.</p> <p>Normal knee motion.</p> Effusion rare.</td> <td> <p>Patellofemoral pain accounts for 70 percent of outpatient visits for knee pain.</p> <p>Structural intra-articular injury must be ruled out if recurrent effusions or unusual findings (eg, abnormal knee motion or laxity detected) present.</p> <p>Patient may describe knee weakness (or \"giving out\"), likely due to reflex inhibition of quadriceps from pain.</p> Chondromalacia patella presents with similar history and examination, but advanced imaging reveals pathologic changes.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Chondromalacia patella </li> </ul> </td> <td>As with patellofemoral pain above.</td> <td>As with patellofemoral pain above.</td> <td>As with patellofemoral pain above.</td> <td>MRI typically not necessary, but reveals pathologic changes in articular cartilage on underside of patella.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"> <ul> <li>Patella stress fracture </li> </ul> </td> <td> <p>History may be unclear; pain likely insidious in onset.</p> <p>Most common in active people training in ballistic sports.</p> Athletes who have increased training volume and/or intensity over past weeks to months.</td> <td>Anterior knee pain made worse by activity, particularly ballistic movements (jumping).</td> <td> <p>Patella tenderness (depends on severity of fracture).</p> Normal knee motion.</td> <td>Fracture may not be apparent in plain radiographs; MRI or CT may be required for diagnosis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Medial knee pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Degenerative medial meniscal tear </li> </ul> </td> <td>Develops over years and presents in older adults, usually without inciting trauma.</td> <td> <p>Symptoms often mild but may complain of baseline discomfort.</p> <p>Pain with pivoting or knee twisting.</p> Knee may catch or lock.</td> <td> <p>Medial joint line tenderness.</p> <p>Knee motion may not be smooth and range may be limited.</p> <p>Provocative tests (eg, Thesaly, McMurray) usually positive.</p> Pain increases with deep squat.</td> <td> <p>US may show calcifications, fraying of peripheral meniscus, and cysts in regions of swelling.</p> MRI generally accurate and diagnostic.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Saphenous nerve entrapment </li> </ul> </td> <td>&nbsp;</td> <td> <p>Pain may be caused by typically benign stimuli or movement.</p> Pain radiates along course of saphenous nerve.</td> <td>Pain increases with palpation or tapping (Tinel sign) at site of entrapment.</td> <td> <p>US may show thickened nerve or surrounding fluid.</p> Nerve block relieves symptoms.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Pes anserine bursitis </li> </ul> </td> <td>Associated with repeated valgus knee strain (genu valgus).</td> <td>Anteromedial knee pain in area of pes anserine tendon insertion.</td> <td> <p>Swelling at proximal anteromedial tibia.</p> <p>Area of bursa tender.</p> Resisted knee flexion or hip adduction elicits pain at area of bursa.</td> <td>US may reveal characteristic changes of bursitis (eg, fluid collection), or pes anserine tendinopathy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Lateral knee pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Iliotibial band syndrome </li> </ul> </td> <td> <p>Insidious onset of lateral knee pain related to overuse.</p> <p>Occurs primarily in runners, but also in cyclists.</p> <p>In runners, pain can vary with pace &#38; increases on sloped surfaces.</p> Pain increases over time if activity continues.</td> <td> <p>Pain where ITB crosses lateral femoral condyle.</p> Pain increases with prolonged exercise but may persist afterwards.</td> <td> <p>Tender ITB where it crosses lateral femoral condyle.</p> Weak hip abduction is common.</td> <td>Generally two patient types: <ul> <li>Novice or female runner with weak hip abduction and internal knee rotation (genu valgum). </li> </ul> <p>OR</p> <ul> <li>Advanced runner with reduced hip adduction and external knee rotation (genu varum). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Degenerative lateral meniscal tear </li> </ul> </td> <td>Develops over years and presents in older adults, typically without inciting trauma.</td> <td> <p>Symptoms often mild but may complain of baseline discomfort.</p> <p>Pain with pivoting or knee twisting.</p> Knee may catch or lock.</td> <td> <p>Lateral joint line tenderness.</p> <p>Knee motion may not be smooth and range may be limited.</p> <p>Provocative tests (eg, Thesaly, McMurray) usually positive.</p> Pain increases with deep squat.</td> <td> <p>US may show calcifications, fraying of peripheral meniscus, and cysts in regions of swelling.</p> MRI generally accurate and diagnostic.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Posterior knee pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Popliteal artery aneurysm </li> </ul> </td> <td>Typically occurs in older individuals with cardiovascular risk factors.</td> <td> <p>Small aneurysms may be asymptomatic.</p> Claudication symptoms with activity.</td> <td>Pulsatile mass may be palpable in popliteal fossa.</td> <td> <p>US can identify aneurysm; can compare with contralateral knee.</p> Associated with abdominal aortic aneurysm.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Popliteal artery entrapment </li> </ul> </td> <td>Not associated with risk factors for cardiovascular disease.</td> <td> <p>Pain deep in calf or popliteal fossa.</p> <p>Claudication symptoms with vigorous activities involving repeated ankle dorsi- and plantar flexion.</p> Asymptomatic at rest.</td> <td>Resting physical examination unremarkable.</td> <td> <p>Rare cause of knee pain.</p> More common in young male athletes.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Popliteal (Baker's) cyst </li> </ul> </td> <td>Damaged protruding posterior knee capsule with many potential causes.</td> <td>Posterior knee pain and tightness.</td> <td>Palpable swollen cystic structure in popliteal fossa.</td> <td> <p>Often associated with intra-articular pathology or knee osteoarthritis.</p> <p>If cyst ruptures, knee pain &#38; tightness typically resolve; fluid may track into calf causing swelling.</p> US shows compressible fluid-filled mass, typically medial to vascular bundle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Popliteus tendinopathy </li> </ul> </td> <td> <p>Gradual onset of posterolateral knee pain.</p> Often caused by excessive running (especially downhill) or sprinting, also by hiking downhill.</td> <td> <p>Posterior knee pain.</p> Pain increases when runner is \"braking\" or trying to prevent acceleration while running downhill.</td> <td> <p>Tenderness at posterior aspect of lateral femoral condyle (palpate popliteal tendon with patient in figure-of-4 position).</p> Resisted tibial external rotation may elicit pain.</td> <td>US reveals characteristic changes of tendinopathy.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: ultrasound; VMO: vastus medialis oblique; MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 111562 Version 2.0</div></div></div>"},"111563":{"type":"graphic_picture","displayName":"Airtraq optical element","title":"Airtraq optical element","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airtraq optical element</div><div class=\"cntnt\"><img style=\"width:292px; height:403px;\" src=\"images/ANEST/111563_Airtraq_optical_element.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This reusable optical element is inserted into a clear plastic shell, and contains prisms and a distal LED for illumination.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright &copy; 2013 Teleflex Incorporated. All rights reserved. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111563 Version 1.0</div></div></div>"},"111564":{"type":"graphic_picture","displayName":"CMAC blades and monitor","title":"CMAC blades and monitor","html":"<div class=\"graphic\"><div style=\"width: 663px\" class=\"figure\"><div class=\"ttl\">CMAC blades and monitor</div><div class=\"cntnt\"><img style=\"width:643px; height:598px;\" src=\"images/ANEST/111564_CMAC_blades_and_monitor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CMAC video laryngoscope is available with both acute-angle blades (shown in foreground), and Macintosh-style blades (shown in the back of this photo). For further information, refer to UpToDate topics on video laryngoscopes for airway management for anesthesia.</div><div class=\"graphic_reference\">©2017 Photo Courtesy of KARL STORZ Endoscopy-America, Inc.</div><div id=\"graphicVersion\">Graphic 111564 Version 1.0</div></div></div>"},"111565":{"type":"graphic_picture","displayName":"CMAC pocket monitor D-blade","title":"CMAC pocket monitor D-blade","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">CMAC pocket monitor D-blade</div><div class=\"cntnt\"><img style=\"width:542px; height:756px;\" src=\"images/ANEST/111565_CMAC_pocket_monitor_Dblade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows the CMAC video laryngoscope with a compact integral \"pocket\" monitor, and the acute-angle D-blade. For further information, refer to UpToDate topics on video laryngoscopes for airway management for anesthesia.</div><div class=\"graphic_reference\">©2017 Photo Courtesy of KARL STORZ Endoscopy-America, Inc.</div><div id=\"graphicVersion\">Graphic 111565 Version 1.0</div></div></div>"},"111566":{"type":"graphic_picture","displayName":"Bonfils scope","title":"Bonfils scope","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Bonfils scope</div><div class=\"cntnt\"><img style=\"width:754px; height:603px;\" src=\"images/ANEST/111566_bonfils.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;Bonfils fiberscope is a rigid scope that contains fiberoptic and light bundles.&nbsp;The tube stop can be adjusted to accommodate endotracheal tubes of different lengths. The image can be viewed through the adjustable eyepiece, or with a video camera display on a monitor. For further information, refer to UpToDate content on video laryngoscopes and optical sylets for airway management for anesthesia.&nbsp;</div><div class=\"graphic_reference\">&copy;2017 Photo Courtesy of KARL STORZ Endoscopy-America, Inc.</div><div id=\"graphicVersion\">Graphic 111566 Version 1.0</div></div></div>"},"111567":{"type":"graphic_picture","displayName":"McGrath MAC","title":"McGrath MAC","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">McGrath MAC</div><div class=\"cntnt\"><img style=\"width:432px; height:705px;\" src=\"images/ANEST/111567_McGrath_MAC_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The McGrath MAC is a nonchannelled video laryngoscope, with an integral LCD monitor.&nbsp;It is&nbsp;shown in this graphic with a single use,&nbsp;Macintosh-style&nbsp;blade cover, which allows either direct&nbsp;or indirect laryngoscopy.&nbsp;For further details, refer to UpToDate content on video laryngoscopy.</div><div class=\"graphic_reference\">© 2017 Medtronic. All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 111567 Version 1.0</div></div></div>"},"111568":{"type":"graphic_picture","displayName":"Glidescope monitor with blades","title":"Glidescope monitor with blades","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glidescope monitor with blades</div><div class=\"cntnt\"><img style=\"width:432px; height:216px;\" src=\"images/ANEST/111568_Glidescope_monitor_blades.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with permission, ©Verathon Inc.</div><div id=\"graphicVersion\">Graphic 111568 Version 1.0</div></div></div>"},"111569":{"type":"graphic_picture","displayName":"Glidescope Ranger","title":"Glidescope Ranger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glidescope Ranger</div><div class=\"cntnt\"><img style=\"width:432px; height:443px;\" src=\"images/ANEST/111569_Glidescope_Ranger_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with permission, ©Verathon Inc.</div><div id=\"graphicVersion\">Graphic 111569 Version 1.0</div></div></div>"},"111570":{"type":"graphic_picture","displayName":"Glidescope AVL","title":"Glidescope AVL","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Glidescope AVL</div><div class=\"cntnt\"><img style=\"width:473px; height:452px;\" src=\"images/ANEST/111570_Glidescope_AVL_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Used with permission, ©Verathon Inc.</div><div id=\"graphicVersion\">Graphic 111570 Version 1.0</div></div></div>"},"111571":{"type":"graphic_picture","displayName":"GlideRite stylet","title":"GlideRite stylet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">GlideRite stylet</div><div class=\"cntnt\"><img style=\"width:422px; height:234px;\" src=\"images/ANEST/111571_GlideRite_stylet_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This preformed, rigid stylet&nbsp;is designed&nbsp;for endotracheal intubation with the Glidescope video laryngoscope.</div><div class=\"graphic_reference\">Used with permission, ©Verathon Inc.</div><div id=\"graphicVersion\">Graphic 111571 Version 1.0</div></div></div>"},"111572":{"type":"graphic_picture","displayName":"King Vision","title":"King Vision video laryngoscope","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">King Vision video laryngoscope</div><div class=\"cntnt\"><img style=\"width:756px; height:525px;\" src=\"images/ANEST/111572_King_Vision_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The King Vision video laryngoscope can be used with either a channelled blade, shown on the far left, far right,&nbsp;and attached to the monitor, or a non-channelled blade.</div><div class=\"graphic_reference\">Reproduced with permission from Ambu. Copyright &#169; 2017. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111572 Version 1.0</div></div></div>"},"111573":{"type":"graphic_picture","displayName":"Levitan","title":"Levitan Optical Stylet","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Levitan Optical Stylet</div><div class=\"cntnt\"><img style=\"width:493px; height:560px;\" src=\"images/ANEST/111573_Levitan_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Clarus Medical, LLC. Copyright &#169; 2017. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111573 Version 1.0</div></div></div>"},"111574":{"type":"graphic_picture","displayName":"Clarus Video System","title":"Clarus Video System","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Clarus Video System</div><div class=\"cntnt\"><img style=\"width:471px; height:361px;\" src=\"images/ANEST/111574_Clarus_video_system_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Clarus Medical, LLC. Copyright &copy; 2017. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111574 Version 2.0</div></div></div>"},"111584":{"type":"graphic_figure","displayName":"Transverse abdominis muscle release","title":"Transverse abdominis muscle release","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Transverse abdominis muscle release</div><div class=\"cntnt\"><img style=\"width:500px; height:704px;\" src=\"images/SURG/111584_Posterior_component_separation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Steps of transverse abdominis muscle release. <br />(Panel A) Following a midline incision and complete adhesiolysis, the posterior rectus sheath is incised 0.5 to 1 cm from the medial edge of the rectus muscle. The retrorectus plane is developed laterally to the semilunaris line. Neurovascular bundles are preserved. <br />(Panel B) The posterior rectus sheath is again incised 0.5 cm medial to the junction of the anterior/posterior rectus sheaths to expose the transverse abdominis muscle fibers, which are divided in a cephalad to caudad direction (the release). <br />(Panel C)&nbsp;The plane between the transverse abdominis muscle ventrally and the transversalis fascia/peritoneum dorsally is developed&nbsp;laterally toward the retroperitoneum/psoas muscle. The same procedure can be repeated on the contralateral side if necessary. <br />(Panel D) Posterior rectus sheaths are reapproximated in the midline. A mesh is typically placed behind the rectus muscles (sublay) and secured with full-thickness, transfascial sutures. The anterior rectus sheaths are then reapproximated at the midline to restore linea alba anterior/ventral to the mesh.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Novitsky YW, Elliott HL, Orenstein SB, Rosen MJ. Transversus abdominis muscle release: a novel approach to posterior component separation during complex abdominal wall reconstruction. Am J Surg 2012; 204:709.</LI>&#xD;&#xA;<LI>Novitsky YW, Fayezizadeh M, Majumder A, et al. Outcomes of Posterior Component Separation With Transversus Abdominis Muscle Release and Synthetic Mesh Sublay Reinforcement. Ann Surg 2016; 264:226.</LI></OL></div><div id=\"graphicVersion\">Graphic 111584 Version 1.0</div></div></div>"},"111588":{"type":"graphic_table","displayName":"2017 ELN risk stratification of AML by genetics","title":"2017 European LeukemiaNet risk stratification of acute myeloid leukemia by genetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2017 European LeukemiaNet risk stratification of acute myeloid leukemia by genetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category*</td> <td class=\"subtitle1\">Genetic abnormality</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Favorable</strong></td> <td>t(8;21)(q22;q22.1); <em>RUNX1-RUNX1T1</em></td> </tr> <tr> <td>inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); <em>CBFB-MYH11</em></td> </tr> <tr> <td>Mutated <em>NPM1</em> without <em>FLT3-ITD</em> or with <em>FLT3-ITD</em><sup>low</sup><sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Biallelic mutated <em>CEBPA</em></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Intermediate</strong></td> <td>Mutated <em>NPM1</em> and <em>FLT3-ITD</em><sup>high</sup><sup>&#182;</sup></td> </tr> <tr> <td>Wild type <em>NPM1</em> without <em>FLT3-ITD</em> or with <em>FLT3-ITD</em><sup>low</sup><sup>&#182;</sup> (without adverse-risk genetic lesions)</td> </tr> <tr> <td>t(9;11)(p21.3;q23.3); <em>MLLT3-KMT2A</em><sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Cytogenetic abnormalities not classified as favorable or adverse</td> </tr> <tr> <td rowspan=\"9\"><strong>Adverse</strong></td> <td>t(6;9)(p23;q34.1); <em>DEK-NUP214</em></td> </tr> <tr> <td>t(v;11q23.3); <em>KMT2A</em> rearranged</td> </tr> <tr> <td>t(9;22)(q34.1;q11.2); <em>BCR-ABL1</em></td> </tr> <tr> <td>inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2,MECOM</em>(<em>EVI1</em>) &ndash;5 or del(5q); &ndash;7; &ndash;17/abn(17p)</td> </tr> <tr> <td>Complex karyotype,<sup>&#9674;</sup> monosomal karyotype<sup>&#167;</sup></td> </tr> <tr> <td>Wild type <em>NPM1</em> and <em>FLT3-ITD</em><sup>high</sup><sup>&#182;</sup></td> </tr> <tr> <td>Mutated <em>RUNX1</em><sup>&#165;</sup></td> </tr> <tr> <td>Mutated <em>ASXL1</em><sup>&#165;</sup></td> </tr> <tr> <td>Mutated <em>TP53</em><sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table describes the European LeukemiaNet stratification of acute myeloid leukemia (AML) based on cytogenetic and molecular characteristics. Note the use of \"allelic ratio\" to stratify based on the&nbsp;<EM innerHtml>FLT3</EM>-ITD mutation. Various research groups calculate this ratio differently and/or use other cutoff values. </div><div class=\"graphic_footnotes\">* Prognostic impact of a marker is treatment-dependent and may change with new therapies.<br />¶ Low, low allelic ratio (&lt;0.5); high, high allelic ratio (&gt;0.5); semi-quantitative assessment of <EM>FLT3-ITD</EM> allelic ratio (using DNA fragment analysis) is determined as ratio of the area under the curve (AUC) \"<EM>FLT3-ITD</EM>\" divided by AUC \"<EM>FLT3</EM>-wild type\"; recent studies indicate that acute myeloid leukemia with <EM>NPM1</EM> mutation and <EM>FLT3-ITD</EM> low allelic ratio may also have a more favorable prognosis and patients should not routinely be assigned to allogeneic hematopoietic-cell transplantation.<SUP>[1-4]</SUP><br />Δ The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.<br /><FONT class=lozenge>◊</FONT> Three or more unrelated chromosome abnormalities in the absence of one of the World Health Organization-designated recurring translocations or inversions, ie, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with <EM>BCR-ABL1</EM>.<br />§ Defined by the presence of one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy or structural chromosome abnormality (excluding core-binding factor AML).<SUP>[5]</SUP><br />¥ These markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes.<br />‡ <EM>TP53</EM> mutations are significantly associated with AML with complex and monosomal karyotype.<SUP>[6-10]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111:2776.</LI>&#xD;&#xA;<LI>Pratcorona M, Brunet S, Nomdedéu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to postremission therapy. Blood 2013; 121:2734.</LI>&#xD;&#xA;<LI>Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITDpositive AML with respect to allogeneic transplantation. Blood 2014; 124:3441.</LI>&#xD;&#xA;<LI>Ho AD, Schetelig J, Bochtler T, et al. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant 2016; 22:462.</LI>&#xD;&#xA;<LI>Breems DA, van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791.</LI>&#xD;&#xA;<LI>Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209.</LI>&#xD;&#xA;<LI>Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008; 22:1539.</LI>&#xD;&#xA;<LI>Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 2009; 23:203.</LI>&#xD;&#xA;<LI>Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119:2114.</LI>&#xD;&#xA;<LI>Devillier R. Mansat-De Mas V, Gelsi-Boyet V, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget 2015; 6:8388.</LI></OL>Reproduced with permission of the American Society of Hematology, from: Döhner H, Estey E, Grimwade D, et al. Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel. Blood 2016; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2016.</div><div id=\"graphicVersion\">Graphic 111588 Version 7.0</div></div></div>"},"111591":{"type":"graphic_picture","displayName":"Airtraq Avant shell","title":"Airtraq Avant disposable shell","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Airtraq Avant disposable shell</div><div class=\"cntnt\"><img style=\"width:756px; height:566px;\" src=\"images/ANEST/111591_Airtraq_avant_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows the clear plastic shell into which the optical element is inserted. The rubber eye piece can be removed and replaced with an adaptor for smart phones or a video camera.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright © 2013 Teleflex Incorporated. All rights reserved. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111591 Version 1.0</div></div></div>"},"111592":{"type":"graphic_picture","displayName":"Parker Flex-it stylet","title":"Parker Flex-it stylet","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Parker Flex-it stylet</div><div class=\"cntnt\"><img style=\"width:504px; height:376px;\" src=\"images/ANEST/111592_Parker_Flex-it_stylet_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Flex-It stylet can be used to set the curve of the endotracheal tube before intubation. The degree of curve can also be changed during intubation by pressing on the thumb control.</div><div class=\"graphic_reference\">Reproduced with permission from Parker Medical. Copyright &#169; 2017. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111592 Version 1.0</div></div></div>"},"111593":{"type":"graphic_picture","displayName":"Truflex stylet","title":"Truflex stylet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Truflex stylet</div><div class=\"cntnt\"><img style=\"width:416px; height:756px;\" src=\"images/ANEST/111593_Truflex_stylet_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tip of the Truflex endotracheal tube stylet can be flexed by pressing on the lever on the proximal end to direct the tip of the endotracheal tube through the vocal cords during intubation.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright © 2013 Teleflex Incorporated. All rights reserved. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111593 Version 1.0</div></div></div>"},"111600":{"type":"graphic_picture","displayName":"Parker Flex-Tip tubes","title":"Parker Flex-Tip endotracheal tubes","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Parker Flex-Tip endotracheal tubes</div><div class=\"cntnt\"><img style=\"width:756px; height:701px;\" src=\"images/ANEST/111600_Parker_Flex-Tip_tubes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These endotracheal tubes are available with a variety of cuffs. They all have a flexible, curved tip that facilitates insertion of the tube without&nbsp;having the tip hang up on airway structures.</div><div class=\"graphic_reference\">Reproduced with permission from Parker Medical. Copyright &#169; 2017. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111600 Version 1.0</div></div></div>"},"111601":{"type":"graphic_figure","displayName":"MCC overall survival based upon extent of disease","title":"Merkel cell carcinoma overall survival based upon extent of disease","html":"<div class=\"graphic\"><div style=\"width: 866px\" class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma overall survival based upon extent of disease</div><div class=\"cntnt\"><img style=\"width:846px; height:858px;\" src=\"images/ONC/111601_MerkelcellsurvAJCC2017B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Five-year OS of 9387 patients with Merkel cell carcinoma in the NCDB, stratified by local, regional nodal, and distant metastatic disease.<br />(B) Five-year OS of 5371 patients with Merkel cell carcinoma in the NCDB with pathological staging, including 1502 patients in stage group I, 493 in stage group IIA, 127 in stage group IIB, 1536 in stage group IIIA, 929 in stage group IIIB, and 784 in stage group IV.</div><div class=\"graphic_footnotes\">OS: overall survival; NCDB: National Cancer Database.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111601 Version 2.0</div></div></div>"},"111602":{"type":"graphic_figure","displayName":"MCC overall survival based on extent of nodal disease","title":"Merkel cell carcinoma overall survival based on extent of nodal disease","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma overall survival based on extent of nodal disease</div><div class=\"cntnt\"><img style=\"width:590px; height:432px;\" src=\"images/ONC/111602_MerkelcellsurvAJCC2017C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five-year OS of 2465 Merkel cell carcinoma patients with regional lymph node metastases in the NCDB, stratified by tumor burden and primary tumor status: clinically and radiologically occult nodal metastasis (N1a) detected by SLNB or otherwise; clinically or radiologically detected and pathologically confirmed nodal metastasis (N1b) with or without the presence of a primary tumor; and in-transit disease (N2). The latter category represents 3-year OS because of the small sample size of 60 patients.</div><div class=\"graphic_footnotes\">OS: overall survival; NCDB: National Cancer Database; SLNB: sentinel lymph node biopsy.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 111602 Version 4.0</div></div></div>"},"111603":{"type":"graphic_table","displayName":"Marasmus vs kwashiorkor","title":"Distinguishing features of marasmus versus kwashiorkor (edematous malnutrition)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing features of marasmus versus kwashiorkor (edematous malnutrition)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Marasmus</td> <td class=\"subtitle1\">Kwashiorkor <br /> (edematous malnutrition)</td> </tr> <tr> <td><strong>Height and weight</strong></td> <td> <p>Low weight for&nbsp;height (wasting).</p> Low height for age (stunting), if also chronically malnourished.</td> <td> <p>Weight for age is variable.</p> Low height for age (stunting) if also chronically malnourished</td> </tr> <tr> <td><strong>Head</strong></td> <td>Appears large relative to body, with staring eyes.</td> <td>Moon face (rounded prominence of the cheeks), with or without facial edema. May appear plump.</td> </tr> <tr> <td><strong>Extremities</strong></td> <td>Emaciated arms, thighs, and buttocks, with loose folds due to loss of subcutaneous fat.</td> <td>Edema: <ul> <li>Mild (1+): involves only the feet </li> <li>Moderate (2+): involves feet, legs, and upper limbs </li> <li>Severe (3+): either generalized edema or moderate plus facial edema </li> </ul> </td> </tr> <tr> <td><strong>Behavior </strong></td> <td>Typically irritable, fretful.</td> <td>Typically apathetic, listless; may be irritable when handled.</td> </tr> <tr> <td><strong>Abdomen</strong></td> <td>&nbsp;</td> <td>Distended, dilated intestinal loops; hepatomegaly.</td> </tr> <tr> <td><strong>Skin</strong></td> <td>Thin, dry skin.</td> <td>Thin, dry and peeling skin, with areas of hyperkeratosis and hyperpigmentation (dermatosis of kwashiorkor).</td> </tr> <tr> <td><strong>Hair</strong></td> <td>Thin, sparse hair that is easily plucked.</td> <td>Dry, dull and hypopigmented hair,&nbsp;which falls out or is easily plucked. Hypopigmentation may occur in stripes if malnutrition has been intermittent (\"flag sign\").</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111603 Version 3.0</div></div></div>"},"111604":{"type":"graphic_picture","displayName":"Exogenous ochronosis on cheek","title":"Exogenous ochronosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Exogenous ochronosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/111604_Exogenous_ochronosis_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue-black patch on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111604 Version 1.0</div></div></div>"},"111605":{"type":"graphic_picture","displayName":"Exogenous ochronosis on face","title":"Exogenous ochronosis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Exogenous ochronosis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/111605_Exogenous_ochronosis_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue-black and brown hyperpigmented patch on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111605 Version 1.0</div></div></div>"},"111607":{"type":"graphic_table","displayName":"FDA advice on fish consumption in pregnant and nursing women","title":"FDA advice on fish consumption in women who are pregnant, might become pregnant, or are nursing ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FDA advice&nbsp;on fish consumption in women who are pregnant, might become pregnant, or&nbsp;are nursing </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Best choices (eat two to three servings a week)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Anchovy </li> <li>Atlantic croaker </li> <li>Atlantic mackerel </li> <li>Black sea bass </li> <li>Butterfish </li> <li>Catfish </li> <li>Clam </li> <li>Cod </li> <li>Crab </li> <li>Crawfish </li> <li>Flounder </li> <li>Haddock </li> </ul> </td> <td style=\"border-left-color: #fff;\"> <ul> <li>Hake </li> <li>Herring </li> <li>Lobster, American and spiny </li> <li>Mullet </li> <li>Oyster </li> <li>Pacific chub mackerel </li> <li>Perch (freshwater and ocean) </li> <li>Pickerel </li> <li>Plaice </li> <li>Pollock </li> <li>Salmon </li> <li>Sardine </li> </ul> </td> <td style=\"border-left-color: #fff;\"> <ul> <li>Scallop </li> <li>Shad </li> <li>Shrimp </li> <li>Skate </li> <li>Smelt </li> <li>Sole </li> <li>Squid </li> <li>Tilapia </li> <li>Trout (freshwater) </li> <li>Tuna, canned light (includes skipjack) </li> <li>Whitefish </li> <li>Whiting </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Good choices (eat one serving a week)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Bluefish </li> <li>Buffalofish </li> <li>Carp </li> <li>Chilean sea bass/Patagonian toothfish </li> <li>Grouper </li> <li>Halibut </li> <li>Mahi mahi/dolphinfish </li> </ul> </td> <td style=\"border-left-color: #fff;\"> <ul> <li>Monkfish </li> <li>Rockfish </li> <li>Sablefish </li> <li>Sheepshead </li> <li>Snapper </li> <li>Spanish mackerel </li> <li>Striped bass (ocean) </li> </ul> </td> <td style=\"border-left-color: #fff;\"> <ul> <li>Tilefish (Atlantic Ocean) </li> <li>Tuna, albacore/white tuna, canned and fresh/frozen </li> <li>Tuna, yellowfin </li> <li>Weakfish/sea trout </li> <li>White croaker/Pacific croaker </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Choices to avoid (highest mercury levels)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>King mackerel </li> <li>Marlin </li> <li>Orange roughy </li> <li>Shark </li> </ul> </td> <td style=\"border-left-color: #fff;\"> <ul> <li>Swordfish </li> <li>Tilefish (Gulf of Mexico) </li> <li>Tuna, bigeye </li> </ul> </td> <td style=\"border-left-color: #fff;\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: On average, farm-raised fish tend to be lower in mercury compared with wild-caught fish.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Karimi R, Fitzgerald TP, Fisher NS. A quantitative synthesis of mercury in commercial seafood and implications for exposure in the United States. Environ Health Perspect 2012; 120:1512.</LI></OL>Reproduced from: U.S. Food and Drug Administration. Food: Eating Fish: What Pregnant Women and Parents Should Know. Available at: <A href=\"http://www.fda.gov/Food/FoodborneIllnessContaminants/Metals/ucm393070.htm\" target=_blank>http://www.fda.gov/Food/FoodborneIllnessContaminants/Metals/ucm393070.htm</A> (Accessed January 26, 2017).</div><div id=\"graphicVersion\">Graphic 111607 Version 3.0</div></div></div>"},"111614":{"type":"graphic_figure","displayName":"Hemoglobin and mitochondrial effects of carbon monoxide","title":"Hemoglobin and mitochondrial effects of carbon monoxide","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Hemoglobin and mitochondrial effects of carbon monoxide</div><div class=\"cntnt\"><img style=\"width:814px; height:480px;\" src=\"images/EM/111614_Hemoglbn_mitochndrl_CO_norm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal: Hb binds oxygen and delivers it to peripheral tissue with low PO<SUB>2</SUB>. Reduced cytochrome c (Cyt<SUB>C</SUB>) transfers its electron (e–) to cytochrome c oxidase Subunit 1 (Cyt<SUB>A</SUB> – binuclear center with heme a and Copper [Cu<SUB>A</SUB>]). The electron reduces oxygen (O<SUB>2</SUB>) at Subunit 2 (Cyt<SUB>A3</SUB> – binuclear center with heme a3 and Copper [Cu<SUB>B</SUB>]), forming water and transporting a proton (H+) through the inner mitochondrial membrane.<br />CO toxicity: CO competitively binds to Hb with O<SUB>2</SUB>, reducing total oxygen carrying capacity by: (1) preferentially binding to CO instead of O<SUB>2</SUB> (anemia like effect) and (2) stabilizes the relaxed quaternary state of Hb, that binds to O<SUB>2</SUB> with higher affinity and will not release it in low PO<SUB>2</SUB> environment. CO binds competitively with O<SUB>2</SUB> at the reduced heme a3 in Subunit 2. This causes: (1) inhibition of the reduction of O<SUB>2</SUB> to water (the end destination of electrons in the electron transport chain); (2) cessation of the transfer of H+ into the intermembrane space, shutting down ATP generation through ATP synthase; and (3) accumulation of electrons entering the electron transport chain through complexes I and III which can produce superoxide leading to deleterious effects.</div><div class=\"graphic_footnotes\">CO: carbon monoxide.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Rose JJ, Wang L, Xu Q, et al. Carbon monoxide poisoning: Pathogenesis, management and future directions of therapy. Am J Respir Crit Care Med. 2016 Oct 18. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 111614 Version 1.0</div></div></div>"},"111615":{"type":"graphic_figure","displayName":"Inflammatory mechanisms of carbon monoxide toxicity","title":"Inflammatory mechanisms of carbon monoxide toxicity","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Inflammatory mechanisms of&nbsp;carbon monoxide&nbsp;toxicity</div><div class=\"cntnt\"><img style=\"width:814px; height:482px;\" src=\"images/EM/111615_Inflmmtry_mchnsms_CO_toxcty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CO activates platelets by displacing platelet nitric oxide (NO) from surface hemoproteins. NO reacts with oxygen free radicals (O<SUB>2</SUB>–) to produce peroxynitrite (ONOO–), which inhibits mitochondrial function and activates platelets and neutrophils itself. Inhibited mitochondria leads to further production of reactive oxygen species (ROS) and causes release of free heme and ensuing increase of heme oxygenase 1 (HO-1), further causing oxidative stress. HO-1 metabolizes free heme to produce more endogenous CO, creating a positive feedback loop locally. Activated neutrophils will degranulate and release myeloperoxidase, causing more neutrophil activation as well as adhesion. Proteases released from neutrophils can oxidize endothelial cell xanthine dehydrogenase (XD) to xanthine oxidase (XO), generating reactive oxygen species causing cellular damage as well as lipid peroxidation, specifically on myelin basic protein (MBP). When peroxidated, MBP forms adducts that cause lymphocyte proliferation, microglia activation and ultimately, neurologic injury. The general effects of hypoxia and effect of CO toxicity directly on mitochondria cause glutamate release, which activates N-Methyl-D-aspartate (NDMA) receptors, further leading to neurologic injury.</div><div class=\"graphic_footnotes\">CO: carbon monoxide.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright © 2017 American Thoracic Society. Rose JJ, Wang L, Xu Q, et al. Carbon monoxide poisoning: Pathogenesis, management and future directions of therapy. Am J Respir Crit Care Med. 2016 Oct 18. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 111615 Version 1.0</div></div></div>"},"111616":{"type":"graphic_table","displayName":"Accurary EUS post chemotherapy tumor stage esoph CA","title":"Pooled sensitivity and specificity of EUS for assessing tumor stage after neoadjuvant chemotherapy for esophageal cancer in a meta-analysis of 16 studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pooled sensitivity and specificity of EUS for assessing tumor stage after neoadjuvant chemotherapy for esophageal cancer&nbsp;in a meta-analysis of 16 studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease stage</td> <td class=\"subtitle1\">Sensitivity (95% CI)</td> <td class=\"subtitle1\">Specificity (95% CI)</td> </tr> <tr> <td class=\"centered\">T1</td> <td class=\"centered\">23 (16-32)</td> <td class=\"centered\">95 (93-97)</td> </tr> <tr> <td class=\"centered\">T2</td> <td class=\"centered\">29 (19-41)</td> <td class=\"centered\">84 (77-88)</td> </tr> <tr> <td class=\"centered\">T3</td> <td class=\"centered\">81 (72-88)</td> <td class=\"centered\">42 (33-52)</td> </tr> <tr> <td class=\"centered\">T4</td> <td class=\"centered\">43 (31-56)</td> <td class=\"centered\">96 (94-97)</td> </tr> <tr> <td class=\"centered\">Nodal (N) stage</td> <td class=\"centered\">69 (58-79)</td> <td class=\"centered\">52 (42-62)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Sun F, Chen T, Han J, et al. Staging accuracy of endoscopic ultrasound for esophageal cancer after neoadjuvant chemotherapy: a meta-analysis and systematic review. Dis Esophagus 2015; 28:757.</div><div id=\"graphicVersion\">Graphic 111616 Version 1.0</div></div></div>"},"111617":{"type":"graphic_figure","displayName":"Pharmacologic therapy T2DM","title":"Pharmacologic therapy in type 2 diabetes mellitus: General recommendations","html":"<div class=\"graphic\"><div style=\"width: 986px\" class=\"figure\"><div class=\"ttl\">Pharmacologic therapy in type 2 diabetes mellitus: General recommendations</div><div class=\"cntnt\"><img style=\"width:966px; height:774px;\" src=\"images/ENDO/111617_AntihyperglycemcthrpyT2DM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The order in the chart was determined by historical availability and the route of administration, with injectables to the right; it is not meant to denote any specific preference. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, with the usual transition moving vertically from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). Lifestyle modifications should be emphasized along with pharmacologic therapy.</div><div class=\"graphic_footnotes\">A1C: glycated hemoglobin; DPP-4: dipeptidyl peptidase-4; SGLT2: sodium-glucose co-transporter 2; GLP-1: glucagon-like peptide-1; TZD: thiazolidinedione; SU: sulfonylurea; DPP-4-i: DPP-4 inhibitor; SGLT2-i: SGLT2 inhibitor; GLP-1 RA: GLP-1 receptor agonist; NPH: neutral protamine hagedorn.<br />* For description of efficacy and cost categorization, refer to Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140.<br />¶ Usually a basal insulin (NPH, glargine, determir, degludec).</div><div class=\"graphic_reference\">From: Pharmacologic approaches to glycemic treatment. Diabetes Care 2017; 40:S64. American Diabetes Association, Diabetes Care. American Diabetes Association, 2017. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 111617 Version 2.0</div></div></div>"},"111618":{"type":"graphic_picture","displayName":"McGrath MAC with X blade","title":"McGrath MAC with X blade","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">McGrath MAC with&nbsp;X blade</div><div class=\"cntnt\"><img style=\"width:628px; height:756px;\" src=\"images/ANEST/111618_McGrath_MAC_x3_blade_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The McGrath MAC is shown with a single use, acutely-angled X blade cover, designed for management of more difficult airways.&nbsp;For further details, refer to UpToDate content on video laryngoscopy.</div><div class=\"graphic_reference\">© 2017 Medtronic. All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 111618 Version 1.0</div></div></div>"},"111619":{"type":"graphic_picture","displayName":"CMAC blade comparison","title":"CMAC blade comparison","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">CMAC blade comparison</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/ANEST/111619_CMAC_blade_comparison_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two Storz CMAC blades are shown to illustrate the Macintosh-style (size 3, on the left) and the acute angled D-blade (on the right).&nbsp;The D-blade&nbsp;may be more versatile, especially for anatomically difficult airways. Direct laryngoscopy may be possible with the Macintosh-style blade, but is usually not&nbsp;feasible with the D-blade. For further details, refer to UpToDate content on video laryngoscopy.</div><div id=\"graphicVersion\">Graphic 111619 Version 1.0</div></div></div>"},"111620":{"type":"graphic_picture","displayName":"Glidescope blade comparison","title":"Glidescope blade comparison","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Glidescope blade comparison</div><div class=\"cntnt\"><img style=\"width:756px; height:488px;\" src=\"images/ANEST/111620_Glidescope_blade_comparison.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reusable Titanium series Glidescopes are shown in this photo. The MAC T4 (on the left) is an example of a Macintosh-style blade. The LoPro T4 (on the right) is an example of an acute-angle blade. For further information, refer to UpToDate content on video laryngoscopy.</div><div id=\"graphicVersion\">Graphic 111620 Version 1.0</div></div></div>"},"111635":{"type":"graphic_table","displayName":"Breast milk composition for preterm and term milk","title":"Estimates of breast milk composition per 100 mL at various postnatal ages (mean ± 2 standard deviations)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimates of breast milk composition per 100 mL at various postnatal ages (mean ± 2 standard deviations)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Energy (kcal)</td> <td class=\"subtitle1\">Protein (g)</td> <td class=\"subtitle1\">Fat (g)</td> <td class=\"subtitle1\">Calcium (mg)</td> <td class=\"subtitle1\">Phosphorus (mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Preterm</td> </tr> <tr> <td class=\"indent1\">1st week</td> <td class=\"centered\">60 (45-75)</td> <td class=\"centered\">2.2 (0.3-4.1)</td> <td class=\"centered\">2.6 (0.5-4.7)</td> <td class=\"centered\">26 (9-43)</td> <td class=\"centered\">11 (1-22)</td> </tr> <tr> <td class=\"indent1\">2nd week</td> <td class=\"centered\">71 (49-94)</td> <td class=\"centered\">1.5 (0.8-2.3)</td> <td class=\"centered\">3.5 (1.2-5.7)</td> <td class=\"centered\">25 (11-39)</td> <td class=\"centered\">15 (8-21)</td> </tr> <tr> <td class=\"indent1\">Week 3/4</td> <td class=\"centered\">77 (61-92)</td> <td class=\"centered\">1.4 (0.6-2.2)</td> <td class=\"centered\">3.5 (1.6-5.5)</td> <td class=\"centered\">25 (13-36)</td> <td class=\"centered\">14 (8-20)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Week 10/12</td> <td class=\"centered\">66 (39-94)</td> <td class=\"centered\">1.0 (0.6-1.4)</td> <td class=\"centered\">3.7 (0.8-6.5)</td> <td class=\"centered\">29 (19-38)</td> <td class=\"centered\">12 (8-15)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Term</td> </tr> <tr> <td class=\"indent1\">1st week</td> <td class=\"centered\">60 (44-77)</td> <td class=\"centered\">1.8 (0.4-3.2)</td> <td class=\"centered\">2.2 (0.7-3.7)</td> <td class=\"centered\">26 (16-36)</td> <td class=\"centered\">12 (6-18)</td> </tr> <tr> <td class=\"indent1\">2nd week</td> <td class=\"centered\">67 (47-86)</td> <td class=\"centered\">1.3 (0.8-1.8)</td> <td class=\"centered\">3.0 (1.2-4.8)</td> <td class=\"centered\">28 (14-42)</td> <td class=\"centered\">17 (8-27)</td> </tr> <tr> <td class=\"indent1\">Week 3/4</td> <td class=\"centered\">66 (48-85)</td> <td class=\"centered\">1.2 (0.8-1.6)</td> <td class=\"centered\">3.3 (1.6-5.1)</td> <td class=\"centered\">27 (18-36)</td> <td class=\"centered\">16 (10-22)</td> </tr> <tr> <td class=\"indent1\">Week 10/12</td> <td class=\"centered\">68 (50-86)</td> <td class=\"centered\">0.9 (0.6-1.2)</td> <td class=\"centered\">3.4 (1.6-5.2)</td> <td class=\"centered\">26 (14-38)</td> <td class=\"centered\">16 (9-22)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Estimates as +/– 2 standard deviations assumed no skew. Energy values were bomb calorimeter measured values except for 10 to 12 weeks, which were calculated values. Protein values are true measured protein, not based on total nitrogen content.</div><div class=\"graphic_reference\">Reproduced from: Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm and term breast milk. BMC Pediatrics 2014; 14:216. Copyright © 2014 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 111635 Version 1.0</div></div></div>"},"111636":{"type":"graphic_picture","displayName":"Histopathology LAM","title":"Histopathology of lymphangioleiomyomatosis (lung)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Histopathology of lymphangioleiomyomatosis (lung)</div><div class=\"cntnt\"><img style=\"width:513px; height:767px;\" src=\"images/PULM/111636_Histopathology_LAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low power view showing cystic air space (arrow) characteristic of lymphangioleiomyomatosis (LAM), which is different to the airspace dilatation typical of emphysema.<br />(B) High power view demonstrating abnormal smooth muscle cell (LAM cell) clusters surrounding the cysts (arrow).<br />(C) Hematoxylin and eosin staining of LAM lung tissue.<br />(D) Immunohistochemical staining with smooth muscle cell actin (SMA) demonstrating the presence of abnormal smooth muscle cells.<br />(E) Focal human melanoma black (HMB)-45 staining confirming the presence of LAM cells.</div><div class=\"graphic_reference\">Pathology slides courtesy of: Kathryn A Wikenheiser-Brokamp MD, Cincinnati, OH.</div><div id=\"graphicVersion\">Graphic 111636 Version 1.0</div></div></div>"},"111637":{"type":"graphic_diagnosticimage","displayName":"CT LAM pneumothorax","title":"Computed tomography of pneumothorax in lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of pneumothorax in lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:323px; height:425px;\" src=\"images/PULM/111637_CT_LAM_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial section of a high resolution computed tomographic scan showing a right-sided pneumothorax in a patient with lymphangioleiomyomatosis. Note the pneumothorax is loculated and has collapsed posterolaterally, a feature that may be missed on plain radiograph.</div><div id=\"graphicVersion\">Graphic 111637 Version 1.0</div></div></div>"},"111638":{"type":"graphic_diagnosticimage","displayName":"CT LAM cysts I","title":"Computed tomography of typical cysts in lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Computed tomography of typical cysts in lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:562px; height:765px;\" src=\"images/PULM/111638_CT_LAM_cysts_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial cut of a high resolution computed tomographic (HRCT) scan in a patient with mild cystic disease due to lymphangioleiomyomatosis (LAM). Notice the characteristic cyst features of LAM: round, uniform, thin-walled cysts without internal structures present in a diffuse distribution with a normal appearing intervening lung parenchyma.<br />(B) This HRCT shows similar features but the patient has severe LAM.</div><div id=\"graphicVersion\">Graphic 111638 Version 1.0</div></div></div>"},"111639":{"type":"graphic_diagnosticimage","displayName":"CT LAM chylous effusion","title":"Computed tomography of chylous effusion and congestion in lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Computed tomography of chylous effusion and congestion in lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:521px; height:746px;\" src=\"images/PULM/111639_CT_LAM_chylous_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial section of a high resolution computed tomographic (HRCT) scan of the chest showing a right-sided chylothorax in a patient with lymphangioleiomyomatosis (LAM). Notice the characteristic cysts in the pulmonary parenchyma.<br />(B) Axial HRCT scan in a patient with LAM showing a left-sided chylothorax and bilateral cysts characteristic of LAM. There is ground glass attenuation (arrow) in the right lower lobe as a result of chylous congestion and reflux.</div><div id=\"graphicVersion\">Graphic 111639 Version 1.0</div></div></div>"},"111640":{"type":"graphic_diagnosticimage","displayName":"CT LAM AMLs","title":"Computed tomography of renal and hepatic angiomyolipomas in lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Computed tomography of renal and hepatic angiomyolipomas in lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:700px; height:485px;\" src=\"images/PULM/111640_CT_LAM_AMLs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic (CT) scan of the abdomen revealing a large, fat containing tumor in the left kidney (arrow) characteristic of an angiomyolipoma (AML) in a patient with tuberous sclerosis complex associated-lymphangioleiomyomatosis. Also notice hepatic AMLs in the same patient (dotted arrows).</div><div id=\"graphicVersion\">Graphic 111640 Version 1.0</div></div></div>"},"111641":{"type":"graphic_diagnosticimage","displayName":"CT LAM AMLs II","title":"Computed tomography of lymphangioleiomyoma size before and after rapamycin in lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 855px\" class=\"figure\"><div class=\"ttl\">Computed tomography of lymphangioleiomyoma size before and after rapamycin in lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:835px; height:420px;\" src=\"images/PULM/111641_CT_LAM_AMLs_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal view of computed tomographic scans showing a significant reduction in the size of lymphangioleiomyomas in a patient with lymphangioleiomyomatosis (arrows).</div><div id=\"graphicVersion\">Graphic 111641 Version 1.0</div></div></div>"},"111642":{"type":"graphic_figure","displayName":"Adherence data","title":"Device download: Adherence","html":"<div class=\"graphic\"><div style=\"width: 868px\" class=\"figure\"><div class=\"ttl\">Device download: Adherence</div><div class=\"cntnt\"><img style=\"width:848px; height:578px;\" src=\"images/PULM/111642_Adherence_data.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows a typical format for downloaded information on adherence to CPAP over a select period.</div><div class=\"graphic_footnotes\">CPAP: continuous positive airway pressure; EPR: expiratory pressure relief; EPR level: settings of 1 to 3 with 3 being the most pressure reduction; AHI: apnea hypopnea index.</div><div class=\"graphic_reference\">From: ResMed AirView 4.1. Copyright © ResMed 2017. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111642 Version 1.0</div></div></div>"},"111648":{"type":"graphic_figure","displayName":"Energy content of preterm and term milk","title":"Measured energy distribution of preterm and term breast milk by postnatal age over the first 12 weeks of lactation, weighted mean and 95% reference interval","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Measured energy distribution of preterm and term breast milk by postnatal age over the first 12 weeks of lactation, weighted mean and 95% reference interval</div><div class=\"cntnt\"><img style=\"width:580px; height:324px;\" src=\"images/PEDS/111648_Energy_preterm_term_milk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reproduced from: Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm and term breast milk. BMC Pediatrics 2014; 14:216. Copyright © 2014 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 111648 Version 1.0</div></div></div>"},"111649":{"type":"graphic_figure","displayName":"Protein content of preterm and term milk","title":"True protein content distribution of preterm and term breast milk in by postnatal age over the first 12 weeks of lactation, weighted mean and 95% reference interval","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">True protein content distribution of preterm and term breast milk in by postnatal age over the first 12 weeks of lactation, weighted mean and 95% reference interval</div><div class=\"cntnt\"><img style=\"width:582px; height:324px;\" src=\"images/PEDS/111649_Protein_preterm_term_milk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reproduced from: Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm and term breast milk. BMC Pediatrics 2014; 14:216. Copyright © 2014 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 111649 Version 1.0</div></div></div>"},"111650":{"type":"graphic_table","displayName":"Composition of colostrum versus mature milk","title":"The milk maturity effect: Comparison of colostrum versus mature milk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The milk maturity effect: Comparison of colostrum versus mature milk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"12\" width=\"7.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Energy<br /> (measured)<br /> kcal/100 mL</td> <td class=\"subtitle1\" colspan=\"2\">Protein <br /> (true protein)<br /> g/100 mL</td> <td class=\"subtitle1\" colspan=\"2\">Fat<br /> g/100 mL</td> <td class=\"subtitle1\" colspan=\"2\">Lactose<br /> kcal/100 mL</td> <td class=\"subtitle1\" colspan=\"2\">Calcium<br /> mg/100 mL</td> <td class=\"subtitle1\" colspan=\"2\">Phosphate<br /> mg/100 mL</td> </tr> <tr> <td class=\"subtitle2\">Preterm</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">Preterm</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">Preterm</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">Preterm</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">Preterm</td> <td class=\"subtitle2\">Term</td> <td class=\"subtitle2\">Preterm</td> <td class=\"subtitle2\">Term</td> </tr> <tr> <td><strong>Colostrum</strong></td> <td class=\"centered\">49</td> <td class=\"centered\">54</td> <td class=\"centered\">2.7</td> <td class=\"centered\">2.0</td> <td class=\"centered\">2.2</td> <td class=\"centered\">1.8</td> <td class=\"centered\">5.1</td> <td class=\"centered\">5.6</td> <td class=\"centered\">25</td> <td class=\"centered\">26</td> <td class=\"centered\">9.5</td> <td class=\"centered\">11</td> </tr> <tr> <td><strong>Mature milk</strong></td> <td class=\"centered\">73</td> <td class=\"centered\">63</td> <td class=\"centered\">1.1</td> <td class=\"centered\">1.0</td> <td class=\"centered\">3.3</td> <td class=\"centered\">3.4</td> <td class=\"centered\">6.2</td> <td class=\"centered\">6.5</td> <td class=\"centered\">29</td> <td class=\"centered\">26</td> <td class=\"centered\">12.8</td> <td class=\"centered\">16</td> </tr> <tr> <td><strong>Difference</strong></td> <td class=\"centered\">49%</td> <td class=\"centered\">16%</td> <td class=\"centered\">&ndash;61%</td> <td class=\"centered\">&ndash;52%</td> <td class=\"centered\">50%</td> <td class=\"centered\">93%</td> <td class=\"centered\">21%</td> <td class=\"centered\">16%</td> <td class=\"centered\">13%</td> <td class=\"centered\">&ndash;2%</td> <td class=\"centered\">35%</td> <td class=\"centered\">41%</td> </tr> <tr> <td><strong>p-value</strong></td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">&#60;0.00001*</td> <td class=\"centered\">0.003</td> <td class=\"centered\">0.62</td> <td class=\"centered\">0.002</td> <td class=\"centered\">0.001</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Colostrum was milk collected in the first 3 days after birth, mature milk was collected between 5 to 12 weeks. The difference values less than 100% reflect lower values for mature milk; differences greater than 100% reflect higher values for colostrum compared&nbsp;with mature milk.</div><div class=\"graphic_footnotes\">* Met our approximate Bonferroni adjusted p-value criteria for statistical significance was &lt;0.001.</div><div class=\"graphic_reference\">Reproduced from: Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm and term breast milk. BMC Pediatrics 2014; 14:216. Copyright © 2014 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 111650 Version 1.0</div></div></div>"},"111651":{"type":"graphic_diagnosticimage","displayName":"Radiograph RUL SPN","title":"Conventional radiograph of a malignant solitary pulmonary nodule","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Conventional radiograph of a malignant solitary pulmonary nodule</div><div class=\"cntnt\"><img style=\"width:651px; height:756px;\" src=\"images/PULM/111651_Radiograph_RUL_SPN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph of lung cancer presenting as a solitary nodule in the right upper lobe, adjacent to a bulla in a patient with severe emphysema.</div><div id=\"graphicVersion\">Graphic 111651 Version 1.0</div></div></div>"},"111652":{"type":"graphic_diagnosticimage","displayName":"Cavitating lung cancer","title":"Conventional radiograph of cavitating lung cancer","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Conventional radiograph of cavitating lung cancer</div><div class=\"cntnt\"><img style=\"width:703px; height:756px;\" src=\"images/PULM/111652_Cavitating_lung_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph. Squamous cell lung cancer with cavitary lesion in the right lower lobe in a patient with emphysema.</div><div id=\"graphicVersion\">Graphic 111652 Version 1.0</div></div></div>"},"111653":{"type":"graphic_diagnosticimage","displayName":"Lung cancer local invasion","title":"Conventional radiograph of locally invasive lung cancer","html":"<div class=\"graphic\"><div style=\"width: 697px\" class=\"figure\"><div class=\"ttl\">Conventional radiograph of locally invasive lung cancer</div><div class=\"cntnt\"><img style=\"width:677px; height:756px;\" src=\"images/PULM/111653_Lung_cancer_local_invasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph. Squamous cell lung cancer with bronchopleural-cutaneous fistula. A right upper lobe cavitary mass is shown with invasion of the chest wall, rib destruction, and extension of gas into the subcutaneous tissues.</div><div id=\"graphicVersion\">Graphic 111653 Version 1.0</div></div></div>"},"111654":{"type":"graphic_diagnosticimage","displayName":"Lung cancer lymphangitis","title":"Conventional radiograph of lung cancer with lymphangitic spread","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Conventional radiograph of lung cancer with lymphangitic spread</div><div class=\"cntnt\"><img style=\"width:756px; height:674px;\" src=\"images/PULM/111654_Lungcancerlymphangitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph. Left lower lobe lung cancer with an infrahilar, para-aortic mass (arrow) is shown with accompanying left-sided, unilateral lymphangitic spread of tumor manifesting as diffuse, unilateral, fine, linear, reticular, and scattered, small nodular opacities.</div><div id=\"graphicVersion\">Graphic 111654 Version 1.0</div></div></div>"},"111655":{"type":"graphic_diagnosticimage","displayName":"Lung cancer involving phrenic nerve","title":"Apical lung cancer with phrenic nerve involvement","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Apical lung cancer with phrenic nerve involvement</div><div class=\"cntnt\"><img style=\"width:748px; height:756px;\" src=\"images/PULM/111655_Lung_cancer_phrenic_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph. Patient with left apico-medial lung cancer, invading the left phrenic nerve. A left apical supra-aortic mass (arrow) as well as marked elevation of the left hemidiaphragm are shown.</div><div id=\"graphicVersion\">Graphic 111655 Version 1.0</div></div></div>"},"111656":{"type":"graphic_diagnosticimage","displayName":"Lung cancer and ILD","title":"Lung cancer and interstitial lung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung cancer and interstitial lung disease</div><div class=\"cntnt\"><img style=\"width:440px; height:826px;\" src=\"images/PULM/111656_Lung_cancer_ILD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest frontal radiograph. Patient with rheumatoid interstitial lung disease (ILD) and superimposed adenocarcinoma of the left lung. Bilateral subpleural reticular opacities from ILD and a wedge-shaped left mid-lung subpleural tumor (arrow) are shown.<br />(B) High resolution axial computed tomogram of the same patient displays bilateral subpleural honeycombing (from ILD) and a left mid-lung, subpleural spiculated mass (arrow).</div><div id=\"graphicVersion\">Graphic 111656 Version 1.0</div></div></div>"},"111657":{"type":"graphic_diagnosticimage","displayName":"Advanced lung cancer","title":"Conventional radiograph of locally advanced lung cancer","html":"<div class=\"graphic\"><div style=\"width: 761px\" class=\"figure\"><div class=\"ttl\">Conventional radiograph of locally advanced lung cancer</div><div class=\"cntnt\"><img style=\"width:741px; height:756px;\" src=\"images/PULM/111657_Advanced_lung_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph in a patient with known advanced right-sided lung cancer showing a left upper lobe metastatic nodule and right-sided hydropneumothorax from advanced parenchymal disease and pleural metastases.</div><div id=\"graphicVersion\">Graphic 111657 Version 1.0</div></div></div>"},"111658":{"type":"graphic_diagnosticimage","displayName":"PET lung cancer","title":"Conventional radiograph and positron emission tomography of lung cancer","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Conventional radiograph and positron emission tomography of lung cancer</div><div class=\"cntnt\"><img style=\"width:765px; height:502px;\" src=\"images/PULM/111658_PET_lung_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest frontal radiograph showing a large left upper lobe mass with hilar invasion and superior mediastinal extension, leading to displacement of the trachea to the right.<br />(B) Sagittal view of an integrated positron emission tomographic-computed tomographic (PET-CT) scan in the same patient that shows a large metabolically active left-sided tumor invading the left hilum and the mediastinum. Contralateral increased hilar and mediastinal lymph node activity is seen as well.</div><div id=\"graphicVersion\">Graphic 111658 Version 1.0</div></div></div>"},"111659":{"type":"graphic_diagnosticimage","displayName":"CT and PET lung cancer","title":"Computed tomography and positron emission tomography of left lung cancer","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Computed tomography and positron emission tomography of left lung cancer</div><div class=\"cntnt\"><img style=\"width:766px; height:548px;\" src=\"images/PULM/111659_CT_PET_lung_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Contrast-enhanced, axial computed tomographic (CT) scan shows a large left perihilar mass invading the left pulmonary artery and the anterior mediastinal fat. Enlarged contralateral hilar lymph nodes are present (thick arrow).<br />(B) Corresponding axial view of an integrated positron emission tomographic-computed tomographic (PET-CT) scan in the same patient that shows the increased metabolic activity in the left lung, hilum, and mediastinum.<br />(C) Axial CT scan of the same patient shows the tumor encasing the left common carotid artery and the left subclavian artery (arrows).<br />(D) Corresponding axial view of an integrated PET-CT scan in the same patient that shows a left upper lobe mass paralleling the aortic arch (arrow) with increased activity in contralateral paratracheal lymph nodes (thick arrow).</div><div id=\"graphicVersion\">Graphic 111659 Version 1.0</div></div></div>"},"111660":{"type":"graphic_diagnosticimage","displayName":"MRI Pancoast's","title":"Magnetic resonance imaging of a Pancoast's tumor","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of a Pancoast's tumor</div><div class=\"cntnt\"><img style=\"width:464px; height:640px;\" src=\"images/PULM/111660_MRI_Pancoasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal spin-echo magnetic resonance imaging. Pancoast tumor invading the spine, spinal canal, and compressing the cord (arrow).</div><div id=\"graphicVersion\">Graphic 111660 Version 1.0</div></div></div>"},"111661":{"type":"graphic_diagnosticimage","displayName":"CT endobronchial cancer","title":"Computed tomography of endobronchial lung cancer","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Computed tomography of endobronchial lung cancer</div><div class=\"cntnt\"><img style=\"width:640px; height:508px;\" src=\"images/PULM/111661_CT_endobronchial_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomographic scan in a patient who presents with hemoptysis showing a polypoid lesion in the right mainstem bronchus subsequently revealed to be squamous cell lung cancer.</div><div id=\"graphicVersion\">Graphic 111661 Version 1.0</div></div></div>"},"111662":{"type":"graphic_diagnosticimage","displayName":"MRI brain metastasis","title":"Magnetic resonance imaging of a brain metastasis from lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of a brain metastasis from lung cancer</div><div class=\"cntnt\"><img style=\"width:442px; height:822px;\" src=\"images/PULM/111662_MRI_brain_metastasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Contrast-enhanced magnetic resonance imaging of the brain in a patient with seizures shows a left-sided peripheral contrast-enhancing mass (arrow) surrounded by vasogenic edema (thick arrow) suspicious for a metastatic lesion.<br />(B) Computed tomography of the chest in the same patient shows a large, cavitating mass in the right upper lobe consistent with a lung cancer that was the source of the brain metastasis.</div><div id=\"graphicVersion\">Graphic 111662 Version 1.0</div></div></div>"},"111663":{"type":"graphic_diagnosticimage","displayName":"MRI lung cancer with liver infiltration","title":"Magnetic resonance imaging of lung cancer with local infiltration of the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of lung cancer with local infiltration of the liver</div><div class=\"cntnt\"><img style=\"width:438px; height:639px;\" src=\"images/PULM/111663_MRI_lng_cncr_liver_infltrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal spin-echo magnetic resonance image in a patient with a large right lower lobe lung cancer invading the right hemidiaphragm (arrow) and infiltrating the liver (thick arrow).</div><div id=\"graphicVersion\">Graphic 111663 Version 1.0</div></div></div>"},"111664":{"type":"graphic_diagnosticimage","displayName":"CT adrenal metastases II","title":"Computed tomography of adrenal metastasis from right-sided lung cancer","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Computed tomography of adrenal metastasis from right-sided lung cancer</div><div class=\"cntnt\"><img style=\"width:512px; height:804px;\" src=\"images/PULM/111664_CT_adrenal_metastases_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial computed tomographic (CT) scan showing a large right middle lobe lung cancer with partial right middle lobe atelectasis, and hilar and mediastinal lymph node enlargement.<br />(B) Axial CT scan of the upper abdomen in the same patient showing a large left adrenal mass (arrow), dorsal to the body of the pancreas, representing an adrenal metastasis that had developed in the preceding three months.</div><div id=\"graphicVersion\">Graphic 111664 Version 1.0</div></div></div>"},"111670":{"type":"graphic_picture","displayName":"Airtraq Avant with ETT","title":"Airtraq Avant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airtraq Avant</div><div class=\"cntnt\"><img style=\"width:380px; height:507px;\" src=\"images/ANEST/111670_Airtraq_avant_ETT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows an endotracheal tube in the channel on the side of the Airtraq Avant video laryngoscope. The arrows point to anterior (thin arrow) and posterior (thick arrow) tabs that hold the tube in place. The endotracheal tube must be carefully disengaged from the flanges after intubation. For further details, refer to UpToDate topics on video laryngoscopes for airway management for anesthesia.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright © 2013 Teleflex Incorporated. All rights reserved. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 111670 Version 1.0</div></div></div>"},"111672":{"type":"graphic_picture","displayName":"Subclavian interposition grafting for traumatic injury","title":"Subclavian interposition grafting for traumatic injury","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Subclavian interposition grafting for traumatic injury</div><div class=\"cntnt\"><img style=\"width:756px; height:332px;\" src=\"images/SURG/111672_Uppr_extremity_revsclrztn3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows the&nbsp;proximal and mid-right subclavian artery with a short Dacron interposition bypass graft.</div><div id=\"graphicVersion\">Graphic 111672 Version 1.0</div></div></div>"},"111673":{"type":"graphic_diagnosticimage","displayName":"Angioplasty stenting for coronary steal syndrome","title":"Angioplasty stenting for coronary steal syndrome","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Angioplasty stenting for coronary steal syndrome</div><div class=\"cntnt\"><img style=\"width:766px; height:396px;\" src=\"images/SURG/111673_Angplsy_stntg_crnry_stl_syn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe left subclavian stenosis is shown (A), with reduced flow into the internal mammary graft. The patient was suffering from coronary steal syndrome. Following left subclavian artery angioplasty and stenting (B), the subclavian artery is widely patent with flow restored into the internal mammary graft. Note the improved caliber of the vertebral as well.</div><div id=\"graphicVersion\">Graphic 111673 Version 1.0</div></div></div>"},"111674":{"type":"graphic_diagnosticimage","displayName":"Innominate artery stenting","title":"Innominate artery stenting","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Innominate artery stenting</div><div class=\"cntnt\"><img style=\"width:510px; height:617px;\" src=\"images/SURG/111674_Innominate_artry_stentng_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows a noncontrast image following carotid and innominate angioplasty and stenting. The patient had a history of right carotid-subclavian artery bypass and subsequently developed high-grade stenoses of the&nbsp;common carotid and innominate arteries, impeding flow into the bypass. An embolic protection filter was placed into the distal carotid artery through the preexisting bypass via a right brachial approach (thin arrow), and femoral access was used to place a stiff wire through the lesion to perform the angioplasty and stenting (thick arrow).</div><div id=\"graphicVersion\">Graphic 111674 Version 1.0</div></div></div>"},"111685":{"type":"graphic_figure","displayName":"Laparoscopic liver resection port placement","title":"Laparoscopic liver resection port placement","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Laparoscopic liver resection port placement</div><div class=\"cntnt\"><img style=\"width:541px; height:345px;\" src=\"images/SURG/111685_Laparoscopic_liver_resection_port_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical port placement for A) laparoscopic right hepatectomy and B) laparoscopic left hepatectomy/left lateral segmentectomy. Potential site for hand assist, if used, is indicated by the dashed line. If performed purely laparoscopically, the 12-mm port site is indicated instead. Specimen extraction may be performed via enlargement of the periumbilical port or through the hand-assist site, if used.</div><div id=\"graphicVersion\">Graphic 111685 Version 1.0</div></div></div>"},"111687":{"type":"graphic_table","displayName":"Summary of studies of laparoscopic major liver resection","title":"Summary of studies of laparoscopic major liver resection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of studies of laparoscopic major liver resection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author (country)</td> <td class=\"subtitle1\">Publication year</td> <td class=\"subtitle1\">Data source</td> <td class=\"subtitle1\">Patients (n)</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Operative time (min)</td> <td class=\"subtitle1\">Conversion rate (%)</td> <td class=\"subtitle1\">Complication rate (%)</td> <td class=\"subtitle1\">Mortality rate (%)</td> </tr> <tr> <td>Koffron<sup>[1]</sup> (USA)</td> <td class=\"centered\">2007</td> <td>Single institution (2001 to 2006)</td> <td class=\"centered\">300</td> <td>Malignant 34%<br /> Benign 59%<br /> Unknown 7%</td> <td class=\"centered\">95 to 157</td> <td class=\"centered\">7</td> <td class=\"centered\">9.3</td> <td class=\"centered\">N/A</td> </tr> <tr> <td>Cannon<sup>[2]</sup> (USA)</td> <td class=\"centered\">2011</td> <td>Single institution (1999 to 2009)</td> <td class=\"centered\">300</td> <td>Malignant 44%<br /> Benign 46%</td> <td class=\"centered\">150</td> <td class=\"centered\">N/A</td> <td class=\"centered\">10.7</td> <td class=\"centered\">1.7</td> </tr> <tr> <td>Johnson<sup>[3]</sup> (USA)</td> <td class=\"centered\">2012</td> <td>Single institution (2004 to 2011)</td> <td class=\"centered\">88</td> <td>Malignant 77%<br /> Benign 23%</td> <td class=\"centered\">238</td> <td class=\"centered\">6.8</td> <td class=\"centered\">6.8</td> <td class=\"centered\">1.1</td> </tr> <tr> <td>Fallazahdeh<sup>[4]</sup> (USA)</td> <td class=\"centered\">2013</td> <td>Single institution (1993 to 2012)</td> <td class=\"centered\">54</td> <td>Malignant 54%<br /> Benign 46%</td> <td class=\"centered\">174</td> <td class=\"centered\">0</td> <td class=\"centered\">26</td> <td class=\"centered\">3.7</td> </tr> <tr> <td>Tranchart<sup>[5]</sup> (France)</td> <td class=\"centered\">2013</td> <td>Multi institution (1996 to 2011)</td> <td class=\"centered\">495</td> <td>Malignant 78%<br /> Benign 22%</td> <td class=\"centered\">275</td> <td class=\"centered\">10.8</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> </tr> <tr> <td>Bueno<sup>[6]</sup> (Spain)</td> <td class=\"centered\">2014</td> <td>Single institution (2000 to 2010)</td> <td class=\"centered\">50</td> <td>Malignant 84%<br /> Benign 16%</td> <td class=\"centered\">240</td> <td class=\"centered\">4</td> <td class=\"centered\">16</td> <td class=\"centered\">2</td> </tr> <tr> <td>Franken<sup>[7]</sup> (USA)</td> <td class=\"centered\">2014</td> <td>Single institution (2004 to 2013)</td> <td class=\"centered\">52</td> <td>Malignant 75%<br /> Benign 25%</td> <td class=\"centered\">219</td> <td class=\"centered\">13</td> <td class=\"centered\">8</td> <td class=\"centered\">2</td> </tr> <tr> <td>L&#243;pez-Ben<sup>[8]</sup> (Spain)</td> <td class=\"centered\">2014</td> <td>Single institution (2005 to 2012)</td> <td class=\"centered\">50</td> <td>Malignant 82%<br /> Benign 18%</td> <td class=\"centered\">295</td> <td class=\"centered\">12</td> <td class=\"centered\">36</td> <td class=\"centered\">2</td> </tr> <tr> <td>He<sup>[9]</sup> (USA)</td> <td class=\"centered\">2015</td> <td>Nationwide Inpatient Sample (2000 to 2012)</td> <td class=\"centered\">1131</td> <td>Malignant 75%<br /> Benign 18%<br /> Unknown 7%</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">38.1</td> <td class=\"centered\">2.8</td> </tr> <tr> <td>He<sup>[9]</sup> (USA)</td> <td class=\"centered\">2015</td> <td>National Surgical Quality Improvement Project (2005 to 2012)</td> <td class=\"centered\">642</td> <td>Malignant 82%<br /> Benign 10%<br /> Unknown 8%</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> <td class=\"centered\">30.7</td> <td class=\"centered\">2.2</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Koffron AJ, Auffenberg G, Kung R, Abecassis M. Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 2007; 246:385.</LI>&#xD;&#xA;<LI>Cannon RM, Scoggins CR, Callender GG, et al. Laparoscopic versus open resection of hepatic colorectal metastases. Surgery 2012; 152:567.</LI>&#xD;&#xA;<LI>Johnson LB, Graham JA, Weiner DA, Smirniotopoulos J. How does laparoscopic-assisted hepatic resection compare with the conventional open surgical approach? J Am Coll Surg 2012; 214:717.</LI>&#xD;&#xA;<LI>Fallahzadeh MK, Zibari GB, Hamidian Jahromi A, et al. Laparoscopic versus open liver resection for benign and malignant solid liver tumors: a case-matched study. J Laparoendosc Adv Surg Tech A 2013; 23:908.</LI>&#xD;&#xA;<LI>Tranchart H, Di Giuro G, Lainas P, et al. Laparoscopic liver resection with selective prior vascular control. Am J Surg 2013; 205:8.</LI>&#xD;&#xA;<LI>Bueno A, Rotellar F, Benito A, et al. Laparoscopic limited liver resection decreases morbidity irrespective of the hepatic segment resected. HPB (Oxford) 2014; 16:320.</LI>&#xD;&#xA;<LI>Franken C, Lau B, Putchakayala K, DiFronzo LA. Comparison of short-term outcomes in laparoscopic vs open hepatectomy. JAMA Surg 2014; 149:941.</LI>&#xD;&#xA;<LI>López-Ben S, Palacios O, Codina-Barreras A, et al. Pure laparoscopic liver resection reduces surgical site infections and hospital stay. Results of a case-matched control study in 50 patients. Langenbecks Arch Surg 2014; 399:307.</LI>&#xD;&#xA;<LI>He J, Amini N, Spolverato G, et al. National trends with a laparoscopic liver resection: results from a population-based analysis. HPB (Oxford) 2015; 17:919.</LI></OL></div><div id=\"graphicVersion\">Graphic 111687 Version 1.0</div></div></div>"},"111688":{"type":"graphic_table","displayName":"Key steps in laparoscopic liver resection","title":"Key steps in laparoscopic liver resection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key steps in laparoscopic liver resection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure steps</td> <td class=\"subtitle1\">Laparoscopic right hepatectomy tips</td> <td class=\"subtitle1\">Laparoscopic left hepatectomy tips</td> <td class=\"subtitle1\">Laparoscopic nonanatomic resection tips</td> </tr> <tr> <td>Create pneumoperitoneum and place ports</td> <td>When necessary, place hand-assist port in midline above umbilicus</td> <td>When necessary, place hand-assist port in midline above umbilicus</td> <td>&nbsp;</td> </tr> <tr> <td>Intraoperative ultrasound</td> <td>Identify targets for resection and exclude pathology in future liver remnant</td> <td>Identify targets for resection and exclude pathology in future liver remnant</td> <td>Identify targets for resection and nearby major vasculature</td> </tr> <tr> <td>Mobilization of ligamentous attachments</td> <td>Avoid injury to diaphragm, phrenic vein, right adrenal gland, inferior vena cava</td> <td>Avoid injury to diaphragm, phrenic vein, left hepatic vein, inferior vena cava</td> <td>&nbsp;</td> </tr> <tr> <td>Cholecystectomy</td> <td>Delay cholecystectomy until parenchyma division to use gallbladder to retract liver</td> <td>&nbsp;</td> <td>Only required when resecting masses in segment IVB or V</td> </tr> <tr> <td>Vascular control</td> <td>Use a stapler with a curved tip to divide right portal vein</td> <td>Dissect at base of umbilical fissure to expose left hepatic artery and portal vein away from bifurcations</td> <td>&nbsp;</td> </tr> <tr> <td>Parenchymal transection</td> <td>Use energy sealing device and vascular stapler</td> <td>Use energy sealing device and vascular stapler</td> <td>May require Pringle maneuver</td> </tr> <tr> <td>Hemostasis</td> <td>Use pressure and bipolar vessel-sealing device</td> <td>Use pressure and bipolar vessel-sealing device</td> <td>Use pressure and bipolar vessel-sealing device</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111688 Version 1.0</div></div></div>"},"111689":{"type":"graphic_table","displayName":"Perioperative outcomes laparoscopic versus open liver resection","title":"Perioperative outcomes laparoscopic versus open liver resection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative outcomes laparoscopic versus open liver resection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"6\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Minor-only series</td> <td class=\"subtitle1\" colspan=\"2\">Major-only series</td> <td class=\"subtitle1\" colspan=\"2\">Combined minor-major series</td> </tr> <tr> <td class=\"subtitle2\">Laparoscopic</td> <td class=\"subtitle2\">Open</td> <td class=\"subtitle2\">Laparoscopic</td> <td class=\"subtitle2\">Open</td> <td class=\"subtitle2\">Laparoscopic</td> <td class=\"subtitle2\">Open</td> </tr> <tr> <td><strong>Complications (%)</strong></td> <td class=\"centered\">13.49</td> <td class=\"centered\">30.52</td> <td class=\"centered\">22.38</td> <td class=\"centered\">43.58</td> <td class=\"centered\">18.31</td> <td class=\"centered\">29.77</td> </tr> <tr> <td><strong>Blood loss</strong></td> <td class=\"centered\">322.62&#177;276.77</td> <td class=\"centered\">572.419&#177;198.21</td> <td class=\"centered\">619.72&#177;411.82</td> <td class=\"centered\">1299.28&#177;816.64</td> <td class=\"centered\">375&#177;329.59</td> <td class=\"centered\">647.6&#177;552.9</td> </tr> <tr> <td><strong>Transfusions (%)</strong></td> <td class=\"centered\">4.02</td> <td class=\"centered\">9.57</td> <td class=\"centered\">7.58</td> <td class=\"centered\">6.58</td> <td class=\"centered\">8.34</td> <td class=\"centered\">20.75</td> </tr> <tr> <td><strong>Operative time</strong></td> <td class=\"centered\">212.66&#177;83.3</td> <td class=\"centered\">212.98&#177;76.33</td> <td class=\"centered\">234.57&#177;51.98</td> <td class=\"centered\">220.02&#177;65.57</td> <td class=\"centered\">216.74&#177;105.65</td> <td class=\"centered\">224.72&#177;77.16</td> </tr> <tr> <td><strong>Hospital stay</strong></td> <td class=\"centered\">8.28&#177;4.49</td> <td class=\"centered\">13.54&#177;8.8</td> <td class=\"centered\">8.3&#177;4.28</td> <td class=\"centered\">16.67&#177;8.3</td> <td class=\"centered\">7.87&#177;5.31</td> <td class=\"centered\">11.8&#177;6.26</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Raw values of rate of complications and transfusions and mean ±SD (adjusted by sample size) for blood loss, operative time, and hospital stay in the 83 comparative series published worldwide.</div><div class=\"graphic_reference\">From: Ciria R, Cherqui D, Geller DA, et al. Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing. Ann Surg 2016; 263(4):761-77. DOI: <A href=\"http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2016&amp;issue=04000&amp;article=00019&amp;type=abstract\" target=_blank>10.1097/SLA.0000000000001413</A>. Copyright © 2016 American Surgical Association and European Surgical Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111689 Version 2.0</div></div></div>"},"111698":{"type":"graphic_algorithm","displayName":"Management of metastatic or recurrent SCC of the head and neck","title":"Management of metastatic or recurrent squamous cell carcinoma of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of metastatic or recurrent squamous cell carcinoma of the head and neck</div><div class=\"cntnt\"><img style=\"width:406px; height:452px;\" src=\"images/ONC/111698_Mgmt_mtstc_rcrnt_SCC_hd_nck.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PD: progressive disease.<br />​* Careful evaluation to include imaging studies of the head and neck for local recurrence and other sites of potential metastases.<br />¶ Refer to UpToDate topics \"Treatment of locally recurrent squamous cell carcinoma of the head and neck\" and \"Reirradation for locally recurrent head and neck cancer.\"<br />Δ Enrollment in a formal clinical trial should be considered whenever possible.<br /><FONT class=lozenge>◊</FONT> Metastasis-directed therapy (surgery, radiation) may be considered for patients with oligometastatic disease.<br />§ Single-agent chemotherapy or supportive care is an option for patients who are not candidates for more aggressive therapy.<br />¥ For patients who remain disease free ≥6 months following platinum-based therapy, consider retreatment with a platinum-based chemotherapy regimen. Factors to consider include cumulative cisplatin dose, depth and duration of prior response, and residual platinum-related toxicity.</div><div id=\"graphicVersion\">Graphic 111698 Version 1.0</div></div></div>"},"111699":{"type":"graphic_diagnosticimage","displayName":"MRI normal appendix","title":"MRI normal appendix","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">MRI normal appendix</div><div class=\"cntnt\"><img style=\"width:471px; height:154px;\" src=\"images/RADIOL/111699_MRI_normal_appendix_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal appendix. MR T2-weighted images (A and B) of the pelvis in a pregnant patient shows the appendix (arrow) that is &lt;6 mm double-layer wall thickness originating from the cecum (asterisk).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Susanna I Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 111699 Version 1.0</div></div></div>"},"111702":{"type":"graphic_diagnosticimage","displayName":"MRI appendicitis","title":"MRI appendicitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI appendicitis</div><div class=\"cntnt\"><img style=\"width:94px; height:146px;\" src=\"images/RADIOL/111702_MRI_appendicitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute appendicitis. MR sagittal T2-weighted image of the pelvis shows a thickened appendix (arrow) with surrounding edema originating from the cecum (asterisk).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Stella K Kang MD, MS.</div><div id=\"graphicVersion\">Graphic 111702 Version 1.0</div></div></div>"},"111704":{"type":"graphic_table","displayName":"Cognitive and behavioral consequences of sleep problems","title":"Cognitive and behavioral consequences of insufficient quantity or quality of sleep in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cognitive and behavioral consequences of insufficient quantity or quality of sleep in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Domain</td> <td class=\"subtitle1\">Impairment</td> </tr> <tr> <td>Attention, vigilance, reaction time</td> <td>Concentration; accuracy and efficiency of work</td> </tr> <tr> <td>Executive function</td> <td>Time management, decision-making, organization, selective attention, judgment, motivation, planning, multitasking, impulse control, and emotional regulation</td> </tr> <tr> <td>Memory</td> <td>Memory consolidation, particularly verbal working memory</td> </tr> <tr> <td>Academic performance</td> <td>Test scores/grades, receptivity to teacher, motivation to achieve</td> </tr> <tr> <td>Emotional regulation</td> <td>Regulation of negative and positive emotions; susceptibility to moodiness, emotional lability, irritability, depression, anxiety, and anger</td> </tr> <tr> <td>Behavior</td> <td>Motor hyperactivity; susceptibility to risk-taking and sensation-seeking behaviors, and to oppositional, defiant, and aggressive behavior</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111704 Version 2.0</div></div></div>"},"111705":{"type":"graphic_table","displayName":"Test performance for diagnosis of appendicitis","title":"Test performance for diagnosis of appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Test performance for diagnosis of appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Sensitivity (95% CI)</td> <td class=\"subtitle1\">Specificity (95% CI)</td> </tr> <tr> <td>WBC</td> <td class=\"centered\">0.84 (0.73 to 0.92)</td> <td class=\"centered\">0.67 (0.50 to 0.81)</td> </tr> <tr> <td>CRP</td> <td class=\"centered\">0.81 (0.74 to 0.87)</td> <td class=\"centered\">0.54 (0.42 to 0.64)</td> </tr> <tr> <td>WBC &#38; CRP</td> <td class=\"centered\">0.93 (0.86 to 1.00)</td> <td class=\"centered\">0.62 (0.37 to 0.86)</td> </tr> <tr> <td>CT</td> <td class=\"centered\">0.96 (0.95 to 0.97)</td> <td class=\"centered\">0.96 (0.93 to 0.97)</td> </tr> <tr> <td>US</td> <td class=\"centered\">0.85 (0.79 to 0.90)</td> <td class=\"centered\">0.90 (0.83 to 0.95)</td> </tr> <tr> <td>MRI</td> <td class=\"centered\">0.95 (0.88 to 0.98)</td> <td class=\"centered\">0.92 (0.87 to 0.95)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CI: confidence intervals; WBC: white blood cell count; CRP: C-reactive protein; CT: computed tomography; US: ultrasound; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Data from: Dahabreh IJ, Adam GP, Halladay CW, et al. Diagnosis of Right Lower Quadrant Pain and Suspected Acute Appendicitis. Comparative Effectiveness Review No. 157. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2012-00012-I.) AHRQ Publication No. 15(16)-EHC025-EF. Rockville, MD: Agency for Healthcare Research and Quality; December 2015. <A spellcheck=true href=\"https://effectivehealthcare.ahrq.gov/topics/appendicitis/research\" target=_blank>https://effectivehealthcare.ahrq.gov/topics/appendicitis/research</A>.</div><div id=\"graphicVersion\">Graphic 111705 Version 2.0</div></div></div>"},"111706":{"type":"graphic_table","displayName":"Manic/hypomanic symptoms observed in youth with bipolar disorder","title":"Prevalence of manic/hypomanic symptoms observed in youth with bipolar disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of manic/hypomanic symptoms observed in youth with bipolar disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Prevalence percent of patients</td> </tr> <tr> <td>Increased energy</td> <td>79</td> </tr> <tr> <td>Irritability</td> <td>77</td> </tr> <tr> <td>Mood lability</td> <td>76</td> </tr> <tr> <td>Distractibility</td> <td>74</td> </tr> <tr> <td>Goal-directed activity</td> <td>72</td> </tr> <tr> <td>Euphoria</td> <td>64</td> </tr> <tr> <td>Pressured speech</td> <td>63</td> </tr> <tr> <td>Hyperactive</td> <td>62</td> </tr> <tr> <td>Racing thoughts</td> <td>61</td> </tr> <tr> <td>Poor judgment</td> <td>61</td> </tr> <tr> <td>Grandiose</td> <td>57</td> </tr> <tr> <td>Inappropriate laughter</td> <td>57</td> </tr> <tr> <td>Decreased need for sleep</td> <td>56</td> </tr> <tr> <td>Flight of ideas</td> <td>54</td> </tr> <tr> <td>Increased productivity</td> <td>47</td> </tr> <tr> <td>Uninhibited people-seeking</td> <td>41</td> </tr> <tr> <td>Creative</td> <td>41</td> </tr> <tr> <td>Hypersexuality</td> <td>32</td> </tr> <tr> <td>Hallucinations</td> <td>31</td> </tr> <tr> <td>Delusions</td> <td>24</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Van Meter AR, Burke C, Kowatch RA, et al. Ten-year updated meta-analysis of the clinical characteristics of pediatric mania and hypomania. Bipolar Disord 2016; 18:19.</div><div id=\"graphicVersion\">Graphic 111706 Version 1.0</div></div></div>"},"111708":{"type":"graphic_table","displayName":"Disease-specific guidelines for hospice HIV disease","title":"Disease-specific criteria for estimating six-month prognosis, and hospice eligibility, in HIV disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease-specific criteria for estimating six-month prognosis, and hospice eligibility, in HIV disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">HIV disease</td> </tr> <tr> <td>Patients will be considered to be in the terminal stage of their illness (life expectancy of six months or less) if they meet the following criteria (1 and 2 should be present; factors from 3 will add supporting documentation):</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>CD4 count &#60;25 cells per microliter or persistent (two or more assays at least one month apart) viral load &#62;100,000 copies/mL, plus one of the following: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Central nervous system (CNS) lymphoma, untreated or persistent despite treatment </li> <li>Wasting (loss of at least 10% lean body mass) </li> <li>Mycobacterium avium complex (MAC) bacteremia, untreated, unresponsive to treatment, or treatment refused </li> <li>Progressive multifocal leukoencephalopathy </li> <li>Systemic lymphoma, with advanced HIV disease and partial response to chemotherapy </li> <li>Visceral Kaposi sarcoma, unresponsive to therapy </li> <li>Renal failure in the absence of dialysis </li> <li>Cryptosporidium infection </li> <li>Toxoplasmosis, unresponsive to therapy </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Decreased performance status, as measured by the Karnofsky Performance Status (KPS) scale, &#8804;50%. </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>Documentation of the following factors will support eligibility for hospice care: </li> </ol> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Chronic persistent diarrhea for one year </li> <li>Persistent serum albumin &#60;2.5 g/dL </li> <li>Concomitant, active substance abuse </li> <li>Age &#62;50 years </li> <li>Absence of or resistance to effective antiretroviral, chemotherapeutic, and prophylactic drug therapy related specifically to HIV disease </li> <li>Advanced AIDS dementia complex </li> <li>Toxoplasmosis </li> <li>Congestive heart failure, symptomatic at rest </li> <li>Advanced liver disease </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Karnofsky = 50: Requires considerable assistance and frequent medical care.<br />Karnofsky &lt;50: Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome.</div><div class=\"graphic_reference\">Sources:&#xD;&#xA;<ol>&#xD;&#xA;    <li>The NHO medical guidelines for non-cancer disease and local medical review policy: hospice access for patients with diseases other than cancer. Hosp J 1999.</li>&#xD;&#xA;    <li>Centers for Medicare &amp; Medicaid Services. <a href=\"https://www.cms.gov/medicare-coverage-database/license/cpt-license.aspx?from=~/overview-and-quick-search.aspx&amp;npage=/medicare-coverage-database/details/lcd-details.aspx&amp;LCDId=33393&amp;ContrId=272&amp;ver=2&amp;ContrVer=1&amp;CntrctrSelected=272*1&amp;Cntrctr=272&amp;name=National+Government+Services%2c+Inc.+(06004%2c+HHH+MAC)&amp;DocType=All&amp;s=56&amp;bc=AggAAAIAAAAAAA%3d%3d&amp;amp;\" target=\"_blank\">Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L33393)</a>. (Accessed on January 18, 2016).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 111708 Version 1.0</div></div></div>"},"111709":{"type":"graphic_picture","displayName":"Ultrasound technique for identifying landmarks prior to LP","title":"Ultrasound technique for identifying landmarks prior to lumbar puncture in infants","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Ultrasound technique for identifying landmarks prior to lumbar puncture in infants</div><div class=\"cntnt\"><img style=\"width:764px; height:543px;\" src=\"images/EM/111709_US_tech_id_lndmrks_prior_LP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pre-LP evaluation of the spinal landmarks. Ultrasonographic findings and probe orientation in longitudinal (panel A and C) and transverse (panel B and D) views of the lower spine. Posterior dural border (arrow); anterior dural border (dashed arrow).<br />(A) Subcutaneous tissue.<br />(B) Spinous process with bone shadowing.<br />(C) Epidural space.<br />(D) CSF in the dural sac.<br />(E) Cauda equina nerves.<br />(F) Vertebral body.</div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; LP: lumbar puncture.</div><div class=\"graphic_reference\">From: Gorn M, Kunkov S, Crain EF. Prospective investigation of a novel ultrasound-assisted lumbar puncture technique on infants in the pediatric emergency department. Acad Emerg Med 2017; 24:6. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/acem.13099/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/acem.13099/abstract</A>. Copyright © 2017 Society for Academic Emergency Medicine. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 111709 Version 1.0</div></div></div>"},"111710":{"type":"graphic_diagnosticimage","displayName":"Ultrasound technique for safe needle depth during LP","title":"Ultrasound technique for determining the safe needle depth during lumbar puncture in young infants","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Ultrasound technique for determining the safe needle depth during lumbar puncture in young infants</div><div class=\"cntnt\"><img style=\"width:579px; height:730px;\" src=\"images/EM/111710_US_tech_safe_needle_dpth_LP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurements performed on patients in the UALP group.<br />(A) The conus medullaris at the T12–L2 spinal level is identified.<br />(B) The probe is advanced caudally, and a measurement of the maximum safe depth is taken from the skin to the anterior border of the dural sac at the L3–4 interspace.<br />(C) The maximum safe depth is marked on a spinal needle with a caliper.</div><div class=\"graphic_reference\">From: Gorn M, Kunkov S, Crain EF. Prospective investigation of a novel ultrasound-assisted lumbar puncture technique on infants in the pediatric emergency department. Acad Emerg Med 2017; 24:6. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/acem.13099/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/acem.13099/abstract</A>. Copyright © 2017 Society for Academic Emergency Medicine. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 111710 Version 1.0</div></div></div>"},"111712":{"type":"graphic_table","displayName":"Causes of elevated procalcitonin","title":"Examples of possible causes of elevated serum procalcitonin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of possible causes of elevated serum procalcitonin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Severe localized or systemic bacterial infection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Bacterial pneumonia </li> <li>Bacterial sepsis </li> <li>Bacterial meningitis </li> <li>Bacterial peritonitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Other infections</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Malaria </li> <li>Certain fungal infections (candidiasis, aspergillosis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Severe physiologic stress (even in the absence of sepsis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Major cardiothoracic or abdominal surgery </li> <li>Cardiogenic shock </li> <li>Bowel ischemia </li> <li>Mechanical trauma </li> <li>Severe burns </li> <li>Acute multiorgan failure </li> <li>Heat stroke </li> <li>Pancreatitis </li> <li>Untreated end-stage renal disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Malignancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Medullary thyroid cancer </li> <li>Non-small cell lung cancer </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Immunoassay test interference</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Monoclonal and polyclonal antibody drugs </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Tulek B, Koylu H, Kanat F, et al. Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients. Contemp Oncol (Pozn) 2013; 17:68.</li>&#xD;&#xA;    <li>Foushee J, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother 2012; 67:2560.</li>&#xD;&#xA;    <li>Gavela T, Cabeza B, Serrano A, Casado-Flores J. C-reactive protein and procalcitonin are predictors of the severity of acute appendicitis in children. Pediatr Emerg Care 2012; 28:416.</li>&#xD;&#xA;    <li>Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48:2325.</li>&#xD;&#xA;    <li>Walter MA, Meier C, Radimerski T, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer 2010; 116:31.</li>&#xD;&#xA;    <li>Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36:941.</li>&#xD;&#xA;    <li>Sitter T, Schmidt M, Schneider S, Schiffl H. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002; 15:297.</li>&#xD;&#xA;    <li>Wanner GA, Keel M, Steckholzer U, et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000; 28:950.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 111712 Version 1.0</div></div></div>"},"111721":{"type":"graphic_figure","displayName":"Example of an emergency pre-intubation checklist","title":"Example of an emergency pre-intubation checklist","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Example of an emergency pre-intubation checklist</div><div class=\"cntnt\"><img style=\"width:598px; height:736px;\" src=\"images/EM/111721_Exmpl_emrgcy_pr-intbn_chklt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RN: registered nurse; ORL: otorhinolaryngology; IVF: intravenous fluid; C-spine: cervical spine; NRB: non-rebreather bag; ETTs: endotracheal tubes; RSI: rapid sequence intubation; ETCO<SUB>2</SUB>: end-tidal carbon dioxide.</div><div class=\"graphic_reference\">Developed by Matthew Eisenberg, MD, and members of the Division of Emergency Medicine, Children's Hospital, Boston, Massachusetts, USA. </div><div id=\"graphicVersion\">Graphic 111721 Version 1.0</div></div></div>"},"111732":{"type":"graphic_algorithm","displayName":"Approach to management of nonpurulent cellulitis in adults","title":"Clinical approach to management of nonpurulent cellulitis in adults","html":"<div class=\"graphic\"><div style=\"width: 1563px\" class=\"figure\"><div class=\"ttl\">Clinical approach to management of nonpurulent cellulitis in adults</div><div class=\"cntnt\"><img style=\"width:1543px; height:847px;\" src=\"images/ID/111732_Appr_npurlnt_cllts_adlt_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines our approach to initial empiric antibiotic therapy of patients with cellulitis or erisypelas without an abscess or purulent drainage. It includes various appropriate antibiotic options depending on the patient presentation. The choice among them further depends on factors such as patient allergies or medication intolerance, expected toxicities or drug interactions, physician familiarity with the different antibiotics, expected local rates of resistance, cost, and convenience of administration.</div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; MSSA: methicillin-susceptible <EM>S. aureus</EM>; IV: intravenously.<br />* The decision to administer antimicrobial therapy parenterally should be individualized based on clinical presentation and patient characteristics. Parenteral antimicrobial therapy is generally appropriate when severe illness or any of these features is present. Comorbidities that increase the risk of severe or complicated infection, such as the presence of an immunocompromising condition (eg, neutropenia, recent organ transplant, advanced HIV infection, B cell or T cell deficiency, or use of immunosuppressive agents), should lower the threshold for parenteral therapy.<br />¶ Five days of antibiotic therapy is generally sufficient; extension up to 14 days may be warranted for slow response to therapy.<br />Δ Intravenous antibiotic dosing as follows (if two doses are listed for a given agent, the higher one is for patients with higher weights [eg, &gt;120 kg] or more severe illness): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Cefazolin 1 to 2 g IV every 8 hours.</LI>&#xD;&#xA;<LI>Ceftriaxone 1 to 2 g IV every 24 hours.</LI>&#xD;&#xA;<LI>Ciprofloxacin 400 mg IV every 12 hours.</LI>&#xD;&#xA;<LI>Clindamycin 600 to 900 mg IV every 8 hours.</LI>&#xD;&#xA;<LI>Daptomycin 4 to 6 mg/kg IV every 24 hours.</LI>&#xD;&#xA;<LI>Flucloxacillin 2 g IV every 6 hours.</LI>&#xD;&#xA;<LI>Nafcillin 2 g IV every 4 hours.</LI>&#xD;&#xA;<LI>Oxacillin 2 g IV every 4 hours.</LI>&#xD;&#xA;<LI>Vancomycin 15 to 20 mg/kg/dose IV every 8 to 12 hours (not to exceed 2 g per dose). &#xD;&#xA;<UL>&#xD;&#xA;<LI>A one-time 25 mg/kg loading dose is appropriate for severely ill patients.</LI>&#xD;&#xA;<LI>A target trough level of 15 to 20 mcg/mL is appropriate in patients with severe and deep-seated infections.</LI>&#xD;&#xA;<LI>A target trough of 10 to 15 mcg/mL is appropriate for non-severe infections.</LI></UL></LI></UL><FONT class=lozenge>◊</FONT> Oral antibiotic dosing as follows (if two doses are listed for a given agent, the higher one is for patients with higher weights [eg, &gt;120 kg] or more severe illness): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Amoxicillin 875 mg orally twice daily.</LI>&#xD;&#xA;<LI>Cefadroxil 1 g orally daily.</LI>&#xD;&#xA;<LI>Cephalexin 500 mg orally four times daily.</LI>&#xD;&#xA;<LI>Clindamycin 300 to 450 mg orally four times daily.</LI>&#xD;&#xA;<LI>Dicloxacillin 500 mg orally four times daily.</LI>&#xD;&#xA;<LI>Doxycycline 100 mg orally twice daily.</LI>&#xD;&#xA;<LI>Flucloxacillin 500 mg orally four times daily.</LI>&#xD;&#xA;<LI>Minocycline 200 mg orally once, then 100 mg orally every 12 hours.</LI>&#xD;&#xA;<LI>Penicillin V potassium 500 mg orally every 6 hours.</LI>&#xD;&#xA;<LI>Trimethoprim-sulfamethoxazole 1 to 2 double-strength tablets orally every 12 hours.</LI></UL>§ Penicillin and amoxicillin are preferred for erysipelas. For patients with a penicillin allergy, cephalexin (depending on the allergy) and clindamycin are alternatives. Linezolid is another alternative but should be reserved for circumstances in which the other options cannot be used.<br />¥ Risk factors for MRSA include: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Recent (eg, within the prior one to two months) hospitalization or surgery.</LI>&#xD;&#xA;<LI>Residence in a long-term care facility.</LI>&#xD;&#xA;<LI>Hemodialysis.</LI>&#xD;&#xA;<LI>HIV infection.</LI></UL>‡ For oral treatment of beta-hemolytic <EM>Streptococcus</EM> and MRSA, we generally favor trimethoprim-sulfamethoxazole, doxycycline, or minocycline because of the greater associated risk of <EM>Clostridium difficile</EM> infection with clindamycin. However, trimethoprim-sulfamethoxazole, doxycycline, and minocycline do not have good antistreptococcal activity and so are administered with amoxicillin. Other active options include linezolid, tedizolid, and delafloxacin, but these should be reserved for circumstances in which the other options cannot be used.<br />† Vancomycin is the preferred parenteral anti-MRSA option. Daptomycin is an acceptable alternative agent for patients who have prior infection or colonization with a MRSA isolate with a minimum inhibitory concentration ≥2, do not respond to vancomycin, have prior treatment failure with vancomycin, or do not tolerate vancomycin. Additional alternative anti-MRSA agents include ceftaroline, linezolid, tedizolid, delafloxacin, telavancin, dalbavancin, and oritavancin; use of these agents is limited by high cost and, in some cases, availability. Refer to the UpToDate topic on the treatment of skin and soft tissue infection due to MRSA for further discussion of the approach to antibiotic selection.</div><div id=\"graphicVersion\">Graphic 111732 Version 2.0</div></div></div>"},"111737":{"type":"graphic_algorithm","displayName":"Treatment of metastatic urothelial carcinoma","title":"Treatment of metastatic urothelial carcinoma*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of metastatic urothelial carcinoma*</div><div class=\"cntnt\"><img style=\"width:372px; height:412px;\" src=\"images/ONC/111737_Trtmnt_mtsttc_urothelial_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PD: progressive disease; GC: gemcitabine cisplatin; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; PGC: paclitaxel, gemcitabine, and cisplatin.<br />* Inclusion in a formal clinical trial should be considered whenever feasible.<br />¶ Creatinine clearance &lt;60 mL/min is not a contraindication to cisplatin chemotherapy if renal function is due to tumor obstruction and can be reversed.<br />Δ Possible regimens include GC, MVAC, dose-dense MVAC, and PGC.<br /><FONT class=lozenge>◊</FONT> Single-agent chemotherapy is an alternative.<br />§ Agents approved for this indication include nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab.\u2028<br />¥ Examples of possible regimens include gemcitabine carboplatin,\u2028 paclitaxel gemcitabine, or docetaxel gemcitabine.<br />‡ Pembrolizumab and atezolizumab are approved for this indication.</div><div id=\"graphicVersion\">Graphic 111737 Version 2.0</div></div></div>"},"111740":{"type":"graphic_table","displayName":"Clinical features of seizures, syncope, and other parox events","title":"Clinical features of seizures, syncope, and other paroxysmal neurologic events in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of seizures, syncope, and other paroxysmal neurologic events in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Recall of the event</td> <td class=\"subtitle1\">Diagnostic tools</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Focal seizure</strong></td> <td>Initial symptoms depend on location in brain; motor and visual symptoms usually \"positive\" (eg, shaking, jerking, flashing lights or visual distortion); may have anatomic \"march\" over seconds; some progress rapidly to GTC</td> <td>Usually &#60;2 minutes; can be difficult to distinguish ictal from postictal phase</td> <td>Variable depending on whether consciousness is impaired</td> <td>EEG may show interictal spikes (poor sensitivity); ambulatory EEG if episodes are frequent enough; MRI may show structural lesion</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Generalized seizure</strong></td> <td>Sudden alteration or loss of consciousness without warning; some have myoclonic jerks or staring; tongue biting and urinary incontinence may occur (for GTC)</td> <td>&#60;5 minutes (for GTC); &#60;1 minute for absence</td> <td>Complete amnesia; patient may recall initial focal symptoms</td> <td>EEG may show generalized spike-and-wave characteristic of specific syndrome; MRI usually normal for generalized epilepsy syndromes, may show structural lesion if focal onset</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Psychogenic nonepileptic seizure</strong>&nbsp;</td> <td>Fluctuating, asynchronous motor activity, often with eye closure, side-to-side head or body movements, pelvic thrusting; most occur in front of a witness; fully or partially alert despite bilateral motor activity; tongue biting is rare&nbsp;</td> <td>Rarely &#60;1 minute; often prolonged (&#62;30 min)&nbsp;</td> <td>Variable&nbsp;</td> <td>Video-EEG monitoring</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Syncope</strong></td> <td>Transient loss of consciousness resulting in loss of postural tone; prodrome of lightheadedness, warm or cold feeing, sweating, palpitations, pallor; myoclonic jerks or tonic posturing may occur, especially if patient is kept upright; no or minimal post-event confusion</td> <td>1 to 2 minutes</td> <td>Patient can recall prodromal symptoms, if present; lack of warning may suggest cardiac source</td> <td>ECG; echocardiography if structural cardiac disease is suspected; ambulatory ECG monitoring if arrhythmia is suspected; orthostatic blood pressure measurements</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Transient ischemic attack</strong></td> <td>Rapid loss of neurologic function due to interrupted blood flow; symptoms depend on vascular territory but are typically \"negative\" (eg, weakness, numbness, aphasia, visual loss); intensity is usually maximal at onset; consciousness usually preserved</td> <td>Several minutes to a few hours</td> <td>Usually complete unless language areas involved</td> <td>MRI/MRA, CTA, vascular risk factors</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Migraine aura</strong></td> <td>Positive and/or negative neurologic symptoms, most often visual and sensory, evolving gradually over &#8805;5 min (slower onset than TIA or focal seizure); slow spread of positive followed by negative symptoms, if present, is very characteristic; usually followed by headache</td> <td>Up to 1 hour</td> <td>Complete</td> <td>Personal or family history of migraine</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Panic attack</strong></td> <td>Palpitations, dyspnea, chest pain, lightheadedness, sense of impending doom; associated hyperventilation may result in perioral and distal limb paresthesias</td> <td>Minutes to hours</td> <td>Complete</td> <td>History of anxiety or depressive symptoms, triggering events or stressors</td> </tr> <tr> <td><strong>Transient global amnesia</strong></td> <td>Prominent anterograde amnesia (inability to form new memories) and variable retrograde amnesia; patient is disoriented in time, asking repetitive questions; other cognitive and motor functions spared; rare in adults younger than 50 years</td> <td>1 to 10 hours (mean six hours)</td> <td>Complete amnesia for the main episode; retrograde amnesia resolves within 24 hours</td> <td>Clinical diagnosis; negative MRI and toxicology screens</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GTC: generalized tonic-clonic; LOC: loss of consciousness; EEG: electroencephalography; MRI: magnetic resonance imaging; MRA: magnetic resonance angiography; CTA: computed tomography angiography; ECG: electrocardiogram; TIA: transient ischemic attack.</div><div id=\"graphicVersion\">Graphic 111740 Version 1.0</div></div></div>"},"111747":{"type":"graphic_table","displayName":"Revised diagnostic criteria RTT","title":"Revised diagnostic criteria for Rett syndrome (RTT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised diagnostic criteria for Rett syndrome (RTT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Required criteria for typical or classic RTT</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>A period of regression followed by recovery or stabilization* </li> <li>All main criteria and all exclusion criteria </li> <li>Supportive criteria are not required, although often present in typical RTT </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Required criteria for atypical or variant RTT</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>A period of regression followed by recovery or stabilization* </li> <li>At least 2 out of the 4 main criteria </li> <li>5 out of 11 supportive criteria </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Main criteria</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Partial or complete loss of acquired purposeful hand skills </li> <li>Partial or complete loss of acquired spoken language<sup>&#182;</sup> </li> <li>Gait abnormalities: Impaired (dyspraxic) or absence of ability </li> <li>Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/rubbing automatisms </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Exclusion criteria for typical RTT</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe infection that causes neurological problems<sup>&#916;</sup> </li> <li>Grossly abnormal psychomotor development in first six months of life<sup>&#9674;</sup> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Supportive criteria for atypical RTT<sup>&#167;</sup></td> </tr> <tr> <td> <ol> <li>Breathing disturbances when awake </li> <li>Bruxism when awake </li> <li>Impaired sleep pattern </li> <li>Abnormal muscle tone </li> <li>Peripheral vasomotor disturbances </li> <li>Scoliosis/kyphosis </li> <li>Growth retardation </li> <li>Small cold hands and feet </li> <li>Inappropriate laughing/screaming spells </li> <li>Diminished response to pain </li> <li>Intense eye communication (eg, \"eye pointing\") </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Consider diagnosis when postnatal deceleration of head growth observed.</div><div class=\"graphic_footnotes\">* Because <em>MECP2</em> mutations are now identified in some individuals prior to any clear evidence of regression, the diagnosis of \"possible\" RTT should be given to those individuals under three years old who have not lost any skills but otherwise have clinical features suggestive of RTT. These individuals should be reassessed every 6 to 12 months for evidence of regression. If regression manifests, the diagnosis should then be changed to definite RTT. However, if the child does not show any evidence of regression by five years, the diagnosis of RTT should be questioned.<br />&para; Loss of acquired language is based on best acquired spoken language skill, not strictly on the acquisition of distinct words or higher language skills. Thus, an individual who had learned to babble but then loses this ability is considered to have a loss of acquired language.<br />&Delta; If an individual has or ever had a clinical feature listed it is counted as a supportive criterion. Many of these features have an age dependency, manifesting and becoming more predominant at certain ages. Therefore, the diagnosis of atypical RTT may be easier for older individuals than for younger. In the case of a younger individual (under five years old) who has a period of regression and &ge;2 main criteria but does not fulfill the requirement of 5/11 supportive criteria, the diagnosis of \"probably atypical RTT\" may be given. Individuals who fall into this category should be reassessed as they age and the diagnosis revised accordingly.<br /><span class=\"lozenge\">&loz;</span> There should be clear evidence (neurological or ophthalmological examination and MRI/CT) that the presumed insult directly resulted in neurological dysfunction.<br />&sect; Grossly abnormal to the point that normal milestones (acquiring head control, swallowing, developing social smile) are not met. Mild generalized hypotonia or other previously reported subtle developmental alterations during the first six months of life is common in RTT and do not constitute an exclusionary criterion.</div><div class=\"graphic_reference\">From: Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010; 68:944. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.22124/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/ana.22124/abstract</A>. Copyright © 2010 American Neurological Association. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 111747 Version 1.0</div></div></div>"},"111766":{"type":"graphic_table","displayName":"Modified Alvarado score for diagnosis of appendicitis","title":"Modified Alvarado score for diagnosis of appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Alvarado score for diagnosis of appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Point</td> </tr> <tr> <td>Migratory right lower quadrant pain</td> <td class=\"centered\">1</td> </tr> <tr> <td>Anorexia</td> <td class=\"centered\">1</td> </tr> <tr> <td>Nausea or vomiting</td> <td class=\"centered\">1</td> </tr> <tr> <td>Tenderness in the right lower quadrant</td> <td class=\"centered\">2</td> </tr> <tr> <td>Rebound tenderness in the right lower quadrant</td> <td class=\"centered\">1</td> </tr> <tr> <td>Fever &#62;37.5&#176;C (&#62;99.5&#176;F)</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td>Leukocytosis of white blood cell count &#62;10 x 10<sup>9</sup>/liter</td> <td class=\"centered\">2</td> </tr> <tr class=\"divider_top\"> <td><strong>Total</strong></td> <td class=\"centered\"><strong>9</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Score of 0 to 3 indicates appendicitis is unlikely and other diagnoses should be pursued. Score of &ge;4 indicates that the patient should be further evaluated for appendicitis.</div><div class=\"graphic_footnotes\">C: centigrade; F: fahrenheit.</div><div class=\"graphic_reference\">Modified from: Alvarado A. A practical score for the early diagnosis of acute appendicitis. Ann Emerg Med 1986; 15:557.</div><div id=\"graphicVersion\">Graphic 111766 Version 1.0</div></div></div>"},"111767":{"type":"graphic_algorithm","displayName":"Diagnostic evaluation of suspected appendicitis","title":"Algorithm: Diagnostic evaluation of suspected appendicitis","html":"<div class=\"graphic\"><div style=\"width: 1030px\" class=\"figure\"><div class=\"ttl\">Algorithm: Diagnostic evaluation of suspected appendicitis</div><div class=\"cntnt\"><img style=\"width:1010px; height:848px;\" src=\"images/SURG/111767_Dx_eval_suspect_appendiciti.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.<br />* Experienced clinicians may use clinical judgment in place of the Alvarado score.<br />¶ Imaging available in &lt;3 hours.<br />Δ Perform imaging if it becomes available during observation period.<br /><FONT class=lozenge>◊</FONT>&nbsp;Intravenous contrast and, if available, low radiation dose image acquisition protocols recommended. If readily available, MRI can substitute for CT in women &lt;30 years when gynecologic conditions are a diagnostic consideration.<br />§ Women of reproductive age should undergo laparoscopic exploration to look for other causes of abdominal pain. Appendectomy is performed at the time of laparoscopy. Most other patients can proceed with appendectomy directly without diagnostic laparoscopy.</div><div id=\"graphicVersion\">Graphic 111767 Version 2.0</div></div></div>"},"111768":{"type":"graphic_picture","displayName":"H syndrome clinical","title":"H syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">H syndrome</div><div class=\"cntnt\"><img style=\"width:444px; height:612px;\" src=\"images/DERM/111768_Hsyndromeclinical.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical presentation of a patient with H syndrome, with hyperpigmentation (inner aspects of the thighs and lower abdomen), and scrotal masses.</div><div class=\"graphic_reference\">From: Doviner V, Maly A, Ne'eman Z, et al. H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases. Am J Dermatopathol 2010; 32(2):118-28. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2010&amp;issue=04000&amp;article=00002&amp;type=abstract\" target=_blank>10.1097/DAD.0b013e3181b28572</A>. Copyright © 2010 International Society of Dermatopathology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111768 Version 2.0</div></div></div>"},"111769":{"type":"graphic_picture","displayName":"H syndrome histology","title":"Histopathologic features of H syndrome","html":"<div class=\"graphic\"><div style=\"width: 683px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of H syndrome</div><div class=\"cntnt\"><img style=\"width:663px; height:764px;\" src=\"images/DERM/111769_Hsyndromehistology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic features of the affected skin in H syndrome at scanning magnification. (A) Widespread fibrosis, moderate in the dermis and marked in the subcutis, noticeably widening the interlobular septae and (B) wiping out subcutaneous fat. H&amp;E stain, original magnification x25.</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">From: Doviner V, Maly A, Ne'eman Z, et al. H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases. Am J Dermatopathol 2010; 32(2):118-28. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2010&amp;issue=04000&amp;article=00002&amp;type=abstract\" target=_blank>10.1097/DAD.0b013e3181b28572</A>. Copyright © 2010 International Society of Dermatopathology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111769 Version 2.0</div></div></div>"},"111771":{"type":"graphic_diagnosticimage","displayName":"Mammary duct ectasia ultrasonography","title":"Mammary duct ectasia ultrasonography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammary duct ectasia ultrasonography</div><div class=\"cntnt\"><img style=\"width:427px; height:764px;\" src=\"images/PEDS/111771_Mammary_duct_ectasia_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ultrasound examination showing a 4.5 × 4.5 × 1 cm swelling in the subareolar tissue, with some prominent vessels.<br />(B) Ultrasound examination showing a 3 × 3 × 1 cm subcutaneous septated cyst in the subareolar tissue.</div><div class=\"graphic_reference\">Reproduced from: McHoney M, Munro F, MacKinlay G. Mammary duct ectasia in children: Report of a short series and review of the literature. Early Hum Dev 2011; 87:527. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111771 Version 1.0</div></div></div>"},"111772":{"type":"graphic_table","displayName":"Imaging modalities for diagnosis of appendicitis","title":"Imaging modalities for diagnosis of appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imaging modalities for diagnosis of appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>US</strong></td> <td>No ionizing radiation</td> <td>Lower diagnostic accuracy than CT or MRI</td> </tr> <tr> <td>Widely available, including at the bedside</td> <td>Patient- and operator-dependent variability in diagnostic performance</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>High rates of indeterminate exams with 50 to 85% of normal appendices not visualized<sup>[1,2]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>CT</strong></td> <td>High diagnostic accuracy</td> <td>Ionizing radiation</td> </tr> <tr class=\"divider_bottom\"> <td>Lowest rates of indeterminate exams with 80 to 90% of normal appendix visualized<sup>[3,4,5]</sup></td> <td>Intravenous iodinated contrast needed for optimum diagnostic performance</td> </tr> <tr> <td rowspan=\"3\"><strong>MRI</strong></td> <td>No ionizing radiation</td> <td>Limited availability</td> </tr> <tr> <td>High diagnostic accuracy</td> <td>Requires patient lie still in an enclosed scanner for 10 to 30 minutes</td> </tr> <tr> <td>Moderates rates of nondiagnostic exams with 20 to 30% normal appendices not visualized<sup>[6]</sup></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: ultrasound; CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Yabunaka K, Katsuda T, Sanada S, Fukutomi T. Sonographic appearance of the normal appendix in adults. J Ultrasound Med 2007; 26:37.</LI>&#xD;&#xA;<LI>Williams R, Shaw J. Ultrasound scanning in the diagnosis of acute appendicitis in pregnancy. Emerg Med J 2007; 24:359.</LI>&#xD;&#xA;<LI>Benjaminov O, Atri M, Hamilton P, Rappaport D. Frequency of visualization and thickness of normal appendix at nonenhanced helical CT. Radiology 2002; 225:400.</LI>&#xD;&#xA;<LI>Nikolaidis P, Hwang CM, Miller FH, Papanicolaou N. The nonvisualized appendix: incidence of acute appendicitis when secondary inflammatory changes are absent. AJR Am J Roentgenol 2004; 183:889.</LI>&#xD;&#xA;<LI>Johnson PT, Horton KM, Kawamoto S, et al. MDCT for suspected appendicitis: effect of reconstruction section thickness on diagnostic accuracy, rate of appendiceal visualization, and reader confidence using axial images. AJR Am J Roentgenol 2009; 192:893.</LI>&#xD;&#xA;<LI>Nikolaidis P, Hammond N, Marko J, et al. Incidence of visualization of the normal appendix on different MRI sequences. Emerg Radiol 2006; 12:223.</LI></OL></div><div id=\"graphicVersion\">Graphic 111772 Version 1.0</div></div></div>"},"111773":{"type":"graphic_table","displayName":"Other embryonal tumors","title":"World Health Organization (WHO) classification of other embryonal tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of other embryonal tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Other embryonal tumors</td> <td class=\"subtitle1\">Grade</td> </tr> <tr> <td>Embryonal tumor with multilayered rosettes, C19MC-altered</td> <td class=\"centered\">IV</td> </tr> <tr> <td>Embryonal tumor with multilayered rosettes, NOS</td> <td class=\"centered\">IV</td> </tr> <tr> <td>Medulloepithelioma</td> <td class=\"centered\">IV</td> </tr> <tr> <td>CNS neuroblastoma</td> <td class=\"centered\">IV</td> </tr> <tr> <td>CNS ganglioneuroblastoma</td> <td class=\"centered\">IV</td> </tr> <tr> <td>CNS embryonal tumor, NOS*</td> <td class=\"centered\">IV</td> </tr> <tr> <td>Atypical teratoid/rhabdoid tumor</td> <td class=\"centered\">IV</td> </tr> <tr> <td>CNS embryonal tumor with rhabdoid features</td> <td class=\"centered\">IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; NOS: not otherwise specified.<br />* Includes a subset of tumors previously called CNS primitive neuroectodermal tumor (PNET).</div><div class=\"graphic_reference\">Adapted from: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). WHO Classification of Tumours of the Central Nervous System (Revised 4th Edition), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 111773 Version 1.0</div></div></div>"},"111774":{"type":"graphic_table","displayName":"Mesenchymal non-meningothelial CNS tumors","title":"World Health Organization (WHO) classification of mesenchymal non-meningothelial CNS tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) classification of mesenchymal non-meningothelial CNS tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Mesenchymal, non-meningothelial tumors of the CNS</td> </tr> <tr> <td class=\"indent1\">Solitary fibrous tumor/hemangiopericytoma</td> </tr> <tr> <td class=\"indent1\">Hemangioblastoma</td> </tr> <tr> <td class=\"indent1\">Hemangioma</td> </tr> <tr> <td class=\"indent1\">Epithelioid hemangioendothelioma</td> </tr> <tr> <td class=\"indent1\">Angiosarcoma</td> </tr> <tr> <td class=\"indent1\">Kaposi sarcoma</td> </tr> <tr> <td class=\"indent1\">Ewing sarcoma/peripheral PNET</td> </tr> <tr> <td class=\"indent1\">Lipoma</td> </tr> <tr> <td class=\"indent1\">Angiolipoma</td> </tr> <tr> <td class=\"indent1\">Hibernoma</td> </tr> <tr> <td class=\"indent1\">Liposarcoma</td> </tr> <tr> <td class=\"indent1\">Desmoid-type fibromatosis</td> </tr> <tr> <td class=\"indent1\">Myofibroblastoma</td> </tr> <tr> <td class=\"indent1\">Inflammatory myofibroblastic tumor</td> </tr> <tr> <td class=\"indent1\">Benign fibrous histiocytoma</td> </tr> <tr> <td class=\"indent1\">Fibrosarcoma</td> </tr> <tr> <td class=\"indent1\">Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma</td> </tr> <tr> <td class=\"indent1\">Leiomyoma</td> </tr> <tr> <td class=\"indent1\">Leiomyosarcoma</td> </tr> <tr> <td class=\"indent1\">Rhabdomyoma</td> </tr> <tr> <td class=\"indent1\">Chondroma</td> </tr> <tr> <td class=\"indent1\">Chondrosarcoma</td> </tr> <tr> <td class=\"indent1\">Osteoma</td> </tr> <tr> <td class=\"indent1\">Osteochondroma</td> </tr> <tr> <td class=\"indent1\">Osteosarcoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; PNET: primitive neuroectodermal tumor.</div><div class=\"graphic_reference\">Adapted from: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). WHO Classification of Tumours of the Central Nervous System (Revised 4th Edition), IARC, Lyon 2016.</div><div id=\"graphicVersion\">Graphic 111774 Version 1.0</div></div></div>"},"111776":{"type":"graphic_table","displayName":"Estimated runner fluid needs per aid station by race distance ","title":"Estimated runner fluid needs per aid station based on race distance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated runner fluid needs per&nbsp;aid station based on race distance</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Race</td> <td class=\"subtitle1\">Fluid type</td> <td class=\"subtitle1\">Normal race conditions (number of on-course aid stations)</td> <td class=\"subtitle1\">Hot/humid conditions (number of on-course aid stations)</td> </tr> <tr class=\"divider_bottom\"> <td>5K</td> <td>Water</td> <td>120 to 240 mL, or 4 to 8 ounces (1 station)</td> <td>240 to 380 mL, or 8 to 12.5 ounces (1 station)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">10K</td> <td>Water</td> <td>120 to 240 mL (1 to 2 stations)</td> <td>240 to 380 mL (1 to 2 stations)</td> </tr> <tr class=\"divider_bottom\"> <td>Sports drink</td> <td>120 to 240 mL</td> <td>120 to 240 mL</td> </tr> <tr> <td rowspan=\"2\">Marathon</td> <td>Water</td> <td>120 to 240 mL (8 to 14 stations)</td> <td>240 to 380 mL (8 to 14 stations)</td> </tr> <tr> <td>Sports drink</td> <td>120 to 240 mL</td> <td>120 to 240 mL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">At each on-course aid station, one 210 to 300 mL cup should be available for each participant. At the start and finish area aid stations, twice the number of cups and twice the volume of fluid should be available.</div><div id=\"graphicVersion\">Graphic 111776 Version 1.0</div></div></div>"},"111779":{"type":"graphic_table","displayName":"Perioperative uses and doses of intravenous opioid agents","title":"Perioperative uses and doses of intravenous opioid agents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative uses and doses of intravenous opioid agents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Induction of general anesthesia</td> <td class=\"subtitle1\">Maintenance of general anesthesia</td> <td class=\"subtitle1\">Monitored anesthesia care (MAC)</td> <td class=\"subtitle1\">Comments</td> <td class=\"subtitle1\">Management of acute postoperative pain</td> </tr> <tr> <td>Fentanyl</td> <td> <p>Bolus dose(s): 25 to 100 mcg or 0.5 to 1 mcg/kg; may be administered in divided doses.</p> High-dose opioid induction (ie, \"cardiac induction\"): 10 to 25 mcg/kg.</td> <td> <p>Bolus dose(s): 25 to 50 mcg as needed.</p> Maintenance infusion to supplement TIVA: 1 to 2 mcg/kg per hour.<sup>&#182;</sup></td> <td>Bolus doses: 25 to 50 mcg.</td> <td> <p>High-dose fentanyl is not commonly used for anesthetic induction, but may be selected for patients with severe myocardial dysfunction.</p> Continuous infusions are not commonly used if extubation is planned at the end of the procedure because emergence may be delayed due to a long context-sensitive half time.</td> <td>Bolus doses: 25 to 50 mcg every five minutes until patient is comfortable.</td> </tr> <tr> <td>Remifentanil</td> <td>Remifentanil intubation technique without an NMBA: 3 to 5 mcg/kg administered with an induction dose of propofol and ephedrine 10 mg.</td> <td>Maintenance infusion to supplement inhalation anesthesia or TIVA: 0.05 to 0.3 mcg/kg per minute.<br /> (Some clinicians administer a loading dose, typically 0.5 to 1 mcg/kg over 60 to 90 seconds.)</td> <td>Before placement of regional block: <ul> <li>90 seconds before: 1 mcg/kg. </li> <li>5 minutes before: 0.5 mcg/kg per minute. </li> </ul> Maintenance dose: Infusion at 0.05 to 0.3 mcg/kg per minute.</td> <td>A different opioid or another analgesic agent or technique should be initiated before the remifentanil infusion is discontinued to ensure adequate postoperative analgesia.</td> <td>&nbsp;</td> </tr> <tr> <td>Sufentanil</td> <td> <p>Bolus dose(s): <span style=\"color: black;\">0.05 to 0.1</span> mcg/kg in divided doses.</p> High-dose opioid induction (ie, \"cardiac induction\"): 1 to 3 mcg/kg.</td> <td> <p>Bolus dose(s): 5 to 100 mcg as needed.</p> Maintenance infusion to supplement TIVA: 0.5 to 1.5 mcg/kg per hour (or 0.008 to 0.025 mcg/kg per minute).</td> <td>&nbsp;</td> <td>Infusion is typically discontinued 30 to 45 minutes prior to end of surgery for a predictable decline in concentration.</td> <td>&nbsp;</td> </tr> <tr> <td>Alfentanil</td> <td> <p>Bolus dose(s): 500 mcg or 50 to 100 mcg/kg; administered in divided doses.</p> Maintenance: 0.5 to 1.5 mcg/kg per minute.</td> <td> <p>Bolus dose(s): 500 mcg as needed.</p> Maintenance infusion to supplement TIVA: 0.5 to 1.5 mcg/kg per minute.</td> <td>&nbsp;</td> <td>Infusion is typically discontinued 30 to 45 minutes prior to end of surgery for a predictable decline in concentration.</td> <td>&nbsp;</td> </tr> <tr> <td>Hydromorphone</td> <td>&nbsp;</td> <td>Bolus doses: 0.2 to 0.5 mg as needed.</td> <td>&nbsp;</td> <td>It is ideal to use hydromorphone towards the end of surgery (rather than during surgery) in order to provide pain relief in the PACU and beyond.</td> <td> <p>Initial bolus doses of 0.2 to 0.5 mg every five minutes until pain is relieved or unwanted side effects become evident.</p> After initial pain control, typical doses are 0.2 to 0.5 mg every three to four hours.</td> </tr> <tr> <td>Morphine</td> <td>&nbsp;</td> <td>Bolus doses: 1 to 2 mg as needed.</td> <td>&nbsp;</td> <td>It is ideal to use morphine towards the end of surgery (rather than during surgery) in order to provide pain relief in the PACU and beyond. The recommended dose at the end of surgery is 0.1 to 0.2 mg/kg IBW about 20 minutes prior to the expected time of extubation.</td> <td> <p>Initial bolus doses of 1 to 3 mg every five minutes until pain is relieved or unwanted side effects become evident.</p> After initial pain control, typical doses are 1 to 3 mg IV every three to four hours.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TIVA: total intravenous anesthesia; NMBA: neuromuscular blocking agents; PACU: post-anesthesia care unit; IBW: ideal body weight; IV: intravenous.<br />* Opioids are used as adjuvant agents during induction and maintenance of general anesthesia and during monitored anesthesia care (MAC).<br />&para; Fentanyl infusion is not commonly used if extubation is planned at the end of the procedure.</div><div id=\"graphicVersion\">Graphic 111779 Version 3.0</div></div></div>"},"111780":{"type":"graphic_table","displayName":"Pharmacokinetics for IV opioids in the perioperative setting","title":"Pharmacokinetics for IV opioids used in the perioperative setting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics for IV opioids used in the perioperative setting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Speed of onset (minutes)</td> <td class=\"subtitle1\">Context-sensitive half time*</td> <td class=\"subtitle1\">Duration of action and elimination half life</td> <td class=\"subtitle1\">Metabolism and clearance</td> <td class=\"subtitle1\">Drug-drug interactions</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Fentanyl</td> <td>Phenylpiperidine opioid</td> <td>4 to 6 minutes</td> <td>May be prolonged and continues to increase as duration of infusion increases (for example, after infusion for 200 minutes, approximately 200 more minutes are necessary to achieve a 50% decrease in effect site concentration).</td> <td> <p>Duration of action (after a bolus dose): 30 to 45 minutes.</p> Elimination half life: 3 to 6 hours.</td> <td> <p>Metabolized in liver by cytochrome CYP3A4 to norfentanyl (an inactive metabolite).</p> Metabolite excreted by kidney with clearance 8 mL/kg per minute.</td> <td> <p>Synergistic effects if coadministered with other anesthetic agents.</p> <p>Caution with coadministered serotonergic agents due to increased risk of serotonin syndrome.</p> Caution with CYP3A4 inhibitors (eg, diltiazem, ritonavir, voriconazole), which may increase plasma levels of fentanyl.</td> <td> <p>Longest duration of action in the phenylpiperidine family.</p> Pharmacokinetics unaffected by renal or hepatic insufficiency.</td> </tr> <tr class=\"divider_bottom\"> <td>Remifentanil</td> <td>Phenylpiperidine opioid</td> <td>1 to 2 minutes</td> <td> <p>Approximately 5 minutes.</p> Duration of action is not affected by duration of infusion.</td> <td> <p>Duration of action: 3 to 10 minutes.</p> Elimination half life: 10 to 20 minutes.</td> <td> <p>Metabolized by nonspecific esterases in plasma, red blood cells, and interstitial tissue to remifentanil acid (an inactive metabolite).</p> Metabolite excreted by kidney with clearance of 40 mL/kg per minute.</td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Fastest onset and shortest duration of action compared with other opioids.</p> <p>Higher incidence of hypotension compared with other opioids.</p> <p>Need for alternative analgesic agent or technique during emergence and the postoperative period if pain is anticipated.</p> In selected circumstances, may be used for a remifentanil intubation technique.</td> </tr> <tr class=\"divider_bottom\"> <td>Sufentanil</td> <td>Phenylpiperidine opioid</td> <td>3 to 5 minutes</td> <td>Context-sensitive half time plateaus at 30 to 45 minutes (shorter than fentanyl).</td> <td>Elimination half life: 2 to 4 hours.</td> <td> <p>Metabolized in liver and small intestines.</p> Metabolites excreted by kidney with renal clearance 12 mL/kg per minute.</td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Used for longer procedures when continuous opioid administration and a postoperative analgesic effect are desirable, and rapid emergence is not needed.</p> Likelihood of muscle and chest wall rigidity, particularly if administered rapidly or in high doses.</td> </tr> <tr class=\"divider_bottom\"> <td>Alfentanil</td> <td>Phenylpiperidine opioid</td> <td>1 to 3 minutes</td> <td>Context-sensitive half time plateaus at 30 to 45 minutes (shorter than fentanyl).</td> <td>Elimination half life: 1.5 to 2 hours.</td> <td> <p>Metabolized in liver by cytochrome CYP3A4 to noralfentanil (an inactive metabolite).</p> Excreted by kidney with renal clearance 5 mL/kg per minute.</td> <td> <p>Synergistic effects if coadministered with other anesthetic agents.</p> Similar to fentanyl, use caution with CYP3A4 inhibitors (eg, diltiazem, ritonavir, voriconazole), which may increase plasma levels of alfentanil.</td> <td> <p>Avoided in patients with risk factors for seizures due to focal activation of the cerebral cortex in susceptible patients.</p> Hepatic metabolism less predictable compared with fentanyl due to inter-individual variability in activity of hepatic CYP3A4.</td> </tr> <tr class=\"divider_bottom\"> <td>Hydromorphone</td> <td>Semi-synthetic phenanthrene opioid</td> <td>Within 10 minutes</td> <td>N/A</td> <td> <p>Duration of action: 2.4 hours.</p> Elimination half life: 2.3 hours.</td> <td> <p>Metabolized in liver to glucuronide metabolites.</p> Hydromorphone-3-glucoronide excreted by kidney; may accumulate with renal insufficiency.</td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Suitable for treatment of postoperative pain.</p> Caution with use in patients with renal insufficiency due to likely accumulation of hydromorphone-3-glucoronide, which causes neuroexcitation that may result in myoclonus or exacerbation of seizures.</td> </tr> <tr> <td>Morphine</td> <td>Phenanthrene opioid</td> <td>Within 20 minutes</td> <td>N/A</td> <td> <p>Duration of action: 4 to 6 hours (but up to 7 hours for active morphine-6-glucuronide metabolite).</p> Elimination half life: 2 to 3 hours, but 7 hours for active metabolite.</td> <td> <p>Metabolized in liver to glucuronide metabolites (morphine-6-glucoronide and morphine 3-glucoronide).</p> Morphine-6-glucoronide is an active metabolite and is excreted by kidney with renal clearance 2.2 mL/kg per minute; may accumulate with renal insufficiency.</td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Suitable for treatment of postoperative pain.</p> Unsuitable for use in patients with renal insufficiency due to likely accumulation of morphine-6-glucoronide, which produces ongoing analgesia, and possible neuroexcitation that may result in myoclonus or exacerbation of seizures.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N/A: not applicable.<br />* Context-sensitive half time is the time in minutes required for a 50% decrease in effect site concentration after the infusion is discontinued.</div><div id=\"graphicVersion\">Graphic 111780 Version 1.0</div></div></div>"},"111781":{"type":"graphic_diagnosticimage","displayName":"Popliteal vein thrombosis","title":"Popliteal vein thrombosis","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Popliteal vein thrombosis</div><div class=\"cntnt\"><img style=\"width:764px; height:600px;\" src=\"images/SURG/111781_Duplx_US_May-Thurner_syndrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cross-sectional B-mode&nbsp;venous ultrasound of the popliteal fossa (A) shows distended, noncompressible, and low-echogenic popliteal vein, all indicative of an acute DVT. A sagittal venous duplex (B) also shows low echogenicity and reduced flow in the popliteal vein. Swelling of the left lower extremity can be seen in the picture (C) of the patient in&nbsp;the prone position.</div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis.</div><div id=\"graphicVersion\">Graphic 111781 Version 1.0</div></div></div>"},"111782":{"type":"graphic_diagnosticimage","displayName":"Diagnosis May-Thurner syndrome","title":"Diagnosis May-Thurner syndrome","html":"<div class=\"graphic\"><div style=\"width: 689px\" class=\"figure\"><div class=\"ttl\">Diagnosis May-Thurner syndrome</div><div class=\"cntnt\"><img style=\"width:669px; height:764px;\" src=\"images/SURG/111782_Dx_May-Thurner_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance angiography demonstrates extrinsic compression of the left iliac vein by the right iliac artery in both axial (A) and sagittal (B,C) projections. In the axial view (A), note the normally enhanced iliac vein on the right anteromedial to the psoas muscle. </div><div id=\"graphicVersion\">Graphic 111782 Version 1.0</div></div></div>"},"111783":{"type":"graphic_diagnosticimage","displayName":"IVC filter prior to left iliac angioplasty","title":"IVC filter prior to left iliac angioplasty","html":"<div class=\"graphic\"><div style=\"width: 767px\" class=\"figure\"><div class=\"ttl\">IVC filter prior to left iliac angioplasty</div><div class=\"cntnt\"><img style=\"width:747px; height:718px;\" src=\"images/SURG/111783_IVC_May-Thurner_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior vena cava (IVC) venogram demonstrating patency and proper placement of retrievable IVC filter placed in a patient with May-Thurner syndrome prior to angioplasty and stenting.</div><div id=\"graphicVersion\">Graphic 111783 Version 1.0</div></div></div>"},"111784":{"type":"graphic_diagnosticimage","displayName":"Iliac vein thrombosis May-Thurner syndrome","title":"Iliac vein thrombosis May-Thurner syndrome","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Iliac vein thrombosis May-Thurner syndrome</div><div class=\"cntnt\"><img style=\"width:765px; height:470px;\" src=\"images/SURG/111784_Ilc_vn_thrmbss_MThrer_sndrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Venogram demonstrating acute deep vein thrombosis of left iliac vein. This patient was shown to have severe stenosis of left common iliac vein using IVUS. It is common to miss venous stenosis on venogram if relying on only one projection of venography.<br />(B) Prior to thrombolysis, a temporary inferior vena cava filter was placed.</div><div class=\"graphic_footnotes\">IVUS: intravascular ultrasound.</div><div id=\"graphicVersion\">Graphic 111784 Version 1.0</div></div></div>"},"111785":{"type":"graphic_diagnosticimage","displayName":"Classic presentation and treatment of May-Thurner syndrome","title":"Classic presentation and treatment of May-Thurner syndrome","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Classic presentation and treatment of May-Thurner syndrome</div><div class=\"cntnt\"><img style=\"width:763px; height:694px;\" src=\"images/SURG/111785_Prsnttn_trtmnt_May-Thrnr_sy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This female in her twenties presented with extensive acute left lower extremity swelling and tenderness.<br />(A) Extensive left iliofemoral DVT was diagnosed on venous duplex ultrasound and confirmed on venography. After 36 hours of thrombolytic therapy, the culprit lesion of the left iliac vein was revealed (arrow).<br />(B) An IVUS catheter (0.035 system) was used to evaluate the ongoing response to lytic therapy.<br />(C) Angioplasty and stenting of stenosed left iliac vein was performed using a self-expanding stent with full resolution on completion venogram (arrow).</div><div class=\"graphic_footnotes\">DVT: deep vein thrombosis; IVUS: intravascular ultrasound.</div><div id=\"graphicVersion\">Graphic 111785 Version 1.0</div></div></div>"},"111786":{"type":"graphic_diagnosticimage","displayName":"May-Thurner syndrome in a child","title":"May-Thurner syndrome in a child","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">May-Thurner syndrome in a child</div><div class=\"cntnt\"><img style=\"width:765px; height:539px;\" src=\"images/SURG/111786_May-Thurner_syndrome_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The venogram shows an acute thrombosis of left iliac vein (prone positioning).<br />(B) Following thrombolysis, venography shows resolution of the thrombus on the left (supine positioning) but with a residual 20% stenosis. Because of the child's age, stenting was not pursued.</div><div id=\"graphicVersion\">Graphic 111786 Version 1.0</div></div></div>"},"111787":{"type":"graphic_diagnosticimage","displayName":"Thrombolysis at 24 and 36 hours","title":"Thrombolysis at 24 and 36 hours","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Thrombolysis at 24 and 36 hours</div><div class=\"cntnt\"><img style=\"width:765px; height:503px;\" src=\"images/SURG/111787_Thrombolysis_24_36_hours.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Venogram at 24 hours showing significant, but still incomplete, resolution of the deep vein thrombosis.<br />(B) At 36 hours, the venogram shows less than 20% residual stenosis of the common iliac system.</div><div id=\"graphicVersion\">Graphic 111787 Version 1.0</div></div></div>"},"111788":{"type":"graphic_diagnosticimage","displayName":"Iliac vein compression following EVAR","title":"Iliac vein compression following EVAR","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Iliac vein compression following EVAR</div><div class=\"cntnt\"><img style=\"width:760px; height:499px;\" src=\"images/SURG/111788_Iliac_vn_compr_fllwing_EVAR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presented with acute left lower extremity swelling following endovascular aneurysm repair. The venogram (prone positioning) showed extensive DVT of left iliac (A) and femoral (B) veins from external compression of left iliac vein by the aortic stent-graft. The patient was treated successfully with thrombolysis and stenting of both left common and external iliac veins (C).</div><div class=\"graphic_footnotes\">EVAR: endovascular aneurysm repair; DVT: deep vein thrombosis.</div><div id=\"graphicVersion\">Graphic 111788 Version 1.0</div></div></div>"},"111789":{"type":"graphic_table","displayName":"Simon Broome Familial Hypercholesterolemia Register for FH","title":"Simon Broome Familial Hypercholesterolemia Register diagnostic criteria for familial hypercholesterolemia<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simon Broome Familial Hypercholesterolemia Register diagnostic criteria for familial hypercholesterolemia<SUP>[1-3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\"><em>a</em></td> <td>Total cholesterol concentration above 7.5 mmol/liter (290 mg/dL) in adults or a total cholesterol concentration above 6.7 mmol/liter (259 mg/dL)&nbsp;in children aged less than 16 years, or</td> </tr> <tr> <td>Low density lipoprotein cholesterol concentration above 4.9&nbsp;mmol/liter&nbsp;(189 mg/dL) in adults or above 4.0 mmol/liter (155 mg/dL) in children</td> </tr> <tr> <td class=\"centered\"><em>b</em></td> <td>Tendinous xanthomata in the patient or a first-degree relative</td> </tr> <tr> <td class=\"centered\"><em>c</em></td> <td>DNA-based evidence of mutation in the <em>LDLR, PCSK9,</em>&nbsp;or <em>APOB</em> gene</td> </tr> <tr> <td class=\"centered\"><em>d</em></td> <td>Family history of myocardial infarction before age 50 years in a second-degree relative or before age 60 years in a first-degree relative</td> </tr> <tr> <td class=\"centered\"><em>e</em></td> <td>Family history of raised total cholesterol concentration above 7.5 mmol/liter (290 mg/dL) in a first- or second-degree relative</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A \"definite\" FH diagnosis requires either criteria <EM>a</EM> and <EM>b</EM>, or criterion <EM>c</EM>. A \"probable\" FH diagnosis requires either criteria <EM>a</EM> and <EM>d</EM>, or criteria <EM>a</EM> and <EM>e</EM>.</div><div class=\"graphic_footnotes\">FH: familial hypercholesterolemia.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303:893.</LI>&#xD;&#xA;<LI>Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142:105.</LI>&#xD;&#xA;<LI>National Collaborating Centre for Primary Care (UK). Identification and Management of Familial Hypercholesterolaemia (FH) [Internet]. London: Royal College of General Practitioners (UK); 2008 Aug. (NICE Clinical Guidelines, No. 71.) Appendix F, Simon Broome Diagnostic criteria for index individuals and relatives.&nbsp;Available from: https://www.ncbi.nlm.nih.gov/books/NBK53810/ </LI></OL>Reproduced from: Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160(5):407-420, by permission of Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 111789 Version 4.0</div></div></div>"},"111793":{"type":"graphic_table","displayName":"Selection criteria for uterus transplant recipient and donor","title":"Selection criteria for uterus transplant recipient and donor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection criteria for uterus transplant recipient and donor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Recipient</td> <td class=\"subtitle1\">Donor</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age</strong></td> <td>38 years or younger</td> <td>Less than 60 years</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Body mass index (kg/m<sup>2</sup>)</strong></td> <td>20 to 29</td> <td>20 to 29</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Medication</strong></td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Menopause status</strong></td> <td>Premenopausal</td> <td>No more than seven years postmenopause</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">History</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"6\">Medical</td> <td>No prior malignancy</td> <td>No prior malignancy</td> </tr> <tr> <td>No hypertension or cardiovascular disease</td> <td>No hypertension or cardiovascular disease</td> </tr> <tr> <td>No diabetes</td> <td>No diabetes</td> </tr> <tr> <td>No lung disease (including asthma and COPD)</td> <td>No lung disease (including asthma and COPD)</td> </tr> <tr> <td>No thromboembolic disorders</td> <td>No thromboembolic disorders</td> </tr> <tr class=\"divider_bottom\"> <td>Normal renal function</td> <td>Normal bilateral kidneys (not pelvic)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Psychiatric</td> <td>No prior hospitalization for psychiatric illness</td> <td>No prior hospitalization for psychiatric illness</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gynecologic</td> <td>No history of human papillomavirus infection</td> <td>No history of human papillomavirus infection</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Uterus</td> <td>Absent (congenital or surgical)</td> <td>No present or past lesions, except myoma can be present if &#60;2 cm*</td> </tr> <tr class=\"divider_bottom\"> <td>Present, but clear absolute uterine factor infertility<sup>&#182;</sup></td> <td>Present, but clear absolute uterine factor infertility<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Vagina</td> <td>Vaginal length &#62;7 cm</td> <td class=\"divider_bottom\" rowspan=\"2\">N/A</td> </tr> <tr class=\"divider_bottom\"> <td>No intestinal neovagina</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ovaries</td> <td>N/A</td> <td>N/A</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Obstetric history</td> <td class=\"divider_bottom\" rowspan=\"4\">N/A</td> <td>At least one prior normal term delivery</td> </tr> <tr> <td>No more than one prior cesarean delivery (through the lower uterine segment)</td> </tr> <tr> <td>No prior preterm deliveries</td> </tr> <tr class=\"divider_bottom\"> <td>No prior preeclampsia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Surgical history</td> <td>No prior major intra-abdominal surgery</td> <td>No prior major intra-abdominal surgery<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Substance use</td> <td>Non-smoker</td> <td>Non-smoker</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Relationship status</td> <td>Stable partnership &#62;2 years' duration</td> <td>N/A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Tests</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Blood group</td> <td>Compatibility with donor</td> <td>Compatibility with recipient</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Human leukocyte antigen</td> <td>Reasonable match with donor</td> <td>Reasonable match with recipient</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Laboratory blood tests (complete blood count, metabolic panel, coagulation studies)</td> <td>Normal</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Human immunodeficiency virus</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Human T-lymphotrophic virus polymerase-chain reaction testing for pro-viral DNA</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatitis B and C testing</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Syphilis</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chlamydia</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gonorrhea</td> <td>Negative</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cervical cytology</td> <td>N/A</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Human papillomavirus high-risk DNA testing</td> <td>Negative</td> <td>Negative</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Imaging</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Renal ultrasound</td> <td>Non-pelvic kidneys</td> <td>Normal bilateral, non-pelvic kidneys</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Abdominal-pelvic magnetic resonance imaging</td> <td>Normal</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chest radiograph</td> <td>Normal</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Electrocardiography</td> <td>Normal</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Exercise electrocardiography</td> <td>N/A</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Angiography of uterus</td> <td>N/A</td> <td>Uterine artery diameter &#62;2 mm at level of lower uterine segment</td> </tr> <tr> <td class=\"indent1\">In vitro fertilization</td> <td>Greater than eight normal embryos cryopreserved</td> <td>N/A</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; N/A: not applicable.<br />* Includes adenomyosis, polyps, dysplasia, or conization.<br />¶ Examples include hypoplastic uterus, major uterine malformation, or severe intrauterine adhesions.<br />Δ Excludes cesarean delivery.</div><div id=\"graphicVersion\">Graphic 111793 Version 1.0</div></div></div>"},"111794":{"type":"graphic_figure","displayName":"Extravesical VUR repair","title":"Extravesical repair for vesicoureteral reflux","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Extravesical repair for vesicoureteral reflux</div><div class=\"cntnt\"><img style=\"width:801px; height:519px;\" src=\"images/PEDS/111794_Extravesical_VUR_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Composite drawing demonstrating sequential steps required for extravesical repair for vesicoureteral reflux. <br /><br />(A) Bladder mucosa is elevated off bladder wall muscle and vest-type sutures are placed.<br />(B) Sagittal section shows suture passing between undermined mucosa and detrusor.<br />(C) Alignment of vest sutures after placement.<br />(D) Sagittal section demonstrates appropriate positioning of sutures.<br />(E) Tying vest sutures advances and anchors ureter onto trigone.<br />(F) Sagittal section of ureteromeatal advancement (arrow reflects advancement of distal ureter within the detrusor tunnel).<br />(G) Closure of detrusor flaps over ureter allows for long submucosal tunnel and completes detrusorrhaphy.</div><div class=\"graphic_reference\">Reproduced with permission from: Zoontz MR, Long CJ. Vesicoureteral Reflux. In: Glenn's Urologic Surgery, 8th ed, Graham SD, Keane TE (Eds), Wolters Kluwer, Philadelphia 2016. Copyright © 2016 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 111794 Version 1.0</div></div></div>"},"111795":{"type":"graphic_picture","displayName":"Bullous systemic lupus erythematosus","title":"Bullous systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Bullous systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/111795_Blls_systmc_lps_erythmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blisters, erosions, and crusting in sites of erythematous skin.</div><div id=\"graphicVersion\">Graphic 111795 Version 1.0</div></div></div>"},"111796":{"type":"graphic_picture","displayName":"Bullous systemic lupus erythematosus in a child","title":"Bullous systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Bullous systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:756px; height:503px;\" src=\"images/DERM/111796_Blls_systmc_lps_eryth_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blistering and erythema on the leg of a child.</div><div id=\"graphicVersion\">Graphic 111796 Version 1.0</div></div></div>"},"111799":{"type":"graphic_picture","displayName":"Bullous systemic lupus erythematosus histopathology","title":"Bullous systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Bullous systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/111799_Blls_systmc_lps_eryth_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subepidermal blister formation in a patient with bullous systemic lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 111799 Version 1.0</div></div></div>"},"111800":{"type":"graphic_picture","displayName":"Bullous systemic lupus erythematosus histopathology 2","title":"Bullous systemic lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Bullous systemic lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/111800_Bll_systmc_lps_eryth_histo2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal detachment and multiple neutrophils at the dermoepidermal junction in a patient with bullous systemic lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 111800 Version 1.0</div></div></div>"},"111801":{"type":"graphic_picture","displayName":"Subacute cutaneous lupus erythematosus","title":"Subacute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Subacute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/DERM/111801_Subacut_lupus_erythematosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous macules with vesicles, erosions, and crusting in a patient with subacute cutaneous lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 111801 Version 1.0</div></div></div>"},"111802":{"type":"graphic_picture","displayName":"Toxic epidermal necrolysis-like acute cutaneous lupus","title":"Toxic epidermal necrolysis-like acute cutaneous lupus erythematous","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Toxic epidermal necrolysis-like acute cutaneous lupus erythematous</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/111802_Tox_epdrml_ncrlys_ctns_lps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive erythema and erosions.</div><div id=\"graphicVersion\">Graphic 111802 Version 1.0</div></div></div>"},"111803":{"type":"graphic_table","displayName":"Antihypertensive therapy for acute aortic syndromes in adults","title":"Antihypertensive therapy for acute aortic syndromes in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antihypertensive therapy for acute aortic syndromes in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Dose range</td> <td class=\"subtitle1\">Onset of action</td> <td class=\"subtitle1\">Duration of action</td> <td class=\"subtitle1\">Adverse effects*</td> <td class=\"subtitle1\">Role<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Anti-impulse therapy</td> </tr> <tr> <td class=\"indent1\">Esmolol*</td> <td>Beta<sub>1</sub>-selective adrenergic receptor blockade</td> <td> <p>250 to 500 mcg/kg IV loading dose over one minute, then initiate IV infusion at 25 to 50 mcg/kg per minute; titrate incrementally up to maximum of 300 mcg/kg per minute.</p> Prior to each upward dose titration, a re-bolus should be given.</td> <td>1 to 2 minutes.</td> <td>10 to 30 minutes.</td> <td> <p>Nausea, flushing, bronchospasm, bradycardia, first-degree heart block, infusion site pain; half-life prolonged in setting of anemia.</p> <p>Vesicant.</p> Infusion volume may be excessive; available concentrations include 10 mg/mL and 20 mg/mL (premixed).</td> <td> <p>Short half-life and ability to rapidly titrate to effect (ie, to assess reaction)&nbsp;are advantages in patients who may be intolerant of beta-blockade (eg, due to airway disease or heart failure).</p> <p>Rapidly cleared by red blood cell esterases (ie, clearance is not dependent on renal or hepatic function).</p> Avoid use in acute decompensated heart failure.</td> </tr> <tr> <td class=\"indent1\">Labetalol</td> <td>Selective blockade of postsynaptic alpha<sub>1</sub>-adrenergic and non-selective blockade for beta-adrenergic receptors</td> <td> <p>Initial bolus of 20 mg IV followed by 20 to 80 mg IV boluses every 10 minutes (maximum 300 mg)<br /> <strong>OR</strong><br /> 0.5 to 2 mg/minute as IV infusion following an initial 20 mg IV bolus (maximum 300 mg).</p> Infusion may be titrated to a maximum of 10 mg/minute.</td> <td>2 to 5 minutes.</td> <td>2 to 6 or more hours (dose dependent).</td> <td>Nausea/vomiting, paresthesias (eg, scalp tingling), bronchospasm, dizziness, nausea, bradycardia, first-degree heart block.</td> <td> <p>Combined alpha and beta-blockade may enable management with single agent.</p> <p>Avoid use in acute decompensated heart failure.</p> Use cautiously in obstructive or reactive airway.</td> </tr> <tr> <td class=\"indent1\">Metoprolol</td> <td>Beta<sub>1</sub>-selective adrenergic blockade</td> <td>Initially 2.5 to 15 mg IV followed by 2.5 to 15 mg IV every three to six hours.</td> <td>20 minutes.</td> <td>5 to 8 hours.</td> <td>Refer to \"Labetalol\" row above.</td> <td>Avoid use in acute decompensated heart failure.</td> </tr> <tr> <td class=\"indent1\">Diltiazem</td> <td>Calcium channel blocker</td> <td>Initial bolus of 0.25 to 0.35 mg/kg IV followed by continuous infusion of 5 to 20 mg/hour.</td> <td>1 to 3 minutes.</td> <td> <p>1 to 3 hours (bolus).</p> 0.5 to 10 hours (after discontinuation of infusion).</td> <td>Dizziness, nausea, bradycardia, first-degree heart block.</td> <td> <p>Alternative anti-impulse therapy in patients who do not tolerate beta-blockade.</p> Avoid use in acute decompensated heart failure.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Verapamil</td> <td>Calcium channel blocker</td> <td>5 to 10 mg IV; may repeat after 5 to 10 minutes.</td> <td>3 to 5 minutes.</td> <td>0.5 to 6 hours.</td> <td>Refer to \"Diltiazem\" row above.</td> <td> <p>Alternative anti-impulse therapy in patients who do not tolerate beta-blockade.</p> Avoid use in acute decompensated heart failure.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Vasodilators<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"7\">First-line</td> </tr> <tr> <td class=\"indent2\">Nitroprusside</td> <td>Direct relaxation of vascular smooth muscle</td> <td>Initially 0.25 to 0.5 mcg/kg per minute as IV infusion titrated to a maximum of 10 mcg/kg per minute.<sup>&#916;</sup></td> <td>Immediate.</td> <td>1 to 10 minutes.</td> <td>Elevated intracranial pressure, decreased cerebral blood flow, reduced coronary blood flow in CAD, cyanide and thiocyanate toxicity, nausea, vomiting, muscle spasm, flushing, sweating.</td> <td> <p>Add-on to beta-blockade for additional lowering of SBP if needed.</p> <p>Rapidly titratable.</p> Continuous monitoring using an intra-arterial cannula from the arm with the highest auscultatory pressure is warranted.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Nicardipine*</td> <td>Calcium channel blocker</td> <td> <p>Initially 2.5 to 5 mg/hour as IV infusion titrated to a maximum of 15 mg/hour.</p> <p>&nbsp;</p> Some patients may require higher doses (eg, up to 30 mg/hour).</td> <td>5 to 15 minutes.</td> <td>0.5 to &#8804;8 minutes.</td> <td> <p>Tachycardia, headache, dizziness, nausea, flushing, local phlebitis, edema.</p> Infusion volume may be excessive; available concentrations include 0.1 and 0.2 mg/mL (premixed).</td> <td>Add-on to beta-blockade for additional lowering of SBP if needed.</td> </tr> <tr> <td class=\"subtitle2_left indent1\" colspan=\"7\">Second-line</td> </tr> <tr> <td class=\"indent2\">Clevidipine</td> <td>Calcium channel blocker</td> <td> <p>Initially 1 to 2 mg/hour as IV infusion with rapid titration.</p> <p>Most patients respond to 4 to 6 mg/hour and are treated with doses of 16 mg/hour or less.</p> Delivered in lipid emulsion. 1000 mL maximum per 24 hours (which is equivalent to 21 mg/hour) due to lipid load.</td> <td>2 to 4 minutes.</td> <td>5 to 15 minutes.</td> <td>Atrial fibrillation, nausea, lipid contains potential allergens (eg, soy, egg).</td> <td> <p>Add-on to beta-blockade for additional lowering of SBP if needed.</p> <p>Rapidly cleared by plasma esterases (ie, clearance is not dependent on renal or hepatic function).</p> </td> </tr> <tr> <td class=\"indent2\">Nitroglycerin (glyceryl trinitrate)</td> <td>Direct relaxation of vascular smooth muscle</td> <td>5 to 200 mcg/minute as IV infusion.</td> <td>2 to 5 minutes.</td> <td>5 to 10 minutes.</td> <td>Hypoxemia, tachycardia (reflex sympathetic activation), headache, vomiting, flushing, methemoglobinemia, tolerance with prolonged use.</td> <td> <p>Potential add-on to beta-blockade if needed for additional blood pressure lowering.</p> May be useful in patients with coronary ischemia or acute pulmonary edema.</td> </tr> <tr> <td class=\"indent2\">Enalaprilat</td> <td>Angiotensin-converting enzyme (ACE) inhibitor</td> <td>1.25 to 5 mg IV every 6 hours.</td> <td>15 to 30 minutes.</td> <td>Approximately 6 hours.</td> <td>Precipitous fall in pressure in high-renin states; variable response, headache, dizziness.</td> <td> <p>Potential add-on to beta-blockade for additional lowering of SBP if needed.</p> <p>Due to slow onset, variable response, and long duration of effect, rarely used.</p> Avoid use in acute myocardial infarction, renal impairment, or pregnancy.</td> </tr> <tr> <td class=\"indent2\">Fenoldopam</td> <td>Agonist for D<sub>1</sub>-like dopamine receptors; binds with moderate affinity to alpha<sub>2</sub>-adrenoceptors</td> <td>Initially 0.1 mcg/kg per minute<sup>&#9674;</sup> as IV infusion titrated to a maximum of 1.6 mcg/kg per minute.</td> <td>5 to 10 minutes.</td> <td>1 to 4 hours.</td> <td>Tachycardia, headache, nausea, flushing, increased serum creatinine.</td> <td> <p>Potential add-on to beta-blockade for additional lowering of SBP if needed.</p> Use caution or avoid with glaucoma or increased intracranial pressure.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; CAD: coronary artery disease; SBP: systolic blood pressure.<br />* Maximize infusion concentration to reduce volume overload during administration.<br />¶ Vasodilator therapy without prior beta blockade may cause reflex tachycardia and increased aortic shear stress. Refer to accompanying text.<br />Δ A maximum dose of 10 mcg/kg per minute for brief periods (up to 10 minutes) has been used when warranted; to minimize risk of cyanide toxicity, infusion duration should be as short as possible and not exceed 2 mcg/kg per minute. Patients who receive higher doses (ie, &gt;500 mcg/kg at a rate exceeding 2 mcg/kg per minute) should receive sodium thiosulfate infusion to avoid cyanide toxicity.<br /><FONT class=lozenge>◊</FONT> Initial fenoldopam doses in range of 0.01 to 0.3 mcg/kg per minute have been described.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hiratzka LF, Bakris GL, Beckman JA et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.</LI>&#xD;&#xA;<LI>Tsai TT, Nienaber CA, Eagle KA. Acute aortic syndromes. Circulation 2005; 112:3802.</LI>&#xD;&#xA;<LI>Marik PE, Rivera R. Hypertensive emergencies: an update. Curr Opin Crit Care 2011; 17:569.</LI></OL></div><div id=\"graphicVersion\">Graphic 111803 Version 1.0</div></div></div>"},"111804":{"type":"graphic_figure","displayName":"Consumption of combustible and smokeless tobacco - United States","title":"Consumption of combustible* and smokeless tobacco<SUP>¶</SUP> - United States, 2000 to 2015","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Consumption of combustible* and smokeless tobacco<SUP>¶</SUP> - United States, 2000 to 2015</div><div class=\"cntnt\"><img style=\"width:784px; height:428px;\" src=\"images/PC/111804_Cnsmpn_cmbstbl_smkls_tbc_US.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Combustible tobacco includes cigarettes, cigars, and loose roll-your-own and pipe tobacco, and is measured as cigarette equivalents per capita.<br />¶ Smokeless tobacco includes chewing tobacco and dry snuff, and is measured as weight (lbs) per capita.</div><div class=\"graphic_reference\">Reproduced from: Wang TW, Kenemer B, Tynan MA, et al. Consumption of Combustible and Smokeless Tobacco — United States, 2000–2015. MMWR Morb Mortal Wkly Rep 2016; 65:1357.</div><div id=\"graphicVersion\">Graphic 111804 Version 1.0</div></div></div>"},"111805":{"type":"graphic_figure","displayName":"Consumption of cigars - United States","title":"Consumption of cigars* - United States, 2000 to 2015","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Consumption of cigars* - United States, 2000 to 2015</div><div class=\"cntnt\"><img style=\"width:680px; height:416px;\" src=\"images/PC/111805_Consumption_cigars_US.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Cigars are measured as cigarette equivalents per capita. Small cigars are defined as cigars that weigh ≤3 lbs (1.36 kg) per 1000 cigars, and large cigars are defined as cigars that weigh &gt;3 lbs per 1000 cigars.</div><div class=\"graphic_reference\">Reproduced from: Wang TW, Kenemer B, Tynan MA, et al. Consumption of Combustible and Smokeless Tobacco — United States, 2000–2015. MMWR Morb Mortal Wkly Rep 2016; 65:1357.</div><div id=\"graphicVersion\">Graphic 111805 Version 1.0</div></div></div>"},"111806":{"type":"graphic_algorithm","displayName":"Approach to knee pain in the adult","title":"Approach to knee pain in the adult","html":"<div class=\"graphic\"><div style=\"width: 1136px\" class=\"figure\"><div class=\"ttl\">Approach to knee pain in the adult</div><div class=\"cntnt\"><img style=\"width:1116px; height:710px;\" src=\"images/SM/111806_Approach_knee_pain_adult.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ED: emergency department; ACL: anterior cruciate ligament; PCL: posterior cruciate ligament; MCL: medial collateral ligament; LCL: lateral collateral ligament; RA: rheumatoid arthritis.<br />* Joint aspiration and fluid analysis are important for diagnosing these conditions.<br />¶ Includes local joint infection or disseminated infection (eg, gonococcal).<br />Δ Osteoarthritis can cause diffuse or focal pain in any of several locations.<br /><FONT class=lozenge>◊</FONT> Symptomatic degenerative meniscal tears may or may not be associated with a small effusion.</div><div id=\"graphicVersion\">Graphic 111806 Version 1.0</div></div></div>"},"111811":{"type":"graphic_table","displayName":"Etiology and management of non-pain symptoms in HIV and AIDS","title":"Etiology of non-pain symptoms in the current era of effective antiretroviral treatment compared with earlier in the HIV epidemic, and the evolution of management strategies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of non-pain symptoms in the current era of effective antiretroviral treatment compared with earlier in the HIV epidemic, and the evolution of management strategies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Etiologies in the early HIV treatment era</td> <td class=\"subtitle1\">Management</td> <td class=\"subtitle1\">Etiology in the ART treatment era</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Pulmonary</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"2\">Dyspnea/cough</td> <td>PJP, bacterial pneumonia</td> <td>Antibiotics</td> <td>COPD</td> <td>Inhalers, steroids, oxygen</td> </tr> <tr class=\"divider_bottom\"> <td>TB</td> <td>Antimycobacterials</td> <td>Pulmonary hypertension</td> <td>Pulmonary vasodilators, afterload reducers, ART</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Gastrointestinal</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">Diarrhea</td> <td>Disseminated MAC</td> <td>Antimycobacterials</td> <td>Irritable bowel syndrome</td> <td>Behavioral modification, dietary changes</td> </tr> <tr> <td>CMV</td> <td>Antivirals</td> <td>Chronic pancreatitis</td> <td>Pancreatic enzymes, antidiarrheals</td> </tr> <tr class=\"divider_bottom\"> <td>Cryptosporidiosis</td> <td>Antifungals</td> <td>Irritable bowel syndrome</td> <td>Behavioral modification, dietary changes, fiber intake</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Constitutional</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fatigue, weight loss, anorexia, tissue wasting</td> <td>AIDS</td> <td>Methylphenidate, dronabinol, testosterone, oxandrolone, megestrol acetate</td> <td>Malignancy</td> <td>Targeted chemotherapy, psychostimulants</td> </tr> <tr> <td>Opportunistic infections</td> <td>Treat opportunistic infections</td> <td>Depression</td> <td>Antidepressants, cognitive behavioral therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; ART: antiretroviral therapy; PJP: pneumocystis jiroveci pneumonia; COPD: chronic obstructive pulmonary disease; TB: tuberculosis; MAC: mycobacterium avium complex; CMV: cytomegalovirus; AIDS: acquired immunodeficiency syndrome.</div><div class=\"graphic_reference\">Adapted from: Pahuja M, Merlin J, Selwyn PA. HIV/AIDS. In: Oxford Textbook of Palliative Medicine, 5th ed, Cherny N, Fallon M, Kaasa S, Portenoy RK, Currow DC (Eds), Oxford University Press, New York 2015.</div><div id=\"graphicVersion\">Graphic 111811 Version 1.0</div></div></div>"},"111812":{"type":"graphic_figure","displayName":"Bimanual laryngoscopy in a child","title":"Bimanual laryngoscopy in a child","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Bimanual&nbsp;laryngoscopy in a child</div><div class=\"cntnt\"><img style=\"width:537px; height:271px;\" src=\"images/EM/111812_Bimanual_laryngoscopy_laryngoscopy_in_a_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">While performing direct laryngoscopy, the laryngoscopist uses the right hand to sweep the thyroid cartilage to the right and upward until the optimal glottis view is obtained. At that point, the laryngoscopist instructs an assistant to place their fingers in the exact same spot and apply the same direction and degree of force so that the endotracheal tube can be placed. </div><div id=\"graphicVersion\">Graphic 111812 Version 1.0</div></div></div>"},"111814":{"type":"graphic_table","displayName":"Dose-dense MVAC chemotherapy for advanced urothelial carcinoma","title":"Dose-dense MVAC chemotherapy for advanced urothelial carcinoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose-dense MVAC chemotherapy for advanced urothelial carcinoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Methotrexate</td> <td>30 mg/m<sup>2</sup> IV</td> <td>Administer as a slow IV push.</td> <td>Day 1</td> </tr> <tr> <td>Vinblastine</td> <td>3 mg/m<sup>2</sup> IV</td> <td>Administer IV push over one minute.</td> <td>Day 2</td> </tr> <tr> <td>Doxorubicin</td> <td>30 mg/m<sup>2</sup> IV</td> <td>Administer over three to five minutes IV push.</td> <td>Day 2</td> </tr> <tr> <td>Cisplatin</td> <td>70 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over 60 minutes.* Do not administer with aluminum needles or sets.</td> <td>Day 2</td> </tr> <tr> <td style=\"border-bottom: #ffffff 1px solid;\">G-CSF</td> <td style=\"border-bottom: #ffffff 1px solid;\">240 mcg/m<sup>2</sup> SC</td> <td style=\"border-bottom: #ffffff 1px solid;\">Treatment with G-CSF is extended as needed up to a total of 14 consecutive days. G-CSF is discontinued if the absolute neutrophil count is &#62;30 &times; 10<sup>9</sup>.</td> <td style=\"border-bottom: #ffffff 1px solid;\">Daily, days 4 to 10</td> </tr> <tr> <td class=\"indent1\" style=\"border-bottom: #ffffff 1px solid;\"><strong>OR</strong></td> <td style=\"border-bottom: #ffffff 1px solid;\"><strong>OR</strong></td> <td style=\"border-bottom: #ffffff 1px solid;\"><strong>OR</strong></td> <td style=\"border-bottom: #ffffff 1px solid;\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Pegylated G-CSF</td> <td>6 mg</td> <td>24 hours after last dose of chemotherapy.<sup>[2]</sup></td> <td>Day 3</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin and vinblastine are vesicants and can cause significant tissue damage; avoid extravasation. Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction, and third-space fluid collections</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of methotrexate may be needed for patients with liver or renal impairment, and in those with third-space fluid collections (ascites, pleural effusion, etc).<sup>[3]</sup> Adjustment of initial vinblastine and doxorubicin doses may be needed for preexisting liver dysfunction.<sup>[4,5]</sup> Adjustment of cisplatin doses may be needed for preexisting renal dysfunction.<sup>[6]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Due to the potential for nephrotoxicity associated with cisplatin, pretreatment hydration with 1 to 2 L of fluid is recommended prior to cisplatin administration; adequate post hydration and urinary output (&#62;100 mL/hour) should be maintained for 24 hours after administration.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiopulmonary issues</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose. Assess LVEF before and regularly during and after treatment with doxorubicin.<sup>[4]</sup> Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[4]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Obtain CBC with differential and platelet count prior to each cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each cycle. Continue close monitoring of renal function after each cycle in high-risk patients. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Evaluate for third-space fluid collections as clinically indicated. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess LVEF prior to treatment initiation and as clinically indicated during therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold all chemotherapy until platelets are &#62;90,000/mm<sup>3</sup> and WBC is &#62;3000/mm<sup>3</sup>.<sup>[6]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full doses of cisplatin; however, if symptoms increase in severity or the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> <li>For severe paresthesias and/or constipation, the dose of vinblastine should be reduced by 50%.<sup>[5]</sup> Vinblastine should be discontinued permanently if an adynamic ileus occurs. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during dose-dense MVAC therapy as clinically indicated. Discontinue doxorubicin in patients who develop signs/symptoms of cardiomyopathy.<sup>[4]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL or creatinine clearance &#62;55 mL/min and/or blood urea nitrogen &#60;25 mg/dL.<sup>[6]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; NS: normal saline; G-CSF: granulocyte-colony stimulating factor; SC: subcutaneous; LVEF: left ventricular ejection fraction; CBC: complete blood count; WBC: white blood cell count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sternberg CN, et al. J Clin Oncol 2001; 19:2638.</LI>&#xD;&#xA;<LI>Choueiri T, et al. J Clin Oncol 2014; 32:1889.</LI>&#xD;&#xA;<LI>Methotrexate for injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on April 25, 2016).</LI>&#xD;&#xA;<LI>Doxorubicin for injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on April 25, 2016).</LI>&#xD;&#xA;<LI>Vinblastine for injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on April 25, 2016).</LI>&#xD;&#xA;<LI>Cisplatin for injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on April 25, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 111814 Version 2.0</div></div></div>"},"111819":{"type":"graphic_picture","displayName":"Neonatal lupus rash","title":"Neonatal lupus rash","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Neonatal lupus rash</div><div class=\"cntnt\"><img style=\"width:498px; height:617px;\" src=\"images/ALLRG/111819_Neonatal_lupus_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical skin rash with predilection for the periorbital area. This rash resolved completely without scarring.</div><div class=\"graphic_reference\">From: Buyon JP, Friedman DM. Neonatal lupus. In: Systemic Lupus Erythematosus, 5<SUP>th</SUP> ed, Lahita RG, Tsokos G, Buyon J, Koike T (Eds), Academic Press, Cambridge MA, 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111819 Version 1.0</div></div></div>"},"111825":{"type":"graphic_picture","displayName":"Endosalpingiosis uterine cysts","title":"Endosalpingiosis in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endosalpingiosis in pregnancy</div><div class=\"cntnt\"><img style=\"width:355px; height:346px;\" src=\"images/OBGYN/111825_Endosalpingiosis_utrn_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macroscopic view of the cystic endosalpingiosis lesions after the cesarean delivery. The uterine fundus and part of the body are completely seeded with multitude of cyst-like structures resembling hydatids of Morgagni but with a harder structure due to the muscular component.</div><div class=\"graphic_reference\">From: Morales-Rosell&oacute; J, Pamplona-Bueno L, Montero-Balaguer B, et al. Florid cystic endosalpingiosis (M&uuml;llerianosis) in pregnancy. Case Rep Obstet Gynecol 2016; 2016:8621570. Copyright &copy; 2016 Jos&eacute; Morales-Rosell&oacute; et al. Available at: <a href=\"https://www.hindawi.com/journals/criog/2016/8621570/\" target=\"_blank\">https://www.hindawi.com/journals/criog/2016/8621570/</a> (Accessed February 15, 2017). Reproduced under the terms of the <a href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 111825 Version 2.0</div></div></div>"},"111829":{"type":"graphic_algorithm","displayName":"CAP outpatient antibiotics","title":"Community-acquired pneumonia: Empiric outpatient antibiotic selection in adults*","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Community-acquired pneumonia: Empiric outpatient antibiotic selection in adults*</div><div class=\"cntnt\"><img style=\"width:684px; height:564px;\" src=\"images/ID/111829_CAP_outpatient_antibiotics.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* This algorithm is intended for patients in whom outpatient therapy is considered appropriate. Refer to related UpToDate content to determine the site of care.<br />¶ Major comorbidities include chronic obstructive pulmonary disease (COPD), liver or renal disease, cancer, diabetes, congestive heart failure, alcoholism, and immunosuppression.<br />Δ In some regions of the world, including the United States, southern Europe, and Asia, the overall prevalence of macrolide-resistant <EM>S. pneumoniae</EM> (high level and low level) is now &gt;25 percent. In such regions, macrolide monotherapy should not be given.<br /><FONT class=lozenge>◊</FONT> Examples of contraindications include increased risk for a prolonged QT interval and allergy.<br />§ Local rates of doxycycline-resistant <EM>S. pneumoniae</EM> are not readily available to most clinicians, but clinicians may be able to determine the local rates of resistance by consulting with their local hospital's microbiology laboratory.<br />¥ Refer to the UpToDate topic review on treatment of community-acquired pneumonia in adults in the outpatient setting for detailed recommendations regarding antimicrobial regimens. Appropriate macrolides include azithromycin and clarithromycin. Preferred beta-lactams include amoxicillin and amoxicillin-clavulanate; alternative beta-lactams include cefpodoxime and cefuroxime. Appropriate fluoroquinolones include levofloxacin, moxifloxacin, and gemifloxacin.<br />‡ The greater convenience of fluoroquinolone monotherapy must be balanced against the severity of adverse effects (including the risk for <EM>Clostridium difficile</EM> infection) and the risk of selection for resistance in colonizing organisms, which are generally thought to be greater with fluoroquinolones. Refer to the UpToDate topic review on treatment of community-acquired pneumonia in adults in the outpatient setting for additional details.<br />† Doxycycline should not be used in pregnant women.</div><div id=\"graphicVersion\">Graphic 111829 Version 3.0</div></div></div>"},"111831":{"type":"graphic_table","displayName":"Serum creatinine values for preterm infants","title":"Serum creatinine values for very preterm infants (gestational age less than 33 weeks)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serum creatinine values for very preterm infants (gestational age less than 33 weeks)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">50<sup>th</sup> percentile value<br /> mg/dL (micromol/L)</td> <td class=\"subtitle1\">95<sup>th</sup> percentile value<br /> mg/dL (micromol/L)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">7 days</td> </tr> <tr> <td class=\"indent1\">25 to 27 weeks gestation</td> <td class=\"centered\">0.87 (76.9)</td> <td class=\"centered\">1.23 (108.7)</td> </tr> <tr> <td class=\"indent1\">28 to 29 weeks gestation</td> <td class=\"centered\">0.84 (74.3)</td> <td class=\"centered\">1.18 (103.9)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">30 to 33 weeks gestation</td> <td class=\"centered\">0.66 (58.3)</td> <td class=\"centered\">0.95 (83.9)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">10 to 14 days</td> </tr> <tr> <td class=\"indent1\">25 to 27 weeks gestation</td> <td class=\"centered\">0.75 (66.3)</td> <td class=\"centered\">1.10 (97.3)</td> </tr> <tr> <td class=\"indent1\">28 to 29 weeks gestation</td> <td class=\"centered\">0.69 (61)</td> <td class=\"centered\">1.02 (90.3)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">30 to 33 weeks gestation</td> <td class=\"centered\">0.57 (50.4)</td> <td class=\"centered\">0.84 (74.1)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">One month</td> </tr> <tr> <td class=\"indent1\">25 to 27 weeks gestation</td> <td class=\"centered\">0.48 (42.4)</td> <td class=\"centered\">0.72 (63.6)</td> </tr> <tr> <td class=\"indent1\">28 to 29 weeks gestation</td> <td class=\"centered\">0.41 (36.2)</td> <td class=\"centered\">0.64 (57)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">30 to 33 weeks gestation</td> <td class=\"centered\">0.35 (30.9)</td> <td class=\"centered\">0.57 (50.2)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Two months</td> </tr> <tr> <td class=\"indent1\">25 to 27 weeks gestation</td> <td class=\"centered\">0.31 (27.4)</td> <td class=\"centered\">0.51 (44.9)</td> </tr> <tr> <td class=\"indent1\">28 to 29 weeks gestation</td> <td class=\"centered\">0.33 (28.8)</td> <td class=\"centered\">0.58 (51.6)</td> </tr> <tr> <td class=\"indent1\">30 to 33 weeks gestation</td> <td class=\"centered\">0.25 (22.2)</td> <td class=\"centered\">Data not available</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Bateman DA, Thomas W, Parravicini E, et al. Serum creatinine concentration in very-low-birth-weight infants from birth to 34-36 wk postmenstrual age. Pediatr Res 2015; 77:696.</div><div id=\"graphicVersion\">Graphic 111831 Version 2.0</div></div></div>"},"111832":{"type":"graphic_diagnosticimage","displayName":"ADEM MRI and histology","title":"Acute disseminated encephalomyelitis in a middle-aged adult","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Acute disseminated encephalomyelitis in a middle-aged adult</div><div class=\"cntnt\"><img style=\"width:514px; height:845px;\" src=\"images/NEURO/111832_ADEM_MRI_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI and brain biopsy findings in a 62-year-old man who initially presented with progressive development of gait dysfunction, urinary incontinence, and encephalopathy over the course of two weeks following four days of a gastrointestinal illness.<br />(A) Axial (T2/FLAIR) MRI showing supratentoria white matter hyperintensities extending from the periventricular region to the subcortical fibers.<br />(B) Sagittal (T2/FLAIR) MRI showing diffuse periventricular white matter intensities.<br />(C) Axial (T2/FLAIR) MRI showing interval improvement and resolution of the periventricular white matter lesions.<br />(D) Sagittal (T2/FLAIR) MRI demonstrating the improvement of the periventricular white matter lesions.<br />(E) H&amp;E stain shows areas of pallor containing macrophage that represent areas of demyelination (original magnification 200x).<br />(F) Clusters of macrophages in the areas of demyelination are highlighted by immunohistochemical staining for macrophage marker CD68 (original magnification 200x).<br />(G) Relative preservation of axons that are seen to traverse the macrophage rich areas of demyelination is demonstrated on neurofilament immunohistochemical stain (original magnification 400x).<br />(H) Multiple pink areas of myelin loss are present in the background of normal appearing blue staining cerebral white matter on Luxol Fast Blue/PAS stain (original magnification 100x).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; H&amp;E: hematoxylin and eosin; PAS: periodic acid-Schiff.</div><div class=\"graphic_reference\">From: Mahdi N, Abdelmalik PA, Curtis M, Bar B. A case of acute disseminated encephalomyelitis in a middle-aged adult. Case Rep Neurol Med 2015; 2015:601706. Copyright &copy; 2015 Nicole Mahdi et al. Available at: <a href=\"https://www.hindawi.com/journals/crinm/2015/601706/\" target=\"_blank\">https://www.hindawi.com/journals/crinm/2015/601706/</a> (Accessed February 15, 2017). Reproduced under the terms of the <a href=\"http://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 111832 Version 1.0</div></div></div>"},"111835":{"type":"graphic_algorithm","displayName":"Management of asthma exacerbations in adults","title":"Management of asthma exacerbations in adults: Emergency department or urgent care","html":"<div class=\"graphic\"><div style=\"width: 1110px\" class=\"figure\"><div class=\"ttl\">Management of asthma exacerbations in adults: Emergency department or urgent care</div><div class=\"cntnt\"><img style=\"width:1090px; height:796px;\" src=\"images/PULM/111835_Mgmt_asthma_excrbtns_adult.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Features that help with assessment of severity (may or may not be present): &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Impending respiratory failure: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Cyanosis, inability to maintain respiratory effort, depressed mental status, SpO<SUB>2</SUB> &lt;90%</LI>&#xD;&#xA;<LI>PaCO<SUB>2</SUB> &gt;40 mmHg</LI></UL></LI>&#xD;&#xA;<LI>Severe exacerbation: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Speaks in single words</LI>&#xD;&#xA;<LI>Sits hunched forward</LI>&#xD;&#xA;<LI>Agitated, diaphoretic</LI>&#xD;&#xA;<LI>Respiratory rate &gt;30 breaths/minute</LI>&#xD;&#xA;<LI>Heart rate &gt;120 beats/minute</LI>&#xD;&#xA;<LI>SpO<SUB>2</SUB> (on air) &lt;90%</LI>&#xD;&#xA;<LI>PEF ≤50% predicted or personal best</LI></UL></LI>&#xD;&#xA;<LI>Mild to moderate exacerbation: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Talks in phrases or sentences</LI>&#xD;&#xA;<LI>Prefers sitting to lying</LI>&#xD;&#xA;<LI>Not agitated</LI>&#xD;&#xA;<LI>Respiratory rate 16 to 30 breaths/minute</LI>&#xD;&#xA;<LI>Heart rate 100 to 120 beats/minute</LI>&#xD;&#xA;<LI>SpO<SUB>2</SUB> &gt;90%</LI>&#xD;&#xA;<LI>PEF &gt;50% but &lt;80% predicted or personal best</LI></UL></LI></UL></div><div class=\"graphic_footnotes\">PEF: peak expiratory flow; ICU: intensive care unit; SABA: short-acting beta agonist (eg, albuterol); SpO<SUB>2</SUB>: pulse oxygen saturation; COPD: chronic obstructive pulmonary disease; MDI: metered dose inhaler; GC: glucocorticoid; PaCO<SUB>2</SUB>: carbon dioxide tension.<br />* Titrate oxygen to SpO<SUB>2</SUB> 93 to 95% for patients with severe exacerbations, particularly if at risk for hypercapnia. Aim for SpO<SUB>2</SUB> &gt;95% in pregnant patients. Titrate to SpO<SUB>2</SUB> 88 to 92%, if asthma-COPD overlap.<br />¶ Magnesium sulfate is 4.06 mmol/g (2 g = 8.1 mmol).<br />Δ Please refer to the UpToDate topic on treatment of asthma exacerbations in adults.<br /><FONT class=lozenge>◊</FONT> Adding ipratropium to albuterol nebulizer treatments is preferred for patients with severe exacerbations; alternatively, SABA/ipratropium can be given via MDI 4 to 8 inhalations every 20 minutes, as needed for up to 3 hours.<br />§ The dose and duration of therapy can be modified based on the patient's past history of response, severity of exacerbation, and response to current treatment.</div><div id=\"graphicVersion\">Graphic 111835 Version 2.0</div></div></div>"},"111837":{"type":"graphic_algorithm","displayName":"Pregnancy (>20 wks) with thrombocytopenia (<80,000/microL)","title":"Approach to a pregnant woman beyond 20 weeks gestation with a platelet count below 80,000/microL","html":"<div class=\"graphic\"><div style=\"width: 1318px\" class=\"figure\"><div class=\"ttl\">Approach to a pregnant woman beyond 20 weeks gestation with a platelet count below 80,000/microL</div><div class=\"cntnt\"><img style=\"width:1298px; height:622px;\" src=\"images/HEME/111837_Prgncy_20wks_thrombocytopen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm does not substitute for the clinical judgment of the treating obstetrician and hematologist. Platelet transfusions are indicated for patients with active bleeding, and anticoagulation is indicated for patients with thrombosis. Early involvement of the appropriate consulting specialist is advised. The threshold platelet count of 80,000/microL was chosen to exclude women with gestational thrombocytopenia. Refer to UpToDate topics on thrombocytopenia in pregnancy and specific conditions for additional possible causes of thrombocytopenia and information about management.</div><div class=\"graphic_footnotes\">CBC: complete blood count; PT: prothrombin time; aPTT: activated partial thromboplastin time; MAHA: microangiopathic hemolytic anemia; AKI: acute kidney injury; DIC: disseminated intravascular coagulation; ITP: immune thrombocytopenia; TTP: thrombotic thrombocytopenic purpura; C-TMA: complement-mediated thrombotic microangiopathy; HELLP: hemolysis, elevated liver function tests, and low platelets; LFTs: liver function tests; IVIG: intravenous immune globulin; PEX: plasma exchange.<br />* Severity of bleeding and source must be evaluated.<br />¶ Gestational thrombocytopenia is extremely unlikely if the platelet count is &lt;80,000/microL.<br />Δ Genetic testing for complement mutations may be appropriate for some patients. Refer to UpToDate for details.</div><div id=\"graphicVersion\">Graphic 111837 Version 2.0</div></div></div>"},"111839":{"type":"graphic_picture","displayName":"Acral persistent papular mucinosis","title":"Acral persistent papular mucinosis (subtype of localized lichen myxedematosus)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Acral persistent papular mucinosis (subtype of localized lichen myxedematosus)</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/DERM/111839_Acral_prs_papular_mucinosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple firm, waxy papules on the dorsal hands and distal forearm.</div><div id=\"graphicVersion\">Graphic 111839 Version 1.0</div></div></div>"},"111840":{"type":"graphic_picture","displayName":"Discrete papular lichen myxedematosus on trunk","title":"Discrete papular lichen myxedematosus","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Discrete papular lichen myxedematosus</div><div class=\"cntnt\"><img style=\"width:720px; height:560px;\" src=\"images/DERM/111840_Discrete_PLM_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple waxy, skin-colored papules on the trunk.</div><div id=\"graphicVersion\">Graphic 111840 Version 1.0</div></div></div>"},"111841":{"type":"graphic_picture","displayName":"Discrete papular lichen myxedematosus","title":"Discrete papular lichen myxedematosus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Discrete papular lichen myxedematosus</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/DERM/111841_Discrete_PLM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple waxy, skin-colored papules on the buttocks and proximal thigh.</div><div id=\"graphicVersion\">Graphic 111841 Version 1.0</div></div></div>"},"111842":{"type":"graphic_picture","displayName":"Cutaneous mucinosis of infancy","title":"Cutaneous mucinosis of infancy (subtype of localized lichen myxedematosus)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Cutaneous mucinosis of infancy (subtype of localized lichen myxedematosus)</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/DERM/111842_Cutaneous_mucinosis_infancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous mucinosis of infancy. Multiple coalescing papules on retroauricular area.</div><div id=\"graphicVersion\">Graphic 111842 Version 1.0</div></div></div>"},"111843":{"type":"graphic_picture","displayName":"Nodular lichen myxedematosus","title":"Nodular lichen myxedematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lichen myxedematosus</div><div class=\"cntnt\"><img style=\"width:260px; height:232px;\" src=\"images/DERM/111843_Nodulr_lichen_myxedematosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple skin-colored nodules on the trunk.</div><div id=\"graphicVersion\">Graphic 111843 Version 1.0</div></div></div>"},"111844":{"type":"graphic_picture","displayName":"Acral persistent papular mucinosis histopathology","title":"Acral persistent papular mucinosis","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Acral persistent papular mucinosis</div><div class=\"cntnt\"><img style=\"width:872px; height:318px;\" src=\"images/DERM/111844_Acral_paplr_mucinosis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Focal mucin deposition in the upper dermis with sparing of the subepidermal zone and absent fibroblast proliferation.<br />(B) Alcian blue stain showing focal dermal mucin deposition.</div><div id=\"graphicVersion\">Graphic 111844 Version 1.0</div></div></div>"},"111845":{"type":"graphic_picture","displayName":"Discrete papular lichen myxedematosus histopathology","title":"Discrete papular lichen myxedematosus","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Discrete papular lichen myxedematosus</div><div class=\"cntnt\"><img style=\"width:656px; height:367px;\" src=\"images/DERM/111845_Discrete_PLM_histopathology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Dermal mucin (manifesting as bluish edema between collagen bundles), slight increase in fibroblasts, and a perivascular lymphocytic infiltrate.<br />(B) Alcian blue stain showing interstitial mucin deposition.</div><div id=\"graphicVersion\">Graphic 111845 Version 1.0</div></div></div>"},"111847":{"type":"graphic_table","displayName":"Subsets and subtypes of lichen myxedematosus","title":"Subsets and subtypes of lichen myxedematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Subsets and subtypes of lichen myxedematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Subsets of lichen myxedematosus (papular mucinosis)</td> </tr> <tr> <td> <ol> <li>Localized form (localized lichen myxedematosus) </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Generalized/diffuse and sclerodermoid form (scleromyxedema) </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>Atypical/intermediate form </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Subtypes of the localized form of lichen myxedematosus</td> </tr> <tr> <td> <ol> <li>Discrete papular lichen myxedematosus </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Acral persistent papular mucinosis </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>Cutaneous mucinosis of infancy </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>Nodular lichen myxedematosus </li> </ol> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111847 Version 1.0</div></div></div>"},"111849":{"type":"graphic_figure","displayName":"Spirometry and PEF in asthma","title":"Spirometry and peak expiratory flow in asthma","html":"<div class=\"graphic\"><div style=\"width: 895px\" class=\"figure\"><div class=\"ttl\">Spirometry and peak expiratory flow in asthma</div><div class=\"cntnt\"><img style=\"width:875px; height:608px;\" src=\"images/PULM/111849_Spirometry_PEF_asthma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume loop (flow-volume plot) and spirometry (volume-time plot) in a patient with moderate airflow&nbsp;limitation (reduced FEV<SUB>1</SUB>/FVC ratio and reduced FEV<SUB>1</SUB>) on spirometry, but normal PEF. This discrepancy reflects rapid emptying of gas from the trachea and central bronchi, but slowed expiratory flow from the remainder of the bronchial tree.</div><div class=\"graphic_footnotes\">95%: the low end of the 95% confidence intervals around the mean; FVC: forced vital capacity; FEV<SUB>1</SUB>: forced expiratory volume in one second; FET: forced expiratory time; PEF: peak expiratory flow.</div><div id=\"graphicVersion\">Graphic 111849 Version 1.0</div></div></div>"},"111850":{"type":"graphic_table","displayName":"Clinical and histologic features localized lichen myxedematosus","title":"Clinical and histologic features of the subtypes of localized lichen myxedematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and histologic features of the subtypes of localized lichen myxedematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Main clinical features</td> <td class=\"subtitle1\">Main histologic features</td> </tr> <tr class=\"divider_bottom\"> <td>Acral persistent papular mucinosis</td> <td>Symmetrical papules on the extensor surface of the hands, wrists, and sometimes forearms; not self-healing; without systemic involvement</td> <td>Focal deposits of mucin in upper reticular dermis sparing a subepidermal area, no increase in the number of fibroblasts</td> </tr> <tr class=\"divider_bottom\"> <td>Discrete papular LM</td> <td>Papules on trunk and limbs, not self-healing, with symmetrical or asymmetrical pattern, and without systemic involvement</td> <td>Mucin deposits between collagen bundles in the reticular dermis with variable fibroblast proliferation</td> </tr> <tr class=\"divider_bottom\"> <td>Cutaneous (papular) mucinosis of infancy</td> <td>Congenital or perinatal, firm papules, not self-healing, without systemic involvement</td> <td>Papillary dermal mucin, without overt fibroblast proliferation</td> </tr> <tr class=\"divider_bottom\"> <td>Nodular LM</td> <td>Nodules with slight or absent papules, not self-healing, without systemic involvement</td> <td>Mucin in the reticular dermis</td> </tr> <tr class=\"divider_bottom\"> <td>Localized LM with monoclonal gammopathy</td> <td>Features of localized LM, monoclonal gammopathy</td> <td>Mucin deposition with variable fibroblast proliferation</td> </tr> <tr> <td>Localized LM with mixed features of different subtypes</td> <td>Mixed features of two or more kinds of localized LM</td> <td>Mucin deposition with variable fibroblast proliferation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LM: lichen myxedematosus.</div><div id=\"graphicVersion\">Graphic 111850 Version 1.0</div></div></div>"},"111852":{"type":"graphic_figure","displayName":"HTR sequence of immunologic events","title":"Sequence of events in a hemolytic transfusion reaction","html":"<div class=\"graphic\"><div style=\"width: 754px\" class=\"figure\"><div class=\"ttl\">Sequence of events in a hemolytic transfusion reaction</div><div class=\"cntnt\"><img style=\"width:734px; height:588px;\" src=\"images/HEME/111852_Time-course_HTR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic&nbsp;shows the sequence of immunologic events involved in&nbsp;a hemolytic transfusion reaction (HTR). Refer to UpToDate for further information on the pathophysiology and clinical presentation of acute and delayed HTRs.</div><div class=\"graphic_footnotes\">TNF-alpha: Tumor necrosis factor alpha.</div><div class=\"graphic_reference\">Reproduced from: Davenport RD. Pathophysiology of Hemolytic Transfusion Reactions. Semin Hematol 2005; 42:165. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 111852 Version 1.0</div></div></div>"},"111898":{"type":"graphic_figure","displayName":"Insomnia related to excessive time in bed","title":"Insomnia in a child related to excessive time in bed","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Insomnia in a child related to excessive time in bed</div><div class=\"cntnt\"><img style=\"width:722px; height:398px;\" src=\"images/SLEEP/111898_Insomnia_excssv_time_bed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is a schematic representation of a child whose time in bed is 12 hours (set by her parents' expectations), which exceeds her intrinsic sleep requirement of 10 hours. As a result, the child has prolonged periods of wakefulness, which may manifest as bedtime resistance, night wakings, or early morning awakening, or some combination of all three. The solution to this problem is to reduce the \"sleep window\" to match sleep needs (in this case 10 hours), typically by delaying bedtime and/or advancing wake time. This can be done incrementally (eg, delaying bedtime by 15 minutes every few nights until the target sleep window is achieved).</div><div class=\"graphic_reference\">Courtesy of Judith A Owens, MD, MPH.</div><div id=\"graphicVersion\">Graphic 111898 Version 1.0</div></div></div>"},"111904":{"type":"graphic_table","displayName":"Modified GEMOX for advanced gallbladder cancer","title":"Modified gemcitabine and oxaliplatin (GEMOX) for advanced gallbladder cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified gemcitabine and oxaliplatin (GEMOX) for advanced gallbladder cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Maximum:</strong> Six cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Oxaliplatin</td> <td>80 mg/m<sup>2</sup> IV*</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine</td> <td>900 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline<sup>&#182;</sup> (concentration no more than 40 mg/mL) and administer over 30 minutes.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on days 1 and 8. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated for gemcitabine or oxaliplatin. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of gemcitabine may be needed for patients with liver impairment.<sup>[2]</sup> A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess pulmonary function prior to each new treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity prior to each new treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle of treatment should not start until the ANC is &#8805;1500/microL and platelet count is &#8805;100,000/microL. Intracycle dose reduction for day 8 treatment: If ANC is &#60;1000/microL and/or platelets are &#60;50,000/microL, interrupt treatment until recovery to ANC &#8805;1500/microL and platelet count is &#8805;75,000/microL. In the event of grade IV neutropenia or thrombocytopenia, reduce chemotherapy doses by 25% once counts have recovered.<sup>[4]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For &#62;grade 1 peripheral sensory neuropathy persisting over seven days, reduce dose of oxaliplatin by 25%. Discontinue oxaliplatin for grade 3 or 4 peripheral sensory neuropathy.<sup>[4]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[2]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Discontinue gemcitabine immediately and permanently. Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topics on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\" and \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; ECG: electrocardiogram; CBC: complete blood count.<br />* Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline and a D5W flush is recommended prior to starting the drug infusion.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sharma A, et al. J Clin Oncol 2016; 34 suppl abstr 4077. Abstract available online at http://meetinglibrary.asco.org/content/167054-176 (Accessed on August 15, 2016).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed June 5, 2012).</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on June 5, 2012).</LI>&#xD;&#xA;<LI>Sharma A, et al. Cancer Chemother Pharmacol 2010; 65:497.</LI></OL></div><div id=\"graphicVersion\">Graphic 111904 Version 3.0</div></div></div>"},"111905":{"type":"graphic_figure","displayName":"Immue hemolysis - intravascular versus extravascular","title":"Differences between mechanisms of intravascular and extravascular immune hemolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Differences between mechanisms of intravascular and extravascular immune hemolysis</div><div class=\"cntnt\"><img style=\"width:444px; height:533px;\" src=\"images/HEME/111905_Intravascular_versus_extravascular_hemolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Intravascular hemolysis occurs when complement is fixed and red blood cells lyse in the circulation, releasing free hemoglobin. Lysis occurs because the membrane attack complex (MAC) creates holes in the red blood cell membrane. Typically IgM is responsible for fixing complement&nbsp;(as shown) although other mechanisms may be involved.&nbsp;&nbsp;<br />B: Extravascular hemolysis occurs when reticuloendothelial macrophages (mostly in the liver and spleen) phagocytize antibody (or complement component C3)-coated red blood cells. This can occur in stages, with production of spherocytes and microspherocytes&nbsp;that are trapped in splenic sinusoids, or all at once.&nbsp;Refer to UpToDate topics on immune hemolysis and hemolytic transfusion reactions&nbsp;for details. </div><div id=\"graphicVersion\">Graphic 111905 Version 3.0</div></div></div>"},"111923":{"type":"graphic_diagnosticimage","displayName":"Myocardial scarring in a patient with previous MI","title":"Myocardial scarring in a patient with previous myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myocardial scarring in a patient with previous myocardial infarction</div><div class=\"cntnt\"><img style=\"width:342px; height:618px;\" src=\"images/CARD/111923_Myocardial_scarring_prev_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A representative example of myocardial scarring in a patient with previous myocardial infarction detected by MRI with late gadolinium enhancement (arrows) on short-axis (A) and four-chamber views (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 111923 Version 1.0</div></div></div>"},"111926":{"type":"graphic_table","displayName":"Molecular testing techniques in NSCLC","title":"Molecular testing techniques for targetable alterations in non-small cell lung cancer (NSCLC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular testing techniques for targetable alterations in non-small cell lung cancer (NSCLC)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"7\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Tissue PCR sequencing</td> <td class=\"subtitle1\">Tissue allele specific PCR sequencing</td> <td class=\"subtitle1\">Tissue FISH</td> <td class=\"subtitle1\">Tissue IHC</td> <td class=\"subtitle1\">Tissue NGS</td> <td class=\"subtitle1\">ctDNA PCR</td> <td class=\"subtitle1\">ctDNA PCR</td> </tr> <tr> <td><strong>EGFR (sensitizing and T790M)</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>HER2 mutation</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>METex14 mutation</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>BRAF mutation</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>KRAS mutation</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>ALK rearrangement</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>ROS1 rearrangement</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>MET amplification</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>RET rearrangement</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>PDL1 protein expression</strong></td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">++</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">++: Highest sensitivity.<br />+: Lower sensitivity (higher chance of false negative).<br />0: Not useful.</div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; NGS: next generation sequencing; ctDNA: circulating tumor DNA.<br />* FISH is highly sensitive but not recommended due to low yield and no approved targeted therapy.</div><div id=\"graphicVersion\">Graphic 111926 Version 1.0</div></div></div>"},"111928":{"type":"graphic_figure","displayName":"Outcome after hemicraniectomy","title":"Functional outcome after decompressive hemicraniectomy for malignant middle cerebral artery territory infarction","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Functional outcome after decompressive hemicraniectomy for malignant middle cerebral artery territory infarction</div><div class=\"cntnt\"><img style=\"width:715px; height:710px;\" src=\"images/NEURO/111928_Outcome_aftr_hemicraniectm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Functional outcome after hemicraniectomy and after medical (conservative) treatment according to the mRS score.<br />(B) Functional outcome after hemicraniectomy and after medical (conservative) treatment according to the mRS score (six months data, five trials).</div><div class=\"graphic_footnotes\">mRS: modified Rankin Scale.</div><div class=\"graphic_reference\">From: Alexander P, Heels-Ansdell D, Siemieniuk R, et al. Hemicraniectomy versus medical treatment with large MCA infarct: a review and meta-analysis. BMJ Open 2016; 6:e014390. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 111928 Version 1.0</div></div></div>"},"111940":{"type":"graphic_figure","displayName":"Intravesical VUR repair","title":"Intravesical repair of vesicoureteral reflux","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Intravesical repair of vesicoureteral reflux</div><div class=\"cntnt\"><img style=\"width:512px; height:554px;\" src=\"images/PEDS/111940_Intravesical_VUR_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Clinical Pediatric Urology, Kelalis PP, King LR, Belman AB (Eds), W.B. Saunders,&nbsp;Philadelphia 1985.</div><div id=\"graphicVersion\">Graphic 111940 Version 1.0</div></div></div>"},"111941":{"type":"graphic_figure","displayName":"Endoscopic VUR repair","title":"Endoscopic repair of vesicoureteral reflux","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Endoscopic repair of vesicoureteral reflux</div><div class=\"cntnt\"><img style=\"width:536px; height:317px;\" src=\"images/PEDS/111941_Endoscopic_VUR_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Diagram showing the injection sites used for endoscopic treatment for vesicoureteral reflux. 1. Intraureteric proximal hydrodistension implantation technique (HIT) site; 2. Intraureteric distal HIT site; 3. Subureteric site.<br />B: Diagram demonstrating the injection of a bulking agent (polymer combination of dextranomer and hyaluronic acid) at the subureteric site, referred to as the STING procedure. </div><div class=\"graphic_footnotes\">STING: subureteral teflon injection.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Deflux Injectable Gel (Q-Med, Uppsala, Sweden), revised 04/2016.</LI>&#xD;&#xA;<LI>Cerwinka WH, Scherz HC, Kirsch AJ. Dynamic hydrodistention classification of the ureter and the double hit method to correct vesicoureteral reflux. Arch Esp Urol 2008; 61:882.</LI>&#xD;&#xA;<LI>​Aransay A. Tratamiento endoscópico del reflujo vesicoureteral. An Pediatr Contin 2007; 5:227.</LI></OL></div><div id=\"graphicVersion\">Graphic 111941 Version 1.0</div></div></div>"},"111949":{"type":"graphic_movie","displayName":"CMAC intubation","title":"CMAC intubation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CMAC intubation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/111949_CMACintubationvid2.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:468px; height:352px;\" src=\"images/ANEST/111949_CMACintubationimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excellent laryngeal exposure with a high-resolution video image showing vallecular placement.</div><div id=\"graphicVersion\">Graphic 111949 Version 1.0</div></div></div>"},"111950":{"type":"graphic_movie","displayName":"Clarus Video System right retromolar approach","title":"Clarus Video System right retromolar approach intubation","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Clarus Video System right retromolar approach intubation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/111950_Clarusrtretromlrapprvid.mp4\" style=\"width:704px;height:496px\"></div><img style=\"width:468px; height:320px;\" src=\"images/ANEST/111950_Clarusrtretromlrapprimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows the Clarus Video System, introduced along the right side of the tongue, advanced toward the right molars, directed medially beneath the epiglottis and just beyond the vocal cords. The tracheal rings are clearly seen. The scope is stabilized and the endotracheal tube (ETT) is advanced into the trachea.</div><div id=\"graphicVersion\">Graphic 111950 Version 1.0</div></div></div>"},"111953":{"type":"graphic_movie","displayName":"King vision intubation","title":"King vision channelled scope intubation","html":"<div class=\"graphic normal\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">King vision channelled scope intubation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/111953_Kingvisionchannelscpvid.mp4\" style=\"width:592px;height:480px\"></div><img style=\"width:479px; height:378px;\" src=\"images/ANEST/111953_Kingvisionchannelscpimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The video demonstrates intubation using the King vision channelled scope. Initial blade insertion provides a good laryngeal view but the operator has difficulty directing the endotracheal tube (ETT) toward the larynx. At approximately 26 seconds, the scope is partially withdrawn, reoriented dorsally and ETT advancement progresses easily. The technique is very similar to that employed with the Airtraq. Although laryngeal exposure with the two devices may be similar, the King vision scope offers much better image quality.</div><div id=\"graphicVersion\">Graphic 111953 Version 1.0</div></div></div>"},"111954":{"type":"graphic_table","displayName":"Seizure characteristics temporal vs frontal lobe localization","title":"Seizure characteristics suggesting temporal versus frontal lobe localization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seizure characteristics suggesting temporal versus frontal lobe localization</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Temporal lobe</td> <td class=\"subtitle1\">Frontal lobe</td> </tr> <tr> <td> <ul> <li>Rising epigastric sensation </li> <li>D&#233;j&#224; vu </li> <li>Olfactory hallucination </li> <li>Auditory hallucination </li> <li>Automatisms (eg, fidgeting with the hands, chewing, lip smacking) </li> </ul> </td> <td> <ul> <li>Hypermotor behavior </li> <li>Automatisms (eg, leg bicycling, pelvic thrusting) </li> <li>Vocalization </li> <li>Tonic or dystonic posturing, including fencer posturing </li> <li>Versive head and eye movements </li> <li>Hemiclonic motor activity with Jacksonian march </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111954 Version 1.0</div></div></div>"},"111955":{"type":"graphic_movie","displayName":"Airtraq Avant intubation","title":"Airtraq Avant intubation","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Airtraq Avant intubation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/111955_Airtraqavantintubatnvid.mp4\" style=\"width:704px;height:496px\"></div><img style=\"width:468px; height:350px;\" src=\"images/ANEST/111955_Airtraqavantintubatnimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows the intubation of a larynx using the Airtraq Avant. The blade was rotated around the tongue base and introduced into the vallecula. The endotracheal tube (ETT) is aligned with the glottis by manipulating the laryngoscope. Note the excellent laryngeal exposure but lower quality image. It is perfectly adequate for intubation but not for diagnostic purposes.</div><div id=\"graphicVersion\">Graphic 111955 Version 1.0</div></div></div>"},"111956":{"type":"graphic_movie","displayName":"Soft tissue injury with VL","title":"Soft tissue injury with video laryngoscopy","html":"<div class=\"graphic normal\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Soft tissue injury with video laryngoscopy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/111956_SofttissueinjuryVLvid.mp4\" style=\"width:612px;height:464px\"></div><img style=\"width:468px; height:348px;\" src=\"images/ANEST/111956_SofttissueinjuryVLimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows soft tissue injury during intubation with a Glidescope. The operator was watching the monitor and thus unable to observe the endotracheal tube (ETT) nearly penetrating the right soft palate (arrow). When the ETT is successfully advanced, minor bleeding is evidenced by a blood-streaked cuff. The operator should directly observe the insertion of the ETT into the mouth until the ETT passes the palate to avoid this complication.&nbsp;At that point, attention can be directed toward the monitor.</div><div id=\"graphicVersion\">Graphic 111956 Version 1.0</div></div></div>"},"111959":{"type":"graphic_figure","displayName":"Layers through which epidural needle goes","title":"Layers through which epidural needle goes","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Layers through which epidural needle goes</div><div class=\"cntnt\"><img style=\"width:567px; height:618px;\" src=\"images/ANEST/111959_Layers_through_which_epidural_needle_goes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For&nbsp;epidural anesthesia, the styletted epidural&nbsp;needle is inserted through the skin and subcutaneous tissue, the supraspinous and interspinous ligaments, and into the ligamentum flavum.&nbsp;The stylet&nbsp;is removed from the needle, and a loss of resistance syringe containing saline, air, or a combination of the two is firmly attached to the needle hub. As the needle is advanced, the epidural space is identified by loss of resistance to injection of air or saline. The syringe is then removed, and an epidural catheter is advanced through the needle and into the epidural space. The needle is removed over the catheter, leaving 4 to 6 cm of the catheter in the space. For further details refer to UpToDate content on epidural technique.</div><div id=\"graphicVersion\">Graphic 111959 Version 1.0</div></div></div>"},"111960":{"type":"graphic_figure","displayName":"Kabnick classification of endovenous heat-induced thrombus","title":"Kabnick classification of endovenous heat-induced thrombus<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kabnick classification of endovenous heat-induced thrombus<SUP>[1]</SUP></div><div class=\"cntnt\"><img style=\"width:359px; height:484px;\" src=\"images/SURG/111960_Kabnick_classification_of_endovenous_heat_induced_thrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Class 1: Venous thrombosis to the superficial-deep junction (ie, saphenofemoral junction or saphenopopliteal junction), but not extending into the deep system.</LI>&#xD;&#xA;<LI>Class 2: Nonocclusive venous thrombosis into the deep venous system (ie, DVT), with an extension into the deep system of a cross-sectional area of less than 50 percent.</LI>&#xD;&#xA;<LI>Class 3: Nonocclusive venous thrombosis into the deep venous system (ie, DVT), with an extension into the deep system of a cross-sectional area of greater than 50 percent.</LI>&#xD;&#xA;<LI>Class 4: Occlusive DVT.</LI></UL></div><div class=\"graphic_footnotes\">EHIT: endovenous heat-induced thrombus; DVT: deep venous thrombosis. </div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Kabnick LS. Thrombus at the SFJ after endovenous ablation: What should I do now? Third International Vein Congress: In-office Techniques. Miami, FL 2005.</LI></OL></div><div id=\"graphicVersion\">Graphic 111960 Version 1.0</div></div></div>"},"111973":{"type":"graphic_figure","displayName":"Jugular venous pulse relations","title":"Jugular venous pulse relations","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Jugular venous pulse relations</div><div class=\"cntnt\"><img style=\"width:554px; height:468px;\" src=\"images/CARD/111973_Jugulr_venous_pulse_relatns.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 111973 Version 1.0</div></div></div>"},"111974":{"type":"graphic_table","displayName":"Distinguishing venous from arterial pulsations","title":"Distinguishing venous from arterial pulsations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing venous from arterial pulsations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Venous pulsations</td> <td class=\"subtitle1\">Arterial pulsations</td> </tr> <tr> <td colspan=\"3\"><strong>Characteristics of pulse</strong></td> </tr> <tr> <td class=\"indent1\">Movement</td> <td>Soft, diffuse, and undulant</td> <td>Discrete and robust</td> </tr> <tr> <td class=\"indent1\">Number of pulsations</td> <td>Two crests and two troughs</td> <td>Single</td> </tr> <tr> <td class=\"indent1\">Effect of inspiration</td> <td>Respirophasic</td> <td>No change</td> </tr> <tr> <td><strong>Position of body</strong></td> <td>Higher in horizontal position and lower in vertical position</td> <td>No significant change</td> </tr> <tr> <td><strong>Abdominal compression</strong></td> <td>May increase</td> <td>No change</td> </tr> <tr> <td><strong>Compression at root of neck</strong></td> <td>Pulsations cease</td> <td>Maintained</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 111974 Version 2.0</div></div></div>"},"111975":{"type":"graphic_table","displayName":"Common clinical manifestations of gluten-related disorders","title":"Common clinical manifestations of gluten-related disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common clinical manifestations of gluten-related disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Celiac disease</td> <td class=\"subtitle1\">Non-celiac gluten sensitivity</td> <td class=\"subtitle1\">Wheat allergy</td> </tr> <tr> <td class=\"subtitle2\" style=\"font-size:1.2em;\">Time from exposure to symptoms</td> <td class=\"subtitle2\">Hours-months</td> <td class=\"subtitle2\">Hours-days</td> <td class=\"subtitle2\">Minutes-hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Abdominal pain</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Constipation</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Gas/bloat/distention</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Poor weight gain</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Malodorous fatty stools</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vomiting</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Extraintestinal</td> </tr> <tr> <td class=\"indent1\">Pubertal delay</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Unexplained weight loss</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Poor height gain</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bone/joint pain</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Rash of DH</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Eczema</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Hives/atopic dermatitis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Fatigue</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Headache/migraine</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Foggy mind</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Angioedema</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anaphylaxis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Respiratory</td> </tr> <tr> <td class=\"indent1\">Asthma</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Cough</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Postnasal drip, throat clearing, rhinitis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Hill ID, Fasano A, Guandalini S, et al. NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. J Pediatr Gastroenterol Nutr 2016; 63(1):156-65. DOI: <A href=\"http://journals.lww.com/jpgn/pages/articleviewer.aspx?year=2016&amp;issue=07000&amp;article=00028&amp;type=abstract\" target=_blank>10.1097/MPG.0000000000001216</A>. Copyright © 2016 ESPGHAN and NASPGHAN. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 111975 Version 2.0</div></div></div>"},"111977":{"type":"graphic_picture","displayName":"Erysipelas-like skin lesion","title":"Erysipelas-like skin lesion","html":"<div class=\"graphic\"><div style=\"width: 798px\" class=\"figure\"><div class=\"ttl\">Erysipelas-like skin lesion</div><div class=\"cntnt\"><img style=\"width:778px; height:344px;\" src=\"images/RHEUM/111977_Erysipelas-like_skin_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erysipelas-like erythema (A) and, following three days, a full spontaneous recovery (B).</div><div class=\"graphic_reference\">Courtesy of Eldad Ben-Chetrit, MD.</div><div id=\"graphicVersion\">Graphic 111977 Version 1.0</div></div></div>"},"111987":{"type":"graphic_picture","displayName":"Naegeli-Franceschetti adermatoglyphia","title":"Naegeli-Franceschetti-Jadassohn syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Naegeli-Franceschetti-Jadassohn syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/111987_NFJS_adermatoglyphia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Absence of dermatoglyphs in a patient with Naegeli-Franceschetti-Jadassohn syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111987 Version 1.0</div></div></div>"},"111989":{"type":"graphic_picture","displayName":"Naegeli-Franceschetti reticulate hyperpigmentation","title":"Naegeli-Franceschetti-Jadassohn syndrome","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Naegeli-Franceschetti-Jadassohn syndrome</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/111989_NF_reticulate_hyperpigmnttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticulate hyperpigmentation of the axilla in a patient with Naegeli-Franceschetti-Jadassohn syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 111989 Version 1.0</div></div></div>"},"111991":{"type":"graphic_picture","displayName":"Wobble board stabilization exercise","title":"Wobble board stabilization exercise","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Wobble board stabilization exercise</div><div class=\"cntnt\"><img style=\"width:759px; height:572px;\" src=\"images/SM/111991_Wbl_brd_snsrimtr_stblztn_ex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wobble board&nbsp;has&nbsp;an unstable surface that&nbsp;rocks in all planes. The wobble board is typically used for rehabilitation and helps to develop balance and proprioception.&nbsp;A&nbsp;double-leg stance on a wobble board is shown in photograph A, and a single-leg stance in photograph B.</div><div class=\"graphic_reference\">Reproduced with permission from Joseph E. Muscolino DC. Copyright © 2014. Originally published in: Muscolino JE. Manual Therapy for the Low Back and Pelvis: A Clinical Orthopedic Approach, Lippincott Williams &amp; Wilkins, Philadelphia 2014.</div><div id=\"graphicVersion\">Graphic 111991 Version 1.0</div></div></div>"},"111995":{"type":"graphic_picture","displayName":"Buck moth caterpillar (Hemileuca maia)","title":"Buck moth caterpillar (<EM>Hemileuca maia</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Buck moth caterpillar (<EM>Hemileuca maia</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:577px;\" src=\"images/DERM/111995_Buck_moth_caterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This relative of the Io moth shows the typical branched urticating spines of Hemileucine caterpillars.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 111995 Version 1.0</div></div></div>"},"111996":{"type":"graphic_figure","displayName":"Increasing incid CRC by age","title":"Increasing incidence of colorectal cancer in the United States with age, SEER 2004-2013","html":"<div class=\"graphic\"><div style=\"width: 886px\" class=\"figure\"><div class=\"ttl\">Increasing incidence of colorectal cancer in the United States with age, SEER 2004-2013</div><div class=\"cntnt\"><img style=\"width:866px; height:512px;\" src=\"images/ONC/111996_Increasing_incid_CRC_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The age-specific incidence of colorectal cancer was measured between 2004 and 2013 in men and women of all races.</div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology, and End Results.</div><div class=\"graphic_reference\">Data from: Surveillance, Epidemiology, and End Results (SEER) Program, 2004-2013. Available at: <A href=\"https://seer.cancer.gov/faststats/selections.php?#Output\" target=_blank>https://seer.cancer.gov/faststats/selections.php?#Output</A> (Accessed on March 21, 2017).</div><div id=\"graphicVersion\">Graphic 111996 Version 1.0</div></div></div>"},"111997":{"type":"graphic_picture","displayName":"Saddleback caterpillar (Acharia stimulea)","title":"Saddleback caterpillar (<EM>Acharia stimulea</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Saddleback caterpillar (<EM>Acharia stimulea</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/111997_Saddleback_caterpillar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The saddleback caterpillar is a type of slug caterpillar bearing numerous clusters of urticating spines.</div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 111997 Version 1.0</div></div></div>"},"111998":{"type":"graphic_picture","displayName":"Buck moth caterpillar (Hemileuca maia) 2","title":"Buck moth caterpillar (<EM>Hemileuca maia</EM>)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buck moth caterpillar (<EM>Hemileuca maia</EM>)</div><div class=\"cntnt\"><img style=\"width:386px; height:576px;\" src=\"images/DERM/111998_Buck_moth_caterpillar2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Photo courtesy of David L Wagner, PhD.</div><div id=\"graphicVersion\">Graphic 111998 Version 1.0</div></div></div>"},"111999":{"type":"graphic_picture","displayName":"Cecrops eyed silkmoth caterpillar (Automeris cecrops pamina)","title":"Cecrops eyed silkmoth caterpillar (<EM>Automeris cecrops pamina</EM>)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Cecrops eyed silkmoth caterpillar (<EM>Automeris cecrops pamina</EM>)</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/111999_Cecrops_eyd_silkmth_ctrpllr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This Hemileucine caterpillar is found in Arizona. Contact with the branched spines causes painful urticarial wheals.</div><div id=\"graphicVersion\">Graphic 111999 Version 1.0</div></div></div>"}};